#begin document (1868042); part 000
1868042	0	1	A	DT	-	-	-	-	-	-	-	-
1868042	0	2	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	3	Channel	NN	-	-	-	-	-	-	-	-
1868042	0	4	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	5	Dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	6	Pathway	NN	-	-	-	-	-	-	-	-
1868042	0	7	within	IN	-	-	-	-	-	-	-	-
1868042	0	8	α	NN	-	-	-	-	-	-	-	(1
1868042	0	9	Cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	10	Regulates	VBZ	-	-	-	-	-	-	-	-
1868042	0	11	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	12	Release	NN	-	-	-	-	-	-	-	-
1868042	0	13	from	IN	-	-	-	-	-	-	-	-
1868042	0	14	Both	DT	-	-	-	-	-	-	-	-
1868042	0	15	Rodent	NN	-	-	-	-	-	-	-	-
1868042	0	16	and	CC	-	-	-	-	-	-	-	-
1868042	0	17	Human	JJ	-	-	-	-	-	-	-	-
1868042	0	18	Islets	NNS	-	-	-	-	-	-	-	-
1868042	0	19	of	IN	-	-	-	-	-	-	-	-
1868042	0	20	Langerhans	NNS	-	-	-	-	-	-	-	-

1868042	0	1	Abstract	NN	-	-	-	-	-	-	-	-

1868042	0	1	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	secreted	VBN	-	-	-	-	-	-	-	-
1868042	0	4	from	IN	-	-	-	-	-	-	-	-
1868042	0	5	pancreatic	JJ	-	-	-	-	-	-	-	(1
1868042	0	6	islet	NN	-	-	-	-	-	-	-	-
1868042	0	7	α	NN	-	-	-	-	-	-	-	-
1868042	0	8	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	stimulates	VBZ	-	-	-	-	-	-	-	-
1868042	0	11	gluconeogenesis	NN	-	-	-	-	-	-	-	-
1868042	0	12	and	CC	-	-	-	-	-	-	-	-
1868042	0	13	liver	NN	-	-	-	-	-	-	-	-
1868042	0	14	glycogen	NN	-	-	-	-	-	-	-	-
1868042	0	15	breakdown	NN	-	-	-	-	-	-	-	-
1868042	0	16	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	mechanism	NN	-	-	-	-	-	-	-	-
1868042	0	3	regulating	VBG	-	-	-	-	-	-	-	-
1868042	0	4	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	5	release	NN	-	-	-	-	-	-	-	3)
1868042	0	6	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	7	debated	VBN	-	-	-	-	-	-	-	-
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	variously	RB	-	-	-	-	-	-	-	-
1868042	0	11	attributed	VBN	-	-	-	-	-	-	-	-
1868042	0	12	to	IN	-	-	-	-	-	-	-	-
1868042	0	13	neuronal	JJ	-	-	-	-	-	-	-	-
1868042	0	14	control	NN	-	-	-	-	-	-	-	-
1868042	0	15	,	,	-	-	-	-	-	-	-	-
1868042	0	16	paracrine	JJ	-	-	-	-	-	-	-	-
1868042	0	17	control	NN	-	-	-	-	-	-	-	-
1868042	0	18	by	IN	-	-	-	-	-	-	-	-
1868042	0	19	neighbouring	VBG	-	-	-	-	-	-	-	-
1868042	0	20	β	NN	-	-	-	-	-	-	-	-
1868042	0	21	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	22	,	,	-	-	-	-	-	-	-	-
1868042	0	23	or	CC	-	-	-	-	-	-	-	-
1868042	0	24	to	IN	-	-	-	-	-	-	-	-
1868042	0	25	an	DT	-	-	-	-	-	-	-	-
1868042	0	26	intrinsic	JJ	-	-	-	-	-	-	-	-
1868042	0	27	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	28	sensing	VBG	-	-	-	-	-	-	-	-
1868042	0	29	by	IN	-	-	-	-	-	-	-	-
1868042	0	30	the	DT	-	-	-	-	-	-	-	(1
1868042	0	31	α	NN	-	-	-	-	-	-	-	-
1868042	0	32	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	33	themselves	PRP	-	-	-	-	-	-	-	1)
1868042	0	34	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	examined	VBD	-	-	-	-	-	-	-	-
1868042	0	3	hormone	NN	-	-	-	-	-	-	-	-
1868042	0	4	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	5	and	CC	-	-	-	-	-	-	-	-
1868042	0	6	Ca2+	NN	-	-	-	-	-	-	-	(6b|(7a|(5)
1868042	0	7	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	8	of	IN	-	-	-	-	-	-	-	6b)
1868042	0	9	α	NN	-	-	-	-	-	-	-	(10a)|(8a)|(9a)|7a)
1868042	0	10	and	CC	-	-	-	-	-	-	-	-
1868042	0	11	β	NN	-	-	-	-	-	-	-	(11a|(6b
1868042	0	12	cells	NNS	-	-	-	-	-	-	-	(10a|(7a|(8a|(9a
1868042	0	13	within	IN	-	-	-	-	-	-	-	-
1868042	0	14	intact	JJ	-	-	-	-	-	-	-	(13|(14a|(12c)|7a)|6b)|11a)|10a)
1868042	0	15	rodent	NN	-	-	-	-	-	-	-	8a)|14a)
1868042	0	16	and	CC	-	-	-	-	-	-	-	-
1868042	0	17	human	JJ	-	-	-	-	-	-	-	(10a|(11a|(12c|(6b|(7a
1868042	0	18	islets	NNS	-	-	-	-	-	-	-	(14a)|(8a)|9a)|7a)|6b)|13)|12c)|11a)|10a)
1868042	0	19	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Glucose	NN	-	-	-	-	-	-	-	-
1868042	0	2	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	3	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	4	suppression	NN	-	-	-	-	-	-	-	-
1868042	0	5	of	IN	-	-	-	-	-	-	-	-
1868042	0	6	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	7	release	NN	-	-	-	-	-	-	-	3)
1868042	0	8	persisted	VBD	-	-	-	-	-	-	-	-
1868042	0	9	when	WRB	-	-	-	-	-	-	-	-
1868042	0	10	paracrine	JJ	-	-	-	-	-	-	-	(15|(16a)
1868042	0	11	GABA	NN	-	-	-	-	-	-	-	15)
1868042	0	12	or	CC	-	-	-	-	-	-	-	-
1868042	0	13	Zn2+	NN	-	-	-	-	-	-	-	(16a)
1868042	0	14	signalling	NN	-	-	-	-	-	-	-	-
1868042	0	15	was	VBD	-	-	-	-	-	-	-	-
1868042	0	16	blocked	VBN	-	-	-	-	-	-	-	-
1868042	0	17	,	,	-	-	-	-	-	-	-	-
1868042	0	18	but	CC	-	-	-	-	-	-	-	-
1868042	0	19	was	VBD	-	-	-	-	-	-	-	-
1868042	0	20	reversed	VBN	-	-	-	-	-	-	-	-
1868042	0	21	by	IN	-	-	-	-	-	-	-	-
1868042	0	22	low	JJ	-	-	-	-	-	-	-	(17
1868042	0	23	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	24	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	25	1	CD	-	-	-	-	-	-	-	-
1868042	0	26	–	SYM	-	-	-	-	-	-	-	-
1868042	0	27	20	CD	-	-	-	-	-	-	-	-
1868042	0	28	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	29	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	30	of	IN	-	-	-	-	-	-	-	-
1868042	0	31	the	DT	-	-	-	-	-	-	-	(18
1868042	0	32	ATP	NN	-	-	-	-	-	-	-	-
1868042	0	33	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	34	sensitive	JJ	-	-	-	-	-	-	-	-
1868042	0	35	K+	NN	-	-	-	-	-	-	-	-
1868042	0	36	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	37	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	38	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	39	channel	NN	-	-	-	-	-	-	-	-
1868042	0	40	opener	NN	-	-	-	-	-	-	-	-
1868042	0	41	diazoxide	NN	-	-	-	-	-	-	-	18)|17)
1868042	0	42	,	,	-	-	-	-	-	-	-	-
1868042	0	43	which	WDT	-	-	-	-	-	-	-	-
1868042	0	44	had	VBD	-	-	-	-	-	-	-	-
1868042	0	45	no	DT	-	-	-	-	-	-	-	-
1868042	0	46	effect	NN	-	-	-	-	-	-	-	-
1868042	0	47	on	IN	-	-	-	-	-	-	-	-
1868042	0	48	insulin	NN	-	-	-	-	-	-	-	(20|(19)
1868042	0	49	release	NN	-	-	-	-	-	-	-	20)
1868042	0	50	or	CC	-	-	-	-	-	-	-	-
1868042	0	51	β	NN	-	-	-	-	-	-	-	(21|(22
1868042	0	52	cell	NN	-	-	-	-	-	-	-	21)
1868042	0	53	responses	NNS	-	-	-	-	-	-	-	22)
1868042	0	54	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	effect	NN	-	-	-	-	-	-	-	-
1868042	0	3	was	VBD	-	-	-	-	-	-	-	-
1868042	0	4	prevented	VBN	-	-	-	-	-	-	-	-
1868042	0	5	by	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	(23
1868042	0	7	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	8	channel	NN	-	-	-	-	-	-	-	-
1868042	0	9	blocker	NN	-	-	-	-	-	-	-	-
1868042	0	10	tolbutamide	NN	-	-	-	-	-	-	-	23)
1868042	0	11	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	12	100	CD	-	-	-	-	-	-	-	-
1868042	0	13	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Higher	JJR	-	-	-	-	-	-	-	-
1868042	0	2	diazoxide	NN	-	-	-	-	-	-	-	-
1868042	0	3	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	4	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	5	≥	SYM	-	-	-	-	-	-	-	-
1868042	0	6	30	CD	-	-	-	-	-	-	-	-
1868042	0	7	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	decreased	VBN	-	-	-	-	-	-	-	-
1868042	0	10	glucagon	NN	-	-	-	-	-	-	-	(24|(26|(25a)
1868042	0	11	and	CC	-	-	-	-	-	-	-	-
1868042	0	12	insulin	NN	-	-	-	-	-	-	-	(27|(19)|24)
1868042	0	13	secretion	NN	-	-	-	-	-	-	-	(25a)|27)|26)
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	and	CC	-	-	-	-	-	-	-	-
1868042	0	16	α	NN	-	-	-	-	-	-	-	(28a
1868042	0	17	-	HYPH	-	-	-	-	-	-	-	28a)
1868042	0	18	and	CC	-	-	-	-	-	-	-	-
1868042	0	19	β	NN	-	-	-	-	-	-	-	(29
1868042	0	20	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	21	cell	NN	-	-	-	-	-	-	-	(28a
1868042	0	22	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	23	responses	NNS	-	-	-	-	-	-	-	29)|28a)
1868042	0	24	,	,	-	-	-	-	-	-	-	-
1868042	0	25	in	IN	-	-	-	-	-	-	-	-
1868042	0	26	parallel	JJ	-	-	-	-	-	-	-	-
1868042	0	27	.	.	-	-	-	-	-	-	-	-

1868042	0	1	In	IN	-	-	-	-	-	-	-	-
1868042	0	2	the	DT	-	-	-	-	-	-	-	(30
1868042	0	3	absence	NN	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	glucose	NN	-	-	-	-	-	-	-	(31)|30)
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	tolbutamide	NN	-	-	-	-	-	-	-	(23)
1868042	0	8	at	IN	-	-	-	-	-	-	-	-
1868042	0	9	low	JJ	-	-	-	-	-	-	-	-
1868042	0	10	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	11	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	12	<	SYM	-	-	-	-	-	-	-	-
1868042	0	13	1	CD	-	-	-	-	-	-	-	-
1868042	0	14	μM	NN	-	-	-	-	-	-	-	-
1868042	0	15	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	16	stimulated	VBN	-	-	-	-	-	-	-	-
1868042	0	17	glucagon	NN	-	-	-	-	-	-	-	(25
1868042	0	18	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	19	,	,	-	-	-	-	-	-	-	-
1868042	0	20	whereas	IN	-	-	-	-	-	-	-	-
1868042	0	21	high	JJ	-	-	-	-	-	-	-	-
1868042	0	22	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	23	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	24	>	SYM	-	-	-	-	-	-	-	-
1868042	0	25	10	CD	-	-	-	-	-	-	-	-
1868042	0	26	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	27	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	28	were	VBD	-	-	-	-	-	-	-	-
1868042	0	29	inhibitory	JJ	-	-	-	-	-	-	-	-
1868042	0	30	.	.	-	-	-	-	-	-	-	-

1868042	0	1	In	IN	-	-	-	-	-	-	-	-
1868042	0	2	the	DT	-	-	-	-	-	-	-	-
1868042	0	3	presence	NN	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	a	DT	-	-	-	-	-	-	-	-
1868042	0	6	maximally	RB	-	-	-	-	-	-	-	-
1868042	0	7	inhibitory	JJ	-	-	-	-	-	-	-	-
1868042	0	8	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	tolbutamide	NN	-	-	-	-	-	-	-	(23)
1868042	0	11	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	12	0.5	CD	-	-	-	-	-	-	-	-
1868042	0	13	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	,	,	-	-	-	-	-	-	-	-
1868042	0	16	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	17	had	VBD	-	-	-	-	-	-	-	-
1868042	0	18	no	DT	-	-	-	-	-	-	-	-
1868042	0	19	additional	JJ	-	-	-	-	-	-	-	-
1868042	0	20	suppressive	JJ	-	-	-	-	-	-	-	-
1868042	0	21	effect	NN	-	-	-	-	-	-	-	-
1868042	0	22	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Downstream	RB	-	-	-	-	-	-	-	-
1868042	0	2	of	IN	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	(32
1868042	0	4	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	5	channel	NN	-	-	-	-	-	-	-	32)
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	8	of	IN	-	-	-	-	-	-	-	-
1868042	0	9	voltage	NN	-	-	-	-	-	-	-	(33a
1868042	0	10	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	11	gated	VBN	-	-	-	-	-	-	-	-
1868042	0	12	Na+	NN	-	-	-	-	-	-	-	33a)
1868042	0	13	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	14	TTX	NN	-	-	-	-	-	-	-	(34)
1868042	0	15	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	16	and	CC	-	-	-	-	-	-	-	-
1868042	0	17	N	NN	-	-	-	-	-	-	-	(35
1868042	0	18	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	19	type	NN	-	-	-	-	-	-	-	-
1868042	0	20	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	21	channels	NNS	-	-	-	-	-	-	-	(33a)|35)
1868042	0	22	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	23	ω	NN	-	-	-	-	-	-	-	(36
1868042	0	24	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	25	conotoxin	NN	-	-	-	-	-	-	-	36)
1868042	0	26	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	27	,	,	-	-	-	-	-	-	-	-
1868042	0	28	but	CC	-	-	-	-	-	-	-	-
1868042	0	29	not	RB	-	-	-	-	-	-	-	-
1868042	0	30	L	NN	-	-	-	-	-	-	-	(37
1868042	0	31	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	32	type	NN	-	-	-	-	-	-	-	-
1868042	0	33	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	34	channels	NNS	-	-	-	-	-	-	-	37)
1868042	0	35	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	36	nifedipine	NN	-	-	-	-	-	-	-	(38)
1868042	0	37	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	38	,	,	-	-	-	-	-	-	-	-
1868042	0	39	prevented	VBD	-	-	-	-	-	-	-	-
1868042	0	40	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	41	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	42	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Both	CC	-	-	-	-	-	-	-	-
1868042	0	2	the	DT	-	-	-	-	-	-	-	(35
1868042	0	3	N	NN	-	-	-	-	-	-	-	-
1868042	0	4	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	5	type	NN	-	-	-	-	-	-	-	-
1868042	0	6	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	7	channels	NNS	-	-	-	-	-	-	-	35)
1868042	0	8	and	CC	-	-	-	-	-	-	-	-
1868042	0	9	α	NN	-	-	-	-	-	-	-	(1|(39
1868042	0	10	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	11	cell	NN	-	-	-	-	-	-	-	1)
1868042	0	12	exocytosis	NN	-	-	-	-	-	-	-	39)
1868042	0	13	were	VBD	-	-	-	-	-	-	-	-
1868042	0	14	inactivated	VBN	-	-	-	-	-	-	-	-
1868042	0	15	at	IN	-	-	-	-	-	-	-	-
1868042	0	16	depolarised	VBN	-	-	-	-	-	-	-	-
1868042	0	17	membrane	NN	-	-	-	-	-	-	-	-
1868042	0	18	potentials	NNS	-	-	-	-	-	-	-	-
1868042	0	19	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Rodent	NN	-	-	-	-	-	-	-	-
1868042	0	2	and	CC	-	-	-	-	-	-	-	-
1868042	0	3	human	JJ	-	-	-	-	-	-	-	(40
1868042	0	4	glucagon	NN	-	-	-	-	-	-	-	-
1868042	0	5	secretion	NN	-	-	-	-	-	-	-	40)
1868042	0	6	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	7	regulated	VBN	-	-	-	-	-	-	-	-
1868042	0	8	by	IN	-	-	-	-	-	-	-	-
1868042	0	9	an	DT	-	-	-	-	-	-	-	-
1868042	0	10	α	NN	-	-	-	-	-	-	-	-
1868042	0	11	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	cell	NN	-	-	-	-	-	-	-	-
1868042	0	13	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	14	channel	NN	-	-	-	-	-	-	-	-
1868042	0	15	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	17	mechanism	NN	-	-	-	-	-	-	-	-
1868042	0	18	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	propose	VBP	-	-	-	-	-	-	-	-
1868042	0	3	that	IN	-	-	-	-	-	-	-	-
1868042	0	4	elevated	VBN	-	-	-	-	-	-	-	(41
1868042	0	5	glucose	NN	-	-	-	-	-	-	-	41)
1868042	0	6	reduces	VBZ	-	-	-	-	-	-	-	-
1868042	0	7	electrical	JJ	-	-	-	-	-	-	-	(42
1868042	0	8	activity	NN	-	-	-	-	-	-	-	42)
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	exocytosis	NN	-	-	-	-	-	-	-	(43)
1868042	0	11	via	IN	-	-	-	-	-	-	-	-
1868042	0	12	depolarisation	NN	-	-	-	-	-	-	-	-
1868042	0	13	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	14	induced	VBN	-	-	-	-	-	-	-	-
1868042	0	15	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	16	of	IN	-	-	-	-	-	-	-	-
1868042	0	17	ion	NN	-	-	-	-	-	-	-	(44
1868042	0	18	channels	NNS	-	-	-	-	-	-	-	-
1868042	0	19	involved	VBN	-	-	-	-	-	-	-	-
1868042	0	20	in	IN	-	-	-	-	-	-	-	-
1868042	0	21	action	NN	-	-	-	-	-	-	-	(45|(46
1868042	0	22	potential	NN	-	-	-	-	-	-	-	45)
1868042	0	23	firing	NN	-	-	-	-	-	-	-	46)
1868042	0	24	and	CC	-	-	-	-	-	-	-	-
1868042	0	25	secretion	NN	-	-	-	-	-	-	-	(47)|44)
1868042	0	26	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Author	NN	-	-	-	-	-	-	-	(48)
1868042	0	2	Summary	NN	-	-	-	-	-	-	-	-

1868042	0	1	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	a	DT	-	-	-	-	-	-	-	-
1868042	0	4	critical	JJ	-	-	-	-	-	-	-	-
1868042	0	5	regulator	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	8	homeostasis	NN	-	-	-	-	-	-	-	-
1868042	0	9	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Its	PRP$	-	-	-	-	-	-	-	(2)
1868042	0	2	major	JJ	-	-	-	-	-	-	-	-
1868042	0	3	action	NN	-	-	-	-	-	-	-	-
1868042	0	4	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	5	to	TO	-	-	-	-	-	-	-	-
1868042	0	6	mobilize	VB	-	-	-	-	-	-	-	-
1868042	0	7	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	8	from	IN	-	-	-	-	-	-	-	-
1868042	0	9	the	DT	-	-	-	-	-	-	-	(49
1868042	0	10	liver	NN	-	-	-	-	-	-	-	49)
1868042	0	11	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Glucagon	NN	-	-	-	-	-	-	-	(50|(2)
1868042	0	2	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	3	from	IN	-	-	-	-	-	-	-	-
1868042	0	4	α	NN	-	-	-	-	-	-	-	(1
1868042	0	5	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	(51
1868042	0	8	pancreatic	JJ	-	-	-	-	-	-	-	-
1868042	0	9	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	10	of	IN	-	-	-	-	-	-	-	-
1868042	0	11	Langerhans	NNP	-	-	-	-	-	-	-	51)|50)|1)
1868042	0	12	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	13	suppressed	VBN	-	-	-	-	-	-	-	-
1868042	0	14	by	IN	-	-	-	-	-	-	-	-
1868042	0	15	elevated	VBN	-	-	-	-	-	-	-	-
1868042	0	16	blood	NN	-	-	-	-	-	-	-	-
1868042	0	17	sugar	NN	-	-	-	-	-	-	-	-
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	a	DT	-	-	-	-	-	-	-	-
1868042	0	20	response	NN	-	-	-	-	-	-	-	-
1868042	0	21	that	WDT	-	-	-	-	-	-	-	-
1868042	0	22	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	23	often	RB	-	-	-	-	-	-	-	-
1868042	0	24	perturbed	VBN	-	-	-	-	-	-	-	-
1868042	0	25	in	IN	-	-	-	-	-	-	-	-
1868042	0	26	diabetes	NN	-	-	-	-	-	-	-	(52)
1868042	0	27	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Much	JJ	-	-	-	-	-	-	-	-
1868042	0	2	work	NN	-	-	-	-	-	-	-	-
1868042	0	3	has	VBZ	-	-	-	-	-	-	-	-
1868042	0	4	focused	VBN	-	-	-	-	-	-	-	-
1868042	0	5	on	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	regulation	NN	-	-	-	-	-	-	-	-
1868042	0	8	of	IN	-	-	-	-	-	-	-	-
1868042	0	9	α	NN	-	-	-	-	-	-	-	(50
1868042	0	10	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	11	cell	NN	-	-	-	-	-	-	-	-
1868042	0	12	glucagon	NN	-	-	-	-	-	-	-	-
1868042	0	13	secretion	NN	-	-	-	-	-	-	-	50)
1868042	0	14	by	IN	-	-	-	-	-	-	-	-
1868042	0	15	neuronal	JJ	-	-	-	-	-	-	-	-
1868042	0	16	factors	NNS	-	-	-	-	-	-	-	-
1868042	0	17	and	CC	-	-	-	-	-	-	-	-
1868042	0	18	by	IN	-	-	-	-	-	-	-	-
1868042	0	19	paracrine	JJ	-	-	-	-	-	-	-	-
1868042	0	20	factors	NNS	-	-	-	-	-	-	-	-
1868042	0	21	from	IN	-	-	-	-	-	-	-	-
1868042	0	22	neighbouring	VBG	-	-	-	-	-	-	-	-
1868042	0	23	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	24	,	,	-	-	-	-	-	-	-	-
1868042	0	25	including	VBG	-	-	-	-	-	-	-	-
1868042	0	26	the	DT	-	-	-	-	-	-	-	(19
1868042	0	27	important	JJ	-	-	-	-	-	-	-	-
1868042	0	28	islet	NN	-	-	-	-	-	-	-	-
1868042	0	29	hormone	NN	-	-	-	-	-	-	-	-
1868042	0	30	insulin	NN	-	-	-	-	-	-	-	19)
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	In	IN	-	-	-	-	-	-	-	-
1868042	0	2	contrast	NN	-	-	-	-	-	-	-	-
1868042	0	3	,	,	-	-	-	-	-	-	-	-
1868042	0	4	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	5	provide	VBP	-	-	-	-	-	-	-	-
1868042	0	6	evidence	NN	-	-	-	-	-	-	-	-
1868042	0	7	in	IN	-	-	-	-	-	-	-	-
1868042	0	8	support	NN	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	a	DT	-	-	-	-	-	-	-	-
1868042	0	11	direct	JJ	-	-	-	-	-	-	-	-
1868042	0	12	effect	NN	-	-	-	-	-	-	-	-
1868042	0	13	of	IN	-	-	-	-	-	-	-	-
1868042	0	14	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	15	on	IN	-	-	-	-	-	-	-	-
1868042	0	16	α	NN	-	-	-	-	-	-	-	(10c|(8b|(9
1868042	0	17	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	18	within	IN	-	-	-	-	-	-	-	-
1868042	0	19	intact	JJ	-	-	-	-	-	-	-	(13|(14b|(12a)|10c)
1868042	0	20	rodent	NN	-	-	-	-	-	-	-	8b)|14b)
1868042	0	21	and	CC	-	-	-	-	-	-	-	-
1868042	0	22	human	JJ	-	-	-	-	-	-	-	(10c|(12a
1868042	0	23	islets	NNS	-	-	-	-	-	-	-	(14b)|(8b)|9)|13)|12a)|10c)
1868042	0	24	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Notably	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	our	PRP$	-	-	-	-	-	-	-	(4)
1868042	0	4	work	NN	-	-	-	-	-	-	-	-
1868042	0	5	implicates	VBZ	-	-	-	-	-	-	-	-
1868042	0	6	an	DT	-	-	-	-	-	-	-	-
1868042	0	7	α	NN	-	-	-	-	-	-	-	-
1868042	0	8	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	cell	NN	-	-	-	-	-	-	-	-
1868042	0	10	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	11	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	sensing	VBG	-	-	-	-	-	-	-	-
1868042	0	13	pathway	NN	-	-	-	-	-	-	-	-
1868042	0	14	similar	JJ	-	-	-	-	-	-	-	-
1868042	0	15	to	IN	-	-	-	-	-	-	-	-
1868042	0	16	that	DT	-	-	-	-	-	-	-	-
1868042	0	17	found	VBN	-	-	-	-	-	-	-	-
1868042	0	18	in	IN	-	-	-	-	-	-	-	-
1868042	0	19	insulin	NN	-	-	-	-	-	-	-	(21
1868042	0	20	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	21	secreting	VBG	-	-	-	-	-	-	-	-
1868042	0	22	β	NN	-	-	-	-	-	-	-	-
1868042	0	23	cells	NNS	-	-	-	-	-	-	-	21)
1868042	0	24	,	,	-	-	-	-	-	-	-	-
1868042	0	25	involving	VBG	-	-	-	-	-	-	-	-
1868042	0	26	closure	NN	-	-	-	-	-	-	-	-
1868042	0	27	of	IN	-	-	-	-	-	-	-	-
1868042	0	28	ATP	NN	-	-	-	-	-	-	-	(32
1868042	0	29	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	30	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	31	K+	NN	-	-	-	-	-	-	-	-
1868042	0	32	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	33	in	IN	-	-	-	-	-	-	-	-
1868042	0	34	the	DT	-	-	-	-	-	-	-	-
1868042	0	35	presence	NN	-	-	-	-	-	-	-	-
1868042	0	36	of	IN	-	-	-	-	-	-	-	-
1868042	0	37	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	38	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Furthermore	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	4	find	VBP	-	-	-	-	-	-	-	-
1868042	0	5	that	IN	-	-	-	-	-	-	-	-
1868042	0	6	membrane	NN	-	-	-	-	-	-	-	(53
1868042	0	7	depolarisation	NN	-	-	-	-	-	-	-	53)
1868042	0	8	results	VBZ	-	-	-	-	-	-	-	-
1868042	0	9	in	IN	-	-	-	-	-	-	-	-
1868042	0	10	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	11	of	IN	-	-	-	-	-	-	-	-
1868042	0	12	Na+	NN	-	-	-	-	-	-	-	(54c)
1868042	0	13	and	CC	-	-	-	-	-	-	-	-
1868042	0	14	Ca2+	NN	-	-	-	-	-	-	-	(55
1868042	0	15	channel	NN	-	-	-	-	-	-	-	(54c)|55)
1868042	0	16	activity	NN	-	-	-	-	-	-	-	-
1868042	0	17	and	CC	-	-	-	-	-	-	-	-
1868042	0	18	α	NN	-	-	-	-	-	-	-	(1|(39
1868042	0	19	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	20	cell	NN	-	-	-	-	-	-	-	1)
1868042	0	21	exocytosis	NN	-	-	-	-	-	-	-	39)
1868042	0	22	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Thus	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	4	propose	VBP	-	-	-	-	-	-	-	-
1868042	0	5	that	IN	-	-	-	-	-	-	-	-
1868042	0	6	elevated	VBN	-	-	-	-	-	-	-	-
1868042	0	7	blood	NN	-	-	-	-	-	-	-	-
1868042	0	8	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	9	reduces	VBZ	-	-	-	-	-	-	-	-
1868042	0	10	α	NN	-	-	-	-	-	-	-	(56
1868042	0	11	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	cell	NN	-	-	-	-	-	-	-	-
1868042	0	13	electrical	JJ	-	-	-	-	-	-	-	-
1868042	0	14	activity	NN	-	-	-	-	-	-	-	56)
1868042	0	15	and	CC	-	-	-	-	-	-	-	-
1868042	0	16	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	17	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	18	by	IN	-	-	-	-	-	-	-	-
1868042	0	19	inactivating	VBG	-	-	-	-	-	-	-	-
1868042	0	20	the	DT	-	-	-	-	-	-	-	(44
1868042	0	21	ion	NN	-	-	-	-	-	-	-	-
1868042	0	22	channels	NNS	-	-	-	-	-	-	-	-
1868042	0	23	involved	VBN	-	-	-	-	-	-	-	-
1868042	0	24	in	IN	-	-	-	-	-	-	-	-
1868042	0	25	action	NN	-	-	-	-	-	-	-	(45|(46
1868042	0	26	potential	NN	-	-	-	-	-	-	-	45)
1868042	0	27	firing	NN	-	-	-	-	-	-	-	46)
1868042	0	28	and	CC	-	-	-	-	-	-	-	-
1868042	0	29	secretion	NN	-	-	-	-	-	-	-	(47)|44)
1868042	0	30	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Introduction	NN	-	-	-	-	-	-	-	-

1868042	0	1	Blood	NN	-	-	-	-	-	-	-	-
1868042	0	2	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	3	levels	NNS	-	-	-	-	-	-	-	-
1868042	0	4	are	VBP	-	-	-	-	-	-	-	-
1868042	0	5	under	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	control	NN	-	-	-	-	-	-	-	-
1868042	0	8	of	IN	-	-	-	-	-	-	-	-
1868042	0	9	two	CD	-	-	-	-	-	-	-	-
1868042	0	10	hormones	NNS	-	-	-	-	-	-	-	-
1868042	0	11	released	VBN	-	-	-	-	-	-	-	-
1868042	0	12	from	IN	-	-	-	-	-	-	-	-
1868042	0	13	the	DT	-	-	-	-	-	-	-	(51
1868042	0	14	pancreatic	JJ	-	-	-	-	-	-	-	-
1868042	0	15	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	16	of	IN	-	-	-	-	-	-	-	-
1868042	0	17	Langerhans	NNP	-	-	-	-	-	-	-	51)
1868042	0	18	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Islet	NN	-	-	-	-	-	-	-	(21
1868042	0	2	β	NN	-	-	-	-	-	-	-	-
1868042	0	3	cells	NNS	-	-	-	-	-	-	-	21)
1868042	0	4	secrete	VBP	-	-	-	-	-	-	-	-
1868042	0	5	insulin	NN	-	-	-	-	-	-	-	(19)
1868042	0	6	when	WRB	-	-	-	-	-	-	-	-
1868042	0	7	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	8	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	9	high	JJ	-	-	-	-	-	-	-	-
1868042	0	10	,	,	-	-	-	-	-	-	-	-
1868042	0	11	decreasing	VBG	-	-	-	-	-	-	-	-
1868042	0	12	glucose	NN	-	-	-	-	-	-	-	(57|(31)
1868042	0	13	production	NN	-	-	-	-	-	-	-	-
1868042	0	14	by	IN	-	-	-	-	-	-	-	-
1868042	0	15	the	DT	-	-	-	-	-	-	-	(49
1868042	0	16	liver	NN	-	-	-	-	-	-	-	57)|49)
1868042	0	17	and	CC	-	-	-	-	-	-	-	-
1868042	0	18	increasing	VBG	-	-	-	-	-	-	-	-
1868042	0	19	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	20	storage	NN	-	-	-	-	-	-	-	-
1868042	0	21	in	IN	-	-	-	-	-	-	-	-
1868042	0	22	multiple	JJ	-	-	-	-	-	-	-	-
1868042	0	23	tissues	NNS	-	-	-	-	-	-	-	-
1868042	0	24	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Regulated	VBN	-	-	-	-	-	-	-	-
1868042	0	2	insulin	NN	-	-	-	-	-	-	-	-
1868042	0	3	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	4	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	5	relatively	RB	-	-	-	-	-	-	-	-
1868042	0	6	well	RB	-	-	-	-	-	-	-	-
1868042	0	7	understood	VBN	-	-	-	-	-	-	-	-
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	involving	VBG	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	-
1868042	0	11	metabolic	JJ	-	-	-	-	-	-	-	-
1868042	0	12	stimulation	NN	-	-	-	-	-	-	-	-
1868042	0	13	of	IN	-	-	-	-	-	-	-	-
1868042	0	14	electrical	JJ	-	-	-	-	-	-	-	(42
1868042	0	15	activity	NN	-	-	-	-	-	-	-	42)
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	Ca2+	NN	-	-	-	-	-	-	-	(58|(5)
1868042	0	18	entry	NN	-	-	-	-	-	-	-	58)
1868042	0	19	,	,	-	-	-	-	-	-	-	-
1868042	0	20	and	CC	-	-	-	-	-	-	-	-
1868042	0	21	exocytosis	NN	-	-	-	-	-	-	-	(43)
1868042	0	22	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	23	1	CD	-	-	-	-	-	-	-	-
1868042	0	24	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	25	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Islet	NN	-	-	-	-	-	-	-	(1
1868042	0	2	α	NN	-	-	-	-	-	-	-	-
1868042	0	3	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	4	secrete	VBP	-	-	-	-	-	-	-	-
1868042	0	5	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	6	in	IN	-	-	-	-	-	-	-	-
1868042	0	7	response	NN	-	-	-	-	-	-	-	-
1868042	0	8	to	IN	-	-	-	-	-	-	-	-
1868042	0	9	decreased	VBN	-	-	-	-	-	-	-	-
1868042	0	10	blood	NN	-	-	-	-	-	-	-	-
1868042	0	11	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	12	,	,	-	-	-	-	-	-	-	-
1868042	0	13	whereas	IN	-	-	-	-	-	-	-	-
1868042	0	14	elevated	VBN	-	-	-	-	-	-	-	(41
1868042	0	15	glucose	NN	-	-	-	-	-	-	-	41)
1868042	0	16	levels	NNS	-	-	-	-	-	-	-	-
1868042	0	17	suppress	VBP	-	-	-	-	-	-	-	-
1868042	0	18	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	19	release	NN	-	-	-	-	-	-	-	3)
1868042	0	20	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	-
1868042	0	4	principal	JJ	-	-	-	-	-	-	-	-
1868042	0	5	factor	NN	-	-	-	-	-	-	-	-
1868042	0	6	stimulating	VBG	-	-	-	-	-	-	-	-
1868042	0	7	glucose	NN	-	-	-	-	-	-	-	(57|(31)
1868042	0	8	production	NN	-	-	-	-	-	-	-	-
1868042	0	9	by	IN	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	(49
1868042	0	11	liver	NN	-	-	-	-	-	-	-	57)|49)
1868042	0	12	.	.	-	-	-	-	-	-	-	-

1868042	0	1	In	IN	-	-	-	-	-	-	-	-
1868042	0	2	diabetes	NN	-	-	-	-	-	-	-	(52)
1868042	0	3	,	,	-	-	-	-	-	-	-	-
1868042	0	4	baseline	NN	-	-	-	-	-	-	-	-
1868042	0	5	glucagon	NN	-	-	-	-	-	-	-	-
1868042	0	6	release	NN	-	-	-	-	-	-	-	-
1868042	0	7	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	8	elevated	JJ	-	-	-	-	-	-	-	-
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	and	CC	-	-	-	-	-	-	-	-
1868042	0	11	glucagon	NN	-	-	-	-	-	-	-	(25
1868042	0	12	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	13	in	IN	-	-	-	-	-	-	-	-
1868042	0	14	the	DT	-	-	-	-	-	-	-	(59
1868042	0	15	low	JJ	-	-	-	-	-	-	-	-
1868042	0	16	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	18	condition	NN	-	-	-	-	-	-	-	59)
1868042	0	19	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	20	blunted	VBN	-	-	-	-	-	-	-	-
1868042	0	21	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	22	2	CD	-	-	-	-	-	-	-	-
1868042	0	23	–	SYM	-	-	-	-	-	-	-	-
1868042	0	24	4	CD	-	-	-	-	-	-	-	-
1868042	0	25	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	26	.	.	-	-	-	-	-	-	-	-

1868042	0	1	These	DT	-	-	-	-	-	-	-	-
1868042	0	2	effects	NNS	-	-	-	-	-	-	-	-
1868042	0	3	contribute	VBP	-	-	-	-	-	-	-	-
1868042	0	4	to	IN	-	-	-	-	-	-	-	-
1868042	0	5	chronic	JJ	-	-	-	-	-	-	-	-
1868042	0	6	hyperglycaemia	NN	-	-	-	-	-	-	-	-
1868042	0	7	and	CC	-	-	-	-	-	-	-	-
1868042	0	8	to	IN	-	-	-	-	-	-	-	-
1868042	0	9	an	DT	-	-	-	-	-	-	-	-
1868042	0	10	increased	VBN	-	-	-	-	-	-	-	-
1868042	0	11	risk	NN	-	-	-	-	-	-	-	-
1868042	0	12	for	IN	-	-	-	-	-	-	-	-
1868042	0	13	acute	JJ	-	-	-	-	-	-	-	-
1868042	0	14	hypoglycaemic	JJ	-	-	-	-	-	-	-	-
1868042	0	15	events	NNS	-	-	-	-	-	-	-	-
1868042	0	16	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	mechanism	NN	-	-	-	-	-	-	-	-
1868042	0	3	regulating	VBG	-	-	-	-	-	-	-	-
1868042	0	4	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	5	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	6	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	7	poorly	RB	-	-	-	-	-	-	-	-
1868042	0	8	understood	VBN	-	-	-	-	-	-	-	-
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	remains	VBZ	-	-	-	-	-	-	-	-
1868042	0	11	hotly	RB	-	-	-	-	-	-	-	-
1868042	0	12	debated	VBN	-	-	-	-	-	-	-	-
1868042	0	13	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	14	5	CD	-	-	-	-	-	-	-	-
1868042	0	15	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	16	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	2	release	NN	-	-	-	-	-	-	-	-
1868042	0	3	in	IN	-	-	-	-	-	-	-	-
1868042	0	4	rodents	NNS	-	-	-	-	-	-	-	(60)
1868042	0	5	may	MD	-	-	-	-	-	-	-	-
1868042	0	6	be	VB	-	-	-	-	-	-	-	-
1868042	0	7	regulated	VBN	-	-	-	-	-	-	-	-
1868042	0	8	by	IN	-	-	-	-	-	-	-	-
1868042	0	9	paracrine	JJ	-	-	-	-	-	-	-	(61
1868042	0	10	signals	NNS	-	-	-	-	-	-	-	61)
1868042	0	11	,	,	-	-	-	-	-	-	-	-
1868042	0	12	including	VBG	-	-	-	-	-	-	-	-
1868042	0	13	γ	NN	-	-	-	-	-	-	-	(15
1868042	0	14	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	15	aminobutyric	JJ	-	-	-	-	-	-	-	-
1868042	0	16	acid	NN	-	-	-	-	-	-	-	15)
1868042	0	17	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	18	GABA	NN	-	-	-	-	-	-	-	-
1868042	0	19	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	20	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	21	6	CD	-	-	-	-	-	-	-	-
1868042	0	22	,	,	-	-	-	-	-	-	-	-
1868042	0	23	7	CD	-	-	-	-	-	-	-	-
1868042	0	24	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	25	,	,	-	-	-	-	-	-	-	-
1868042	0	26	Zn2+	NN	-	-	-	-	-	-	-	(16)
1868042	0	27	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	28	8	CD	-	-	-	-	-	-	-	-
1868042	0	29	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	30	,	,	-	-	-	-	-	-	-	-
1868042	0	31	and	CC	-	-	-	-	-	-	-	-
1868042	0	32	insulin	NN	-	-	-	-	-	-	-	(19)
1868042	0	33	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	34	9	CD	-	-	-	-	-	-	-	-
1868042	0	35	,	,	-	-	-	-	-	-	-	-
1868042	0	36	10	CD	-	-	-	-	-	-	-	-
1868042	0	37	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	38	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Conversely	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	4	may	MD	-	-	-	-	-	-	-	-
1868042	0	5	suppress	VB	-	-	-	-	-	-	-	-
1868042	0	6	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	7	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	8	through	IN	-	-	-	-	-	-	-	-
1868042	0	9	a	DT	-	-	-	-	-	-	-	-
1868042	0	10	direct	JJ	-	-	-	-	-	-	-	-
1868042	0	11	effect	NN	-	-	-	-	-	-	-	-
1868042	0	12	on	IN	-	-	-	-	-	-	-	-
1868042	0	13	α	NN	-	-	-	-	-	-	-	-
1868042	0	14	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	15	cell	NN	-	-	-	-	-	-	-	-
1868042	0	16	activity	NN	-	-	-	-	-	-	-	-
1868042	0	17	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	18	11	CD	-	-	-	-	-	-	-	-
1868042	0	19	–	SYM	-	-	-	-	-	-	-	-
1868042	0	20	14	CD	-	-	-	-	-	-	-	-
1868042	0	21	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	22	.	.	-	-	-	-	-	-	-	-

1868042	0	1	There	EX	-	-	-	-	-	-	-	-
1868042	0	2	are	VBP	-	-	-	-	-	-	-	-
1868042	0	3	also	RB	-	-	-	-	-	-	-	-
1868042	0	4	studies	NNS	-	-	-	-	-	-	-	-
1868042	0	5	suggesting	VBG	-	-	-	-	-	-	-	-
1868042	0	6	that	IN	-	-	-	-	-	-	-	-
1868042	0	7	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	8	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	9	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	10	under	IN	-	-	-	-	-	-	-	-
1868042	0	11	hypothalamic	JJ	-	-	-	-	-	-	-	-
1868042	0	12	control	NN	-	-	-	-	-	-	-	-
1868042	0	13	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	14	15	CD	-	-	-	-	-	-	-	-
1868042	0	15	,	,	-	-	-	-	-	-	-	-
1868042	0	16	16	CD	-	-	-	-	-	-	-	-
1868042	0	17	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	18	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Human	JJ	-	-	-	-	-	-	-	-
1868042	0	2	in	FW	-	-	-	-	-	-	-	-
1868042	0	3	vivo	FW	-	-	-	-	-	-	-	-
1868042	0	4	studies	NNS	-	-	-	-	-	-	-	-
1868042	0	5	provide	VBP	-	-	-	-	-	-	-	-
1868042	0	6	conflicting	VBG	-	-	-	-	-	-	-	-
1868042	0	7	evidence	NN	-	-	-	-	-	-	-	-
1868042	0	8	regarding	VBG	-	-	-	-	-	-	-	-
1868042	0	9	the	DT	-	-	-	-	-	-	-	-
1868042	0	10	control	NN	-	-	-	-	-	-	-	-
1868042	0	11	of	IN	-	-	-	-	-	-	-	-
1868042	0	12	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	13	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	14	by	IN	-	-	-	-	-	-	-	-
1868042	0	15	paracrine	JJ	-	-	-	-	-	-	-	-
1868042	0	16	or	CC	-	-	-	-	-	-	-	-
1868042	0	17	intrinsic	JJ	-	-	-	-	-	-	-	-
1868042	0	18	regulation	NN	-	-	-	-	-	-	-	-
1868042	0	19	of	IN	-	-	-	-	-	-	-	-
1868042	0	20	α	NN	-	-	-	-	-	-	-	(1
1868042	0	21	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	22	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	23	17	CD	-	-	-	-	-	-	-	-
1868042	0	24	–	SYM	-	-	-	-	-	-	-	-
1868042	0	25	30	CD	-	-	-	-	-	-	-	-
1868042	0	26	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	27	,	,	-	-	-	-	-	-	-	-
1868042	0	28	and	CC	-	-	-	-	-	-	-	-
1868042	0	29	very	RB	-	-	-	-	-	-	-	-
1868042	0	30	little	JJ	-	-	-	-	-	-	-	-
1868042	0	31	work	NN	-	-	-	-	-	-	-	-
1868042	0	32	has	VBZ	-	-	-	-	-	-	-	-
1868042	0	33	been	VBN	-	-	-	-	-	-	-	-
1868042	0	34	done	VBN	-	-	-	-	-	-	-	-
1868042	0	35	to	TO	-	-	-	-	-	-	-	-
1868042	0	36	examine	VB	-	-	-	-	-	-	-	-
1868042	0	37	this	DT	-	-	-	-	-	-	-	-
1868042	0	38	question	NN	-	-	-	-	-	-	-	-
1868042	0	39	in	IN	-	-	-	-	-	-	-	-
1868042	0	40	isolated	VBN	-	-	-	-	-	-	-	(62
1868042	0	41	human	JJ	-	-	-	-	-	-	-	-
1868042	0	42	islets	NNS	-	-	-	-	-	-	-	62)
1868042	0	43	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Islet	NN	-	-	-	-	-	-	-	(1
1868042	0	2	α	NN	-	-	-	-	-	-	-	-
1868042	0	3	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	4	express	VBP	-	-	-	-	-	-	-	-
1868042	0	5	ATP	NN	-	-	-	-	-	-	-	(32
1868042	0	6	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	8	K+	NN	-	-	-	-	-	-	-	-
1868042	0	9	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	10	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	11	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	12	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	13	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	14	9	CD	-	-	-	-	-	-	-	-
1868042	0	15	,	,	-	-	-	-	-	-	-	-
1868042	0	16	13	CD	-	-	-	-	-	-	-	-
1868042	0	17	,	,	-	-	-	-	-	-	-	-
1868042	0	18	14	CD	-	-	-	-	-	-	-	-
1868042	0	19	,	,	-	-	-	-	-	-	-	-
1868042	0	20	31	CD	-	-	-	-	-	-	-	-
1868042	0	21	,	,	-	-	-	-	-	-	-	-
1868042	0	22	32	CD	-	-	-	-	-	-	-	-
1868042	0	23	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	24	that	WDT	-	-	-	-	-	-	-	-
1868042	0	25	can	MD	-	-	-	-	-	-	-	-
1868042	0	26	be	VB	-	-	-	-	-	-	-	-
1868042	0	27	closed	VBN	-	-	-	-	-	-	-	-
1868042	0	28	by	IN	-	-	-	-	-	-	-	-
1868042	0	29	ATP	NN	-	-	-	-	-	-	-	-
1868042	0	30	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	31	9	CD	-	-	-	-	-	-	-	-
1868042	0	32	,	,	-	-	-	-	-	-	-	-
1868042	0	33	31	CD	-	-	-	-	-	-	-	-
1868042	0	34	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	35	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	2	increases	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	intracellular	JJ	-	-	-	-	-	-	-	-
1868042	0	4	free	JJ	-	-	-	-	-	-	-	-
1868042	0	5	ATP	NN	-	-	-	-	-	-	-	-
1868042	0	6	in	IN	-	-	-	-	-	-	-	-
1868042	0	7	α	NN	-	-	-	-	-	-	-	(1
1868042	0	8	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	9	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	10	8	CD	-	-	-	-	-	-	-	-
1868042	0	11	,	,	-	-	-	-	-	-	-	-
1868042	0	12	10	CD	-	-	-	-	-	-	-	-
1868042	0	13	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	although	IN	-	-	-	-	-	-	-	-
1868042	0	16	reports	NNS	-	-	-	-	-	-	-	-
1868042	0	17	vary	VBP	-	-	-	-	-	-	-	-
1868042	0	18	as	IN	-	-	-	-	-	-	-	-
1868042	0	19	to	IN	-	-	-	-	-	-	-	-
1868042	0	20	the	DT	-	-	-	-	-	-	-	-
1868042	0	21	ability	NN	-	-	-	-	-	-	-	-
1868042	0	22	of	IN	-	-	-	-	-	-	-	-
1868042	0	23	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	24	to	TO	-	-	-	-	-	-	-	-
1868042	0	25	inhibit	VB	-	-	-	-	-	-	-	-
1868042	0	26	α	NN	-	-	-	-	-	-	-	(63
1868042	0	27	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	28	cell	NN	-	-	-	-	-	-	-	-
1868042	0	29	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	30	channels	NNS	-	-	-	-	-	-	-	63)
1868042	0	31	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	32	13	CD	-	-	-	-	-	-	-	-
1868042	0	33	,	,	-	-	-	-	-	-	-	-
1868042	0	34	31	CD	-	-	-	-	-	-	-	-
1868042	0	35	,	,	-	-	-	-	-	-	-	-
1868042	0	36	33	CD	-	-	-	-	-	-	-	-
1868042	0	37	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	38	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Evidence	NN	-	-	-	-	-	-	-	-
1868042	0	2	from	IN	-	-	-	-	-	-	-	-
1868042	0	3	SUR1	NN	-	-	-	-	-	-	-	(64
1868042	0	4	−	SYM	-	-	-	-	-	-	-	-
1868042	0	5	/	HYPH	-	-	-	-	-	-	-	-
1868042	0	6	−	SYM	-	-	-	-	-	-	-	-
1868042	0	7	mice	NNS	-	-	-	-	-	-	-	64)
1868042	0	8	implicate	VBP	-	-	-	-	-	-	-	-
1868042	0	9	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	10	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	11	as	IN	-	-	-	-	-	-	-	-
1868042	0	12	regulators	NNS	-	-	-	-	-	-	-	(65
1868042	0	13	of	IN	-	-	-	-	-	-	-	-
1868042	0	14	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	15	release	NN	-	-	-	-	-	-	-	65)|3)
1868042	0	16	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	17	13	CD	-	-	-	-	-	-	-	-
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	34	CD	-	-	-	-	-	-	-	-
1868042	0	20	,	,	-	-	-	-	-	-	-	-
1868042	0	21	35	CD	-	-	-	-	-	-	-	-
1868042	0	22	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	However	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	because	IN	-	-	-	-	-	-	-	-
1868042	0	4	both	CC	-	-	-	-	-	-	-	(66
1868042	0	5	α	NN	-	-	-	-	-	-	-	(1b)
1868042	0	6	and	CC	-	-	-	-	-	-	-	-
1868042	0	7	β	NN	-	-	-	-	-	-	-	(21
1868042	0	8	cells	NNS	-	-	-	-	-	-	-	(1b)|66)|21)
1868042	0	9	possess	VBP	-	-	-	-	-	-	-	-
1868042	0	10	molecularly	RB	-	-	-	-	-	-	-	-
1868042	0	11	identical	JJ	-	-	-	-	-	-	-	-
1868042	0	12	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	13	channels	NNS	-	-	-	-	-	-	-	-
1868042	0	14	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	15	36	CD	-	-	-	-	-	-	-	-
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	37	CD	-	-	-	-	-	-	-	-
1868042	0	18	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	19	,	,	-	-	-	-	-	-	-	-
1868042	0	20	it	PRP	-	-	-	-	-	-	-	-
1868042	0	21	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	22	not	RB	-	-	-	-	-	-	-	-
1868042	0	23	clear	JJ	-	-	-	-	-	-	-	-
1868042	0	24	how	WRB	-	-	-	-	-	-	-	-
1868042	0	25	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	26	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	27	mediated	VBN	-	-	-	-	-	-	-	-
1868042	0	28	depolarisation	NN	-	-	-	-	-	-	-	-
1868042	0	29	would	MD	-	-	-	-	-	-	-	-
1868042	0	30	stimulate	VB	-	-	-	-	-	-	-	-
1868042	0	31	insulin	NN	-	-	-	-	-	-	-	(27|(19)
1868042	0	32	secretion	NN	-	-	-	-	-	-	-	27)
1868042	0	33	but	CC	-	-	-	-	-	-	-	-
1868042	0	34	suppress	VBP	-	-	-	-	-	-	-	-
1868042	0	35	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	36	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	37	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	answer	NN	-	-	-	-	-	-	-	-
1868042	0	3	may	MD	-	-	-	-	-	-	-	-
1868042	0	4	lie	VB	-	-	-	-	-	-	-	-
1868042	0	5	in	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	downstream	JJ	-	-	-	-	-	-	-	-
1868042	0	8	machinery	NN	-	-	-	-	-	-	-	-
1868042	0	9	regulating	VBG	-	-	-	-	-	-	-	-
1868042	0	10	electrical	JJ	-	-	-	-	-	-	-	(42
1868042	0	11	activity	NN	-	-	-	-	-	-	-	42)
1868042	0	12	and	CC	-	-	-	-	-	-	-	-
1868042	0	13	Ca2+	NN	-	-	-	-	-	-	-	(58|(5)
1868042	0	14	entry	NN	-	-	-	-	-	-	-	58)
1868042	0	15	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Unlike	IN	-	-	-	-	-	-	-	-
1868042	0	2	β	NN	-	-	-	-	-	-	-	(21
1868042	0	3	cells	NNS	-	-	-	-	-	-	-	21)
1868042	0	4	,	,	-	-	-	-	-	-	-	-
1868042	0	5	α	NN	-	-	-	-	-	-	-	(1
1868042	0	6	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	7	possess	VBP	-	-	-	-	-	-	-	-
1868042	0	8	a	DT	-	-	-	-	-	-	-	-
1868042	0	9	large	JJ	-	-	-	-	-	-	-	-
1868042	0	10	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	11	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	13	Na+	NN	-	-	-	-	-	-	-	-
1868042	0	14	current	NN	-	-	-	-	-	-	-	-
1868042	0	15	that	WDT	-	-	-	-	-	-	-	-
1868042	0	16	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	17	essential	JJ	-	-	-	-	-	-	-	-
1868042	0	18	for	IN	-	-	-	-	-	-	-	-
1868042	0	19	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	20	release	NN	-	-	-	-	-	-	-	3)
1868042	0	21	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	22	14	CD	-	-	-	-	-	-	-	-
1868042	0	23	,	,	-	-	-	-	-	-	-	-
1868042	0	24	33	CD	-	-	-	-	-	-	-	-
1868042	0	25	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	26	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	have	VBP	-	-	-	-	-	-	-	-
1868042	0	3	previously	RB	-	-	-	-	-	-	-	-
1868042	0	4	proposed	VBN	-	-	-	-	-	-	-	-
1868042	0	5	that	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	depolarisation	NN	-	-	-	-	-	-	-	-
1868042	0	8	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	induced	VBN	-	-	-	-	-	-	-	-
1868042	0	10	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	11	of	IN	-	-	-	-	-	-	-	-
1868042	0	12	this	DT	-	-	-	-	-	-	-	(32
1868042	0	13	channel	NN	-	-	-	-	-	-	-	32)
1868042	0	14	contributes	VBZ	-	-	-	-	-	-	-	-
1868042	0	15	to	IN	-	-	-	-	-	-	-	-
1868042	0	16	the	DT	-	-	-	-	-	-	-	-
1868042	0	17	cessation	NN	-	-	-	-	-	-	-	-
1868042	0	18	of	IN	-	-	-	-	-	-	-	-
1868042	0	19	action	NN	-	-	-	-	-	-	-	(45|(46
1868042	0	20	potential	NN	-	-	-	-	-	-	-	45)
1868042	0	21	firing	NN	-	-	-	-	-	-	-	46)
1868042	0	22	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	23	14	CD	-	-	-	-	-	-	-	-
1868042	0	24	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	25	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Additionally	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	activation	NN	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	voltage	NN	-	-	-	-	-	-	-	(67
1868042	0	6	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	8	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	9	channels	NNS	-	-	-	-	-	-	-	67)
1868042	0	10	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	11	VDCCs	NNS	-	-	-	-	-	-	-	-
1868042	0	12	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	13	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	14	essential	JJ	-	-	-	-	-	-	-	-
1868042	0	15	for	IN	-	-	-	-	-	-	-	-
1868042	0	16	Ca2+	NN	-	-	-	-	-	-	-	(58|(5)
1868042	0	17	entry	NN	-	-	-	-	-	-	-	58)
1868042	0	18	and	CC	-	-	-	-	-	-	-	-
1868042	0	19	α	NN	-	-	-	-	-	-	-	(1|(68
1868042	0	20	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	21	cell	NN	-	-	-	-	-	-	-	1)
1868042	0	22	function	NN	-	-	-	-	-	-	-	68)
1868042	0	23	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	24	38	CD	-	-	-	-	-	-	-	-
1868042	0	25	,	,	-	-	-	-	-	-	-	-
1868042	0	26	39	CD	-	-	-	-	-	-	-	-
1868042	0	27	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	28	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Accordingly	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	-
1868042	0	4	α	NN	-	-	-	-	-	-	-	(69
1868042	0	5	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	6	cell	NN	-	-	-	-	-	-	-	-
1868042	0	7	intracellular	JJ	-	-	-	-	-	-	-	-
1868042	0	8	Ca2+	NN	-	-	-	-	-	-	-	69)
1868042	0	9	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	10	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	11	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	12	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	13	i	NN	-	-	-	-	-	-	-	-
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	oscillations	NNS	-	-	-	-	-	-	-	-
1868042	0	16	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	17	reflecting	VBG	-	-	-	-	-	-	-	-
1868042	0	18	α	NN	-	-	-	-	-	-	-	(56
1868042	0	19	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	20	cell	NN	-	-	-	-	-	-	-	-
1868042	0	21	electrical	JJ	-	-	-	-	-	-	-	-
1868042	0	22	activity	NN	-	-	-	-	-	-	-	56)
1868042	0	23	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	24	are	VBP	-	-	-	-	-	-	-	-
1868042	0	25	suppressed	VBN	-	-	-	-	-	-	-	-
1868042	0	26	in	IN	-	-	-	-	-	-	-	-
1868042	0	27	parallel	NN	-	-	-	-	-	-	-	-
1868042	0	28	with	IN	-	-	-	-	-	-	-	-
1868042	0	29	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	30	release	NN	-	-	-	-	-	-	-	3)
1868042	0	31	by	IN	-	-	-	-	-	-	-	-
1868042	0	32	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	33	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	34	40	CD	-	-	-	-	-	-	-	-
1868042	0	35	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	36	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Multiple	JJ	-	-	-	-	-	-	-	-
1868042	0	2	VDCCs	NNS	-	-	-	-	-	-	-	-
1868042	0	3	regulate	VBP	-	-	-	-	-	-	-	-
1868042	0	4	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	5	release	NN	-	-	-	-	-	-	-	3)
1868042	0	6	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	7	14	CD	-	-	-	-	-	-	-	-
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	41	CD	-	-	-	-	-	-	-	-
1868042	0	10	–	SYM	-	-	-	-	-	-	-	-
1868042	0	11	43	CD	-	-	-	-	-	-	-	-
1868042	0	12	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	13	,	,	-	-	-	-	-	-	-	-
1868042	0	14	although	IN	-	-	-	-	-	-	-	-
1868042	0	15	the	DT	-	-	-	-	-	-	-	(35
1868042	0	16	N	NN	-	-	-	-	-	-	-	-
1868042	0	17	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	18	type	NN	-	-	-	-	-	-	-	-
1868042	0	19	channels	NNS	-	-	-	-	-	-	-	35)
1868042	0	20	appear	VBP	-	-	-	-	-	-	-	-
1868042	0	21	to	TO	-	-	-	-	-	-	-	-
1868042	0	22	be	VB	-	-	-	-	-	-	-	-
1868042	0	23	particularly	RB	-	-	-	-	-	-	-	-
1868042	0	24	important	JJ	-	-	-	-	-	-	-	-
1868042	0	25	for	IN	-	-	-	-	-	-	-	-
1868042	0	26	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	27	release	NN	-	-	-	-	-	-	-	-
1868042	0	28	evoked	VBN	-	-	-	-	-	-	-	-
1868042	0	29	by	IN	-	-	-	-	-	-	-	-
1868042	0	30	hypoglycaemia	NN	-	-	-	-	-	-	-	(70
1868042	0	31	alone	RB	-	-	-	-	-	-	-	70)
1868042	0	32	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	33	33	CD	-	-	-	-	-	-	-	-
1868042	0	34	,	,	-	-	-	-	-	-	-	-
1868042	0	35	44	CD	-	-	-	-	-	-	-	-
1868042	0	36	,	,	-	-	-	-	-	-	-	-
1868042	0	37	45	CD	-	-	-	-	-	-	-	-
1868042	0	38	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	39	,	,	-	-	-	-	-	-	-	-
1868042	0	40	at	RB	-	-	-	-	-	-	-	-
1868042	0	41	least	RBS	-	-	-	-	-	-	-	-
1868042	0	42	in	IN	-	-	-	-	-	-	-	-
1868042	0	43	mouse	NN	-	-	-	-	-	-	-	(71
1868042	0	44	islets	NNS	-	-	-	-	-	-	-	71)
1868042	0	45	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	in	IN	-	-	-	-	-	-	-	-
1868042	0	4	contrast	NN	-	-	-	-	-	-	-	-
1868042	0	5	to	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	(21
1868042	0	7	β	NN	-	-	-	-	-	-	-	-
1868042	0	8	cell	NN	-	-	-	-	-	-	-	21)
1868042	0	9	in	IN	-	-	-	-	-	-	-	-
1868042	0	10	which	WDT	-	-	-	-	-	-	-	-
1868042	0	11	the	DT	-	-	-	-	-	-	-	(37
1868042	0	12	L	NN	-	-	-	-	-	-	-	-
1868042	0	13	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	14	type	NN	-	-	-	-	-	-	-	-
1868042	0	15	VDCC	NN	-	-	-	-	-	-	-	37)
1868042	0	16	functionally	RB	-	-	-	-	-	-	-	-
1868042	0	17	predominates	VBZ	-	-	-	-	-	-	-	-
1868042	0	18	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	19	46	CD	-	-	-	-	-	-	-	-
1868042	0	20	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	21	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	have	VBP	-	-	-	-	-	-	-	-
1868042	0	3	now	RB	-	-	-	-	-	-	-	-
1868042	0	4	compared	VBN	-	-	-	-	-	-	-	-
1868042	0	5	insulin	NN	-	-	-	-	-	-	-	(24|(72|(19)|(20a)
1868042	0	6	and	CC	-	-	-	-	-	-	-	-
1868042	0	7	glucagon	NN	-	-	-	-	-	-	-	(3|(2)|24)
1868042	0	8	release	NN	-	-	-	-	-	-	-	(20a)|72)|3)
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	α	NN	-	-	-	-	-	-	-	(7c
1868042	0	11	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	and	CC	-	-	-	-	-	-	-	7c)
1868042	0	13	β	NN	-	-	-	-	-	-	-	(6a
1868042	0	14	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	15	cell	NN	-	-	-	-	-	-	-	(7c
1868042	0	16	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	17	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	18	in	IN	-	-	-	-	-	-	-	-
1868042	0	19	intact	JJ	-	-	-	-	-	-	-	(73a|(12b)|7c)|6a)
1868042	0	20	mouse	NN	-	-	-	-	-	-	-	73a)
1868042	0	21	,	,	-	-	-	-	-	-	-	-
1868042	0	22	rat	NN	-	-	-	-	-	-	-	-
1868042	0	23	,	,	-	-	-	-	-	-	-	-
1868042	0	24	and	CC	-	-	-	-	-	-	-	-
1868042	0	25	human	JJ	-	-	-	-	-	-	-	(12b|(6a|(7c
1868042	0	26	pancreatic	JJ	-	-	-	-	-	-	-	(73a
1868042	0	27	islets	NNS	-	-	-	-	-	-	-	7c)|73a)|6a)|12b)
1868042	0	28	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	show	VBP	-	-	-	-	-	-	-	-
1868042	0	3	that	IN	-	-	-	-	-	-	-	-
1868042	0	4	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	5	retained	VBD	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	ability	NN	-	-	-	-	-	-	-	-
1868042	0	8	to	TO	-	-	-	-	-	-	-	-
1868042	0	9	suppress	VB	-	-	-	-	-	-	-	-
1868042	0	10	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	11	release	NN	-	-	-	-	-	-	-	-
1868042	0	12	from	IN	-	-	-	-	-	-	-	-
1868042	0	13	isolated	VBN	-	-	-	-	-	-	-	(74
1868042	0	14	islets	NNS	-	-	-	-	-	-	-	74)
1868042	0	15	during	IN	-	-	-	-	-	-	-	-
1868042	0	16	blockade	NN	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	the	DT	-	-	-	-	-	-	-	-
1868042	0	19	Zn2+	NN	-	-	-	-	-	-	-	-
1868042	0	20	and	CC	-	-	-	-	-	-	-	-
1868042	0	21	GABA	NN	-	-	-	-	-	-	-	-
1868042	0	22	paracrine	JJ	-	-	-	-	-	-	-	-
1868042	0	23	pathways	NNS	-	-	-	-	-	-	-	-
1868042	0	24	,	,	-	-	-	-	-	-	-	-
1868042	0	25	and	CC	-	-	-	-	-	-	-	-
1868042	0	26	in	IN	-	-	-	-	-	-	-	-
1868042	0	27	the	DT	-	-	-	-	-	-	-	-
1868042	0	28	absence	NN	-	-	-	-	-	-	-	-
1868042	0	29	of	IN	-	-	-	-	-	-	-	-
1868042	0	30	stimulated	VBN	-	-	-	-	-	-	-	-
1868042	0	31	insulin	NN	-	-	-	-	-	-	-	-
1868042	0	32	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	33	or	CC	-	-	-	-	-	-	-	-
1868042	0	34	β	NN	-	-	-	-	-	-	-	(29
1868042	0	35	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	36	cell	NN	-	-	-	-	-	-	-	-
1868042	0	37	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	38	responses	NNS	-	-	-	-	-	-	-	29)
1868042	0	39	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Thus	RB	-	-	-	-	-	-	-	-
1868042	0	2	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	3	now	RB	-	-	-	-	-	-	-	-
1868042	0	4	provide	VBP	-	-	-	-	-	-	-	-
1868042	0	5	evidence	NN	-	-	-	-	-	-	-	-
1868042	0	6	in	IN	-	-	-	-	-	-	-	-
1868042	0	7	both	CC	-	-	-	-	-	-	-	-
1868042	0	8	rodent	NN	-	-	-	-	-	-	-	(60)
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	human	JJ	-	-	-	-	-	-	-	-
1868042	0	11	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	12	supporting	VBG	-	-	-	-	-	-	-	-
1868042	0	13	the	DT	-	-	-	-	-	-	-	-
1868042	0	14	direct	JJ	-	-	-	-	-	-	-	-
1868042	0	15	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	16	intrinsic	JJ	-	-	-	-	-	-	-	-
1868042	0	17	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	18	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	19	regulation	NN	-	-	-	-	-	-	-	-
1868042	0	20	of	IN	-	-	-	-	-	-	-	-
1868042	0	21	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	22	release	NN	-	-	-	-	-	-	-	-
1868042	0	23	from	IN	-	-	-	-	-	-	-	-
1868042	0	24	pancreatic	JJ	-	-	-	-	-	-	-	(1
1868042	0	25	α	NN	-	-	-	-	-	-	-	-
1868042	0	26	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	27	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Results	NNS	-	-	-	-	-	-	-	-

1868042	0	1	Glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	2	Can	MD	-	-	-	-	-	-	-	-
1868042	0	3	Regulate	VB	-	-	-	-	-	-	-	-
1868042	0	4	Glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	5	Secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	6	Directly	RB	-	-	-	-	-	-	-	-

1868042	0	1	To	TO	-	-	-	-	-	-	-	-
1868042	0	2	examine	VB	-	-	-	-	-	-	-	-
1868042	0	3	a	DT	-	-	-	-	-	-	-	-
1868042	0	4	role	NN	-	-	-	-	-	-	-	-
1868042	0	5	for	IN	-	-	-	-	-	-	-	-
1868042	0	6	GABA	NN	-	-	-	-	-	-	-	(15)
1868042	0	7	and	CC	-	-	-	-	-	-	-	-
1868042	0	8	Zn2+	NN	-	-	-	-	-	-	-	(16)
1868042	0	9	as	IN	-	-	-	-	-	-	-	-
1868042	0	10	paracrine	JJ	-	-	-	-	-	-	-	-
1868042	0	11	mediators	NNS	-	-	-	-	-	-	-	-
1868042	0	12	of	IN	-	-	-	-	-	-	-	-
1868042	0	13	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	14	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	15	,	,	-	-	-	-	-	-	-	-
1868042	0	16	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	17	examined	VBD	-	-	-	-	-	-	-	-
1868042	0	18	the	DT	-	-	-	-	-	-	-	-
1868042	0	19	ability	NN	-	-	-	-	-	-	-	-
1868042	0	20	of	IN	-	-	-	-	-	-	-	-
1868042	0	21	the	DT	-	-	-	-	-	-	-	(75
1868042	0	22	GABAA	NN	-	-	-	-	-	-	-	-
1868042	0	23	receptor	NN	-	-	-	-	-	-	-	-
1868042	0	24	antagonist	NN	-	-	-	-	-	-	-	-
1868042	0	25	SR	NN	-	-	-	-	-	-	-	-
1868042	0	26	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	27	95531	CD	-	-	-	-	-	-	-	75)
1868042	0	28	and	CC	-	-	-	-	-	-	-	-
1868042	0	29	Zn2+	NN	-	-	-	-	-	-	-	(76|(16)
1868042	0	30	chelation	NN	-	-	-	-	-	-	-	-
1868042	0	31	with	IN	-	-	-	-	-	-	-	-
1868042	0	32	Ca2+	NN	-	-	-	-	-	-	-	(77
1868042	0	33	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	34	EDTA	NN	-	-	-	-	-	-	-	77)|76)
1868042	0	35	to	TO	-	-	-	-	-	-	-	-
1868042	0	36	prevent	VB	-	-	-	-	-	-	-	-
1868042	0	37	the	DT	-	-	-	-	-	-	-	-
1868042	0	38	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	39	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	40	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	41	suppression	NN	-	-	-	-	-	-	-	-
1868042	0	42	of	IN	-	-	-	-	-	-	-	-
1868042	0	43	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	44	release	NN	-	-	-	-	-	-	-	3)
1868042	0	45	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	at	IN	-	-	-	-	-	-	-	-
1868042	0	4	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	5	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	6	7	CD	-	-	-	-	-	-	-	(78a)
1868042	0	7	and	CC	-	-	-	-	-	-	-	-
1868042	0	8	8.3	CD	-	-	-	-	-	-	-	(79
1868042	0	9	mM	NN	-	-	-	-	-	-	-	(78a)|79)
1868042	0	10	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	11	just	RB	-	-	-	-	-	-	-	-
1868042	0	12	above	IN	-	-	-	-	-	-	-	-
1868042	0	13	the	DT	-	-	-	-	-	-	-	-
1868042	0	14	threshold	NN	-	-	-	-	-	-	-	-
1868042	0	15	for	IN	-	-	-	-	-	-	-	-
1868042	0	16	insulin	NN	-	-	-	-	-	-	-	(20|(19)
1868042	0	17	release	NN	-	-	-	-	-	-	-	20)
1868042	0	18	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	19	see	VB	-	-	-	-	-	-	-	-
1868042	0	20	below	RB	-	-	-	-	-	-	-	-
1868042	0	21	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	22	,	,	-	-	-	-	-	-	-	-
1868042	0	23	suppressed	VBN	-	-	-	-	-	-	-	-
1868042	0	24	glucagon	NN	-	-	-	-	-	-	-	-
1868042	0	25	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	26	from	IN	-	-	-	-	-	-	-	-
1868042	0	27	isolated	VBN	-	-	-	-	-	-	-	(80a
1868042	0	28	mouse	NN	-	-	-	-	-	-	-	80a)
1868042	0	29	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	30	Figure	NN	-	-	-	-	-	-	-	(82|(81)
1868042	0	31	1A	NN	-	-	-	-	-	-	-	82)
1868042	0	32	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	33	and	CC	-	-	-	-	-	-	-	-
1868042	0	34	rat	NN	-	-	-	-	-	-	-	-
1868042	0	35	islets	NNS	-	-	-	-	-	-	-	(80a)
1868042	0	36	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	37	Figure	NN	-	-	-	-	-	-	-	(83|(81)
1868042	0	38	1B	NN	-	-	-	-	-	-	-	83)
1868042	0	39	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	40	by	IN	-	-	-	-	-	-	-	-
1868042	0	41	60	CD	-	-	-	-	-	-	-	-
1868042	0	42	%	NN	-	-	-	-	-	-	-	-
1868042	0	43	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	44	n	NN	-	-	-	-	-	-	-	-
1868042	0	45	=	SYM	-	-	-	-	-	-	-	-
1868042	0	46	15	CD	-	-	-	-	-	-	-	-
1868042	0	47	,	,	-	-	-	-	-	-	-	-
1868042	0	48	p	NN	-	-	-	-	-	-	-	-
1868042	0	49	<	SYM	-	-	-	-	-	-	-	-
1868042	0	50	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	51	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	52	and	CC	-	-	-	-	-	-	-	-
1868042	0	53	57	CD	-	-	-	-	-	-	-	-
1868042	0	54	%	NN	-	-	-	-	-	-	-	-
1868042	0	55	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	56	n	NN	-	-	-	-	-	-	-	-
1868042	0	57	=	SYM	-	-	-	-	-	-	-	-
1868042	0	58	10	CD	-	-	-	-	-	-	-	-
1868042	0	59	,	,	-	-	-	-	-	-	-	-
1868042	0	60	p	NN	-	-	-	-	-	-	-	-
1868042	0	61	<	SYM	-	-	-	-	-	-	-	-
1868042	0	62	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	63	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	64	,	,	-	-	-	-	-	-	-	-
1868042	0	65	respectively	RB	-	-	-	-	-	-	-	-
1868042	0	66	.	.	-	-	-	-	-	-	-	-

1868042	0	1	In	IN	-	-	-	-	-	-	-	-
1868042	0	2	both	CC	-	-	-	-	-	-	-	(84
1868042	0	3	mouse	NN	-	-	-	-	-	-	-	(71b)
1868042	0	4	and	CC	-	-	-	-	-	-	-	-
1868042	0	5	rat	NN	-	-	-	-	-	-	-	(85
1868042	0	6	islets	NNS	-	-	-	-	-	-	-	(71b)|85)|84)
1868042	0	7	,	,	-	-	-	-	-	-	-	-
1868042	0	8	the	DT	-	-	-	-	-	-	-	-
1868042	0	9	ability	NN	-	-	-	-	-	-	-	-
1868042	0	10	of	IN	-	-	-	-	-	-	-	-
1868042	0	11	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	12	to	TO	-	-	-	-	-	-	-	-
1868042	0	13	inhibit	VB	-	-	-	-	-	-	-	-
1868042	0	14	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	15	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	16	persisted	VBD	-	-	-	-	-	-	-	-
1868042	0	17	in	IN	-	-	-	-	-	-	-	-
1868042	0	18	the	DT	-	-	-	-	-	-	-	-
1868042	0	19	presence	NN	-	-	-	-	-	-	-	-
1868042	0	20	of	IN	-	-	-	-	-	-	-	-
1868042	0	21	Ca2+	NN	-	-	-	-	-	-	-	(77
1868042	0	22	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	23	EDTA	NN	-	-	-	-	-	-	-	77)
1868042	0	24	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	25	43	CD	-	-	-	-	-	-	-	-
1868042	0	26	%	NN	-	-	-	-	-	-	-	-
1868042	0	27	and	CC	-	-	-	-	-	-	-	-
1868042	0	28	48	CD	-	-	-	-	-	-	-	-
1868042	0	29	%	NN	-	-	-	-	-	-	-	-
1868042	0	30	,	,	-	-	-	-	-	-	-	-
1868042	0	31	n	NN	-	-	-	-	-	-	-	-
1868042	0	32	=	SYM	-	-	-	-	-	-	-	-
1868042	0	33	10	CD	-	-	-	-	-	-	-	-
1868042	0	34	,	,	-	-	-	-	-	-	-	-
1868042	0	35	p	NN	-	-	-	-	-	-	-	-
1868042	0	36	<	SYM	-	-	-	-	-	-	-	-
1868042	0	37	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	38	,	,	-	-	-	-	-	-	-	-
1868042	0	39	respectively	RB	-	-	-	-	-	-	-	-
1868042	0	40	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	41	and	CC	-	-	-	-	-	-	-	-
1868042	0	42	SR	NN	-	-	-	-	-	-	-	(75
1868042	0	43	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	44	95531	CD	-	-	-	-	-	-	-	75)
1868042	0	45	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	46	31	CD	-	-	-	-	-	-	-	-
1868042	0	47	%	NN	-	-	-	-	-	-	-	-
1868042	0	48	and	CC	-	-	-	-	-	-	-	-
1868042	0	49	46	CD	-	-	-	-	-	-	-	-
1868042	0	50	%	NN	-	-	-	-	-	-	-	-
1868042	0	51	,	,	-	-	-	-	-	-	-	-
1868042	0	52	n	NN	-	-	-	-	-	-	-	-
1868042	0	53	=	SYM	-	-	-	-	-	-	-	-
1868042	0	54	8	CD	-	-	-	-	-	-	-	-
1868042	0	55	and	CC	-	-	-	-	-	-	-	-
1868042	0	56	10	CD	-	-	-	-	-	-	-	-
1868042	0	57	,	,	-	-	-	-	-	-	-	-
1868042	0	58	p	NN	-	-	-	-	-	-	-	-
1868042	0	59	<	SYM	-	-	-	-	-	-	-	-
1868042	0	60	0.01	CD	-	-	-	-	-	-	-	-
1868042	0	61	and	CC	-	-	-	-	-	-	-	-
1868042	0	62	p	NN	-	-	-	-	-	-	-	-
1868042	0	63	<	SYM	-	-	-	-	-	-	-	-
1868042	0	64	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	65	,	,	-	-	-	-	-	-	-	-
1868042	0	66	respectively	RB	-	-	-	-	-	-	-	-
1868042	0	67	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	68	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	69	Figure	NN	-	-	-	-	-	-	-	(86|(81)
1868042	0	70	1	CD	-	-	-	-	-	-	-	86)
1868042	0	71	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	72	.	.	-	-	-	-	-	-	-	-

1868042	0	1	It	PRP	-	-	-	-	-	-	-	-
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	worth	JJ	-	-	-	-	-	-	-	-
1868042	0	4	noting	VBG	-	-	-	-	-	-	-	-
1868042	0	5	that	IN	-	-	-	-	-	-	-	-
1868042	0	6	in	IN	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	-
1868042	0	8	presence	NN	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	(75
1868042	0	11	GABAA	NN	-	-	-	-	-	-	-	-
1868042	0	12	antagonist	NN	-	-	-	-	-	-	-	75)
1868042	0	13	,	,	-	-	-	-	-	-	-	-
1868042	0	14	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	15	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	16	was	VBD	-	-	-	-	-	-	-	-
1868042	0	17	increased	VBN	-	-	-	-	-	-	-	-
1868042	0	18	under	IN	-	-	-	-	-	-	-	-
1868042	0	19	both	CC	-	-	-	-	-	-	-	-
1868042	0	20	low	JJ	-	-	-	-	-	-	-	(59b
1868042	0	21	-	HYPH	-	-	-	-	-	-	-	59b)
1868042	0	22	and	CC	-	-	-	-	-	-	-	-
1868042	0	23	high	JJ	-	-	-	-	-	-	-	(87
1868042	0	24	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	25	glucose	NN	-	-	-	-	-	-	-	(59b
1868042	0	26	conditions	NNS	-	-	-	-	-	-	-	87)|59b)
1868042	0	27	,	,	-	-	-	-	-	-	-	-
1868042	0	28	and	CC	-	-	-	-	-	-	-	-
1868042	0	29	furthermore	RB	-	-	-	-	-	-	-	-
1868042	0	30	,	,	-	-	-	-	-	-	-	-
1868042	0	31	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	32	was	VBD	-	-	-	-	-	-	-	-
1868042	0	33	approximately	RB	-	-	-	-	-	-	-	-
1868042	0	34	50	CD	-	-	-	-	-	-	-	-
1868042	0	35	%	NN	-	-	-	-	-	-	-	-
1868042	0	36	less	RBR	-	-	-	-	-	-	-	-
1868042	0	37	effective	JJ	-	-	-	-	-	-	-	-
1868042	0	38	in	IN	-	-	-	-	-	-	-	-
1868042	0	39	suppressing	VBG	-	-	-	-	-	-	-	-
1868042	0	40	glucagon	NN	-	-	-	-	-	-	-	(88|(2)
1868042	0	41	release	NN	-	-	-	-	-	-	-	-
1868042	0	42	from	IN	-	-	-	-	-	-	-	-
1868042	0	43	mouse	NN	-	-	-	-	-	-	-	(71
1868042	0	44	islets	NNS	-	-	-	-	-	-	-	88)|71)
1868042	0	45	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	46	31	CD	-	-	-	-	-	-	-	-
1868042	0	47	%	NN	-	-	-	-	-	-	-	-
1868042	0	48	versus	CC	-	-	-	-	-	-	-	-
1868042	0	49	60	CD	-	-	-	-	-	-	-	-
1868042	0	50	%	NN	-	-	-	-	-	-	-	-
1868042	0	51	,	,	-	-	-	-	-	-	-	-
1868042	0	52	respectively	RB	-	-	-	-	-	-	-	-
1868042	0	53	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	54	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	55	Figure	NN	-	-	-	-	-	-	-	(82|(81)
1868042	0	56	1A	NN	-	-	-	-	-	-	-	82)
1868042	0	57	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	58	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Additionally	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	somatostatin	NN	-	-	-	-	-	-	-	-
1868042	0	4	released	VBN	-	-	-	-	-	-	-	-
1868042	0	5	from	IN	-	-	-	-	-	-	-	-
1868042	0	6	pancreatic	JJ	-	-	-	-	-	-	-	-
1868042	0	7	δ	NN	-	-	-	-	-	-	-	-
1868042	0	8	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	9	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	10	suggested	VBN	-	-	-	-	-	-	-	-
1868042	0	11	to	TO	-	-	-	-	-	-	-	-
1868042	0	12	be	VB	-	-	-	-	-	-	-	-
1868042	0	13	a	DT	-	-	-	-	-	-	-	-
1868042	0	14	potential	JJ	-	-	-	-	-	-	-	-
1868042	0	15	paracrine	JJ	-	-	-	-	-	-	-	-
1868042	0	16	regulator	NN	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	19	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	20	.	.	-	-	-	-	-	-	-	-

1868042	0	1	However	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	(89
1868042	0	4	somatostatin	NN	-	-	-	-	-	-	-	-
1868042	0	5	receptor	NN	-	-	-	-	-	-	-	-
1868042	0	6	2	CD	-	-	-	-	-	-	-	-
1868042	0	7	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	8	SSTR	NN	-	-	-	-	-	-	-	-
1868042	0	9	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	2	CD	-	-	-	-	-	-	-	-
1868042	0	11	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	12	antagonist	NN	-	-	-	-	-	-	-	-
1868042	0	13	PRL	NN	-	-	-	-	-	-	-	-
1868042	0	14	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	15	2903	CD	-	-	-	-	-	-	-	89)
1868042	0	16	does	VBZ	-	-	-	-	-	-	-	-
1868042	0	17	not	RB	-	-	-	-	-	-	-	-
1868042	0	18	interfere	VB	-	-	-	-	-	-	-	-
1868042	0	19	with	IN	-	-	-	-	-	-	-	-
1868042	0	20	the	DT	-	-	-	-	-	-	-	-
1868042	0	21	ability	NN	-	-	-	-	-	-	-	-
1868042	0	22	of	IN	-	-	-	-	-	-	-	-
1868042	0	23	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	24	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	25	at	IN	-	-	-	-	-	-	-	-
1868042	0	26	3	CD	-	-	-	-	-	-	-	-
1868042	0	27	and	CC	-	-	-	-	-	-	-	-
1868042	0	28	7	CD	-	-	-	-	-	-	-	-
1868042	0	29	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	30	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	31	to	TO	-	-	-	-	-	-	-	-
1868042	0	32	inhibit	VB	-	-	-	-	-	-	-	-
1868042	0	33	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	34	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	35	from	IN	-	-	-	-	-	-	-	-
1868042	0	36	mouse	NN	-	-	-	-	-	-	-	(71
1868042	0	37	islets	NNS	-	-	-	-	-	-	-	71)
1868042	0	38	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	39	47	CD	-	-	-	-	-	-	-	-
1868042	0	40	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	41	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Like	IN	-	-	-	-	-	-	-	-
1868042	0	2	the	DT	-	-	-	-	-	-	-	(75
1868042	0	3	GABAA	NN	-	-	-	-	-	-	-	(90
1868042	0	4	receptor	NN	-	-	-	-	-	-	-	90)
1868042	0	5	antagonist	NN	-	-	-	-	-	-	-	75)
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	however	RB	-	-	-	-	-	-	-	-
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	PRL	NN	-	-	-	-	-	-	-	(89
1868042	0	10	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	11	2903	CD	-	-	-	-	-	-	-	89)
1868042	0	12	increased	VBD	-	-	-	-	-	-	-	-
1868042	0	13	glucagon	NN	-	-	-	-	-	-	-	(25
1868042	0	14	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	15	in	IN	-	-	-	-	-	-	-	-
1868042	0	16	low	JJ	-	-	-	-	-	-	-	(59
1868042	0	17	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	18	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	19	conditions	NNS	-	-	-	-	-	-	-	59)
1868042	0	20	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	21	47	CD	-	-	-	-	-	-	-	-
1868042	0	22	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Thus	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	although	IN	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	present	JJ	-	-	-	-	-	-	-	-
1868042	0	6	data	NNS	-	-	-	-	-	-	-	-
1868042	0	7	do	VBP	-	-	-	-	-	-	-	-
1868042	0	8	not	RB	-	-	-	-	-	-	-	-
1868042	0	9	entirely	RB	-	-	-	-	-	-	-	-
1868042	0	10	rule	VB	-	-	-	-	-	-	-	-
1868042	0	11	out	RP	-	-	-	-	-	-	-	-
1868042	0	12	these	DT	-	-	-	-	-	-	-	(91
1868042	0	13	pathways	NNS	-	-	-	-	-	-	-	91)
1868042	0	14	as	IN	-	-	-	-	-	-	-	-
1868042	0	15	modulators	NNS	-	-	-	-	-	-	-	-
1868042	0	16	of	IN	-	-	-	-	-	-	-	-
1868042	0	17	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	18	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	19	,	,	-	-	-	-	-	-	-	-
1868042	0	20	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	21	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	22	clearly	RB	-	-	-	-	-	-	-	-
1868042	0	23	able	JJ	-	-	-	-	-	-	-	-
1868042	0	24	to	TO	-	-	-	-	-	-	-	-
1868042	0	25	suppress	VB	-	-	-	-	-	-	-	-
1868042	0	26	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	27	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	28	independently	RB	-	-	-	-	-	-	-	-
1868042	0	29	of	IN	-	-	-	-	-	-	-	-
1868042	0	30	these	DT	-	-	-	-	-	-	-	(91)
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	α	NN	-	-	-	-	-	-	-	(63
1868042	0	2	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	3	Cell	NN	-	-	-	-	-	-	-	-
1868042	0	4	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	5	Channels	NNS	-	-	-	-	-	-	-	63)
1868042	0	6	Regulate	VBP	-	-	-	-	-	-	-	-
1868042	0	7	Glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	8	Secretion	NN	-	-	-	-	-	-	-	25)

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	next	RB	-	-	-	-	-	-	-	-
1868042	0	3	examined	VBD	-	-	-	-	-	-	-	-
1868042	0	4	glucagon	NN	-	-	-	-	-	-	-	(24|(2)
1868042	0	5	and	CC	-	-	-	-	-	-	-	-
1868042	0	6	insulin	NN	-	-	-	-	-	-	-	(19)|24)
1868042	0	7	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	8	during	IN	-	-	-	-	-	-	-	-
1868042	0	9	pharmacological	JJ	-	-	-	-	-	-	-	-
1868042	0	10	manipulation	NN	-	-	-	-	-	-	-	-
1868042	0	11	of	IN	-	-	-	-	-	-	-	-
1868042	0	12	KATP	NN	-	-	-	-	-	-	-	(32|(92
1868042	0	13	channel	NN	-	-	-	-	-	-	-	32)
1868042	0	14	activity	NN	-	-	-	-	-	-	-	92)
1868042	0	15	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Here	RB	-	-	-	-	-	-	-	-
1868042	0	2	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	3	have	VBP	-	-	-	-	-	-	-	-
1868042	0	4	examined	VBN	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	-
1868042	0	6	role	NN	-	-	-	-	-	-	-	-
1868042	0	7	of	IN	-	-	-	-	-	-	-	-
1868042	0	8	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	9	channels	NNS	-	-	-	-	-	-	-	-
1868042	0	10	in	IN	-	-	-	-	-	-	-	-
1868042	0	11	intact	JJ	-	-	-	-	-	-	-	(93
1868042	0	12	islets	NNS	-	-	-	-	-	-	-	93)
1868042	0	13	by	IN	-	-	-	-	-	-	-	-
1868042	0	14	applying	VBG	-	-	-	-	-	-	-	-
1868042	0	15	an	DT	-	-	-	-	-	-	-	-
1868042	0	16	indirect	JJ	-	-	-	-	-	-	-	-
1868042	0	17	,	,	-	-	-	-	-	-	-	-
1868042	0	18	but	CC	-	-	-	-	-	-	-	-
1868042	0	19	minimally	RB	-	-	-	-	-	-	-	-
1868042	0	20	invasive	JJ	-	-	-	-	-	-	-	-
1868042	0	21	,	,	-	-	-	-	-	-	-	-
1868042	0	22	technique	NN	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	It	PRP	-	-	-	-	-	-	-	-
1868042	0	2	would	MD	-	-	-	-	-	-	-	-
1868042	0	3	have	VB	-	-	-	-	-	-	-	-
1868042	0	4	been	VBN	-	-	-	-	-	-	-	-
1868042	0	5	difficult	JJ	-	-	-	-	-	-	-	-
1868042	0	6	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	7	if	IN	-	-	-	-	-	-	-	-
1868042	0	8	not	RB	-	-	-	-	-	-	-	-
1868042	0	9	impossible	JJ	-	-	-	-	-	-	-	-
1868042	0	10	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	11	to	TO	-	-	-	-	-	-	-	-
1868042	0	12	study	VB	-	-	-	-	-	-	-	-
1868042	0	13	the	DT	-	-	-	-	-	-	-	(94
1868042	0	14	effects	NNS	-	-	-	-	-	-	-	-
1868042	0	15	of	IN	-	-	-	-	-	-	-	-
1868042	0	16	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	17	on	IN	-	-	-	-	-	-	-	-
1868042	0	18	α	NN	-	-	-	-	-	-	-	(63|(95
1868042	0	19	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	20	cell	NN	-	-	-	-	-	-	-	-
1868042	0	21	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	22	channel	NN	-	-	-	-	-	-	-	63)
1868042	0	23	activity	NN	-	-	-	-	-	-	-	95)|94)
1868042	0	24	using	VBG	-	-	-	-	-	-	-	-
1868042	0	25	the	DT	-	-	-	-	-	-	-	-
1868042	0	26	patch	NN	-	-	-	-	-	-	-	-
1868042	0	27	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	28	clamp	NN	-	-	-	-	-	-	-	-
1868042	0	29	technique	NN	-	-	-	-	-	-	-	-
1868042	0	30	because	IN	-	-	-	-	-	-	-	-
1868042	0	31	of	IN	-	-	-	-	-	-	-	-
1868042	0	32	the	DT	-	-	-	-	-	-	-	-
1868042	0	33	smallness	NN	-	-	-	-	-	-	-	-
1868042	0	34	of	IN	-	-	-	-	-	-	-	-
1868042	0	35	the	DT	-	-	-	-	-	-	-	-
1868042	0	36	α	NN	-	-	-	-	-	-	-	-
1868042	0	37	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	38	cell	NN	-	-	-	-	-	-	-	-
1868042	0	39	resting	NN	-	-	-	-	-	-	-	-
1868042	0	40	conductance	NN	-	-	-	-	-	-	-	-
1868042	0	41	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	42	0.15	CD	-	-	-	-	-	-	-	-
1868042	0	43	nS	NNS	-	-	-	-	-	-	-	-
1868042	0	44	/	SYM	-	-	-	-	-	-	-	-
1868042	0	45	pF	NN	-	-	-	-	-	-	-	-
1868042	0	46	in	IN	-	-	-	-	-	-	-	-
1868042	0	47	the	DT	-	-	-	-	-	-	-	(30
1868042	0	48	absence	NN	-	-	-	-	-	-	-	-
1868042	0	49	of	IN	-	-	-	-	-	-	-	-
1868042	0	50	glucose	NN	-	-	-	-	-	-	-	(31)|30)
1868042	0	51	,	,	-	-	-	-	-	-	-	-
1868042	0	52	of	IN	-	-	-	-	-	-	-	-
1868042	0	53	which	WDT	-	-	-	-	-	-	-	-
1868042	0	54	two	CD	-	-	-	-	-	-	-	-
1868042	0	55	thirds	NNS	-	-	-	-	-	-	-	-
1868042	0	56	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	57	attributable	JJ	-	-	-	-	-	-	-	-
1868042	0	58	to	IN	-	-	-	-	-	-	-	-
1868042	0	59	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	60	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	61	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	62	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	63	13	CD	-	-	-	-	-	-	-	-
1868042	0	64	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	65	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	have	VBP	-	-	-	-	-	-	-	-
1868042	0	3	instead	RB	-	-	-	-	-	-	-	-
1868042	0	4	used	VBN	-	-	-	-	-	-	-	-
1868042	0	5	increasing	VBG	-	-	-	-	-	-	-	(96
1868042	0	6	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	7	of	IN	-	-	-	-	-	-	-	-
1868042	0	8	diazoxide	NN	-	-	-	-	-	-	-	(97|(18)|96)
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	tolbutamide	NN	-	-	-	-	-	-	-	(23)|97)
1868042	0	11	to	TO	-	-	-	-	-	-	-	-
1868042	0	12	“	``	-	-	-	-	-	-	-	-
1868042	0	13	titrate	VB	-	-	-	-	-	-	-	-
1868042	0	14	”	''	-	-	-	-	-	-	-	-
1868042	0	15	the	DT	-	-	-	-	-	-	-	-
1868042	0	16	influence	NN	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	19	channel	NN	-	-	-	-	-	-	-	32)
1868042	0	20	activity	NN	-	-	-	-	-	-	-	-
1868042	0	21	on	IN	-	-	-	-	-	-	-	-
1868042	0	22	α	NN	-	-	-	-	-	-	-	(69
1868042	0	23	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	24	cell	NN	-	-	-	-	-	-	-	-
1868042	0	25	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	26	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	27	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	28	i	NN	-	-	-	-	-	-	-	69)
1868042	0	29	and	CC	-	-	-	-	-	-	-	-
1868042	0	30	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	31	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	32	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Increasing	VBG	-	-	-	-	-	-	-	(96
1868042	0	2	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	3	of	IN	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	(18
1868042	0	5	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	6	channel	NN	-	-	-	-	-	-	-	-
1868042	0	7	activator	NN	-	-	-	-	-	-	-	-
1868042	0	8	diazoxide	NN	-	-	-	-	-	-	-	96)|18)
1868042	0	9	demonstrated	VBD	-	-	-	-	-	-	-	-
1868042	0	10	that	IN	-	-	-	-	-	-	-	-
1868042	0	11	moderate	JJ	-	-	-	-	-	-	-	-
1868042	0	12	activation	NN	-	-	-	-	-	-	-	-
1868042	0	13	of	IN	-	-	-	-	-	-	-	-
1868042	0	14	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	15	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	16	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	17	0.3	CD	-	-	-	-	-	-	-	-
1868042	0	18	–	SYM	-	-	-	-	-	-	-	-
1868042	0	19	10	CD	-	-	-	-	-	-	-	-
1868042	0	20	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	21	diazoxide	NN	-	-	-	-	-	-	-	-
1868042	0	22	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	relieved	VBD	-	-	-	-	-	-	-	-
1868042	0	24	the	DT	-	-	-	-	-	-	-	-
1868042	0	25	suppression	NN	-	-	-	-	-	-	-	-
1868042	0	26	of	IN	-	-	-	-	-	-	-	-
1868042	0	27	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	28	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	29	from	IN	-	-	-	-	-	-	-	-
1868042	0	30	both	CC	-	-	-	-	-	-	-	(84a
1868042	0	31	mouse	NN	-	-	-	-	-	-	-	(71a)|84a)
1868042	0	32	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	33	Figure	NN	-	-	-	-	-	-	-	(98|(81)
1868042	0	34	2A	NN	-	-	-	-	-	-	-	98)
1868042	0	35	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	36	and	CC	-	-	-	-	-	-	-	(84a
1868042	0	37	rat	NN	-	-	-	-	-	-	-	(85a)|84a)
1868042	0	38	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	39	Figure	NN	-	-	-	-	-	-	-	(99|(81)
1868042	0	40	2B	NN	-	-	-	-	-	-	-	99)
1868042	0	41	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	42	islets	NNS	-	-	-	-	-	-	-	(71a)|(84a)|(85a)
1868042	0	43	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Stimulation	NN	-	-	-	-	-	-	-	-
1868042	0	2	of	IN	-	-	-	-	-	-	-	-
1868042	0	3	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	4	release	NN	-	-	-	-	-	-	-	3)
1868042	0	5	was	VBD	-	-	-	-	-	-	-	-
1868042	0	6	half	RB	-	-	-	-	-	-	-	-
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	9	at	IN	-	-	-	-	-	-	-	-
1868042	0	10	approximately	RB	-	-	-	-	-	-	-	-
1868042	0	11	1	CD	-	-	-	-	-	-	-	-
1868042	0	12	μM	NN	-	-	-	-	-	-	-	-
1868042	0	13	diazoxide	NN	-	-	-	-	-	-	-	-
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	which	WDT	-	-	-	-	-	-	-	-
1868042	0	16	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	17	well	RB	-	-	-	-	-	-	-	-
1868042	0	18	below	IN	-	-	-	-	-	-	-	-
1868042	0	19	that	DT	-	-	-	-	-	-	-	-
1868042	0	20	required	VBN	-	-	-	-	-	-	-	-
1868042	0	21	to	TO	-	-	-	-	-	-	-	-
1868042	0	22	inhibit	VB	-	-	-	-	-	-	-	-
1868042	0	23	insulin	NN	-	-	-	-	-	-	-	(20|(19)
1868042	0	24	release	NN	-	-	-	-	-	-	-	20)
1868042	0	25	,	,	-	-	-	-	-	-	-	-
1868042	0	26	suggesting	VBG	-	-	-	-	-	-	-	-
1868042	0	27	that	IN	-	-	-	-	-	-	-	-
1868042	0	28	“	``	-	-	-	-	-	-	-	-
1868042	0	29	re-activation	NN	-	-	-	-	-	-	-	-
1868042	0	30	”	''	-	-	-	-	-	-	-	-
1868042	0	31	of	IN	-	-	-	-	-	-	-	-
1868042	0	32	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	33	release	NN	-	-	-	-	-	-	-	3)
1868042	0	34	was	VBD	-	-	-	-	-	-	-	-
1868042	0	35	not	RB	-	-	-	-	-	-	-	-
1868042	0	36	secondary	JJ	-	-	-	-	-	-	-	-
1868042	0	37	to	IN	-	-	-	-	-	-	-	-
1868042	0	38	reduced	VBN	-	-	-	-	-	-	-	-
1868042	0	39	β	NN	-	-	-	-	-	-	-	-
1868042	0	40	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	41	cell	NN	-	-	-	-	-	-	-	-
1868042	0	42	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	43	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Increasing	VBG	-	-	-	-	-	-	-	-
1868042	0	2	the	DT	-	-	-	-	-	-	-	-
1868042	0	3	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	6	beyond	IN	-	-	-	-	-	-	-	-
1868042	0	7	10	CD	-	-	-	-	-	-	-	-
1868042	0	8	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	9	inhibited	VBD	-	-	-	-	-	-	-	-
1868042	0	10	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	11	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	12	in	IN	-	-	-	-	-	-	-	-
1868042	0	13	parallel	NN	-	-	-	-	-	-	-	-
1868042	0	14	with	IN	-	-	-	-	-	-	-	-
1868042	0	15	an	DT	-	-	-	-	-	-	-	-
1868042	0	16	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	insulin	NN	-	-	-	-	-	-	-	(20|(19)
1868042	0	19	release	NN	-	-	-	-	-	-	-	20)
1868042	0	20	from	IN	-	-	-	-	-	-	-	-
1868042	0	21	both	CC	-	-	-	-	-	-	-	(84
1868042	0	22	mouse	NN	-	-	-	-	-	-	-	(71c)
1868042	0	23	and	CC	-	-	-	-	-	-	-	-
1868042	0	24	rat	NN	-	-	-	-	-	-	-	(85
1868042	0	25	islets	NNS	-	-	-	-	-	-	-	(71c)|85)|84)
1868042	0	26	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	27	Figure	NN	-	-	-	-	-	-	-	(98|(81)|(99a)
1868042	0	28	2A	NN	-	-	-	-	-	-	-	98)
1868042	0	29	and	CC	-	-	-	-	-	-	-	-
1868042	0	30	2B	NN	-	-	-	-	-	-	-	(99a)
1868042	0	31	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	32	.	.	-	-	-	-	-	-	-	-

1868042	0	1	When	WRB	-	-	-	-	-	-	-	-
1868042	0	2	instead	RB	-	-	-	-	-	-	-	-
1868042	0	3	applied	VBN	-	-	-	-	-	-	-	-
1868042	0	4	in	IN	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	(100
1868042	0	6	presence	NN	-	-	-	-	-	-	-	-
1868042	0	7	of	IN	-	-	-	-	-	-	-	-
1868042	0	8	1	CD	-	-	-	-	-	-	-	(101
1868042	0	9	mM	NN	-	-	-	-	-	-	-	-
1868042	0	10	glucose	NN	-	-	-	-	-	-	-	101)|100)
1868042	0	11	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	12	at	IN	-	-	-	-	-	-	-	-
1868042	0	13	which	WDT	-	-	-	-	-	-	-	-
1868042	0	14	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	15	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	16	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	17	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	18	stimulated	VBN	-	-	-	-	-	-	-	-
1868042	0	19	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	20	,	,	-	-	-	-	-	-	-	-
1868042	0	21	increasing	VBG	-	-	-	-	-	-	-	-
1868042	0	22	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	23	produced	VBD	-	-	-	-	-	-	-	-
1868042	0	24	a	DT	-	-	-	-	-	-	-	-
1868042	0	25	monotonic	JJ	-	-	-	-	-	-	-	-
1868042	0	26	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	27	of	IN	-	-	-	-	-	-	-	-
1868042	0	28	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	29	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	30	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	31	Figure	NN	-	-	-	-	-	-	-	(102|(81)
1868042	0	32	2C	NN	-	-	-	-	-	-	-	102)
1868042	0	33	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	34	with	IN	-	-	-	-	-	-	-	-
1868042	0	35	a	DT	-	-	-	-	-	-	-	-
1868042	0	36	half	RB	-	-	-	-	-	-	-	-
1868042	0	37	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	38	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	39	inhibitory	JJ	-	-	-	-	-	-	-	-
1868042	0	40	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	41	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	42	IC50	NN	-	-	-	-	-	-	-	-
1868042	0	43	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	44	that	WDT	-	-	-	-	-	-	-	-
1868042	0	45	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	46	much	RB	-	-	-	-	-	-	-	-
1868042	0	47	lower	JJR	-	-	-	-	-	-	-	-
1868042	0	48	than	IN	-	-	-	-	-	-	-	-
1868042	0	49	what	WP	-	-	-	-	-	-	-	-
1868042	0	50	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	51	seen	VBN	-	-	-	-	-	-	-	-
1868042	0	52	under	IN	-	-	-	-	-	-	-	-
1868042	0	53	high	JJ	-	-	-	-	-	-	-	(87
1868042	0	54	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	55	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	56	conditions	NNS	-	-	-	-	-	-	-	87)
1868042	0	57	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	58	∼	SYM	-	-	-	-	-	-	-	-
1868042	0	59	2	CD	-	-	-	-	-	-	-	-
1868042	0	60	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	61	versus	CC	-	-	-	-	-	-	-	-
1868042	0	62	∼	SYM	-	-	-	-	-	-	-	-
1868042	0	63	50	CD	-	-	-	-	-	-	-	-
1868042	0	64	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	65	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	66	.	.	-	-	-	-	-	-	-	-

1868042	0	1	In	IN	-	-	-	-	-	-	-	-
1868042	0	2	the	DT	-	-	-	-	-	-	-	-
1868042	0	3	complete	JJ	-	-	-	-	-	-	-	-
1868042	0	4	absence	NN	-	-	-	-	-	-	-	-
1868042	0	5	of	IN	-	-	-	-	-	-	-	-
1868042	0	6	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	7	,	,	-	-	-	-	-	-	-	-
1868042	0	8	when	WRB	-	-	-	-	-	-	-	-
1868042	0	9	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	10	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	11	are	VBP	-	-	-	-	-	-	-	-
1868042	0	12	expected	VBN	-	-	-	-	-	-	-	-
1868042	0	13	to	TO	-	-	-	-	-	-	-	-
1868042	0	14	be	VB	-	-	-	-	-	-	-	-
1868042	0	15	open	JJ	-	-	-	-	-	-	-	-
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	the	DT	-	-	-	-	-	-	-	(23
1868042	0	18	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	19	channel	NN	-	-	-	-	-	-	-	-
1868042	0	20	antagonist	NN	-	-	-	-	-	-	-	-
1868042	0	21	tolbutamide	NN	-	-	-	-	-	-	-	23)
1868042	0	22	also	RB	-	-	-	-	-	-	-	-
1868042	0	23	produced	VBD	-	-	-	-	-	-	-	-
1868042	0	24	a	DT	-	-	-	-	-	-	-	-
1868042	0	25	biphasic	JJ	-	-	-	-	-	-	-	-
1868042	0	26	effect	NN	-	-	-	-	-	-	-	-
1868042	0	27	on	IN	-	-	-	-	-	-	-	-
1868042	0	28	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	29	release	NN	-	-	-	-	-	-	-	3)
1868042	0	30	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Augmentation	NN	-	-	-	-	-	-	-	-
1868042	0	2	of	IN	-	-	-	-	-	-	-	-
1868042	0	3	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	4	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	5	was	VBD	-	-	-	-	-	-	-	-
1868042	0	6	seen	VBN	-	-	-	-	-	-	-	-
1868042	0	7	at	IN	-	-	-	-	-	-	-	-
1868042	0	8	tolbutamide	NN	-	-	-	-	-	-	-	(23)
1868042	0	9	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	10	of	IN	-	-	-	-	-	-	-	-
1868042	0	11	up	IN	-	-	-	-	-	-	-	-
1868042	0	12	to	IN	-	-	-	-	-	-	-	-
1868042	0	13	1	CD	-	-	-	-	-	-	-	-
1868042	0	14	μM	NN	-	-	-	-	-	-	-	-
1868042	0	15	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	16	stimulation	NN	-	-	-	-	-	-	-	-
1868042	0	17	being	VBG	-	-	-	-	-	-	-	-
1868042	0	18	half	RB	-	-	-	-	-	-	-	-
1868042	0	19	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	20	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	21	at	IN	-	-	-	-	-	-	-	-
1868042	0	22	0.1	CD	-	-	-	-	-	-	-	-
1868042	0	23	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	24	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	25	,	,	-	-	-	-	-	-	-	-
1868042	0	26	whereas	IN	-	-	-	-	-	-	-	-
1868042	0	27	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	28	was	VBD	-	-	-	-	-	-	-	-
1868042	0	29	observed	VBN	-	-	-	-	-	-	-	-
1868042	0	30	at	IN	-	-	-	-	-	-	-	-
1868042	0	31	higher	JJR	-	-	-	-	-	-	-	-
1868042	0	32	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	33	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	34	Figure	NN	-	-	-	-	-	-	-	(103|(81)
1868042	0	35	2D	NN	-	-	-	-	-	-	-	103)
1868042	0	36	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	37	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Importantly	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	in	IN	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	presence	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	a	DT	-	-	-	-	-	-	-	-
1868042	0	8	maximally	RB	-	-	-	-	-	-	-	-
1868042	0	9	inhibitory	JJ	-	-	-	-	-	-	-	-
1868042	0	10	tolbutamide	NN	-	-	-	-	-	-	-	-
1868042	0	11	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	12	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	13	0.5	CD	-	-	-	-	-	-	-	-
1868042	0	14	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	15	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	18	was	VBD	-	-	-	-	-	-	-	-
1868042	0	19	unable	JJ	-	-	-	-	-	-	-	-
1868042	0	20	to	TO	-	-	-	-	-	-	-	-
1868042	0	21	produce	VB	-	-	-	-	-	-	-	-
1868042	0	22	any	DT	-	-	-	-	-	-	-	-
1868042	0	23	further	JJ	-	-	-	-	-	-	-	-
1868042	0	24	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	25	of	IN	-	-	-	-	-	-	-	-
1868042	0	26	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	27	release	NN	-	-	-	-	-	-	-	3)
1868042	0	28	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	29	Figure	NN	-	-	-	-	-	-	-	(104|(81)
1868042	0	30	3A	NN	-	-	-	-	-	-	-	104)
1868042	0	31	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	32	.	.	-	-	-	-	-	-	-	-

1868042	0	1	These	DT	-	-	-	-	-	-	-	(105
1868042	0	2	data	NNS	-	-	-	-	-	-	-	105)
1868042	0	3	are	VBP	-	-	-	-	-	-	-	-
1868042	0	4	inconsistent	JJ	-	-	-	-	-	-	-	-
1868042	0	5	with	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	idea	NN	-	-	-	-	-	-	-	-
1868042	0	8	that	IN	-	-	-	-	-	-	-	-
1868042	0	9	β	NN	-	-	-	-	-	-	-	(106
1868042	0	10	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	11	cell	NN	-	-	-	-	-	-	-	-
1868042	0	12	secretion	NN	-	-	-	-	-	-	-	106)
1868042	0	13	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	14	the	DT	-	-	-	-	-	-	-	-
1868042	0	15	primary	JJ	-	-	-	-	-	-	-	-
1868042	0	16	inhibitor	NN	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	α	NN	-	-	-	-	-	-	-	-
1868042	0	19	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	20	cell	NN	-	-	-	-	-	-	-	-
1868042	0	21	glucagon	NN	-	-	-	-	-	-	-	-
1868042	0	22	release	NN	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	They	PRP	-	-	-	-	-	-	-	(105)
1868042	0	2	also	RB	-	-	-	-	-	-	-	-
1868042	0	3	suggest	VBP	-	-	-	-	-	-	-	-
1868042	0	4	that	IN	-	-	-	-	-	-	-	-
1868042	0	5	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	6	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	7	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	8	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	9	within	IN	-	-	-	-	-	-	-	-
1868042	0	10	a	DT	-	-	-	-	-	-	-	-
1868042	0	11	“	``	-	-	-	-	-	-	-	-
1868042	0	12	window	NN	-	-	-	-	-	-	-	-
1868042	0	13	”	''	-	-	-	-	-	-	-	-
1868042	0	14	of	IN	-	-	-	-	-	-	-	-
1868042	0	15	intermediate	JJ	-	-	-	-	-	-	-	(107
1868042	0	16	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	17	channel	NN	-	-	-	-	-	-	-	-
1868042	0	18	activity	NN	-	-	-	-	-	-	-	107)
1868042	0	19	.	.	-	-	-	-	-	-	-	-

1868042	0	1	To	TO	-	-	-	-	-	-	-	-
1868042	0	2	further	RB	-	-	-	-	-	-	-	-
1868042	0	3	investigate	VB	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	role	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	α	NN	-	-	-	-	-	-	-	(63
1868042	0	8	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	cell	NN	-	-	-	-	-	-	-	-
1868042	0	10	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	11	channels	NNS	-	-	-	-	-	-	-	63)
1868042	0	12	as	IN	-	-	-	-	-	-	-	-
1868042	0	13	regulators	NNS	-	-	-	-	-	-	-	-
1868042	0	14	of	IN	-	-	-	-	-	-	-	-
1868042	0	15	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	16	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	17	,	,	-	-	-	-	-	-	-	-
1868042	0	18	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	19	studied	VBD	-	-	-	-	-	-	-	-
1868042	0	20	islets	NNS	-	-	-	-	-	-	-	(108
1868042	0	21	from	IN	-	-	-	-	-	-	-	-
1868042	0	22	Kir6.2Y12X	NN	-	-	-	-	-	-	-	(109
1868042	0	23	mice	NNS	-	-	-	-	-	-	-	108)
1868042	0	24	,	,	-	-	-	-	-	-	-	-
1868042	0	25	which	WDT	-	-	-	-	-	-	-	-
1868042	0	26	posses	VBZ	-	-	-	-	-	-	-	-
1868042	0	27	a	DT	-	-	-	-	-	-	-	-
1868042	0	28	Tyr12STOP	NN	-	-	-	-	-	-	-	-
1868042	0	29	mutation	NN	-	-	-	-	-	-	-	-
1868042	0	30	in	IN	-	-	-	-	-	-	-	-
1868042	0	31	the	DT	-	-	-	-	-	-	-	(110
1868042	0	32	Kcnj11	NN	-	-	-	-	-	-	-	-
1868042	0	33	gene	NN	-	-	-	-	-	-	-	110)|109)
1868042	0	34	,	,	-	-	-	-	-	-	-	-
1868042	0	35	leading	VBG	-	-	-	-	-	-	-	-
1868042	0	36	to	IN	-	-	-	-	-	-	-	-
1868042	0	37	premature	JJ	-	-	-	-	-	-	-	-
1868042	0	38	termination	NN	-	-	-	-	-	-	-	-
1868042	0	39	of	IN	-	-	-	-	-	-	-	-
1868042	0	40	the	DT	-	-	-	-	-	-	-	-
1868042	0	41	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	42	channel	NN	-	-	-	-	-	-	-	-
1868042	0	43	pore	NN	-	-	-	-	-	-	-	-
1868042	0	44	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	45	forming	VBG	-	-	-	-	-	-	-	-
1868042	0	46	subunit	NN	-	-	-	-	-	-	-	-
1868042	0	47	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	48	48	CD	-	-	-	-	-	-	-	-
1868042	0	49	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	50	.	.	-	-	-	-	-	-	-	-

1868042	0	1	At	IN	-	-	-	-	-	-	-	-
1868042	0	2	low	JJ	-	-	-	-	-	-	-	(111
1868042	0	3	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	4	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	5	concentrations	NNS	-	-	-	-	-	-	-	111)
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	8	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	9	from	IN	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	(108
1868042	0	11	Kir6.2Y12X	NN	-	-	-	-	-	-	-	-
1868042	0	12	islets	NNS	-	-	-	-	-	-	-	108)
1868042	0	13	was	VBD	-	-	-	-	-	-	-	-
1868042	0	14	already	RB	-	-	-	-	-	-	-	-
1868042	0	15	suppressed	VBN	-	-	-	-	-	-	-	-
1868042	0	16	compared	VBN	-	-	-	-	-	-	-	-
1868042	0	17	with	IN	-	-	-	-	-	-	-	-
1868042	0	18	that	DT	-	-	-	-	-	-	-	-
1868042	0	19	from	IN	-	-	-	-	-	-	-	-
1868042	0	20	wild	JJ	-	-	-	-	-	-	-	(112
1868042	0	21	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	22	type	NN	-	-	-	-	-	-	-	-
1868042	0	23	islets	NNS	-	-	-	-	-	-	-	112)
1868042	0	24	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	25	Figure	NN	-	-	-	-	-	-	-	(113|(81)
1868042	0	26	3B	NN	-	-	-	-	-	-	-	113)
1868042	0	27	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	28	,	,	-	-	-	-	-	-	-	-
1868042	0	29	similar	JJ	-	-	-	-	-	-	-	-
1868042	0	30	to	IN	-	-	-	-	-	-	-	-
1868042	0	31	the	DT	-	-	-	-	-	-	-	-
1868042	0	32	effect	NN	-	-	-	-	-	-	-	-
1868042	0	33	of	IN	-	-	-	-	-	-	-	-
1868042	0	34	glucose	NN	-	-	-	-	-	-	-	(114|(31)
1868042	0	35	stimulation	NN	-	-	-	-	-	-	-	114)
1868042	0	36	or	CC	-	-	-	-	-	-	-	-
1868042	0	37	pharmacological	JJ	-	-	-	-	-	-	-	-
1868042	0	38	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	39	channel	NN	-	-	-	-	-	-	-	-
1868042	0	40	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	41	observed	VBN	-	-	-	-	-	-	-	-
1868042	0	42	in	IN	-	-	-	-	-	-	-	-
1868042	0	43	Figures	NNS	-	-	-	-	-	-	-	(103|(81)
1868042	0	44	2D	NN	-	-	-	-	-	-	-	103)
1868042	0	45	and	CC	-	-	-	-	-	-	-	-
1868042	0	46	3A	NN	-	-	-	-	-	-	-	-
1868042	0	47	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Consistent	JJ	-	-	-	-	-	-	-	-
1868042	0	2	with	IN	-	-	-	-	-	-	-	-
1868042	0	3	a	DT	-	-	-	-	-	-	-	-
1868042	0	4	recent	JJ	-	-	-	-	-	-	-	-
1868042	0	5	report	NN	-	-	-	-	-	-	-	-
1868042	0	6	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	7	49	CD	-	-	-	-	-	-	-	-
1868042	0	8	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	higher	JJR	-	-	-	-	-	-	-	-
1868042	0	11	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	12	levels	NNS	-	-	-	-	-	-	-	-
1868042	0	13	stimulated	VBD	-	-	-	-	-	-	-	-
1868042	0	14	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	15	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	perhaps	RB	-	-	-	-	-	-	-	-
1868042	0	18	due	IN	-	-	-	-	-	-	-	-
1868042	0	19	to	IN	-	-	-	-	-	-	-	-
1868042	0	20	a	DT	-	-	-	-	-	-	-	-
1868042	0	21	direct	JJ	-	-	-	-	-	-	-	-
1868042	0	22	effect	NN	-	-	-	-	-	-	-	-
1868042	0	23	of	IN	-	-	-	-	-	-	-	-
1868042	0	24	metabolism	NN	-	-	-	-	-	-	-	-
1868042	0	25	on	IN	-	-	-	-	-	-	-	-
1868042	0	26	secretion	NN	-	-	-	-	-	-	-	(47)
1868042	0	27	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	28	33	CD	-	-	-	-	-	-	-	-
1868042	0	29	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	30	.	.	-	-	-	-	-	-	-	-

1868042	0	1	In	IN	-	-	-	-	-	-	-	-
1868042	0	2	wild	JJ	-	-	-	-	-	-	-	(112
1868042	0	3	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	4	type	NN	-	-	-	-	-	-	-	-
1868042	0	5	islets	NNS	-	-	-	-	-	-	-	112)
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	8	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	9	exhibited	VBD	-	-	-	-	-	-	-	-
1868042	0	10	a	DT	-	-	-	-	-	-	-	-
1868042	0	11	nadir	NN	-	-	-	-	-	-	-	-
1868042	0	12	at	IN	-	-	-	-	-	-	-	-
1868042	0	13	5	CD	-	-	-	-	-	-	-	(115
1868042	0	14	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	15	glucose	NN	-	-	-	-	-	-	-	115)
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	and	CC	-	-	-	-	-	-	-	-
1868042	0	18	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	19	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	20	at	IN	-	-	-	-	-	-	-	-
1868042	0	21	20	CD	-	-	-	-	-	-	-	(116
1868042	0	22	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	23	glucose	NN	-	-	-	-	-	-	-	116)
1868042	0	24	was	VBD	-	-	-	-	-	-	-	-
1868042	0	25	40	CD	-	-	-	-	-	-	-	-
1868042	0	26	%	NN	-	-	-	-	-	-	-	-
1868042	0	27	higher	JJR	-	-	-	-	-	-	-	-
1868042	0	28	than	IN	-	-	-	-	-	-	-	-
1868042	0	29	at	IN	-	-	-	-	-	-	-	-
1868042	0	30	5	CD	-	-	-	-	-	-	-	(115
1868042	0	31	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	32	glucose	NN	-	-	-	-	-	-	-	115)
1868042	0	33	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Insulin	NN	-	-	-	-	-	-	-	(19)
1868042	0	2	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	3	in	IN	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	Kir6.2Y12X	NN	-	-	-	-	-	-	-	(108
1868042	0	6	islets	NNS	-	-	-	-	-	-	-	108)
1868042	0	7	was	VBD	-	-	-	-	-	-	-	-
1868042	0	8	elevated	VBN	-	-	-	-	-	-	-	-
1868042	0	9	at	IN	-	-	-	-	-	-	-	-
1868042	0	10	low	JJ	-	-	-	-	-	-	-	(111
1868042	0	11	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	13	concentrations	NNS	-	-	-	-	-	-	-	111)
1868042	0	14	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	15	Figure	NN	-	-	-	-	-	-	-	(117|(81)
1868042	0	16	3C	NN	-	-	-	-	-	-	-	117)
1868042	0	17	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	whereas	IN	-	-	-	-	-	-	-	-
1868042	0	20	glucose	NN	-	-	-	-	-	-	-	(118
1868042	0	21	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	22	stimulated	VBN	-	-	-	-	-	-	-	-
1868042	0	23	insulin	NN	-	-	-	-	-	-	-	-
1868042	0	24	secretion	NN	-	-	-	-	-	-	-	118)
1868042	0	25	was	VBD	-	-	-	-	-	-	-	-
1868042	0	26	blunted	VBN	-	-	-	-	-	-	-	-
1868042	0	27	.	.	-	-	-	-	-	-	-	-

1868042	0	1	It	PRP	-	-	-	-	-	-	-	-
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	notable	JJ	-	-	-	-	-	-	-	-
1868042	0	4	that	IN	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	-
1868042	0	6	increase	NN	-	-	-	-	-	-	-	-
1868042	0	7	in	IN	-	-	-	-	-	-	-	-
1868042	0	8	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	9	release	NN	-	-	-	-	-	-	-	-
1868042	0	10	from	IN	-	-	-	-	-	-	-	-
1868042	0	11	the	DT	-	-	-	-	-	-	-	(108
1868042	0	12	Kir6.2Y12X	NN	-	-	-	-	-	-	-	-
1868042	0	13	islets	NNS	-	-	-	-	-	-	-	108)
1868042	0	14	was	VBD	-	-	-	-	-	-	-	-
1868042	0	15	coincident	JJ	-	-	-	-	-	-	-	-
1868042	0	16	with	IN	-	-	-	-	-	-	-	-
1868042	0	17	increased	VBN	-	-	-	-	-	-	-	-
1868042	0	18	insulin	NN	-	-	-	-	-	-	-	-
1868042	0	19	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	20	,	,	-	-	-	-	-	-	-	-
1868042	0	21	reinforcing	VBG	-	-	-	-	-	-	-	-
1868042	0	22	the	DT	-	-	-	-	-	-	-	-
1868042	0	23	view	NN	-	-	-	-	-	-	-	-
1868042	0	24	that	IN	-	-	-	-	-	-	-	-
1868042	0	25	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	26	of	IN	-	-	-	-	-	-	-	-
1868042	0	27	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	28	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	29	not	RB	-	-	-	-	-	-	-	-
1868042	0	30	mediated	VBN	-	-	-	-	-	-	-	-
1868042	0	31	by	IN	-	-	-	-	-	-	-	-
1868042	0	32	a	DT	-	-	-	-	-	-	-	-
1868042	0	33	factor	NN	-	-	-	-	-	-	-	-
1868042	0	34	released	VBN	-	-	-	-	-	-	-	-
1868042	0	35	by	IN	-	-	-	-	-	-	-	-
1868042	0	36	the	DT	-	-	-	-	-	-	-	(21
1868042	0	37	β	NN	-	-	-	-	-	-	-	-
1868042	0	38	cells	NNS	-	-	-	-	-	-	-	21)
1868042	0	39	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Furthermore	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	in	IN	-	-	-	-	-	-	-	-
1868042	0	4	control	NN	-	-	-	-	-	-	-	-
1868042	0	5	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	-
1868042	0	8	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	11	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	12	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	13	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	14	at	IN	-	-	-	-	-	-	-	-
1868042	0	15	a	DT	-	-	-	-	-	-	-	-
1868042	0	16	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	5	CD	-	-	-	-	-	-	-	-
1868042	0	21	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	22	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	that	WDT	-	-	-	-	-	-	-	-
1868042	0	24	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	25	without	IN	-	-	-	-	-	-	-	-
1868042	0	26	stimulatory	JJ	-	-	-	-	-	-	-	-
1868042	0	27	action	NN	-	-	-	-	-	-	-	-
1868042	0	28	on	IN	-	-	-	-	-	-	-	-
1868042	0	29	insulin	NN	-	-	-	-	-	-	-	(27|(19)
1868042	0	30	secretion	NN	-	-	-	-	-	-	-	27)
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	next	RB	-	-	-	-	-	-	-	-
1868042	0	3	examined	VBD	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	function	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	α	NN	-	-	-	-	-	-	-	(119|(120b)
1868042	0	8	and	CC	-	-	-	-	-	-	-	-
1868042	0	9	β	NN	-	-	-	-	-	-	-	(121
1868042	0	10	cells	NNS	-	-	-	-	-	-	-	(120b
1868042	0	11	in	FW	-	-	-	-	-	-	-	-
1868042	0	12	situ	FW	-	-	-	-	-	-	-	121)|120b)|119)
1868042	0	13	by	IN	-	-	-	-	-	-	-	-
1868042	0	14	monitoring	VBG	-	-	-	-	-	-	-	-
1868042	0	15	the	DT	-	-	-	-	-	-	-	-
1868042	0	16	[	-LRB-	-	-	-	-	-	-	-	(122
1868042	0	17	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	18	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	19	i	NN	-	-	-	-	-	-	-	122)
1868042	0	20	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	21	of	IN	-	-	-	-	-	-	-	-
1868042	0	22	single	JJ	-	-	-	-	-	-	-	-
1868042	0	23	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	24	within	IN	-	-	-	-	-	-	-	-
1868042	0	25	intact	JJ	-	-	-	-	-	-	-	(73
1868042	0	26	mouse	NN	-	-	-	-	-	-	-	-
1868042	0	27	islets	NNS	-	-	-	-	-	-	-	73)
1868042	0	28	.	.	-	-	-	-	-	-	-	-

1868042	0	1	These	DT	-	-	-	-	-	-	-	(119)
1868042	0	2	were	VBD	-	-	-	-	-	-	-	-
1868042	0	3	functionally	RB	-	-	-	-	-	-	-	-
1868042	0	4	identified	VBN	-	-	-	-	-	-	-	-
1868042	0	5	by	IN	-	-	-	-	-	-	-	-
1868042	0	6	their	PRP$	-	-	-	-	-	-	-	(119)
1868042	0	7	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	8	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	9	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	10	i	NN	-	-	-	-	-	-	-	-
1868042	0	11	response	NN	-	-	-	-	-	-	-	-
1868042	0	12	to	IN	-	-	-	-	-	-	-	-
1868042	0	13	0.5	CD	-	-	-	-	-	-	-	-
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	2	CD	-	-	-	-	-	-	-	-
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	and	CC	-	-	-	-	-	-	-	-
1868042	0	18	11	CD	-	-	-	-	-	-	-	(123
1868042	0	19	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	20	glucose	NN	-	-	-	-	-	-	-	123)
1868042	0	21	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	22	50	CD	-	-	-	-	-	-	-	-
1868042	0	23	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	24	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Glucose	NN	-	-	-	-	-	-	-	(114|(31)
1868042	0	2	stimulation	NN	-	-	-	-	-	-	-	114)
1868042	0	3	suppressed	VBD	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	[	-LRB-	-	-	-	-	-	-	-	(122
1868042	0	6	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	7	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	8	i	NN	-	-	-	-	-	-	-	122)
1868042	0	9	response	NN	-	-	-	-	-	-	-	-
1868042	0	10	of	IN	-	-	-	-	-	-	-	-
1868042	0	11	α	NN	-	-	-	-	-	-	-	(1
1868042	0	12	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	13	by	IN	-	-	-	-	-	-	-	-
1868042	0	14	51	CD	-	-	-	-	-	-	-	-
1868042	0	15	±	SYM	-	-	-	-	-	-	-	-
1868042	0	16	3	CD	-	-	-	-	-	-	-	-
1868042	0	17	%	NN	-	-	-	-	-	-	-	-
1868042	0	18	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	19	n	NN	-	-	-	-	-	-	-	-
1868042	0	20	=	SYM	-	-	-	-	-	-	-	-
1868042	0	21	63	CD	-	-	-	-	-	-	-	-
1868042	0	22	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	23	in	IN	-	-	-	-	-	-	-	-
1868042	0	24	15	CD	-	-	-	-	-	-	-	-
1868042	0	25	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	26	,	,	-	-	-	-	-	-	-	-
1868042	0	27	p	NN	-	-	-	-	-	-	-	-
1868042	0	28	<	SYM	-	-	-	-	-	-	-	-
1868042	0	29	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	30	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	31	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	32	Figure	NN	-	-	-	-	-	-	-	(124|(125|(126b)|(81)
1868042	0	33	4A	NN	-	-	-	-	-	-	-	124)
1868042	0	34	and	CC	-	-	-	-	-	-	-	-
1868042	0	35	4B	NN	-	-	-	-	-	-	-	(126b)|125)
1868042	0	36	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	37	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	suppressive	JJ	-	-	-	-	-	-	-	-
1868042	0	3	effect	NN	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	6	was	VBD	-	-	-	-	-	-	-	-
1868042	0	7	alleviated	VBN	-	-	-	-	-	-	-	-
1868042	0	8	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	9	to	IN	-	-	-	-	-	-	-	-
1868042	0	10	101	CD	-	-	-	-	-	-	-	-
1868042	0	11	±	SYM	-	-	-	-	-	-	-	-
1868042	0	12	11	CD	-	-	-	-	-	-	-	-
1868042	0	13	%	NN	-	-	-	-	-	-	-	-
1868042	0	14	of	IN	-	-	-	-	-	-	-	-
1868042	0	15	initial	JJ	-	-	-	-	-	-	-	-
1868042	0	16	values	NNS	-	-	-	-	-	-	-	-
1868042	0	17	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	18	by	IN	-	-	-	-	-	-	-	-
1868042	0	19	application	NN	-	-	-	-	-	-	-	-
1868042	0	20	of	IN	-	-	-	-	-	-	-	-
1868042	0	21	2	CD	-	-	-	-	-	-	-	(127
1868042	0	22	μM	NN	-	-	-	-	-	-	-	-
1868042	0	23	diazoxide	NN	-	-	-	-	-	-	-	127)
1868042	0	24	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	25	Figure	NN	-	-	-	-	-	-	-	(124|(125|(126a)|(81)
1868042	0	26	4A	NN	-	-	-	-	-	-	-	124)
1868042	0	27	and	CC	-	-	-	-	-	-	-	-
1868042	0	28	4B	NN	-	-	-	-	-	-	-	(126a)|125)
1868042	0	29	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	30	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	(127
1868042	0	2	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	3	of	IN	-	-	-	-	-	-	-	-
1868042	0	4	diazoxide	NN	-	-	-	-	-	-	-	(18)|127)
1868042	0	5	was	VBD	-	-	-	-	-	-	-	-
1868042	0	6	similar	JJ	-	-	-	-	-	-	-	-
1868042	0	7	to	IN	-	-	-	-	-	-	-	-
1868042	0	8	that	DT	-	-	-	-	-	-	-	-
1868042	0	9	which	WDT	-	-	-	-	-	-	-	-
1868042	0	10	produced	VBD	-	-	-	-	-	-	-	-
1868042	0	11	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	12	stimulation	NN	-	-	-	-	-	-	-	-
1868042	0	13	of	IN	-	-	-	-	-	-	-	-
1868042	0	14	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	15	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	16	and	CC	-	-	-	-	-	-	-	-
1868042	0	17	much	JJ	-	-	-	-	-	-	-	-
1868042	0	18	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	19	∼	SYM	-	-	-	-	-	-	-	-
1868042	0	20	15-fold	RB	-	-	-	-	-	-	-	-
1868042	0	21	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	22	lower	JJR	-	-	-	-	-	-	-	-
1868042	0	23	than	IN	-	-	-	-	-	-	-	-
1868042	0	24	necessary	JJ	-	-	-	-	-	-	-	-
1868042	0	25	to	TO	-	-	-	-	-	-	-	-
1868042	0	26	inhibit	VB	-	-	-	-	-	-	-	-
1868042	0	27	insulin	NN	-	-	-	-	-	-	-	(27|(19)
1868042	0	28	secretion	NN	-	-	-	-	-	-	-	27)
1868042	0	29	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	30	Figure	NN	-	-	-	-	-	-	-	(99|(81)
1868042	0	31	2B	NN	-	-	-	-	-	-	-	99)
1868042	0	32	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	33	or	CC	-	-	-	-	-	-	-	-
1868042	0	34	β	NN	-	-	-	-	-	-	-	-
1868042	0	35	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	36	cell	NN	-	-	-	-	-	-	-	-
1868042	0	37	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	38	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	39	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	40	i	NN	-	-	-	-	-	-	-	-
1868042	0	41	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	42	to	IN	-	-	-	-	-	-	-	-
1868042	0	43	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	44	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	45	Figure	NN	-	-	-	-	-	-	-	(124|(81)
1868042	0	46	4A	NN	-	-	-	-	-	-	-	124)
1868042	0	47	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	48	.	.	-	-	-	-	-	-	-	-

1868042	0	1	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	2	Channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	3	Regulate	VBP	-	-	-	-	-	-	-	-
1868042	0	4	Human	JJ	-	-	-	-	-	-	-	(10
1868042	0	5	α	NN	-	-	-	-	-	-	-	-
1868042	0	6	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	Cell	NN	-	-	-	-	-	-	-	10)
1868042	0	8	Activity	NN	-	-	-	-	-	-	-	-

1868042	0	1	Little	JJ	-	-	-	-	-	-	-	-
1868042	0	2	work	NN	-	-	-	-	-	-	-	-
1868042	0	3	has	VBZ	-	-	-	-	-	-	-	-
1868042	0	4	been	VBN	-	-	-	-	-	-	-	-
1868042	0	5	done	VBN	-	-	-	-	-	-	-	-
1868042	0	6	to	TO	-	-	-	-	-	-	-	-
1868042	0	7	examine	VB	-	-	-	-	-	-	-	-
1868042	0	8	the	DT	-	-	-	-	-	-	-	-
1868042	0	9	mechanism	NN	-	-	-	-	-	-	-	-
1868042	0	10	of	IN	-	-	-	-	-	-	-	-
1868042	0	11	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	12	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	13	regulated	VBN	-	-	-	-	-	-	-	-
1868042	0	14	glucagon	NN	-	-	-	-	-	-	-	-
1868042	0	15	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	16	from	IN	-	-	-	-	-	-	-	-
1868042	0	17	isolated	VBN	-	-	-	-	-	-	-	(62
1868042	0	18	human	JJ	-	-	-	-	-	-	-	-
1868042	0	19	islets	NNS	-	-	-	-	-	-	-	62)
1868042	0	20	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	21	51	CD	-	-	-	-	-	-	-	-
1868042	0	22	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Glucagon	NN	-	-	-	-	-	-	-	(24|(2)
1868042	0	2	and	CC	-	-	-	-	-	-	-	-
1868042	0	3	insulin	NN	-	-	-	-	-	-	-	(19)|24)
1868042	0	4	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	5	from	IN	-	-	-	-	-	-	-	-
1868042	0	6	islets	NNS	-	-	-	-	-	-	-	(128
1868042	0	7	isolated	VBN	-	-	-	-	-	-	-	-
1868042	0	8	from	IN	-	-	-	-	-	-	-	-
1868042	0	9	healthy	JJ	-	-	-	-	-	-	-	-
1868042	0	10	donors	NNS	-	-	-	-	-	-	-	128)
1868042	0	11	was	VBD	-	-	-	-	-	-	-	-
1868042	0	12	examined	VBN	-	-	-	-	-	-	-	-
1868042	0	13	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Similar	JJ	-	-	-	-	-	-	-	-
1868042	0	2	to	IN	-	-	-	-	-	-	-	-
1868042	0	3	above	RB	-	-	-	-	-	-	-	-
1868042	0	4	,	,	-	-	-	-	-	-	-	-
1868042	0	5	glucagon	NN	-	-	-	-	-	-	-	(40|(2)
1868042	0	6	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	7	from	IN	-	-	-	-	-	-	-	-
1868042	0	8	human	JJ	-	-	-	-	-	-	-	-
1868042	0	9	islets	NNS	-	-	-	-	-	-	-	40)
1868042	0	10	was	VBD	-	-	-	-	-	-	-	-
1868042	0	11	suppressed	VBN	-	-	-	-	-	-	-	-
1868042	0	12	by	IN	-	-	-	-	-	-	-	-
1868042	0	13	58	CD	-	-	-	-	-	-	-	-
1868042	0	14	±	SYM	-	-	-	-	-	-	-	-
1868042	0	15	3	CD	-	-	-	-	-	-	-	-
1868042	0	16	%	NN	-	-	-	-	-	-	-	-
1868042	0	17	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	18	n	NN	-	-	-	-	-	-	-	-
1868042	0	19	=	SYM	-	-	-	-	-	-	-	-
1868042	0	20	9	CD	-	-	-	-	-	-	-	-
1868042	0	21	,	,	-	-	-	-	-	-	-	-
1868042	0	22	p	NN	-	-	-	-	-	-	-	-
1868042	0	23	<	SYM	-	-	-	-	-	-	-	-
1868042	0	24	0.05	CD	-	-	-	-	-	-	-	-
1868042	0	25	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	26	upon	IN	-	-	-	-	-	-	-	-
1868042	0	27	raising	VBG	-	-	-	-	-	-	-	-
1868042	0	28	the	DT	-	-	-	-	-	-	-	-
1868042	0	29	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	30	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	31	from	IN	-	-	-	-	-	-	-	-
1868042	0	32	0	CD	-	-	-	-	-	-	-	-
1868042	0	33	to	IN	-	-	-	-	-	-	-	-
1868042	0	34	10	CD	-	-	-	-	-	-	-	-
1868042	0	35	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	36	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Tolbutamide	NN	-	-	-	-	-	-	-	(23)
1868042	0	2	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	3	200	CD	-	-	-	-	-	-	-	-
1868042	0	4	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	5	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	6	inhibited	VBD	-	-	-	-	-	-	-	-
1868042	0	7	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	8	release	NN	-	-	-	-	-	-	-	-
1868042	0	9	by	IN	-	-	-	-	-	-	-	-
1868042	0	10	43	CD	-	-	-	-	-	-	-	-
1868042	0	11	±	SYM	-	-	-	-	-	-	-	-
1868042	0	12	14	CD	-	-	-	-	-	-	-	-
1868042	0	13	%	NN	-	-	-	-	-	-	-	-
1868042	0	14	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	15	n	NN	-	-	-	-	-	-	-	-
1868042	0	16	=	SYM	-	-	-	-	-	-	-	-
1868042	0	17	7	CD	-	-	-	-	-	-	-	-
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	p	NN	-	-	-	-	-	-	-	-
1868042	0	20	<	SYM	-	-	-	-	-	-	-	-
1868042	0	21	0.05	CD	-	-	-	-	-	-	-	-
1868042	0	22	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	At	IN	-	-	-	-	-	-	-	-
1868042	0	2	the	DT	-	-	-	-	-	-	-	-
1868042	0	3	same	JJ	-	-	-	-	-	-	-	-
1868042	0	4	time	NN	-	-	-	-	-	-	-	-
1868042	0	5	,	,	-	-	-	-	-	-	-	-
1868042	0	6	insulin	NN	-	-	-	-	-	-	-	(27|(19)
1868042	0	7	secretion	NN	-	-	-	-	-	-	-	27)
1868042	0	8	was	VBD	-	-	-	-	-	-	-	-
1868042	0	9	increased	VBN	-	-	-	-	-	-	-	-
1868042	0	10	6.4	CD	-	-	-	-	-	-	-	-
1868042	0	11	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	and	CC	-	-	-	-	-	-	-	-
1868042	0	13	4.4-fold	RB	-	-	-	-	-	-	-	-
1868042	0	14	by	IN	-	-	-	-	-	-	-	-
1868042	0	15	glucose	NN	-	-	-	-	-	-	-	(114a)|(31)
1868042	0	16	and	CC	-	-	-	-	-	-	-	-
1868042	0	17	tolbutamide	NN	-	-	-	-	-	-	-	(23)
1868042	0	18	stimulation	NN	-	-	-	-	-	-	-	(114a)
1868042	0	19	,	,	-	-	-	-	-	-	-	-
1868042	0	20	respectively	RB	-	-	-	-	-	-	-	-
1868042	0	21	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	22	Figure	NN	-	-	-	-	-	-	-	(129|(81)
1868042	0	23	5A	NN	-	-	-	-	-	-	-	129)
1868042	0	24	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	25	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Moderate	JJ	-	-	-	-	-	-	-	-
1868042	0	2	re-activation	NN	-	-	-	-	-	-	-	-
1868042	0	3	of	IN	-	-	-	-	-	-	-	-
1868042	0	4	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	5	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	6	with	IN	-	-	-	-	-	-	-	-
1868042	0	7	2	CD	-	-	-	-	-	-	-	(127
1868042	0	8	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	9	diazoxide	NN	-	-	-	-	-	-	-	127)
1868042	0	10	antagonized	VBD	-	-	-	-	-	-	-	-
1868042	0	11	the	DT	-	-	-	-	-	-	-	(130
1868042	0	12	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	13	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	14	induced	VBN	-	-	-	-	-	-	-	-
1868042	0	15	suppression	NN	-	-	-	-	-	-	-	-
1868042	0	16	of	IN	-	-	-	-	-	-	-	-
1868042	0	17	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	18	release	NN	-	-	-	-	-	-	-	3)|130)
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	n	NN	-	-	-	-	-	-	-	-
1868042	0	21	=	SYM	-	-	-	-	-	-	-	-
1868042	0	22	7	CD	-	-	-	-	-	-	-	-
1868042	0	23	,	,	-	-	-	-	-	-	-	-
1868042	0	24	p	NN	-	-	-	-	-	-	-	-
1868042	0	25	<	SYM	-	-	-	-	-	-	-	-
1868042	0	26	0.01	CD	-	-	-	-	-	-	-	-
1868042	0	27	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	28	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	29	Figure	NN	-	-	-	-	-	-	-	(131|(81)
1868042	0	30	5B	NN	-	-	-	-	-	-	-	131)
1868042	0	31	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	32	.	.	-	-	-	-	-	-	-	-

1868042	0	1	A	DT	-	-	-	-	-	-	-	-
1868042	0	2	10-fold	RB	-	-	-	-	-	-	-	-
1868042	0	3	higher	JJR	-	-	-	-	-	-	-	-
1868042	0	4	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	5	of	IN	-	-	-	-	-	-	-	-
1868042	0	6	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	7	had	VBD	-	-	-	-	-	-	-	-
1868042	0	8	significantly	RB	-	-	-	-	-	-	-	-
1868042	0	9	less	JJR	-	-	-	-	-	-	-	-
1868042	0	10	stimulatory	JJ	-	-	-	-	-	-	-	-
1868042	0	11	effect	NN	-	-	-	-	-	-	-	-
1868042	0	12	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	13	p	NN	-	-	-	-	-	-	-	-
1868042	0	14	<	SYM	-	-	-	-	-	-	-	-
1868042	0	15	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	16	versus	CC	-	-	-	-	-	-	-	-
1868042	0	17	2	CD	-	-	-	-	-	-	-	(127
1868042	0	18	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	19	diazoxide	NN	-	-	-	-	-	-	-	127)
1868042	0	20	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	21	,	,	-	-	-	-	-	-	-	-
1868042	0	22	and	CC	-	-	-	-	-	-	-	-
1868042	0	23	in	IN	-	-	-	-	-	-	-	-
1868042	0	24	the	DT	-	-	-	-	-	-	-	-
1868042	0	25	presence	NN	-	-	-	-	-	-	-	-
1868042	0	26	of	IN	-	-	-	-	-	-	-	-
1868042	0	27	200	CD	-	-	-	-	-	-	-	(132
1868042	0	28	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	29	diazoxide	NN	-	-	-	-	-	-	-	132)
1868042	0	30	,	,	-	-	-	-	-	-	-	-
1868042	0	31	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	32	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	33	was	VBD	-	-	-	-	-	-	-	-
1868042	0	34	not	RB	-	-	-	-	-	-	-	-
1868042	0	35	different	JJ	-	-	-	-	-	-	-	-
1868042	0	36	from	IN	-	-	-	-	-	-	-	-
1868042	0	37	that	DT	-	-	-	-	-	-	-	-
1868042	0	38	observed	VBN	-	-	-	-	-	-	-	-
1868042	0	39	in	IN	-	-	-	-	-	-	-	-
1868042	0	40	the	DT	-	-	-	-	-	-	-	-
1868042	0	41	absence	NN	-	-	-	-	-	-	-	-
1868042	0	42	of	IN	-	-	-	-	-	-	-	-
1868042	0	43	the	DT	-	-	-	-	-	-	-	(18
1868042	0	44	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	45	channel	NN	-	-	-	-	-	-	-	32)
1868042	0	46	activator	NN	-	-	-	-	-	-	-	18)
1868042	0	47	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Importantly	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	-
1868042	0	4	lowest	JJS	-	-	-	-	-	-	-	-
1868042	0	5	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	8	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	9	2	CD	-	-	-	-	-	-	-	-
1868042	0	10	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	11	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	12	,	,	-	-	-	-	-	-	-	-
1868042	0	13	which	WDT	-	-	-	-	-	-	-	-
1868042	0	14	produced	VBD	-	-	-	-	-	-	-	-
1868042	0	15	the	DT	-	-	-	-	-	-	-	-
1868042	0	16	strongest	JJS	-	-	-	-	-	-	-	-
1868042	0	17	stimulation	NN	-	-	-	-	-	-	-	-
1868042	0	18	of	IN	-	-	-	-	-	-	-	-
1868042	0	19	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	20	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	21	,	,	-	-	-	-	-	-	-	-
1868042	0	22	had	VBD	-	-	-	-	-	-	-	-
1868042	0	23	no	DT	-	-	-	-	-	-	-	-
1868042	0	24	inhibitory	JJ	-	-	-	-	-	-	-	-
1868042	0	25	effect	NN	-	-	-	-	-	-	-	-
1868042	0	26	on	IN	-	-	-	-	-	-	-	-
1868042	0	27	glucose	NN	-	-	-	-	-	-	-	(118
1868042	0	28	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	29	stimulated	VBN	-	-	-	-	-	-	-	-
1868042	0	30	insulin	NN	-	-	-	-	-	-	-	-
1868042	0	31	secretion	NN	-	-	-	-	-	-	-	118)
1868042	0	32	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	33	n	NN	-	-	-	-	-	-	-	-
1868042	0	34	=	SYM	-	-	-	-	-	-	-	-
1868042	0	35	5	CD	-	-	-	-	-	-	-	-
1868042	0	36	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	37	,	,	-	-	-	-	-	-	-	-
1868042	0	38	whereas	IN	-	-	-	-	-	-	-	-
1868042	0	39	20	CD	-	-	-	-	-	-	-	-
1868042	0	40	and	CC	-	-	-	-	-	-	-	-
1868042	0	41	200	CD	-	-	-	-	-	-	-	(132
1868042	0	42	μM	NNS	-	-	-	-	-	-	-	132)
1868042	0	43	produced	VBD	-	-	-	-	-	-	-	-
1868042	0	44	partial	JJ	-	-	-	-	-	-	-	-
1868042	0	45	or	CC	-	-	-	-	-	-	-	-
1868042	0	46	complete	JJ	-	-	-	-	-	-	-	-
1868042	0	47	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	48	of	IN	-	-	-	-	-	-	-	-
1868042	0	49	insulin	NN	-	-	-	-	-	-	-	(27|(19)
1868042	0	50	secretion	NN	-	-	-	-	-	-	-	27)
1868042	0	51	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	(75
1868042	0	2	GABAA	NN	-	-	-	-	-	-	-	-
1868042	0	3	receptor	NN	-	-	-	-	-	-	-	-
1868042	0	4	antagonist	NN	-	-	-	-	-	-	-	-
1868042	0	5	SR95531	NN	-	-	-	-	-	-	-	75)
1868042	0	6	had	VBD	-	-	-	-	-	-	-	-
1868042	0	7	no	DT	-	-	-	-	-	-	-	-
1868042	0	8	effect	NN	-	-	-	-	-	-	-	-
1868042	0	9	on	IN	-	-	-	-	-	-	-	-
1868042	0	10	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	11	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	induced	VBN	-	-	-	-	-	-	-	-
1868042	0	13	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	14	of	IN	-	-	-	-	-	-	-	-
1868042	0	15	glucagon	NN	-	-	-	-	-	-	-	(40|(2)
1868042	0	16	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	17	from	IN	-	-	-	-	-	-	-	-
1868042	0	18	human	JJ	-	-	-	-	-	-	-	-
1868042	0	19	islets	NNS	-	-	-	-	-	-	-	40)
1868042	0	20	,	,	-	-	-	-	-	-	-	-
1868042	0	21	and	CC	-	-	-	-	-	-	-	-
1868042	0	22	whole	JJ	-	-	-	-	-	-	-	-
1868042	0	23	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	24	cell	NN	-	-	-	-	-	-	-	-
1868042	0	25	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	26	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	27	clamp	NN	-	-	-	-	-	-	-	-
1868042	0	28	measurements	NNS	-	-	-	-	-	-	-	-
1868042	0	29	indicate	VBP	-	-	-	-	-	-	-	-
1868042	0	30	that	IN	-	-	-	-	-	-	-	-
1868042	0	31	human	JJ	-	-	-	-	-	-	-	(10
1868042	0	32	α	NN	-	-	-	-	-	-	-	-
1868042	0	33	cells	NNS	-	-	-	-	-	-	-	10)
1868042	0	34	,	,	-	-	-	-	-	-	-	-
1868042	0	35	unlike	IN	-	-	-	-	-	-	-	-
1868042	0	36	human	JJ	-	-	-	-	-	-	-	(11b
1868042	0	37	β	NN	-	-	-	-	-	-	-	11b)
1868042	0	38	and	CC	-	-	-	-	-	-	-	-
1868042	0	39	δ	NN	-	-	-	-	-	-	-	-
1868042	0	40	cells	NNS	-	-	-	-	-	-	-	(11b)
1868042	0	41	,	,	-	-	-	-	-	-	-	-
1868042	0	42	express	VBP	-	-	-	-	-	-	-	-
1868042	0	43	few	JJ	-	-	-	-	-	-	-	-
1868042	0	44	if	IN	-	-	-	-	-	-	-	-
1868042	0	45	any	DT	-	-	-	-	-	-	-	-
1868042	0	46	GABAA	NN	-	-	-	-	-	-	-	(90
1868042	0	47	receptor	NN	-	-	-	-	-	-	-	90)
1868042	0	48	Cl	NN	-	-	-	-	-	-	-	-
1868042	0	49	−	SYM	-	-	-	-	-	-	-	-
1868042	0	50	channels	NNS	-	-	-	-	-	-	-	-
1868042	0	51	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	52	M.	NNP	-	-	-	-	-	-	-	-
1868042	0	53	Braun	NNP	-	-	-	-	-	-	-	-
1868042	0	54	,	,	-	-	-	-	-	-	-	-
1868042	0	55	R.	NNP	-	-	-	-	-	-	-	-
1868042	0	56	Ramracheya	NNP	-	-	-	-	-	-	-	-
1868042	0	57	,	,	-	-	-	-	-	-	-	-
1868042	0	58	and	CC	-	-	-	-	-	-	-	-
1868042	0	59	P.	NNP	-	-	-	-	-	-	-	-
1868042	0	60	Rorsman	NNP	-	-	-	-	-	-	-	-
1868042	0	61	,	,	-	-	-	-	-	-	-	-
1868042	0	62	unpublished	JJ	-	-	-	-	-	-	-	(133
1868042	0	63	data	NNS	-	-	-	-	-	-	-	133)
1868042	0	64	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	65	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Examination	NN	-	-	-	-	-	-	-	-
1868042	0	2	of	IN	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	(7b
1868042	0	4	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	5	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	single	JJ	-	-	-	-	-	-	-	(10b
1868042	0	8	α	NN	-	-	-	-	-	-	-	7b)|10b)
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	β	NN	-	-	-	-	-	-	-	-
1868042	0	11	cells	NNS	-	-	-	-	-	-	-	(10b|(7b
1868042	0	12	within	IN	-	-	-	-	-	-	-	-
1868042	0	13	intact	JJ	-	-	-	-	-	-	-	(12
1868042	0	14	human	JJ	-	-	-	-	-	-	-	-
1868042	0	15	islets	NNS	-	-	-	-	-	-	-	7b)|12)|10b)
1868042	0	16	demonstrated	VBD	-	-	-	-	-	-	-	-
1868042	0	17	that	IN	-	-	-	-	-	-	-	-
1868042	0	18	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	19	decreased	VBD	-	-	-	-	-	-	-	-
1868042	0	20	[	-LRB-	-	-	-	-	-	-	-	(122
1868042	0	21	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	22	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	i	NN	-	-	-	-	-	-	-	122)
1868042	0	24	by	IN	-	-	-	-	-	-	-	-
1868042	0	25	62	CD	-	-	-	-	-	-	-	-
1868042	0	26	±	SYM	-	-	-	-	-	-	-	-
1868042	0	27	3	CD	-	-	-	-	-	-	-	-
1868042	0	28	%	NN	-	-	-	-	-	-	-	-
1868042	0	29	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	30	n	NN	-	-	-	-	-	-	-	-
1868042	0	31	=	SYM	-	-	-	-	-	-	-	-
1868042	0	32	42	CD	-	-	-	-	-	-	-	-
1868042	0	33	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	34	in	IN	-	-	-	-	-	-	-	-
1868042	0	35	7	CD	-	-	-	-	-	-	-	-
1868042	0	36	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	37	,	,	-	-	-	-	-	-	-	-
1868042	0	38	p	NN	-	-	-	-	-	-	-	-
1868042	0	39	<	SYM	-	-	-	-	-	-	-	-
1868042	0	40	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	41	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	42	in	IN	-	-	-	-	-	-	-	-
1868042	0	43	α	NN	-	-	-	-	-	-	-	(1
1868042	0	44	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	45	,	,	-	-	-	-	-	-	-	-
1868042	0	46	and	CC	-	-	-	-	-	-	-	-
1868042	0	47	that	IN	-	-	-	-	-	-	-	-
1868042	0	48	this	DT	-	-	-	-	-	-	-	-
1868042	0	49	effect	NN	-	-	-	-	-	-	-	-
1868042	0	50	could	MD	-	-	-	-	-	-	-	-
1868042	0	51	be	VB	-	-	-	-	-	-	-	-
1868042	0	52	completely	RB	-	-	-	-	-	-	-	-
1868042	0	53	reversed	VBN	-	-	-	-	-	-	-	-
1868042	0	54	by	IN	-	-	-	-	-	-	-	-
1868042	0	55	2	CD	-	-	-	-	-	-	-	(127
1868042	0	56	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	57	diazoxide	NN	-	-	-	-	-	-	-	127)
1868042	0	58	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	59	Figure	NN	-	-	-	-	-	-	-	(134|(135a)|(81)
1868042	0	60	6A	NN	-	-	-	-	-	-	-	134)
1868042	0	61	and	CC	-	-	-	-	-	-	-	-
1868042	0	62	6B	NN	-	-	-	-	-	-	-	(135a)
1868042	0	63	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	64	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Furthermore	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	-
1868042	0	4	re-activation	NN	-	-	-	-	-	-	-	-
1868042	0	5	of	IN	-	-	-	-	-	-	-	-
1868042	0	6	α	NN	-	-	-	-	-	-	-	(69
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	cell	NN	-	-	-	-	-	-	-	-
1868042	0	9	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	10	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	11	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	12	i	NN	-	-	-	-	-	-	-	69)
1868042	0	13	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	14	by	IN	-	-	-	-	-	-	-	-
1868042	0	15	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	16	could	MD	-	-	-	-	-	-	-	-
1868042	0	17	be	VB	-	-	-	-	-	-	-	-
1868042	0	18	prevented	VBN	-	-	-	-	-	-	-	-
1868042	0	19	by	IN	-	-	-	-	-	-	-	-
1868042	0	20	application	NN	-	-	-	-	-	-	-	-
1868042	0	21	of	IN	-	-	-	-	-	-	-	-
1868042	0	22	100	CD	-	-	-	-	-	-	-	(136
1868042	0	23	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	24	tolbutamide	NN	-	-	-	-	-	-	-	136)
1868042	0	25	,	,	-	-	-	-	-	-	-	-
1868042	0	26	confirming	VBG	-	-	-	-	-	-	-	-
1868042	0	27	the	DT	-	-	-	-	-	-	-	-
1868042	0	28	role	NN	-	-	-	-	-	-	-	-
1868042	0	29	of	IN	-	-	-	-	-	-	-	-
1868042	0	30	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	31	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	32	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	33	Figure	NN	-	-	-	-	-	-	-	(137|(81)
1868042	0	34	6C	NN	-	-	-	-	-	-	-	137)
1868042	0	35	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	36	.	.	-	-	-	-	-	-	-	-

1868042	0	1	An	DT	-	-	-	-	-	-	-	-
1868042	0	2	analysis	NN	-	-	-	-	-	-	-	-
1868042	0	3	of	IN	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	dose	NN	-	-	-	-	-	-	-	-
1868042	0	6	–	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	response	NN	-	-	-	-	-	-	-	-
1868042	0	8	relationship	NN	-	-	-	-	-	-	-	-
1868042	0	9	to	IN	-	-	-	-	-	-	-	-
1868042	0	10	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	11	demonstrated	VBD	-	-	-	-	-	-	-	-
1868042	0	12	a	DT	-	-	-	-	-	-	-	-
1868042	0	13	maximally	RB	-	-	-	-	-	-	-	-
1868042	0	14	effective	JJ	-	-	-	-	-	-	-	-
1868042	0	15	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	16	of	IN	-	-	-	-	-	-	-	-
1868042	0	17	1.7	CD	-	-	-	-	-	-	-	-
1868042	0	18	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	Figure	NN	-	-	-	-	-	-	-	(138|(81)
1868042	0	21	6D	NN	-	-	-	-	-	-	-	138)
1868042	0	22	and	CC	-	-	-	-	-	-	-	-
1868042	0	23	6E	NN	-	-	-	-	-	-	-	-
1868042	0	24	;	:	-	-	-	-	-	-	-	-
1868042	0	25	n	NN	-	-	-	-	-	-	-	-
1868042	0	26	=	SYM	-	-	-	-	-	-	-	-
1868042	0	27	38	CD	-	-	-	-	-	-	-	-
1868042	0	28	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	29	in	IN	-	-	-	-	-	-	-	-
1868042	0	30	9	CD	-	-	-	-	-	-	-	-
1868042	0	31	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	32	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	33	,	,	-	-	-	-	-	-	-	-
1868042	0	34	far	RB	-	-	-	-	-	-	-	-
1868042	0	35	below	IN	-	-	-	-	-	-	-	-
1868042	0	36	the	DT	-	-	-	-	-	-	-	-
1868042	0	37	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	38	necessary	JJ	-	-	-	-	-	-	-	-
1868042	0	39	to	TO	-	-	-	-	-	-	-	-
1868042	0	40	block	VB	-	-	-	-	-	-	-	-
1868042	0	41	β	NN	-	-	-	-	-	-	-	(22
1868042	0	42	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	43	cell	NN	-	-	-	-	-	-	-	-
1868042	0	44	responses	NNS	-	-	-	-	-	-	-	22)
1868042	0	45	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	46	Figure	NN	-	-	-	-	-	-	-	(138|(81)
1868042	0	47	6D	NN	-	-	-	-	-	-	-	138)
1868042	0	48	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	49	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Increases	NNS	-	-	-	-	-	-	-	-
1868042	0	2	in	IN	-	-	-	-	-	-	-	-
1868042	0	3	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	4	above	IN	-	-	-	-	-	-	-	-
1868042	0	5	20	CD	-	-	-	-	-	-	-	-
1868042	0	6	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	7	blocked	VBD	-	-	-	-	-	-	-	-
1868042	0	8	the	DT	-	-	-	-	-	-	-	(139a|(69
1868042	0	9	[	-LRB-	-	-	-	-	-	-	-	(122
1868042	0	10	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	11	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	12	i	NN	-	-	-	-	-	-	-	122)
1868042	0	13	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	14	of	IN	-	-	-	-	-	-	-	139a)
1868042	0	15	α	NN	-	-	-	-	-	-	-	(1
1868042	0	16	cells	NNS	-	-	-	-	-	-	-	69)|1)
1868042	0	17	and	CC	-	-	-	-	-	-	-	-
1868042	0	18	β	NN	-	-	-	-	-	-	-	(139a|(21
1868042	0	19	cells	NNS	-	-	-	-	-	-	-	21)|139a)
1868042	0	20	in	IN	-	-	-	-	-	-	-	-
1868042	0	21	parallel	JJ	-	-	-	-	-	-	-	-
1868042	0	22	,	,	-	-	-	-	-	-	-	-
1868042	0	23	consistent	JJ	-	-	-	-	-	-	-	-
1868042	0	24	with	IN	-	-	-	-	-	-	-	-
1868042	0	25	the	DT	-	-	-	-	-	-	-	-
1868042	0	26	effect	NN	-	-	-	-	-	-	-	-
1868042	0	27	on	IN	-	-	-	-	-	-	-	-
1868042	0	28	glucagon	NN	-	-	-	-	-	-	-	(24|(72|(2)
1868042	0	29	and	CC	-	-	-	-	-	-	-	-
1868042	0	30	insulin	NN	-	-	-	-	-	-	-	(20|(19)|24)
1868042	0	31	release	NN	-	-	-	-	-	-	-	72)|20)
1868042	0	32	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Na+	NN	-	-	-	-	-	-	-	(140
1868042	0	2	Channels	NNS	-	-	-	-	-	-	-	140)
1868042	0	3	Regulate	VBP	-	-	-	-	-	-	-	-
1868042	0	4	Low	JJ	-	-	-	-	-	-	-	-
1868042	0	5	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	6	Glucose	NN	-	-	-	-	-	-	-	-
1868042	0	7	–	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	Stimulated	VBN	-	-	-	-	-	-	-	-
1868042	0	9	Glucagon	NN	-	-	-	-	-	-	-	-
1868042	0	10	Secretion	NN	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	above	JJ	-	-	-	-	-	-	-	-
1868042	0	3	data	NNS	-	-	-	-	-	-	-	-
1868042	0	4	suggest	VBP	-	-	-	-	-	-	-	-
1868042	0	5	that	IN	-	-	-	-	-	-	-	-
1868042	0	6	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	9	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	10	of	IN	-	-	-	-	-	-	-	-
1868042	0	11	α	NN	-	-	-	-	-	-	-	(63
1868042	0	12	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	13	cell	NN	-	-	-	-	-	-	-	-
1868042	0	14	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	15	channels	NNS	-	-	-	-	-	-	-	63)
1868042	0	16	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	17	involved	VBN	-	-	-	-	-	-	-	-
1868042	0	18	in	IN	-	-	-	-	-	-	-	-
1868042	0	19	the	DT	-	-	-	-	-	-	-	(141
1868042	0	20	suppression	NN	-	-	-	-	-	-	-	-
1868042	0	21	of	IN	-	-	-	-	-	-	-	-
1868042	0	22	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	23	secretion	NN	-	-	-	-	-	-	-	25)|141)
1868042	0	24	.	.	-	-	-	-	-	-	-	-

1868042	0	1	It	PRP	-	-	-	-	-	-	-	-
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	not	RB	-	-	-	-	-	-	-	-
1868042	0	4	clear	JJ	-	-	-	-	-	-	-	-
1868042	0	5	however	RB	-	-	-	-	-	-	-	-
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	how	WRB	-	-	-	-	-	-	-	-
1868042	0	8	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	9	channel	NN	-	-	-	-	-	-	-	32)
1868042	0	10	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	11	and	CC	-	-	-	-	-	-	-	-
1868042	0	12	membrane	NN	-	-	-	-	-	-	-	(53
1868042	0	13	depolarisation	NN	-	-	-	-	-	-	-	53)
1868042	0	14	result	VBP	-	-	-	-	-	-	-	-
1868042	0	15	in	IN	-	-	-	-	-	-	-	-
1868042	0	16	suppression	NN	-	-	-	-	-	-	-	(141
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	secretion	NN	-	-	-	-	-	-	-	(47)|141)
1868042	0	19	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Unlike	IN	-	-	-	-	-	-	-	-
1868042	0	2	in	IN	-	-	-	-	-	-	-	-
1868042	0	3	β	NN	-	-	-	-	-	-	-	(21
1868042	0	4	cells	NNS	-	-	-	-	-	-	-	21)
1868042	0	5	,	,	-	-	-	-	-	-	-	-
1868042	0	6	α	NN	-	-	-	-	-	-	-	(142
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	cell	NN	-	-	-	-	-	-	-	-
1868042	0	9	Na+	NN	-	-	-	-	-	-	-	-
1868042	0	10	channels	NNS	-	-	-	-	-	-	-	142)
1868042	0	11	are	VBP	-	-	-	-	-	-	-	-
1868042	0	12	active	JJ	-	-	-	-	-	-	-	-
1868042	0	13	in	IN	-	-	-	-	-	-	-	-
1868042	0	14	the	DT	-	-	-	-	-	-	-	-
1868042	0	15	physiological	JJ	-	-	-	-	-	-	-	-
1868042	0	16	range	NN	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	membrane	NN	-	-	-	-	-	-	-	(143
1868042	0	19	potentials	NNS	-	-	-	-	-	-	-	143)
1868042	0	20	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Previous	JJ	-	-	-	-	-	-	-	-
1868042	0	2	work	NN	-	-	-	-	-	-	-	-
1868042	0	3	from	IN	-	-	-	-	-	-	-	-
1868042	0	4	our	PRP$	-	-	-	-	-	-	-	(4)
1868042	0	5	group	NN	-	-	-	-	-	-	-	-
1868042	0	6	suggested	VBD	-	-	-	-	-	-	-	-
1868042	0	7	that	IN	-	-	-	-	-	-	-	-
1868042	0	8	the	DT	-	-	-	-	-	-	-	(144
1868042	0	9	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	10	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	11	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	12	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	13	of	IN	-	-	-	-	-	-	-	-
1868042	0	14	Na+	NN	-	-	-	-	-	-	-	(140
1868042	0	15	channels	NNS	-	-	-	-	-	-	-	144)|140)
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	which	WDT	-	-	-	-	-	-	-	-
1868042	0	18	in	IN	-	-	-	-	-	-	-	-
1868042	0	19	mouse	NN	-	-	-	-	-	-	-	(145
1868042	0	20	α	NN	-	-	-	-	-	-	-	-
1868042	0	21	cells	NNS	-	-	-	-	-	-	-	145)
1868042	0	22	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	23	half	RB	-	-	-	-	-	-	-	-
1868042	0	24	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	25	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	26	at	IN	-	-	-	-	-	-	-	-
1868042	0	27	−	SYM	-	-	-	-	-	-	-	-
1868042	0	28	42	CD	-	-	-	-	-	-	-	-
1868042	0	29	mV	NNS	-	-	-	-	-	-	-	-
1868042	0	30	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	31	43	CD	-	-	-	-	-	-	-	-
1868042	0	32	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	33	,	,	-	-	-	-	-	-	-	-
1868042	0	34	contributes	VBZ	-	-	-	-	-	-	-	-
1868042	0	35	to	IN	-	-	-	-	-	-	-	-
1868042	0	36	cessation	NN	-	-	-	-	-	-	-	-
1868042	0	37	of	IN	-	-	-	-	-	-	-	-
1868042	0	38	electrical	JJ	-	-	-	-	-	-	-	(42
1868042	0	39	activity	NN	-	-	-	-	-	-	-	42)
1868042	0	40	upon	IN	-	-	-	-	-	-	-	-
1868042	0	41	α	NN	-	-	-	-	-	-	-	(1
1868042	0	42	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	43	cell	NN	-	-	-	-	-	-	-	1)
1868042	0	44	depolarisation	NN	-	-	-	-	-	-	-	-
1868042	0	45	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	46	14	CD	-	-	-	-	-	-	-	-
1868042	0	47	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	48	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	thus	RB	-	-	-	-	-	-	-	-
1868042	0	3	used	VBD	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	(34
1868042	0	5	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	6	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	8	Na+	NN	-	-	-	-	-	-	-	-
1868042	0	9	channel	NN	-	-	-	-	-	-	-	-
1868042	0	10	antagonist	NN	-	-	-	-	-	-	-	-
1868042	0	11	tetrodotoxin	NN	-	-	-	-	-	-	-	34)
1868042	0	12	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	13	TTX	NN	-	-	-	-	-	-	-	-
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	to	TO	-	-	-	-	-	-	-	-
1868042	0	16	test	VB	-	-	-	-	-	-	-	-
1868042	0	17	a	DT	-	-	-	-	-	-	-	-
1868042	0	18	role	NN	-	-	-	-	-	-	-	-
1868042	0	19	for	IN	-	-	-	-	-	-	-	-
1868042	0	20	these	DT	-	-	-	-	-	-	-	(142
1868042	0	21	channels	NNS	-	-	-	-	-	-	-	142)
1868042	0	22	in	IN	-	-	-	-	-	-	-	-
1868042	0	23	α	NN	-	-	-	-	-	-	-	(1|(68
1868042	0	24	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	25	cell	NN	-	-	-	-	-	-	-	1)
1868042	0	26	function	NN	-	-	-	-	-	-	-	68)
1868042	0	27	and	CC	-	-	-	-	-	-	-	-
1868042	0	28	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	29	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	30	.	.	-	-	-	-	-	-	-	-

1868042	0	1	TTX	NN	-	-	-	-	-	-	-	(34)
1868042	0	2	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	3	0.1	CD	-	-	-	-	-	-	-	-
1868042	0	4	μg	NNS	-	-	-	-	-	-	-	-
1868042	0	5	/	SYM	-	-	-	-	-	-	-	-
1868042	0	6	ml	NN	-	-	-	-	-	-	-	-
1868042	0	7	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	8	suppressed	VBD	-	-	-	-	-	-	-	-
1868042	0	9	glucagon	NN	-	-	-	-	-	-	-	(88|(2)
1868042	0	10	release	NN	-	-	-	-	-	-	-	-
1868042	0	11	from	IN	-	-	-	-	-	-	-	-
1868042	0	12	mouse	NN	-	-	-	-	-	-	-	(71
1868042	0	13	islets	NNS	-	-	-	-	-	-	-	88)|71)
1868042	0	14	by	IN	-	-	-	-	-	-	-	-
1868042	0	15	56	CD	-	-	-	-	-	-	-	-
1868042	0	16	±	SYM	-	-	-	-	-	-	-	-
1868042	0	17	5	CD	-	-	-	-	-	-	-	-
1868042	0	18	%	NN	-	-	-	-	-	-	-	-
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	n	NN	-	-	-	-	-	-	-	-
1868042	0	21	=	SYM	-	-	-	-	-	-	-	-
1868042	0	22	10	CD	-	-	-	-	-	-	-	-
1868042	0	23	,	,	-	-	-	-	-	-	-	-
1868042	0	24	p	NN	-	-	-	-	-	-	-	-
1868042	0	25	<	SYM	-	-	-	-	-	-	-	-
1868042	0	26	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	27	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	28	under	IN	-	-	-	-	-	-	-	-
1868042	0	29	low	JJ	-	-	-	-	-	-	-	(59
1868042	0	30	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	31	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	32	conditions	NNS	-	-	-	-	-	-	-	59)
1868042	0	33	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	34	Figure	NN	-	-	-	-	-	-	-	(146|(81)
1868042	0	35	7A	NN	-	-	-	-	-	-	-	146)
1868042	0	36	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	37	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	effect	NN	-	-	-	-	-	-	-	-
1868042	0	3	of	IN	-	-	-	-	-	-	-	-
1868042	0	4	TTX	NN	-	-	-	-	-	-	-	(34)
1868042	0	5	in	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	(59
1868042	0	7	low	JJ	-	-	-	-	-	-	-	-
1868042	0	8	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	10	condition	NN	-	-	-	-	-	-	-	59)
1868042	0	11	was	VBD	-	-	-	-	-	-	-	-
1868042	0	12	similar	JJ	-	-	-	-	-	-	-	-
1868042	0	13	to	IN	-	-	-	-	-	-	-	-
1868042	0	14	what	WP	-	-	-	-	-	-	-	-
1868042	0	15	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	16	observed	VBD	-	-	-	-	-	-	-	-
1868042	0	17	with	IN	-	-	-	-	-	-	-	-
1868042	0	18	high	JJ	-	-	-	-	-	-	-	-
1868042	0	19	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	20	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	21	stimulation	NN	-	-	-	-	-	-	-	-
1868042	0	22	alone	RB	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	With	IN	-	-	-	-	-	-	-	-
1868042	0	2	TTX	NN	-	-	-	-	-	-	-	(34)
1868042	0	3	present	NN	-	-	-	-	-	-	-	-
1868042	0	4	,	,	-	-	-	-	-	-	-	-
1868042	0	5	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	6	was	VBD	-	-	-	-	-	-	-	-
1868042	0	7	without	IN	-	-	-	-	-	-	-	-
1868042	0	8	further	JJ	-	-	-	-	-	-	-	-
1868042	0	9	inhibitory	JJ	-	-	-	-	-	-	-	-
1868042	0	10	action	NN	-	-	-	-	-	-	-	-
1868042	0	11	,	,	-	-	-	-	-	-	-	-
1868042	0	12	suggesting	VBG	-	-	-	-	-	-	-	-
1868042	0	13	that	IN	-	-	-	-	-	-	-	-
1868042	0	14	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	15	inhibits	VBZ	-	-	-	-	-	-	-	-
1868042	0	16	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	17	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	18	through	IN	-	-	-	-	-	-	-	-
1868042	0	19	a	DT	-	-	-	-	-	-	-	-
1868042	0	20	Na+	NN	-	-	-	-	-	-	-	-
1868042	0	21	channel	NN	-	-	-	-	-	-	-	-
1868042	0	22	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	23	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	24	mechanism	NN	-	-	-	-	-	-	-	-
1868042	0	25	.	.	-	-	-	-	-	-	-	-

1868042	0	1	TTX	NN	-	-	-	-	-	-	-	(34)
1868042	0	2	has	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	no	DT	-	-	-	-	-	-	-	-
1868042	0	4	effect	NN	-	-	-	-	-	-	-	-
1868042	0	5	on	IN	-	-	-	-	-	-	-	-
1868042	0	6	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	stimulated	VBN	-	-	-	-	-	-	-	-
1868042	0	9	insulin	NN	-	-	-	-	-	-	-	-
1868042	0	10	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	11	in	IN	-	-	-	-	-	-	-	-
1868042	0	12	mouse	NN	-	-	-	-	-	-	-	(71
1868042	0	13	islets	NNS	-	-	-	-	-	-	-	71)
1868042	0	14	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	15	Figure	NN	-	-	-	-	-	-	-	(146|(81)
1868042	0	16	7A	NN	-	-	-	-	-	-	-	146)
1868042	0	17	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	18	;	:	-	-	-	-	-	-	-	-
1868042	0	19	again	RB	-	-	-	-	-	-	-	-
1868042	0	20	suggestive	JJ	-	-	-	-	-	-	-	-
1868042	0	21	of	IN	-	-	-	-	-	-	-	-
1868042	0	22	a	DT	-	-	-	-	-	-	-	-
1868042	0	23	direct	JJ	-	-	-	-	-	-	-	-
1868042	0	24	rather	RB	-	-	-	-	-	-	-	-
1868042	0	25	than	IN	-	-	-	-	-	-	-	-
1868042	0	26	indirect	JJ	-	-	-	-	-	-	-	-
1868042	0	27	effect	NN	-	-	-	-	-	-	-	-
1868042	0	28	on	IN	-	-	-	-	-	-	-	-
1868042	0	29	α	NN	-	-	-	-	-	-	-	(1
1868042	0	30	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	In	IN	-	-	-	-	-	-	-	-
1868042	0	2	accordance	NN	-	-	-	-	-	-	-	-
1868042	0	3	with	IN	-	-	-	-	-	-	-	-
1868042	0	4	this	DT	-	-	-	-	-	-	-	-
1868042	0	5	,	,	-	-	-	-	-	-	-	-
1868042	0	6	application	NN	-	-	-	-	-	-	-	-
1868042	0	7	of	IN	-	-	-	-	-	-	-	-
1868042	0	8	0.1	CD	-	-	-	-	-	-	-	-
1868042	0	9	μg	NNS	-	-	-	-	-	-	-	-
1868042	0	10	/	SYM	-	-	-	-	-	-	-	-
1868042	0	11	ml	NN	-	-	-	-	-	-	-	-
1868042	0	12	TTX	NN	-	-	-	-	-	-	-	-
1868042	0	13	to	IN	-	-	-	-	-	-	-	-
1868042	0	14	mouse	NN	-	-	-	-	-	-	-	(71
1868042	0	15	islets	NNS	-	-	-	-	-	-	-	71)
1868042	0	16	reversibly	RB	-	-	-	-	-	-	-	-
1868042	0	17	abolished	VBD	-	-	-	-	-	-	-	-
1868042	0	18	the	DT	-	-	-	-	-	-	-	-
1868042	0	19	α	NN	-	-	-	-	-	-	-	-
1868042	0	20	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	21	cell	NN	-	-	-	-	-	-	-	-
1868042	0	22	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	23	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	24	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	25	i	NN	-	-	-	-	-	-	-	-
1868042	0	26	response	NN	-	-	-	-	-	-	-	-
1868042	0	27	evoked	VBN	-	-	-	-	-	-	-	-
1868042	0	28	by	IN	-	-	-	-	-	-	-	-
1868042	0	29	low	JJ	-	-	-	-	-	-	-	(111
1868042	0	30	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	31	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	32	concentrations	NNS	-	-	-	-	-	-	-	111)
1868042	0	33	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	34	Figure	NN	-	-	-	-	-	-	-	(147|(148a)|(81)
1868042	0	35	7B	NN	-	-	-	-	-	-	-	147)
1868042	0	36	and	CC	-	-	-	-	-	-	-	-
1868042	0	37	7C	NN	-	-	-	-	-	-	-	(148a)
1868042	0	38	;	:	-	-	-	-	-	-	-	-
1868042	0	39	n	NN	-	-	-	-	-	-	-	-
1868042	0	40	=	SYM	-	-	-	-	-	-	-	-
1868042	0	41	18	CD	-	-	-	-	-	-	-	-
1868042	0	42	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	43	in	IN	-	-	-	-	-	-	-	-
1868042	0	44	4	CD	-	-	-	-	-	-	-	-
1868042	0	45	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	46	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	47	,	,	-	-	-	-	-	-	-	-
1868042	0	48	but	CC	-	-	-	-	-	-	-	-
1868042	0	49	had	VBD	-	-	-	-	-	-	-	-
1868042	0	50	no	DT	-	-	-	-	-	-	-	-
1868042	0	51	effect	NN	-	-	-	-	-	-	-	-
1868042	0	52	on	IN	-	-	-	-	-	-	-	-
1868042	0	53	β	NN	-	-	-	-	-	-	-	(139
1868042	0	54	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	55	cell	NN	-	-	-	-	-	-	-	-
1868042	0	56	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	57	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	58	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	59	i	NN	-	-	-	-	-	-	-	139)
1868042	0	60	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	61	unpublished	JJ	-	-	-	-	-	-	-	(133
1868042	0	62	data	NNS	-	-	-	-	-	-	-	133)
1868042	0	63	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	64	.	.	-	-	-	-	-	-	-	-

1868042	0	1	N	NN	-	-	-	-	-	-	-	(35
1868042	0	2	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	3	Type	NN	-	-	-	-	-	-	-	-
1868042	0	4	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	5	Channels	NNS	-	-	-	-	-	-	-	35)
1868042	0	6	Mediate	VBP	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	-
1868042	0	8	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	9	Influx	NN	-	-	-	-	-	-	-	-
1868042	0	10	That	WDT	-	-	-	-	-	-	-	-
1868042	0	11	Triggers	VBZ	-	-	-	-	-	-	-	-
1868042	0	12	Glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	13	Secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	14	and	CC	-	-	-	-	-	-	-	-
1868042	0	15	α	NN	-	-	-	-	-	-	-	(39
1868042	0	16	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	Cell	NN	-	-	-	-	-	-	-	-
1868042	0	18	Exocytosis	NN	-	-	-	-	-	-	-	39)

1868042	0	1	Downstream	RB	-	-	-	-	-	-	-	-
1868042	0	2	of	IN	-	-	-	-	-	-	-	-
1868042	0	3	Na+	NN	-	-	-	-	-	-	-	(140|(149
1868042	0	4	channel	NN	-	-	-	-	-	-	-	140)
1868042	0	5	activation	NN	-	-	-	-	-	-	-	149)
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	-
1868042	0	8	opening	NN	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	VDCCs	NNS	-	-	-	-	-	-	-	(67)
1868042	0	11	allows	VBZ	-	-	-	-	-	-	-	-
1868042	0	12	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	13	into	IN	-	-	-	-	-	-	-	-
1868042	0	14	α	NN	-	-	-	-	-	-	-	(1
1868042	0	15	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	triggering	VBG	-	-	-	-	-	-	-	-
1868042	0	18	the	DT	-	-	-	-	-	-	-	-
1868042	0	19	exocytosis	NN	-	-	-	-	-	-	-	-
1868042	0	20	of	IN	-	-	-	-	-	-	-	-
1868042	0	21	glucagon	NN	-	-	-	-	-	-	-	-
1868042	0	22	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	23	containing	VBG	-	-	-	-	-	-	-	-
1868042	0	24	vesicles	NNS	-	-	-	-	-	-	-	-
1868042	0	25	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	applied	VBD	-	-	-	-	-	-	-	-
1868042	0	3	whole	JJ	-	-	-	-	-	-	-	-
1868042	0	4	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	5	cell	NN	-	-	-	-	-	-	-	-
1868042	0	6	patch	NN	-	-	-	-	-	-	-	-
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	clamp	NN	-	-	-	-	-	-	-	-
1868042	0	9	recordings	NNS	-	-	-	-	-	-	-	-
1868042	0	10	to	TO	-	-	-	-	-	-	-	-
1868042	0	11	establish	VB	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	α	NN	-	-	-	-	-	-	-	-
1868042	0	14	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	15	cell	NN	-	-	-	-	-	-	-	-
1868042	0	16	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	17	channel	NN	-	-	-	-	-	-	-	-
1868042	0	18	complement	NN	-	-	-	-	-	-	-	-
1868042	0	19	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	integrated	JJ	-	-	-	-	-	-	-	-
1868042	0	3	whole	JJ	-	-	-	-	-	-	-	-
1868042	0	4	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	5	cell	NN	-	-	-	-	-	-	-	-
1868042	0	6	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	7	current	NN	-	-	-	-	-	-	-	-
1868042	0	8	measured	VBN	-	-	-	-	-	-	-	-
1868042	0	9	during	IN	-	-	-	-	-	-	-	-
1868042	0	10	50	CD	-	-	-	-	-	-	-	-
1868042	0	11	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	ms	NN	-	-	-	-	-	-	-	-
1868042	0	13	depolarisations	NNS	-	-	-	-	-	-	-	-
1868042	0	14	from	IN	-	-	-	-	-	-	-	-
1868042	0	15	−	SYM	-	-	-	-	-	-	-	(150
1868042	0	16	70	CD	-	-	-	-	-	-	-	-
1868042	0	17	mV	NNS	-	-	-	-	-	-	-	150)
1868042	0	18	to	IN	-	-	-	-	-	-	-	-
1868042	0	19	0	CD	-	-	-	-	-	-	-	(151
1868042	0	20	mV	NNS	-	-	-	-	-	-	-	151)
1868042	0	21	amounted	VBD	-	-	-	-	-	-	-	-
1868042	0	22	to	IN	-	-	-	-	-	-	-	-
1868042	0	23	6.2	CD	-	-	-	-	-	-	-	-
1868042	0	24	±	SYM	-	-	-	-	-	-	-	-
1868042	0	25	0.8	CD	-	-	-	-	-	-	-	-
1868042	0	26	pC	NN	-	-	-	-	-	-	-	-
1868042	0	27	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	28	n	NN	-	-	-	-	-	-	-	-
1868042	0	29	=	SYM	-	-	-	-	-	-	-	-
1868042	0	30	15	CD	-	-	-	-	-	-	-	-
1868042	0	31	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	32	under	IN	-	-	-	-	-	-	-	-
1868042	0	33	control	NN	-	-	-	-	-	-	-	(152
1868042	0	34	conditions	NNS	-	-	-	-	-	-	-	152)
1868042	0	35	,	,	-	-	-	-	-	-	-	-
1868042	0	36	2.6	CD	-	-	-	-	-	-	-	-
1868042	0	37	±	SYM	-	-	-	-	-	-	-	-
1868042	0	38	0.8	CD	-	-	-	-	-	-	-	-
1868042	0	39	pC	NN	-	-	-	-	-	-	-	-
1868042	0	40	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	41	n	NN	-	-	-	-	-	-	-	-
1868042	0	42	=	SYM	-	-	-	-	-	-	-	-
1868042	0	43	10	CD	-	-	-	-	-	-	-	-
1868042	0	44	;	:	-	-	-	-	-	-	-	-
1868042	0	45	p	NN	-	-	-	-	-	-	-	-
1868042	0	46	<	SYM	-	-	-	-	-	-	-	-
1868042	0	47	0.05	CD	-	-	-	-	-	-	-	-
1868042	0	48	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	49	in	IN	-	-	-	-	-	-	-	-
1868042	0	50	the	DT	-	-	-	-	-	-	-	-
1868042	0	51	presence	NN	-	-	-	-	-	-	-	-
1868042	0	52	of	IN	-	-	-	-	-	-	-	-
1868042	0	53	50	CD	-	-	-	-	-	-	-	(153
1868042	0	54	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	55	nifedipine	NN	-	-	-	-	-	-	-	153)
1868042	0	56	,	,	-	-	-	-	-	-	-	-
1868042	0	57	and	CC	-	-	-	-	-	-	-	-
1868042	0	58	4.1	CD	-	-	-	-	-	-	-	-
1868042	0	59	±	SYM	-	-	-	-	-	-	-	-
1868042	0	60	0.5	CD	-	-	-	-	-	-	-	-
1868042	0	61	pC	NN	-	-	-	-	-	-	-	-
1868042	0	62	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	63	n	NN	-	-	-	-	-	-	-	-
1868042	0	64	=	SYM	-	-	-	-	-	-	-	-
1868042	0	65	12	CD	-	-	-	-	-	-	-	-
1868042	0	66	;	:	-	-	-	-	-	-	-	-
1868042	0	67	p	NN	-	-	-	-	-	-	-	-
1868042	0	68	<	SYM	-	-	-	-	-	-	-	-
1868042	0	69	0.01	CD	-	-	-	-	-	-	-	-
1868042	0	70	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	71	in	IN	-	-	-	-	-	-	-	-
1868042	0	72	the	DT	-	-	-	-	-	-	-	-
1868042	0	73	presence	NN	-	-	-	-	-	-	-	-
1868042	0	74	of	IN	-	-	-	-	-	-	-	-
1868042	0	75	1	CD	-	-	-	-	-	-	-	-
1868042	0	76	μM	NN	-	-	-	-	-	-	-	-
1868042	0	77	ω	NN	-	-	-	-	-	-	-	-
1868042	0	78	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	79	conotoxin	NN	-	-	-	-	-	-	-	-
1868042	0	80	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Thus	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	L	NN	-	-	-	-	-	-	-	(37a
1868042	0	4	-	HYPH	-	-	-	-	-	-	-	37a)
1868042	0	5	and	CC	-	-	-	-	-	-	-	-
1868042	0	6	N	NN	-	-	-	-	-	-	-	(35
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	type	NN	-	-	-	-	-	-	-	(37a
1868042	0	9	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	10	channels	NNS	-	-	-	-	-	-	-	37a)|35)
1868042	0	11	account	VBP	-	-	-	-	-	-	-	-
1868042	0	12	for	IN	-	-	-	-	-	-	-	-
1868042	0	13	58	CD	-	-	-	-	-	-	-	-
1868042	0	14	%	NN	-	-	-	-	-	-	-	-
1868042	0	15	and	CC	-	-	-	-	-	-	-	-
1868042	0	16	34	CD	-	-	-	-	-	-	-	-
1868042	0	17	%	NN	-	-	-	-	-	-	-	-
1868042	0	18	of	IN	-	-	-	-	-	-	-	-
1868042	0	19	the	DT	-	-	-	-	-	-	-	-
1868042	0	20	α	NN	-	-	-	-	-	-	-	-
1868042	0	21	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	22	cell	NN	-	-	-	-	-	-	-	-
1868042	0	23	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	24	current	NN	-	-	-	-	-	-	-	-
1868042	0	25	,	,	-	-	-	-	-	-	-	-
1868042	0	26	respectively	RB	-	-	-	-	-	-	-	-
1868042	0	27	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Figure	NN	-	-	-	-	-	-	-	(154|(81)
1868042	0	2	8A	NN	-	-	-	-	-	-	-	154)
1868042	0	3	compares	VBZ	-	-	-	-	-	-	-	-
1868042	0	4	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	5	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	6	at	IN	-	-	-	-	-	-	-	-
1868042	0	7	1	CD	-	-	-	-	-	-	-	(155|(101d)
1868042	0	8	and	CC	-	-	-	-	-	-	-	-
1868042	0	9	20	CD	-	-	-	-	-	-	-	(116
1868042	0	10	mM	NNS	-	-	-	-	-	-	-	(101d
1868042	0	11	glucose	NN	-	-	-	-	-	-	-	155)|116)|101d)
1868042	0	12	under	IN	-	-	-	-	-	-	-	-
1868042	0	13	control	NN	-	-	-	-	-	-	-	(152
1868042	0	14	conditions	NNS	-	-	-	-	-	-	-	152)
1868042	0	15	and	CC	-	-	-	-	-	-	-	-
1868042	0	16	in	IN	-	-	-	-	-	-	-	-
1868042	0	17	the	DT	-	-	-	-	-	-	-	(156|(157b
1868042	0	18	presence	NN	-	-	-	-	-	-	-	-
1868042	0	19	of	IN	-	-	-	-	-	-	-	157b)
1868042	0	20	100	CD	-	-	-	-	-	-	-	(158
1868042	0	21	nM	NNS	-	-	-	-	-	-	-	-
1868042	0	22	ω	NN	-	-	-	-	-	-	-	-
1868042	0	23	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	24	conotoxin	NN	-	-	-	-	-	-	-	158)|156)
1868042	0	25	and	CC	-	-	-	-	-	-	-	-
1868042	0	26	20	CD	-	-	-	-	-	-	-	(157b|(159
1868042	0	27	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	28	nifedipine	NN	-	-	-	-	-	-	-	159)|157b)
1868042	0	29	,	,	-	-	-	-	-	-	-	-
1868042	0	30	respectively	RB	-	-	-	-	-	-	-	-
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	found	VBD	-	-	-	-	-	-	-	-
1868042	0	3	that	IN	-	-	-	-	-	-	-	-
1868042	0	4	whereas	IN	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	(38
1868042	0	6	L	NN	-	-	-	-	-	-	-	-
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	type	NN	-	-	-	-	-	-	-	-
1868042	0	9	channel	NN	-	-	-	-	-	-	-	-
1868042	0	10	blocker	NN	-	-	-	-	-	-	-	-
1868042	0	11	nifedipine	NN	-	-	-	-	-	-	-	38)
1868042	0	12	had	VBD	-	-	-	-	-	-	-	-
1868042	0	13	no	DT	-	-	-	-	-	-	-	-
1868042	0	14	effect	NN	-	-	-	-	-	-	-	-
1868042	0	15	on	IN	-	-	-	-	-	-	-	-
1868042	0	16	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	17	release	NN	-	-	-	-	-	-	-	3)
1868042	0	18	at	IN	-	-	-	-	-	-	-	-
1868042	0	19	1	CD	-	-	-	-	-	-	-	(101b)
1868042	0	20	or	CC	-	-	-	-	-	-	-	-
1868042	0	21	20	CD	-	-	-	-	-	-	-	(116
1868042	0	22	mM	NNS	-	-	-	-	-	-	-	(101b
1868042	0	23	glucose	NN	-	-	-	-	-	-	-	116)|101b)
1868042	0	24	,	,	-	-	-	-	-	-	-	-
1868042	0	25	the	DT	-	-	-	-	-	-	-	(36
1868042	0	26	N	NN	-	-	-	-	-	-	-	-
1868042	0	27	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	28	type	NN	-	-	-	-	-	-	-	-
1868042	0	29	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	30	channel	NN	-	-	-	-	-	-	-	-
1868042	0	31	blocker	NN	-	-	-	-	-	-	-	-
1868042	0	32	ω	NN	-	-	-	-	-	-	-	-
1868042	0	33	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	34	conotoxin	NN	-	-	-	-	-	-	-	36)
1868042	0	35	inhibited	VBD	-	-	-	-	-	-	-	-
1868042	0	36	the	DT	-	-	-	-	-	-	-	-
1868042	0	37	release	NN	-	-	-	-	-	-	-	-
1868042	0	38	of	IN	-	-	-	-	-	-	-	-
1868042	0	39	the	DT	-	-	-	-	-	-	-	(2
1868042	0	40	hormone	NN	-	-	-	-	-	-	-	2)
1868042	0	41	to	IN	-	-	-	-	-	-	-	-
1868042	0	42	a	DT	-	-	-	-	-	-	-	-
1868042	0	43	level	NN	-	-	-	-	-	-	-	-
1868042	0	44	similar	JJ	-	-	-	-	-	-	-	-
1868042	0	45	to	IN	-	-	-	-	-	-	-	-
1868042	0	46	that	DT	-	-	-	-	-	-	-	-
1868042	0	47	of	IN	-	-	-	-	-	-	-	-
1868042	0	48	high	JJ	-	-	-	-	-	-	-	(160
1868042	0	49	glucose	NN	-	-	-	-	-	-	-	160)
1868042	0	50	,	,	-	-	-	-	-	-	-	-
1868042	0	51	tolbutamide	NN	-	-	-	-	-	-	-	(23)
1868042	0	52	,	,	-	-	-	-	-	-	-	-
1868042	0	53	and	CC	-	-	-	-	-	-	-	-
1868042	0	54	TTX	NN	-	-	-	-	-	-	-	(34)
1868042	0	55	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Furthermore	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	4	exerted	VBD	-	-	-	-	-	-	-	-
1868042	0	5	no	DT	-	-	-	-	-	-	-	-
1868042	0	6	additional	JJ	-	-	-	-	-	-	-	-
1868042	0	7	inhibitory	JJ	-	-	-	-	-	-	-	-
1868042	0	8	action	NN	-	-	-	-	-	-	-	-
1868042	0	9	in	IN	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	(161
1868042	0	11	presence	NN	-	-	-	-	-	-	-	-
1868042	0	12	of	IN	-	-	-	-	-	-	-	-
1868042	0	13	ω	NN	-	-	-	-	-	-	-	(36
1868042	0	14	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	15	conotoxin	NN	-	-	-	-	-	-	-	36)|161)
1868042	0	16	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Thus	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	4	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	5	stimulated	VBN	-	-	-	-	-	-	-	-
1868042	0	6	by	IN	-	-	-	-	-	-	-	-
1868042	0	7	low	JJ	-	-	-	-	-	-	-	(162
1868042	0	8	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	10	levels	NNS	-	-	-	-	-	-	-	162)
1868042	0	11	depends	VBZ	-	-	-	-	-	-	-	-
1868042	0	12	principally	RB	-	-	-	-	-	-	-	-
1868042	0	13	on	IN	-	-	-	-	-	-	-	-
1868042	0	14	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	15	influx	NN	-	-	-	-	-	-	-	-
1868042	0	16	through	IN	-	-	-	-	-	-	-	-
1868042	0	17	N	NN	-	-	-	-	-	-	-	(35
1868042	0	18	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	19	type	NN	-	-	-	-	-	-	-	-
1868042	0	20	channels	NNS	-	-	-	-	-	-	-	35)
1868042	0	21	,	,	-	-	-	-	-	-	-	-
1868042	0	22	although	IN	-	-	-	-	-	-	-	-
1868042	0	23	these	DT	-	-	-	-	-	-	-	-
1868042	0	24	only	RB	-	-	-	-	-	-	-	-
1868042	0	25	account	VBP	-	-	-	-	-	-	-	-
1868042	0	26	for	IN	-	-	-	-	-	-	-	-
1868042	0	27	one	CD	-	-	-	-	-	-	-	-
1868042	0	28	third	NN	-	-	-	-	-	-	-	-
1868042	0	29	of	IN	-	-	-	-	-	-	-	-
1868042	0	30	the	DT	-	-	-	-	-	-	-	(163
1868042	0	31	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	32	current	NN	-	-	-	-	-	-	-	163)
1868042	0	33	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	confirmed	VBD	-	-	-	-	-	-	-	-
1868042	0	3	this	DT	-	-	-	-	-	-	-	-
1868042	0	4	Ca2+	NN	-	-	-	-	-	-	-	(55
1868042	0	5	channel	NN	-	-	-	-	-	-	-	55)
1868042	0	6	dependence	NN	-	-	-	-	-	-	-	-
1868042	0	7	by	IN	-	-	-	-	-	-	-	-
1868042	0	8	conducting	VBG	-	-	-	-	-	-	-	-
1868042	0	9	high	JJ	-	-	-	-	-	-	-	-
1868042	0	10	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	11	resolution	NN	-	-	-	-	-	-	-	-
1868042	0	12	single	JJ	-	-	-	-	-	-	-	-
1868042	0	13	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	14	cell	NN	-	-	-	-	-	-	-	-
1868042	0	15	capacitance	NN	-	-	-	-	-	-	-	-
1868042	0	16	measurements	NNS	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	exocytosis	NN	-	-	-	-	-	-	-	(43)
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	Figure	NN	-	-	-	-	-	-	-	(164|(81)
1868042	0	21	8B	NN	-	-	-	-	-	-	-	164)
1868042	0	22	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Exocytosis	NN	-	-	-	-	-	-	-	-
1868042	0	2	elicited	VBN	-	-	-	-	-	-	-	-
1868042	0	3	by	IN	-	-	-	-	-	-	-	-
1868042	0	4	500	CD	-	-	-	-	-	-	-	-
1868042	0	5	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	6	ms	NN	-	-	-	-	-	-	-	-
1868042	0	7	step	NN	-	-	-	-	-	-	-	-
1868042	0	8	depolarisations	NNS	-	-	-	-	-	-	-	-
1868042	0	9	from	IN	-	-	-	-	-	-	-	-
1868042	0	10	−	SYM	-	-	-	-	-	-	-	(150b
1868042	0	11	70	CD	-	-	-	-	-	-	-	150b)
1868042	0	12	to	IN	-	-	-	-	-	-	-	-
1868042	0	13	0	CD	-	-	-	-	-	-	-	(151
1868042	0	14	mV	NNS	-	-	-	-	-	-	-	(150b)|151)
1868042	0	15	averaged	VBD	-	-	-	-	-	-	-	-
1868042	0	16	approximately	RB	-	-	-	-	-	-	-	-
1868042	0	17	150	CD	-	-	-	-	-	-	-	-
1868042	0	18	fF	NNS	-	-	-	-	-	-	-	-
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	corresponding	VBG	-	-	-	-	-	-	-	-
1868042	0	21	to	IN	-	-	-	-	-	-	-	-
1868042	0	22	the	DT	-	-	-	-	-	-	-	-
1868042	0	23	fusion	NN	-	-	-	-	-	-	-	-
1868042	0	24	of	IN	-	-	-	-	-	-	-	-
1868042	0	25	∼	SYM	-	-	-	-	-	-	-	-
1868042	0	26	75	CD	-	-	-	-	-	-	-	-
1868042	0	27	secretory	JJ	-	-	-	-	-	-	-	-
1868042	0	28	granules	NNS	-	-	-	-	-	-	-	-
1868042	0	29	with	IN	-	-	-	-	-	-	-	-
1868042	0	30	the	DT	-	-	-	-	-	-	-	-
1868042	0	31	plasma	NN	-	-	-	-	-	-	-	-
1868042	0	32	membrane	NN	-	-	-	-	-	-	-	-
1868042	0	33	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	34	43	CD	-	-	-	-	-	-	-	-
1868042	0	35	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	36	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	37	under	IN	-	-	-	-	-	-	-	-
1868042	0	38	control	NN	-	-	-	-	-	-	-	(152
1868042	0	39	conditions	NNS	-	-	-	-	-	-	-	152)
1868042	0	40	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	41	Ctrl	NN	-	-	-	-	-	-	-	-
1868042	0	42	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	43	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	response	NN	-	-	-	-	-	-	-	-
1868042	0	3	was	VBD	-	-	-	-	-	-	-	-
1868042	0	4	not	RB	-	-	-	-	-	-	-	-
1868042	0	5	significantly	RB	-	-	-	-	-	-	-	-
1868042	0	6	affected	VBN	-	-	-	-	-	-	-	-
1868042	0	7	by	IN	-	-	-	-	-	-	-	-
1868042	0	8	50	CD	-	-	-	-	-	-	-	(153
1868042	0	9	μM	NN	-	-	-	-	-	-	-	-
1868042	0	10	nifedipine	NN	-	-	-	-	-	-	-	-
1868042	0	11	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	12	nif	NN	-	-	-	-	-	-	-	-
1868042	0	13	)	-RRB-	-	-	-	-	-	-	-	153)
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	but	CC	-	-	-	-	-	-	-	-
1868042	0	16	was	VBD	-	-	-	-	-	-	-	-
1868042	0	17	nearly	RB	-	-	-	-	-	-	-	-
1868042	0	18	abolished	VBN	-	-	-	-	-	-	-	-
1868042	0	19	by	IN	-	-	-	-	-	-	-	-
1868042	0	20	1	CD	-	-	-	-	-	-	-	-
1868042	0	21	μM	NN	-	-	-	-	-	-	-	-
1868042	0	22	ω	NN	-	-	-	-	-	-	-	-
1868042	0	23	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	24	conotoxin	NN	-	-	-	-	-	-	-	-
1868042	0	25	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	26	ω	NN	-	-	-	-	-	-	-	(36
1868042	0	27	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	28	con	NN	-	-	-	-	-	-	-	36)
1868042	0	29	;	:	-	-	-	-	-	-	-	-
1868042	0	30	Figure	NN	-	-	-	-	-	-	-	(165|(81)
1868042	0	31	8C	NN	-	-	-	-	-	-	-	165)
1868042	0	32	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	33	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Inactivation	NN	-	-	-	-	-	-	-	(166
1868042	0	2	of	IN	-	-	-	-	-	-	-	-
1868042	0	3	N	NN	-	-	-	-	-	-	-	(35
1868042	0	4	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	5	Type	NN	-	-	-	-	-	-	-	-
1868042	0	6	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	7	Channels	NNS	-	-	-	-	-	-	-	35)|166)
1868042	0	8	Underlie	VBP	-	-	-	-	-	-	-	-
1868042	0	9	Glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	10	Inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	11	of	IN	-	-	-	-	-	-	-	-
1868042	0	12	Glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	13	Secretion	NN	-	-	-	-	-	-	-	25)

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	next	RB	-	-	-	-	-	-	-	-
1868042	0	3	examined	VBD	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	mechanism	NN	-	-	-	-	-	-	-	-
1868042	0	6	by	IN	-	-	-	-	-	-	-	-
1868042	0	7	which	WDT	-	-	-	-	-	-	-	-
1868042	0	8	N	NN	-	-	-	-	-	-	-	(35
1868042	0	9	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	type	NN	-	-	-	-	-	-	-	-
1868042	0	11	channels	NNS	-	-	-	-	-	-	-	35)
1868042	0	12	regulate	VBP	-	-	-	-	-	-	-	-
1868042	0	13	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	14	release	NN	-	-	-	-	-	-	-	-
1868042	0	15	in	IN	-	-	-	-	-	-	-	-
1868042	0	16	response	NN	-	-	-	-	-	-	-	-
1868042	0	17	to	IN	-	-	-	-	-	-	-	-
1868042	0	18	membrane	NN	-	-	-	-	-	-	-	-
1868042	0	19	depolarisation	NN	-	-	-	-	-	-	-	-
1868042	0	20	/	HYPH	-	-	-	-	-	-	-	-
1868042	0	21	hyperpolarisation	NN	-	-	-	-	-	-	-	-
1868042	0	22	in	IN	-	-	-	-	-	-	-	-
1868042	0	23	mouse	NN	-	-	-	-	-	-	-	(145
1868042	0	24	α	NN	-	-	-	-	-	-	-	-
1868042	0	25	cells	NNS	-	-	-	-	-	-	-	145)
1868042	0	26	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Non–L	JJ	-	-	-	-	-	-	-	-
1868042	0	2	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	3	type	NN	-	-	-	-	-	-	-	-
1868042	0	4	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	5	isradipine	NN	-	-	-	-	-	-	-	-
1868042	0	6	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	resistant	JJ	-	-	-	-	-	-	-	-
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	10	currents	NNS	-	-	-	-	-	-	-	-
1868042	0	11	were	VBD	-	-	-	-	-	-	-	-
1868042	0	12	elicited	VBN	-	-	-	-	-	-	-	-
1868042	0	13	by	IN	-	-	-	-	-	-	-	-
1868042	0	14	step	NN	-	-	-	-	-	-	-	-
1868042	0	15	depolarization	NN	-	-	-	-	-	-	-	-
1868042	0	16	to	IN	-	-	-	-	-	-	-	-
1868042	0	17	0	CD	-	-	-	-	-	-	-	(151
1868042	0	18	mV	NNS	-	-	-	-	-	-	-	151)
1868042	0	19	in	IN	-	-	-	-	-	-	-	-
1868042	0	20	the	DT	-	-	-	-	-	-	-	-
1868042	0	21	absence	NN	-	-	-	-	-	-	-	-
1868042	0	22	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	23	black	JJ	-	-	-	-	-	-	-	-
1868042	0	24	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	25	or	CC	-	-	-	-	-	-	-	-
1868042	0	26	presence	NN	-	-	-	-	-	-	-	-
1868042	0	27	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	28	red	JJ	-	-	-	-	-	-	-	-
1868042	0	29	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	30	of	IN	-	-	-	-	-	-	-	-
1868042	0	31	1	CD	-	-	-	-	-	-	-	-
1868042	0	32	μM	NN	-	-	-	-	-	-	-	-
1868042	0	33	ω	NN	-	-	-	-	-	-	-	-
1868042	0	34	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	35	conotoxin	NN	-	-	-	-	-	-	-	-
1868042	0	36	following	IN	-	-	-	-	-	-	-	-
1868042	0	37	a	DT	-	-	-	-	-	-	-	(167a
1868042	0	38	200	CD	-	-	-	-	-	-	-	-
1868042	0	39	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	40	ms	NN	-	-	-	-	-	-	-	-
1868042	0	41	conditioning	NN	-	-	-	-	-	-	-	-
1868042	0	42	pulse	NN	-	-	-	-	-	-	-	-
1868042	0	43	to	IN	-	-	-	-	-	-	-	167a)
1868042	0	44	−	SYM	-	-	-	-	-	-	-	(150
1868042	0	45	70	CD	-	-	-	-	-	-	-	-
1868042	0	46	mV	NNS	-	-	-	-	-	-	-	150)
1868042	0	47	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	48	Figure	NN	-	-	-	-	-	-	-	(168|(81)
1868042	0	49	9A	NN	-	-	-	-	-	-	-	168)
1868042	0	50	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	51	or	CC	-	-	-	-	-	-	-	-
1868042	0	52	+	SYM	-	-	-	-	-	-	-	(167a|(169
1868042	0	53	10	CD	-	-	-	-	-	-	-	-
1868042	0	54	mV	NNS	-	-	-	-	-	-	-	169)|167a)
1868042	0	55	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	56	Figure	NN	-	-	-	-	-	-	-	(170|(81)
1868042	0	57	9B	NN	-	-	-	-	-	-	-	170)
1868042	0	58	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	59	.	.	-	-	-	-	-	-	-	-

1868042	0	1	It	PRP	-	-	-	-	-	-	-	-
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	evident	JJ	-	-	-	-	-	-	-	-
1868042	0	4	that	IN	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	(171
1868042	0	6	ω	NN	-	-	-	-	-	-	-	-
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	conotoxin	NN	-	-	-	-	-	-	-	-
1868042	0	9	–	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	sensitive	JJ	-	-	-	-	-	-	-	-
1868042	0	11	component	NN	-	-	-	-	-	-	-	171)
1868042	0	12	was	VBD	-	-	-	-	-	-	-	-
1868042	0	13	abolished	VBN	-	-	-	-	-	-	-	-
1868042	0	14	by	IN	-	-	-	-	-	-	-	-
1868042	0	15	the	DT	-	-	-	-	-	-	-	(167
1868042	0	16	+	SYM	-	-	-	-	-	-	-	-
1868042	0	17	10	CD	-	-	-	-	-	-	-	-
1868042	0	18	mV	NN	-	-	-	-	-	-	-	-
1868042	0	19	conditioning	NN	-	-	-	-	-	-	-	-
1868042	0	20	pulse	NN	-	-	-	-	-	-	-	167)
1868042	0	21	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Figure	NN	-	-	-	-	-	-	-	(172|(81)
1868042	0	2	9C	NN	-	-	-	-	-	-	-	172)
1868042	0	3	summarizes	VBZ	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	relationship	NN	-	-	-	-	-	-	-	-
1868042	0	6	between	IN	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	-
1868042	0	8	conditioning	NN	-	-	-	-	-	-	-	-
1868042	0	9	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	10	and	CC	-	-	-	-	-	-	-	-
1868042	0	11	the	DT	-	-	-	-	-	-	-	-
1868042	0	12	Ca2+	NN	-	-	-	-	-	-	-	(163
1868042	0	13	current	NN	-	-	-	-	-	-	-	163)
1868042	0	14	amplitude	NN	-	-	-	-	-	-	-	-
1868042	0	15	in	IN	-	-	-	-	-	-	-	-
1868042	0	16	the	DT	-	-	-	-	-	-	-	-
1868042	0	17	absence	NN	-	-	-	-	-	-	-	-
1868042	0	18	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	19	open	JJ	-	-	-	-	-	-	-	(173
1868042	0	20	squares	NNS	-	-	-	-	-	-	-	173)
1868042	0	21	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	22	and	CC	-	-	-	-	-	-	-	-
1868042	0	23	presence	NN	-	-	-	-	-	-	-	-
1868042	0	24	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	25	circles	NNS	-	-	-	-	-	-	-	-
1868042	0	26	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	27	of	IN	-	-	-	-	-	-	-	-
1868042	0	28	ω	NN	-	-	-	-	-	-	-	(36
1868042	0	29	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	30	conotoxin	NN	-	-	-	-	-	-	-	36)
1868042	0	31	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	32	upper	JJ	-	-	-	-	-	-	-	-
1868042	0	33	panel	NN	-	-	-	-	-	-	-	-
1868042	0	34	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	35	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	(171
1868042	0	2	ω	NN	-	-	-	-	-	-	-	-
1868042	0	3	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	4	conotoxin	NN	-	-	-	-	-	-	-	-
1868042	0	5	–	HYPH	-	-	-	-	-	-	-	-
1868042	0	6	sensitive	JJ	-	-	-	-	-	-	-	-
1868042	0	7	N	NN	-	-	-	-	-	-	-	-
1868042	0	8	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	type	NN	-	-	-	-	-	-	-	-
1868042	0	10	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	11	current	NN	-	-	-	-	-	-	-	-
1868042	0	12	component	NN	-	-	-	-	-	-	-	171)
1868042	0	13	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	14	shown	VBN	-	-	-	-	-	-	-	-
1868042	0	15	in	IN	-	-	-	-	-	-	-	-
1868042	0	16	the	DT	-	-	-	-	-	-	-	-
1868042	0	17	lower	JJR	-	-	-	-	-	-	-	-
1868042	0	18	panel	NN	-	-	-	-	-	-	-	-
1868042	0	19	of	IN	-	-	-	-	-	-	-	-
1868042	0	20	Figure	NN	-	-	-	-	-	-	-	(172|(81)
1868042	0	21	9C	NN	-	-	-	-	-	-	-	172)
1868042	0	22	,	,	-	-	-	-	-	-	-	-
1868042	0	23	and	CC	-	-	-	-	-	-	-	-
1868042	0	24	underwent	VBD	-	-	-	-	-	-	-	-
1868042	0	25	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	26	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	27	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	28	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	29	that	WDT	-	-	-	-	-	-	-	-
1868042	0	30	was	VBD	-	-	-	-	-	-	-	-
1868042	0	31	half	RB	-	-	-	-	-	-	-	-
1868042	0	32	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	33	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	34	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	35	V0.5	NN	-	-	-	-	-	-	-	-
1868042	0	36	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	37	at	IN	-	-	-	-	-	-	-	-
1868042	0	38	−	SYM	-	-	-	-	-	-	-	-
1868042	0	39	31	CD	-	-	-	-	-	-	-	-
1868042	0	40	±	SYM	-	-	-	-	-	-	-	-
1868042	0	41	6	CD	-	-	-	-	-	-	-	-
1868042	0	42	mV	NNS	-	-	-	-	-	-	-	-
1868042	0	43	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	44	n	NN	-	-	-	-	-	-	-	-
1868042	0	45	=	SYM	-	-	-	-	-	-	-	-
1868042	0	46	6	CD	-	-	-	-	-	-	-	-
1868042	0	47	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	48	.	.	-	-	-	-	-	-	-	-

1868042	0	1	A	DT	-	-	-	-	-	-	-	-
1868042	0	2	residual	JJ	-	-	-	-	-	-	-	-
1868042	0	3	,	,	-	-	-	-	-	-	-	-
1868042	0	4	ω	NN	-	-	-	-	-	-	-	-
1868042	0	5	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	6	conotoxin	NN	-	-	-	-	-	-	-	-
1868042	0	7	–	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	insensitive	JJ	-	-	-	-	-	-	-	-
1868042	0	9	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	10	current	NN	-	-	-	-	-	-	-	-
1868042	0	11	also	RB	-	-	-	-	-	-	-	-
1868042	0	12	appears	VBZ	-	-	-	-	-	-	-	-
1868042	0	13	to	TO	-	-	-	-	-	-	-	-
1868042	0	14	undergo	VB	-	-	-	-	-	-	-	-
1868042	0	15	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	16	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	18	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	Figure	NN	-	-	-	-	-	-	-	(172|(81)
1868042	0	21	9C	NN	-	-	-	-	-	-	-	172)
1868042	0	22	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	accounts	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	for	IN	-	-	-	-	-	-	-	-
1868042	0	4	less	JJR	-	-	-	-	-	-	-	-
1868042	0	5	than	IN	-	-	-	-	-	-	-	-
1868042	0	6	15	CD	-	-	-	-	-	-	-	-
1868042	0	7	%	NN	-	-	-	-	-	-	-	-
1868042	0	8	of	IN	-	-	-	-	-	-	-	-
1868042	0	9	the	DT	-	-	-	-	-	-	-	-
1868042	0	10	inactivating	VBG	-	-	-	-	-	-	-	-
1868042	0	11	current	NN	-	-	-	-	-	-	-	-
1868042	0	12	,	,	-	-	-	-	-	-	-	-
1868042	0	13	and	CC	-	-	-	-	-	-	-	-
1868042	0	14	may	MD	-	-	-	-	-	-	-	-
1868042	0	15	be	VB	-	-	-	-	-	-	-	-
1868042	0	16	attributable	JJ	-	-	-	-	-	-	-	-
1868042	0	17	to	IN	-	-	-	-	-	-	-	-
1868042	0	18	T	NN	-	-	-	-	-	-	-	-
1868042	0	19	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	20	type	NN	-	-	-	-	-	-	-	-
1868042	0	21	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	22	channels	NNS	-	-	-	-	-	-	-	-
1868042	0	23	that	WDT	-	-	-	-	-	-	-	-
1868042	0	24	have	VBP	-	-	-	-	-	-	-	-
1868042	0	25	been	VBN	-	-	-	-	-	-	-	-
1868042	0	26	reported	VBN	-	-	-	-	-	-	-	-
1868042	0	27	in	IN	-	-	-	-	-	-	-	-
1868042	0	28	α	NN	-	-	-	-	-	-	-	(1
1868042	0	29	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	30	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	31	14	CD	-	-	-	-	-	-	-	-
1868042	0	32	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	33	.	.	-	-	-	-	-	-	-	-

1868042	0	1	In	IN	-	-	-	-	-	-	-	-
1868042	0	2	Figure	NN	-	-	-	-	-	-	-	(174|(81)
1868042	0	3	9D	NN	-	-	-	-	-	-	-	174)
1868042	0	4	,	,	-	-	-	-	-	-	-	-
1868042	0	5	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	6	examined	VBD	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	-
1868042	0	8	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	9	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	11	activation	NN	-	-	-	-	-	-	-	-
1868042	0	12	of	IN	-	-	-	-	-	-	-	-
1868042	0	13	α	NN	-	-	-	-	-	-	-	(39
1868042	0	14	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	15	cell	NN	-	-	-	-	-	-	-	-
1868042	0	16	exocytosis	NN	-	-	-	-	-	-	-	39)
1868042	0	17	using	VBG	-	-	-	-	-	-	-	-
1868042	0	18	step	NN	-	-	-	-	-	-	-	-
1868042	0	19	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	20	wise	JJ	-	-	-	-	-	-	-	-
1868042	0	21	depolarisations	NNS	-	-	-	-	-	-	-	-
1868042	0	22	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	23	500	CD	-	-	-	-	-	-	-	-
1868042	0	24	ms	NNS	-	-	-	-	-	-	-	-
1868042	0	25	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	26	from	IN	-	-	-	-	-	-	-	-
1868042	0	27	−	SYM	-	-	-	-	-	-	-	(150
1868042	0	28	70	CD	-	-	-	-	-	-	-	-
1868042	0	29	mV	NNS	-	-	-	-	-	-	-	150)
1868042	0	30	to	IN	-	-	-	-	-	-	-	-
1868042	0	31	between	IN	-	-	-	-	-	-	-	-
1868042	0	32	−	SYM	-	-	-	-	-	-	-	(175a
1868042	0	33	50	CD	-	-	-	-	-	-	-	175a)
1868042	0	34	and	CC	-	-	-	-	-	-	-	-
1868042	0	35	20	CD	-	-	-	-	-	-	-	(176
1868042	0	36	mV	NNS	-	-	-	-	-	-	-	(175a)|176)
1868042	0	37	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	38	Figure	NN	-	-	-	-	-	-	-	(174|(81)
1868042	0	39	9D	NN	-	-	-	-	-	-	-	174)
1868042	0	40	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	41	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	(177
1868042	0	2	capacitance	NN	-	-	-	-	-	-	-	-
1868042	0	3	response	NN	-	-	-	-	-	-	-	177)
1868042	0	4	versus	CC	-	-	-	-	-	-	-	-
1868042	0	5	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	6	relationship	NN	-	-	-	-	-	-	-	-
1868042	0	7	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	8	Figure	NN	-	-	-	-	-	-	-	(178|(81)
1868042	0	9	9E	NN	-	-	-	-	-	-	-	178)
1868042	0	10	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	11	demonstrates	VBZ	-	-	-	-	-	-	-	-
1868042	0	12	a	DT	-	-	-	-	-	-	-	-
1868042	0	13	marked	JJ	-	-	-	-	-	-	-	-
1868042	0	14	increase	NN	-	-	-	-	-	-	-	-
1868042	0	15	in	IN	-	-	-	-	-	-	-	-
1868042	0	16	the	DT	-	-	-	-	-	-	-	(177
1868042	0	17	capacitance	NN	-	-	-	-	-	-	-	-
1868042	0	18	response	NN	-	-	-	-	-	-	-	177)
1868042	0	19	between	IN	-	-	-	-	-	-	-	-
1868042	0	20	−	SYM	-	-	-	-	-	-	-	(179b|(180
1868042	0	21	10	CD	-	-	-	-	-	-	-	179b)
1868042	0	22	and	CC	-	-	-	-	-	-	-	-
1868042	0	23	10	CD	-	-	-	-	-	-	-	(169
1868042	0	24	mV	NNS	-	-	-	-	-	-	-	(179b)|180)|169)
1868042	0	25	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Thus	RB	-	-	-	-	-	-	-	-
1868042	0	2	any	DT	-	-	-	-	-	-	-	-
1868042	0	3	reduction	NN	-	-	-	-	-	-	-	-
1868042	0	4	in	IN	-	-	-	-	-	-	-	-
1868042	0	5	action	NN	-	-	-	-	-	-	-	(181|(45
1868042	0	6	potential	NN	-	-	-	-	-	-	-	45)
1868042	0	7	amplitude	NN	-	-	-	-	-	-	-	181)
1868042	0	8	within	IN	-	-	-	-	-	-	-	-
1868042	0	9	this	DT	-	-	-	-	-	-	-	-
1868042	0	10	range	NN	-	-	-	-	-	-	-	-
1868042	0	11	would	MD	-	-	-	-	-	-	-	-
1868042	0	12	severely	RB	-	-	-	-	-	-	-	-
1868042	0	13	attenuate	VB	-	-	-	-	-	-	-	-
1868042	0	14	α	NN	-	-	-	-	-	-	-	(39
1868042	0	15	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	cell	NN	-	-	-	-	-	-	-	-
1868042	0	17	exocytosis	NN	-	-	-	-	-	-	-	39)
1868042	0	18	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	(182
1868042	0	2	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	3	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	4	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	5	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	α	NN	-	-	-	-	-	-	-	(39
1868042	0	8	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	cell	NN	-	-	-	-	-	-	-	-
1868042	0	10	exocytosis	NN	-	-	-	-	-	-	-	39)|182)
1868042	0	11	was	VBD	-	-	-	-	-	-	-	-
1868042	0	12	examined	VBN	-	-	-	-	-	-	-	-
1868042	0	13	next	RB	-	-	-	-	-	-	-	-
1868042	0	14	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	15	Figure	NN	-	-	-	-	-	-	-	(183|(81)
1868042	0	16	9F	NN	-	-	-	-	-	-	-	183)
1868042	0	17	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	18	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Cells	NNS	-	-	-	-	-	-	-	(1)
1868042	0	2	were	VBD	-	-	-	-	-	-	-	-
1868042	0	3	held	VBN	-	-	-	-	-	-	-	-
1868042	0	4	at	IN	-	-	-	-	-	-	-	-
1868042	0	5	conditioning	NN	-	-	-	-	-	-	-	-
1868042	0	6	potentials	NNS	-	-	-	-	-	-	-	-
1868042	0	7	between	IN	-	-	-	-	-	-	-	-
1868042	0	8	−	SYM	-	-	-	-	-	-	-	(150e
1868042	0	9	70	CD	-	-	-	-	-	-	-	150e)
1868042	0	10	and	CC	-	-	-	-	-	-	-	-
1868042	0	11	−	SYM	-	-	-	-	-	-	-	(184
1868042	0	12	30	CD	-	-	-	-	-	-	-	-
1868042	0	13	mV	NNS	-	-	-	-	-	-	-	(150e)|184)
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	after	IN	-	-	-	-	-	-	-	-
1868042	0	16	which	WDT	-	-	-	-	-	-	-	-
1868042	0	17	exocytosis	NN	-	-	-	-	-	-	-	(43)
1868042	0	18	was	VBD	-	-	-	-	-	-	-	-
1868042	0	19	elicited	VBN	-	-	-	-	-	-	-	-
1868042	0	20	by	IN	-	-	-	-	-	-	-	-
1868042	0	21	depolarisation	NN	-	-	-	-	-	-	-	(185
1868042	0	22	to	IN	-	-	-	-	-	-	-	-
1868042	0	23	0	CD	-	-	-	-	-	-	-	(151
1868042	0	24	mV	NNS	-	-	-	-	-	-	-	185)|151)
1868042	0	25	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Exocytosis	NN	-	-	-	-	-	-	-	-
1868042	0	2	stimulated	VBN	-	-	-	-	-	-	-	-
1868042	0	3	from	IN	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	−	SYM	-	-	-	-	-	-	-	(184
1868042	0	6	30	CD	-	-	-	-	-	-	-	-
1868042	0	7	mV	NN	-	-	-	-	-	-	-	184)
1868042	0	8	conditioning	NN	-	-	-	-	-	-	-	-
1868042	0	9	potential	NN	-	-	-	-	-	-	-	-
1868042	0	10	was	VBD	-	-	-	-	-	-	-	-
1868042	0	11	only	RB	-	-	-	-	-	-	-	-
1868042	0	12	25	CD	-	-	-	-	-	-	-	-
1868042	0	13	%	NN	-	-	-	-	-	-	-	-
1868042	0	14	of	IN	-	-	-	-	-	-	-	-
1868042	0	15	that	DT	-	-	-	-	-	-	-	-
1868042	0	16	elicited	VBN	-	-	-	-	-	-	-	-
1868042	0	17	from	IN	-	-	-	-	-	-	-	-
1868042	0	18	−	SYM	-	-	-	-	-	-	-	(150
1868042	0	19	70	CD	-	-	-	-	-	-	-	-
1868042	0	20	mV	NN	-	-	-	-	-	-	-	150)
1868042	0	21	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	22	Figure	NN	-	-	-	-	-	-	-	(186|(81)
1868042	0	23	9G	NN	-	-	-	-	-	-	-	186)
1868042	0	24	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	25	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	3	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	4	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	5	decline	NN	-	-	-	-	-	-	-	-
1868042	0	6	in	IN	-	-	-	-	-	-	-	-
1868042	0	7	exocytosis	NN	-	-	-	-	-	-	-	(43)
1868042	0	8	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	9	attributable	JJ	-	-	-	-	-	-	-	-
1868042	0	10	to	IN	-	-	-	-	-	-	-	-
1868042	0	11	the	DT	-	-	-	-	-	-	-	(187
1868042	0	12	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	13	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	14	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	15	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	16	of	IN	-	-	-	-	-	-	-	-
1868042	0	17	the	DT	-	-	-	-	-	-	-	(35
1868042	0	18	N	NN	-	-	-	-	-	-	-	-
1868042	0	19	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	20	type	NN	-	-	-	-	-	-	-	-
1868042	0	21	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	22	channels	NNS	-	-	-	-	-	-	-	35)|187)
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	fact	NN	-	-	-	-	-	-	-	-
1868042	0	3	that	IN	-	-	-	-	-	-	-	-
1868042	0	4	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	5	of	IN	-	-	-	-	-	-	-	-
1868042	0	6	exocytosis	NN	-	-	-	-	-	-	-	(43)
1868042	0	7	appears	VBZ	-	-	-	-	-	-	-	-
1868042	0	8	to	TO	-	-	-	-	-	-	-	-
1868042	0	9	occur	VB	-	-	-	-	-	-	-	-
1868042	0	10	at	IN	-	-	-	-	-	-	-	-
1868042	0	11	more	RB	-	-	-	-	-	-	-	-
1868042	0	12	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	13	negative	JJ	-	-	-	-	-	-	-	-
1868042	0	14	voltages	NNS	-	-	-	-	-	-	-	-
1868042	0	15	than	IN	-	-	-	-	-	-	-	-
1868042	0	16	that	DT	-	-	-	-	-	-	-	-
1868042	0	17	documented	VBN	-	-	-	-	-	-	-	-
1868042	0	18	for	IN	-	-	-	-	-	-	-	-
1868042	0	19	the	DT	-	-	-	-	-	-	-	(166
1868042	0	20	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	21	of	IN	-	-	-	-	-	-	-	-
1868042	0	22	the	DT	-	-	-	-	-	-	-	(35
1868042	0	23	N	NN	-	-	-	-	-	-	-	-
1868042	0	24	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	25	type	NN	-	-	-	-	-	-	-	-
1868042	0	26	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	27	channels	NNS	-	-	-	-	-	-	-	35)|166)
1868042	0	28	can	MD	-	-	-	-	-	-	-	-
1868042	0	29	be	VB	-	-	-	-	-	-	-	-
1868042	0	30	attributed	VBN	-	-	-	-	-	-	-	-
1868042	0	31	to	IN	-	-	-	-	-	-	-	-
1868042	0	32	the	DT	-	-	-	-	-	-	-	-
1868042	0	33	brevity	NN	-	-	-	-	-	-	-	-
1868042	0	34	of	IN	-	-	-	-	-	-	-	-
1868042	0	35	the	DT	-	-	-	-	-	-	-	-
1868042	0	36	conditioning	NN	-	-	-	-	-	-	-	-
1868042	0	37	pulses	NNS	-	-	-	-	-	-	-	-
1868042	0	38	in	IN	-	-	-	-	-	-	-	-
1868042	0	39	Figure	NN	-	-	-	-	-	-	-	(81)
1868042	0	40	9A	NN	-	-	-	-	-	-	-	-
1868042	0	41	–	SYM	-	-	-	-	-	-	-	-
1868042	0	42	9C	NN	-	-	-	-	-	-	-	-
1868042	0	43	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	44	200	CD	-	-	-	-	-	-	-	-
1868042	0	45	ms	NNS	-	-	-	-	-	-	-	-
1868042	0	46	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	47	,	,	-	-	-	-	-	-	-	-
1868042	0	48	whereas	IN	-	-	-	-	-	-	-	-
1868042	0	49	in	IN	-	-	-	-	-	-	-	-
1868042	0	50	Figure	NN	-	-	-	-	-	-	-	(186|(81)
1868042	0	51	9G	NN	-	-	-	-	-	-	-	186)
1868042	0	52	the	DT	-	-	-	-	-	-	-	(188
1868042	0	53	holding	NN	-	-	-	-	-	-	-	-
1868042	0	54	potential	NN	-	-	-	-	-	-	-	188)
1868042	0	55	was	VBD	-	-	-	-	-	-	-	-
1868042	0	56	varied	JJ	-	-	-	-	-	-	-	-
1868042	0	57	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Discussion	NN	-	-	-	-	-	-	-	-

1868042	0	1	Regulated	VBN	-	-	-	-	-	-	-	-
1868042	0	2	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	3	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	4	from	IN	-	-	-	-	-	-	-	-
1868042	0	5	pancreatic	JJ	-	-	-	-	-	-	-	(1
1868042	0	6	α	NN	-	-	-	-	-	-	-	-
1868042	0	7	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	8	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	9	a	DT	-	-	-	-	-	-	-	-
1868042	0	10	major	JJ	-	-	-	-	-	-	-	-
1868042	0	11	component	NN	-	-	-	-	-	-	-	-
1868042	0	12	of	IN	-	-	-	-	-	-	-	-
1868042	0	13	the	DT	-	-	-	-	-	-	-	-
1868042	0	14	counter-regulatory	JJ	-	-	-	-	-	-	-	-
1868042	0	15	response	NN	-	-	-	-	-	-	-	-
1868042	0	16	to	IN	-	-	-	-	-	-	-	-
1868042	0	17	hypoglycaemia	NN	-	-	-	-	-	-	-	(70)
1868042	0	18	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Diabetes	NN	-	-	-	-	-	-	-	(52
1868042	0	2	mellitus	NN	-	-	-	-	-	-	-	52)
1868042	0	3	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	4	associated	JJ	-	-	-	-	-	-	-	-
1868042	0	5	with	IN	-	-	-	-	-	-	-	-
1868042	0	6	defects	NNS	-	-	-	-	-	-	-	-
1868042	0	7	of	IN	-	-	-	-	-	-	-	-
1868042	0	8	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	9	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	10	that	WDT	-	-	-	-	-	-	-	-
1868042	0	11	exacerbate	VBP	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	consequences	NNS	-	-	-	-	-	-	-	-
1868042	0	14	of	IN	-	-	-	-	-	-	-	-
1868042	0	15	impaired	JJ	-	-	-	-	-	-	-	-
1868042	0	16	insulin	NN	-	-	-	-	-	-	-	-
1868042	0	17	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	18	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	19	2	CD	-	-	-	-	-	-	-	-
1868042	0	20	–	SYM	-	-	-	-	-	-	-	-
1868042	0	21	4	CD	-	-	-	-	-	-	-	-
1868042	0	22	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	mechanism	NN	-	-	-	-	-	-	-	-
1868042	0	3	regulating	VBG	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	release	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	this	DT	-	-	-	-	-	-	-	(19
1868042	0	8	important	JJ	-	-	-	-	-	-	-	-
1868042	0	9	hormone	NN	-	-	-	-	-	-	-	19)
1868042	0	10	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	11	incompletely	RB	-	-	-	-	-	-	-	-
1868042	0	12	understood	VBN	-	-	-	-	-	-	-	-
1868042	0	13	and	CC	-	-	-	-	-	-	-	-
1868042	0	14	currently	RB	-	-	-	-	-	-	-	-
1868042	0	15	the	DT	-	-	-	-	-	-	-	-
1868042	0	16	source	NN	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	much	JJ	-	-	-	-	-	-	-	-
1868042	0	19	debate	NN	-	-	-	-	-	-	-	-
1868042	0	20	.	.	-	-	-	-	-	-	-	-

1868042	0	1	In	IN	-	-	-	-	-	-	-	-
1868042	0	2	the	DT	-	-	-	-	-	-	-	(189
1868042	0	3	present	JJ	-	-	-	-	-	-	-	-
1868042	0	4	study	NN	-	-	-	-	-	-	-	189)
1868042	0	5	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	6	examined	VBD	-	-	-	-	-	-	-	-
1868042	0	7	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	8	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	-
1868042	0	11	[	-LRB-	-	-	-	-	-	-	-	(122
1868042	0	12	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	13	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	14	i	NN	-	-	-	-	-	-	-	122)
1868042	0	15	response	NN	-	-	-	-	-	-	-	-
1868042	0	16	of	IN	-	-	-	-	-	-	-	-
1868042	0	17	in	FW	-	-	-	-	-	-	-	-
1868042	0	18	situ	FW	-	-	-	-	-	-	-	-
1868042	0	19	α	NN	-	-	-	-	-	-	-	-
1868042	0	20	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	21	of	IN	-	-	-	-	-	-	-	-
1868042	0	22	isolated	VBN	-	-	-	-	-	-	-	(62b)
1868042	0	23	rodent	NN	-	-	-	-	-	-	-	-
1868042	0	24	and	CC	-	-	-	-	-	-	-	-
1868042	0	25	human	JJ	-	-	-	-	-	-	-	(62b
1868042	0	26	islets	NNS	-	-	-	-	-	-	-	62b)
1868042	0	27	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	further	RB	-	-	-	-	-	-	-	-
1868042	0	3	characterised	VBD	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	(163
1868042	0	5	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	6	currents	NNS	-	-	-	-	-	-	-	163)
1868042	0	7	and	CC	-	-	-	-	-	-	-	-
1868042	0	8	capacitance	NN	-	-	-	-	-	-	-	-
1868042	0	9	changes	NNS	-	-	-	-	-	-	-	-
1868042	0	10	of	IN	-	-	-	-	-	-	-	-
1868042	0	11	single	JJ	-	-	-	-	-	-	-	(190
1868042	0	12	isolated	JJ	-	-	-	-	-	-	-	-
1868042	0	13	α	NN	-	-	-	-	-	-	-	-
1868042	0	14	cells	NNS	-	-	-	-	-	-	-	190)
1868042	0	15	,	,	-	-	-	-	-	-	-	-
1868042	0	16	to	TO	-	-	-	-	-	-	-	-
1868042	0	17	dissect	VB	-	-	-	-	-	-	-	-
1868042	0	18	the	DT	-	-	-	-	-	-	-	-
1868042	0	19	mechanism	NN	-	-	-	-	-	-	-	-
1868042	0	20	regulating	VBG	-	-	-	-	-	-	-	-
1868042	0	21	downstream	JJ	-	-	-	-	-	-	-	-
1868042	0	22	control	NN	-	-	-	-	-	-	-	-
1868042	0	23	of	IN	-	-	-	-	-	-	-	-
1868042	0	24	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	25	release	NN	-	-	-	-	-	-	-	3)
1868042	0	26	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Previous	JJ	-	-	-	-	-	-	-	-
1868042	0	2	work	NN	-	-	-	-	-	-	-	-
1868042	0	3	with	IN	-	-	-	-	-	-	-	-
1868042	0	4	genetic	JJ	-	-	-	-	-	-	-	-
1868042	0	5	mouse	NN	-	-	-	-	-	-	-	-
1868042	0	6	models	NNS	-	-	-	-	-	-	-	-
1868042	0	7	,	,	-	-	-	-	-	-	-	-
1868042	0	8	including	VBG	-	-	-	-	-	-	-	-
1868042	0	9	SUR1	NN	-	-	-	-	-	-	-	(64a
1868042	0	10	−	SYM	-	-	-	-	-	-	-	-
1868042	0	11	/	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	−	SYM	-	-	-	-	-	-	-	64a)
1868042	0	13	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	14	13	CD	-	-	-	-	-	-	-	-
1868042	0	15	,	,	-	-	-	-	-	-	-	-
1868042	0	16	34	CD	-	-	-	-	-	-	-	-
1868042	0	17	,	,	-	-	-	-	-	-	-	-
1868042	0	18	35	CD	-	-	-	-	-	-	-	-
1868042	0	19	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	20	and	CC	-	-	-	-	-	-	-	-
1868042	0	21	Kir6.2	NN	-	-	-	-	-	-	-	-
1868042	0	22	−	SYM	-	-	-	-	-	-	-	-
1868042	0	23	/	HYPH	-	-	-	-	-	-	-	-
1868042	0	24	−	SYM	-	-	-	-	-	-	-	-
1868042	0	25	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	26	16	CD	-	-	-	-	-	-	-	-
1868042	0	27	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	28	mice	NNS	-	-	-	-	-	-	-	(64a)
1868042	0	29	,	,	-	-	-	-	-	-	-	-
1868042	0	30	suggests	VBZ	-	-	-	-	-	-	-	-
1868042	0	31	an	DT	-	-	-	-	-	-	-	-
1868042	0	32	important	JJ	-	-	-	-	-	-	-	-
1868042	0	33	role	NN	-	-	-	-	-	-	-	-
1868042	0	34	for	IN	-	-	-	-	-	-	-	-
1868042	0	35	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	36	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	37	in	IN	-	-	-	-	-	-	-	-
1868042	0	38	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	39	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	40	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Three	CD	-	-	-	-	-	-	-	-
1868042	0	2	pieces	NNS	-	-	-	-	-	-	-	-
1868042	0	3	of	IN	-	-	-	-	-	-	-	-
1868042	0	4	evidence	NN	-	-	-	-	-	-	-	-
1868042	0	5	argue	VBP	-	-	-	-	-	-	-	-
1868042	0	6	for	IN	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	-
1868042	0	8	importance	NN	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	islet	NN	-	-	-	-	-	-	-	-
1868042	0	11	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	12	channels	NNS	-	-	-	-	-	-	-	-
1868042	0	13	in	IN	-	-	-	-	-	-	-	-
1868042	0	14	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	15	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	16	.	.	-	-	-	-	-	-	-	-

1868042	0	1	First	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	introduction	NN	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	-
1868042	0	6	Tyr12STOP	NN	-	-	-	-	-	-	-	-
1868042	0	7	mutation	NN	-	-	-	-	-	-	-	-
1868042	0	8	into	IN	-	-	-	-	-	-	-	-
1868042	0	9	the	DT	-	-	-	-	-	-	-	-
1868042	0	10	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	11	channel	NN	-	-	-	-	-	-	-	-
1868042	0	12	subunits	NNS	-	-	-	-	-	-	-	-
1868042	0	13	in	IN	-	-	-	-	-	-	-	-
1868042	0	14	the	DT	-	-	-	-	-	-	-	(108
1868042	0	15	Kir6.2Y12X	NN	-	-	-	-	-	-	-	-
1868042	0	16	islets	NNS	-	-	-	-	-	-	-	108)
1868042	0	17	results	VBZ	-	-	-	-	-	-	-	-
1868042	0	18	in	IN	-	-	-	-	-	-	-	-
1868042	0	19	suppression	NN	-	-	-	-	-	-	-	-
1868042	0	20	of	IN	-	-	-	-	-	-	-	-
1868042	0	21	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	22	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	23	at	IN	-	-	-	-	-	-	-	-
1868042	0	24	low	JJ	-	-	-	-	-	-	-	(162
1868042	0	25	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	26	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	27	levels	NNS	-	-	-	-	-	-	-	162)
1868042	0	28	and	CC	-	-	-	-	-	-	-	-
1868042	0	29	causes	VBZ	-	-	-	-	-	-	-	-
1868042	0	30	loss	NN	-	-	-	-	-	-	-	-
1868042	0	31	of	IN	-	-	-	-	-	-	-	-
1868042	0	32	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	33	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	34	induced	VBN	-	-	-	-	-	-	-	-
1868042	0	35	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	36	of	IN	-	-	-	-	-	-	-	-
1868042	0	37	secretion	NN	-	-	-	-	-	-	-	(47)
1868042	0	38	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Second	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	(23
1868042	0	4	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	5	channel	NN	-	-	-	-	-	-	-	-
1868042	0	6	inhibitor	NN	-	-	-	-	-	-	-	-
1868042	0	7	tolbutamide	NN	-	-	-	-	-	-	-	23)
1868042	0	8	when	WRB	-	-	-	-	-	-	-	-
1868042	0	9	applied	VBN	-	-	-	-	-	-	-	-
1868042	0	10	at	IN	-	-	-	-	-	-	-	-
1868042	0	11	maximally	RB	-	-	-	-	-	-	-	-
1868042	0	12	effective	JJ	-	-	-	-	-	-	-	-
1868042	0	13	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	14	inhibits	VBZ	-	-	-	-	-	-	-	-
1868042	0	15	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	16	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	17	from	IN	-	-	-	-	-	-	-	-
1868042	0	18	isolated	VBN	-	-	-	-	-	-	-	(74
1868042	0	19	islets	NNS	-	-	-	-	-	-	-	74)
1868042	0	20	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Third	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	a	DT	-	-	-	-	-	-	-	(191
1868042	0	4	low	JJ	-	-	-	-	-	-	-	-
1868042	0	5	dose	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	(18
1868042	0	8	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	9	channel	NN	-	-	-	-	-	-	-	-
1868042	0	10	activator	NN	-	-	-	-	-	-	-	-
1868042	0	11	diazoxide	NN	-	-	-	-	-	-	-	191)|18)
1868042	0	12	restores	VBZ	-	-	-	-	-	-	-	-
1868042	0	13	α	NN	-	-	-	-	-	-	-	(28
1868042	0	14	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	15	cell	NN	-	-	-	-	-	-	-	-
1868042	0	16	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	17	responses	NNS	-	-	-	-	-	-	-	28)
1868042	0	18	and	CC	-	-	-	-	-	-	-	-
1868042	0	19	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	20	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	21	in	IN	-	-	-	-	-	-	-	-
1868042	0	22	high	JJ	-	-	-	-	-	-	-	(87
1868042	0	23	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	24	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	25	conditions	NNS	-	-	-	-	-	-	-	87)
1868042	0	26	.	.	-	-	-	-	-	-	-	-

1868042	0	1	What	WDT	-	-	-	-	-	-	-	-
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	not	RB	-	-	-	-	-	-	-	-
1868042	0	4	immediately	RB	-	-	-	-	-	-	-	-
1868042	0	5	clear	JJ	-	-	-	-	-	-	-	-
1868042	0	6	from	IN	-	-	-	-	-	-	-	-
1868042	0	7	these	DT	-	-	-	-	-	-	-	-
1868042	0	8	arguments	NNS	-	-	-	-	-	-	-	-
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	and	CC	-	-	-	-	-	-	-	-
1868042	0	11	from	IN	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	previous	JJ	-	-	-	-	-	-	-	-
1868042	0	14	SUR1	NN	-	-	-	-	-	-	-	-
1868042	0	15	−	SYM	-	-	-	-	-	-	-	-
1868042	0	16	/	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	−	SYM	-	-	-	-	-	-	-	-
1868042	0	18	genetic	JJ	-	-	-	-	-	-	-	-
1868042	0	19	studies	NNS	-	-	-	-	-	-	-	-
1868042	0	20	,	,	-	-	-	-	-	-	-	-
1868042	0	21	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	22	whether	IN	-	-	-	-	-	-	-	-
1868042	0	23	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	24	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	25	being	VBG	-	-	-	-	-	-	-	-
1868042	0	26	controlled	VBN	-	-	-	-	-	-	-	-
1868042	0	27	by	IN	-	-	-	-	-	-	-	-
1868042	0	28	the	DT	-	-	-	-	-	-	-	(63a
1868042	0	29	α	NN	-	-	-	-	-	-	-	-
1868042	0	30	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	31	cell	NN	-	-	-	-	-	-	-	63a)
1868042	0	32	or	CC	-	-	-	-	-	-	-	-
1868042	0	33	the	DT	-	-	-	-	-	-	-	-
1868042	0	34	β	NN	-	-	-	-	-	-	-	-
1868042	0	35	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	36	cell	NN	-	-	-	-	-	-	-	-
1868042	0	37	KATP	NN	-	-	-	-	-	-	-	(63a
1868042	0	38	channels	NNS	-	-	-	-	-	-	-	63a)
1868042	0	39	,	,	-	-	-	-	-	-	-	-
1868042	0	40	as	IN	-	-	-	-	-	-	-	-
1868042	0	41	the	DT	-	-	-	-	-	-	-	-
1868042	0	42	latter	JJ	-	-	-	-	-	-	-	-
1868042	0	43	may	MD	-	-	-	-	-	-	-	-
1868042	0	44	regulate	VB	-	-	-	-	-	-	-	-
1868042	0	45	α	NN	-	-	-	-	-	-	-	(68
1868042	0	46	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	47	cell	NN	-	-	-	-	-	-	-	-
1868042	0	48	function	NN	-	-	-	-	-	-	-	68)
1868042	0	49	indirectly	RB	-	-	-	-	-	-	-	-
1868042	0	50	via	IN	-	-	-	-	-	-	-	-
1868042	0	51	paracrine	JJ	-	-	-	-	-	-	-	-
1868042	0	52	pathways	NNS	-	-	-	-	-	-	-	-
1868042	0	53	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	therefore	RB	-	-	-	-	-	-	-	-
1868042	0	3	examined	VBD	-	-	-	-	-	-	-	-
1868042	0	4	insulin	NN	-	-	-	-	-	-	-	(24|(26|(19)|(27a)
1868042	0	5	and	CC	-	-	-	-	-	-	-	-
1868042	0	6	glucagon	NN	-	-	-	-	-	-	-	(25|(2)|24)
1868042	0	7	secretion	NN	-	-	-	-	-	-	-	(27a)|26)|25)
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	-
1868042	0	11	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	12	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	13	of	IN	-	-	-	-	-	-	-	-
1868042	0	14	α	NN	-	-	-	-	-	-	-	(119|(120a)
1868042	0	15	and	CC	-	-	-	-	-	-	-	-
1868042	0	16	β	NN	-	-	-	-	-	-	-	(121
1868042	0	17	cells	NNS	-	-	-	-	-	-	-	(120a
1868042	0	18	in	FW	-	-	-	-	-	-	-	-
1868042	0	19	situ	FW	-	-	-	-	-	-	-	121)|120a)|119)
1868042	0	20	in	IN	-	-	-	-	-	-	-	-
1868042	0	21	parallel	NN	-	-	-	-	-	-	-	-
1868042	0	22	to	TO	-	-	-	-	-	-	-	-
1868042	0	23	determine	VB	-	-	-	-	-	-	-	-
1868042	0	24	the	DT	-	-	-	-	-	-	-	-
1868042	0	25	functional	JJ	-	-	-	-	-	-	-	-
1868042	0	26	relationship	NN	-	-	-	-	-	-	-	-
1868042	0	27	between	IN	-	-	-	-	-	-	-	-
1868042	0	28	these	DT	-	-	-	-	-	-	-	(119
1868042	0	29	cells	NNS	-	-	-	-	-	-	-	119)
1868042	0	30	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Furthermore	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	4	measured	VBD	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	-
1868042	0	6	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	7	response	NN	-	-	-	-	-	-	-	-
1868042	0	8	to	IN	-	-	-	-	-	-	-	-
1868042	0	9	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	10	during	IN	-	-	-	-	-	-	-	-
1868042	0	11	blockade	NN	-	-	-	-	-	-	-	-
1868042	0	12	of	IN	-	-	-	-	-	-	-	-
1868042	0	13	putative	JJ	-	-	-	-	-	-	-	(192
1868042	0	14	paracrine	JJ	-	-	-	-	-	-	-	-
1868042	0	15	signalling	NN	-	-	-	-	-	-	-	-
1868042	0	16	pathways	NNS	-	-	-	-	-	-	-	192)
1868042	0	17	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Studies	NNS	-	-	-	-	-	-	-	-
1868042	0	2	on	IN	-	-	-	-	-	-	-	-
1868042	0	3	rat	NN	-	-	-	-	-	-	-	(85
1868042	0	4	islets	NNS	-	-	-	-	-	-	-	85)
1868042	0	5	support	VBP	-	-	-	-	-	-	-	-
1868042	0	6	an	DT	-	-	-	-	-	-	-	-
1868042	0	7	important	JJ	-	-	-	-	-	-	-	-
1868042	0	8	role	NN	-	-	-	-	-	-	-	-
1868042	0	9	for	IN	-	-	-	-	-	-	-	-
1868042	0	10	paracrine	JJ	-	-	-	-	-	-	-	(61
1868042	0	11	signals	NNS	-	-	-	-	-	-	-	61)
1868042	0	12	as	IN	-	-	-	-	-	-	-	-
1868042	0	13	regulators	NNS	-	-	-	-	-	-	-	(65
1868042	0	14	of	IN	-	-	-	-	-	-	-	-
1868042	0	15	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	16	release	NN	-	-	-	-	-	-	-	65)|3)
1868042	0	17	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	18	33	CD	-	-	-	-	-	-	-	-
1868042	0	19	,	,	-	-	-	-	-	-	-	-
1868042	0	20	52	CD	-	-	-	-	-	-	-	-
1868042	0	21	,	,	-	-	-	-	-	-	-	-
1868042	0	22	53	CD	-	-	-	-	-	-	-	-
1868042	0	23	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	24	,	,	-	-	-	-	-	-	-	-
1868042	0	25	whereas	IN	-	-	-	-	-	-	-	-
1868042	0	26	the	DT	-	-	-	-	-	-	-	-
1868042	0	27	case	NN	-	-	-	-	-	-	-	-
1868042	0	28	for	IN	-	-	-	-	-	-	-	-
1868042	0	29	paracrine	JJ	-	-	-	-	-	-	-	-
1868042	0	30	regulation	NN	-	-	-	-	-	-	-	-
1868042	0	31	of	IN	-	-	-	-	-	-	-	-
1868042	0	32	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	33	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	34	from	IN	-	-	-	-	-	-	-	-
1868042	0	35	mouse	NN	-	-	-	-	-	-	-	(145b)
1868042	0	36	and	CC	-	-	-	-	-	-	-	-
1868042	0	37	human	JJ	-	-	-	-	-	-	-	(10
1868042	0	38	α	NN	-	-	-	-	-	-	-	(145b
1868042	0	39	cells	NNS	-	-	-	-	-	-	-	145b)|10)
1868042	0	40	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	41	less	RBR	-	-	-	-	-	-	-	-
1868042	0	42	clear	JJ	-	-	-	-	-	-	-	-
1868042	0	43	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	44	9	CD	-	-	-	-	-	-	-	-
1868042	0	45	,	,	-	-	-	-	-	-	-	-
1868042	0	46	10	CD	-	-	-	-	-	-	-	-
1868042	0	47	,	,	-	-	-	-	-	-	-	-
1868042	0	48	14	CD	-	-	-	-	-	-	-	-
1868042	0	49	,	,	-	-	-	-	-	-	-	-
1868042	0	50	17	CD	-	-	-	-	-	-	-	-
1868042	0	51	–	SYM	-	-	-	-	-	-	-	-
1868042	0	52	21	CD	-	-	-	-	-	-	-	-
1868042	0	53	,	,	-	-	-	-	-	-	-	-
1868042	0	54	27	CD	-	-	-	-	-	-	-	-
1868042	0	55	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	56	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Although	IN	-	-	-	-	-	-	-	-
1868042	0	2	it	PRP	-	-	-	-	-	-	-	-
1868042	0	3	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	4	clear	JJ	-	-	-	-	-	-	-	-
1868042	0	5	that	IN	-	-	-	-	-	-	-	-
1868042	0	6	Zn2+	NN	-	-	-	-	-	-	-	(16)
1868042	0	7	,	,	-	-	-	-	-	-	-	-
1868042	0	8	GABA	NN	-	-	-	-	-	-	-	(15)
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	and	CC	-	-	-	-	-	-	-	-
1868042	0	11	somatostatin	NN	-	-	-	-	-	-	-	-
1868042	0	12	can	MD	-	-	-	-	-	-	-	-
1868042	0	13	exert	VB	-	-	-	-	-	-	-	-
1868042	0	14	a	DT	-	-	-	-	-	-	-	-
1868042	0	15	paracrine	JJ	-	-	-	-	-	-	-	-
1868042	0	16	control	NN	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	19	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	20	under	IN	-	-	-	-	-	-	-	-
1868042	0	21	certain	JJ	-	-	-	-	-	-	-	-
1868042	0	22	conditions	NNS	-	-	-	-	-	-	-	-
1868042	0	23	,	,	-	-	-	-	-	-	-	-
1868042	0	24	the	DT	-	-	-	-	-	-	-	-
1868042	0	25	data	NNS	-	-	-	-	-	-	-	-
1868042	0	26	shown	VBN	-	-	-	-	-	-	-	-
1868042	0	27	here	RB	-	-	-	-	-	-	-	-
1868042	0	28	firmly	RB	-	-	-	-	-	-	-	-
1868042	0	29	establish	VB	-	-	-	-	-	-	-	-
1868042	0	30	that	DT	-	-	-	-	-	-	-	-
1868042	0	31	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	32	can	MD	-	-	-	-	-	-	-	-
1868042	0	33	suppress	VB	-	-	-	-	-	-	-	-
1868042	0	34	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	35	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	36	independently	RB	-	-	-	-	-	-	-	-
1868042	0	37	of	IN	-	-	-	-	-	-	-	-
1868042	0	38	these	DT	-	-	-	-	-	-	-	(192
1868042	0	39	pathways	NNS	-	-	-	-	-	-	-	192)
1868042	0	40	as	IN	-	-	-	-	-	-	-	-
1868042	0	41	demonstrated	VBN	-	-	-	-	-	-	-	-
1868042	0	42	in	IN	-	-	-	-	-	-	-	-
1868042	0	43	Figure	NN	-	-	-	-	-	-	-	(86|(81)
1868042	0	44	1	CD	-	-	-	-	-	-	-	86)
1868042	0	45	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	46	and	CC	-	-	-	-	-	-	-	-
1868042	0	47	in	IN	-	-	-	-	-	-	-	-
1868042	0	48	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	49	47	CD	-	-	-	-	-	-	-	-
1868042	0	50	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	51	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	52	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Furthermore	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	and	CC	-	-	-	-	-	-	-	-
1868042	0	4	in	IN	-	-	-	-	-	-	-	-
1868042	0	5	agreement	NN	-	-	-	-	-	-	-	-
1868042	0	6	with	IN	-	-	-	-	-	-	-	-
1868042	0	7	recently	RB	-	-	-	-	-	-	-	-
1868042	0	8	published	VBN	-	-	-	-	-	-	-	-
1868042	0	9	results	NNS	-	-	-	-	-	-	-	-
1868042	0	10	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	11	47	CD	-	-	-	-	-	-	-	-
1868042	0	12	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	13	,	,	-	-	-	-	-	-	-	-
1868042	0	14	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	15	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	16	of	IN	-	-	-	-	-	-	-	-
1868042	0	17	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	18	release	NN	-	-	-	-	-	-	-	3)
1868042	0	19	occurs	VBZ	-	-	-	-	-	-	-	-
1868042	0	20	at	IN	-	-	-	-	-	-	-	-
1868042	0	21	levels	NNS	-	-	-	-	-	-	-	-
1868042	0	22	equal	JJ	-	-	-	-	-	-	-	-
1868042	0	23	to	IN	-	-	-	-	-	-	-	-
1868042	0	24	or	CC	-	-	-	-	-	-	-	-
1868042	0	25	lower	JJR	-	-	-	-	-	-	-	-
1868042	0	26	than	IN	-	-	-	-	-	-	-	-
1868042	0	27	5	CD	-	-	-	-	-	-	-	(115
1868042	0	28	mM	NN	-	-	-	-	-	-	-	-
1868042	0	29	glucose	NN	-	-	-	-	-	-	-	115)
1868042	0	30	,	,	-	-	-	-	-	-	-	-
1868042	0	31	whereas	IN	-	-	-	-	-	-	-	-
1868042	0	32	the	DT	-	-	-	-	-	-	-	-
1868042	0	33	stimulation	NN	-	-	-	-	-	-	-	-
1868042	0	34	of	IN	-	-	-	-	-	-	-	-
1868042	0	35	insulin	NN	-	-	-	-	-	-	-	(20|(19)
1868042	0	36	release	NN	-	-	-	-	-	-	-	20)
1868042	0	37	requires	VBZ	-	-	-	-	-	-	-	-
1868042	0	38	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	39	levels	NNS	-	-	-	-	-	-	-	-
1868042	0	40	greater	JJR	-	-	-	-	-	-	-	-
1868042	0	41	than	IN	-	-	-	-	-	-	-	-
1868042	0	42	5	CD	-	-	-	-	-	-	-	-
1868042	0	43	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	44	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	45	Figure	NN	-	-	-	-	-	-	-	(193|(81)
1868042	0	46	3	CD	-	-	-	-	-	-	-	193)
1868042	0	47	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	48	,	,	-	-	-	-	-	-	-	-
1868042	0	49	suggesting	VBG	-	-	-	-	-	-	-	-
1868042	0	50	that	IN	-	-	-	-	-	-	-	-
1868042	0	51	products	NNS	-	-	-	-	-	-	-	-
1868042	0	52	of	IN	-	-	-	-	-	-	-	-
1868042	0	53	β	NN	-	-	-	-	-	-	-	(106
1868042	0	54	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	55	cell	NN	-	-	-	-	-	-	-	-
1868042	0	56	secretion	NN	-	-	-	-	-	-	-	106)
1868042	0	57	are	VBP	-	-	-	-	-	-	-	-
1868042	0	58	not	RB	-	-	-	-	-	-	-	-
1868042	0	59	required	VBN	-	-	-	-	-	-	-	-
1868042	0	60	for	IN	-	-	-	-	-	-	-	-
1868042	0	61	suppression	NN	-	-	-	-	-	-	-	-
1868042	0	62	of	IN	-	-	-	-	-	-	-	-
1868042	0	63	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	64	release	NN	-	-	-	-	-	-	-	3)
1868042	0	65	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	conclusion	NN	-	-	-	-	-	-	-	-
1868042	0	3	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	4	further	RB	-	-	-	-	-	-	-	-
1868042	0	5	underpinned	VBN	-	-	-	-	-	-	-	-
1868042	0	6	by	IN	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	-
1868042	0	8	significant	JJ	-	-	-	-	-	-	-	-
1868042	0	9	discordance	NN	-	-	-	-	-	-	-	-
1868042	0	10	between	IN	-	-	-	-	-	-	-	-
1868042	0	11	insulin	NN	-	-	-	-	-	-	-	(24|(72|(19)
1868042	0	12	and	CC	-	-	-	-	-	-	-	-
1868042	0	13	glucagon	NN	-	-	-	-	-	-	-	(3|(2)|24)
1868042	0	14	release	NN	-	-	-	-	-	-	-	72)|3)
1868042	0	15	,	,	-	-	-	-	-	-	-	-
1868042	0	16	and	CC	-	-	-	-	-	-	-	-
1868042	0	17	the	DT	-	-	-	-	-	-	-	(29a
1868042	0	18	β	NN	-	-	-	-	-	-	-	-
1868042	0	19	-	HYPH	-	-	-	-	-	-	-	29a)
1868042	0	20	and	CC	-	-	-	-	-	-	-	-
1868042	0	21	α	NN	-	-	-	-	-	-	-	(28
1868042	0	22	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	23	cell	NN	-	-	-	-	-	-	-	(29a
1868042	0	24	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	25	responses	NNS	-	-	-	-	-	-	-	29a)|28)
1868042	0	26	,	,	-	-	-	-	-	-	-	-
1868042	0	27	under	IN	-	-	-	-	-	-	-	-
1868042	0	28	several	JJ	-	-	-	-	-	-	-	-
1868042	0	29	conditions	NNS	-	-	-	-	-	-	-	-
1868042	0	30	:	:	-	-	-	-	-	-	-	-
1868042	0	31	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	32	1	LS	-	-	-	-	-	-	-	-
1868042	0	33	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	34	low	JJ	-	-	-	-	-	-	-	(191
1868042	0	35	doses	NNS	-	-	-	-	-	-	-	-
1868042	0	36	of	IN	-	-	-	-	-	-	-	-
1868042	0	37	the	DT	-	-	-	-	-	-	-	(18
1868042	0	38	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	39	channel	NN	-	-	-	-	-	-	-	-
1868042	0	40	opener	NN	-	-	-	-	-	-	-	-
1868042	0	41	diazoxide	NN	-	-	-	-	-	-	-	18)
1868042	0	42	that	WDT	-	-	-	-	-	-	-	-
1868042	0	43	stimulate	VBP	-	-	-	-	-	-	-	-
1868042	0	44	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	45	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	46	while	IN	-	-	-	-	-	-	-	-
1868042	0	47	not	RB	-	-	-	-	-	-	-	-
1868042	0	48	affecting	VBG	-	-	-	-	-	-	-	-
1868042	0	49	insulin	NN	-	-	-	-	-	-	-	(20|(19)
1868042	0	50	release	NN	-	-	-	-	-	-	-	20)|191)
1868042	0	51	;	:	-	-	-	-	-	-	-	-
1868042	0	52	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	53	2	LS	-	-	-	-	-	-	-	-
1868042	0	54	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	55	high	JJ	-	-	-	-	-	-	-	-
1868042	0	56	doses	NNS	-	-	-	-	-	-	-	-
1868042	0	57	of	IN	-	-	-	-	-	-	-	-
1868042	0	58	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	59	at	IN	-	-	-	-	-	-	-	-
1868042	0	60	which	WDT	-	-	-	-	-	-	-	-
1868042	0	61	suppression	NN	-	-	-	-	-	-	-	-
1868042	0	62	of	IN	-	-	-	-	-	-	-	-
1868042	0	63	β	NN	-	-	-	-	-	-	-	(106
1868042	0	64	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	65	cell	NN	-	-	-	-	-	-	-	-
1868042	0	66	secretion	NN	-	-	-	-	-	-	-	106)
1868042	0	67	would	MD	-	-	-	-	-	-	-	-
1868042	0	68	be	VB	-	-	-	-	-	-	-	-
1868042	0	69	expected	VBN	-	-	-	-	-	-	-	-
1868042	0	70	to	TO	-	-	-	-	-	-	-	-
1868042	0	71	elevate	VB	-	-	-	-	-	-	-	-
1868042	0	72	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	73	release	NN	-	-	-	-	-	-	-	3)
1868042	0	74	;	:	-	-	-	-	-	-	-	-
1868042	0	75	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	76	3	LS	-	-	-	-	-	-	-	-
1868042	0	77	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	78	in	IN	-	-	-	-	-	-	-	-
1868042	0	79	the	DT	-	-	-	-	-	-	-	(108
1868042	0	80	Kir6.2Y12X	NN	-	-	-	-	-	-	-	-
1868042	0	81	islets	NNS	-	-	-	-	-	-	-	108)
1868042	0	82	;	:	-	-	-	-	-	-	-	-
1868042	0	83	and	CC	-	-	-	-	-	-	-	-
1868042	0	84	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	85	4	LS	-	-	-	-	-	-	-	-
1868042	0	86	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	87	in	IN	-	-	-	-	-	-	-	-
1868042	0	88	response	NN	-	-	-	-	-	-	-	-
1868042	0	89	to	IN	-	-	-	-	-	-	-	-
1868042	0	90	the	DT	-	-	-	-	-	-	-	(34
1868042	0	91	Na+	NN	-	-	-	-	-	-	-	-
1868042	0	92	channel	NN	-	-	-	-	-	-	-	-
1868042	0	93	blocker	NN	-	-	-	-	-	-	-	-
1868042	0	94	TTX	NN	-	-	-	-	-	-	-	34)
1868042	0	95	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Therefore	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	our	PRP$	-	-	-	-	-	-	-	(194|(4)
1868042	0	4	data	NNS	-	-	-	-	-	-	-	194)
1868042	0	5	argue	VBP	-	-	-	-	-	-	-	-
1868042	0	6	that	IN	-	-	-	-	-	-	-	-
1868042	0	7	glucagon	NN	-	-	-	-	-	-	-	(195
1868042	0	8	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	producing	VBG	-	-	-	-	-	-	-	-
1868042	0	10	α	NN	-	-	-	-	-	-	-	-
1868042	0	11	cells	NNS	-	-	-	-	-	-	-	195)
1868042	0	12	possess	VBP	-	-	-	-	-	-	-	-
1868042	0	13	an	DT	-	-	-	-	-	-	-	-
1868042	0	14	intrinsic	JJ	-	-	-	-	-	-	-	-
1868042	0	15	mechanism	NN	-	-	-	-	-	-	-	-
1868042	0	16	for	IN	-	-	-	-	-	-	-	-
1868042	0	17	regulation	NN	-	-	-	-	-	-	-	-
1868042	0	18	by	IN	-	-	-	-	-	-	-	-
1868042	0	19	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	20	and	CC	-	-	-	-	-	-	-	-
1868042	0	21	that	WDT	-	-	-	-	-	-	-	-
1868042	0	22	involves	VBZ	-	-	-	-	-	-	-	-
1868042	0	23	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	24	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	25	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	at	IN	-	-	-	-	-	-	-	-
1868042	0	4	variance	NN	-	-	-	-	-	-	-	-
1868042	0	5	with	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	data	NNS	-	-	-	-	-	-	-	-
1868042	0	8	of	IN	-	-	-	-	-	-	-	-
1868042	0	9	Liu	NNP	-	-	-	-	-	-	-	-
1868042	0	10	et	FW	-	-	-	-	-	-	-	-
1868042	0	11	al.	FW	-	-	-	-	-	-	-	-
1868042	0	12	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	13	12	CD	-	-	-	-	-	-	-	-
1868042	0	14	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	who	WP	-	-	-	-	-	-	-	-
1868042	0	16	report	VBP	-	-	-	-	-	-	-	-
1868042	0	17	that	IN	-	-	-	-	-	-	-	-
1868042	0	18	tolbutamide	NN	-	-	-	-	-	-	-	(23)
1868042	0	19	has	VBZ	-	-	-	-	-	-	-	-
1868042	0	20	no	DT	-	-	-	-	-	-	-	-
1868042	0	21	effect	NN	-	-	-	-	-	-	-	-
1868042	0	22	on	IN	-	-	-	-	-	-	-	-
1868042	0	23	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	24	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	25	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	26	i	NN	-	-	-	-	-	-	-	-
1868042	0	27	in	IN	-	-	-	-	-	-	-	-
1868042	0	28	single	JJ	-	-	-	-	-	-	-	(190
1868042	0	29	,	,	-	-	-	-	-	-	-	-
1868042	0	30	isolated	VBN	-	-	-	-	-	-	-	-
1868042	0	31	α	NN	-	-	-	-	-	-	-	-
1868042	0	32	cells	NNS	-	-	-	-	-	-	-	190)
1868042	0	33	,	,	-	-	-	-	-	-	-	-
1868042	0	34	but	CC	-	-	-	-	-	-	-	-
1868042	0	35	in	IN	-	-	-	-	-	-	-	-
1868042	0	36	agreement	NN	-	-	-	-	-	-	-	-
1868042	0	37	with	IN	-	-	-	-	-	-	-	-
1868042	0	38	the	DT	-	-	-	-	-	-	-	-
1868042	0	39	conclusion	NN	-	-	-	-	-	-	-	-
1868042	0	40	of	IN	-	-	-	-	-	-	-	-
1868042	0	41	Ostenson	NNP	-	-	-	-	-	-	-	-
1868042	0	42	et	FW	-	-	-	-	-	-	-	-
1868042	0	43	al.	FW	-	-	-	-	-	-	-	-
1868042	0	44	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	45	54	CD	-	-	-	-	-	-	-	-
1868042	0	46	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	47	,	,	-	-	-	-	-	-	-	-
1868042	0	48	that	IN	-	-	-	-	-	-	-	-
1868042	0	49	sulfonylureas	NNS	-	-	-	-	-	-	-	-
1868042	0	50	can	MD	-	-	-	-	-	-	-	-
1868042	0	51	inhibit	VB	-	-	-	-	-	-	-	-
1868042	0	52	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	53	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	54	by	IN	-	-	-	-	-	-	-	-
1868042	0	55	a	DT	-	-	-	-	-	-	-	-
1868042	0	56	direct	JJ	-	-	-	-	-	-	-	-
1868042	0	57	,	,	-	-	-	-	-	-	-	-
1868042	0	58	non-paracrine	JJ	-	-	-	-	-	-	-	-
1868042	0	59	mechanism	NN	-	-	-	-	-	-	-	-
1868042	0	60	.	.	-	-	-	-	-	-	-	-

1868042	0	1	On	IN	-	-	-	-	-	-	-	-
1868042	0	2	the	DT	-	-	-	-	-	-	-	-
1868042	0	3	basis	NN	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	our	PRP$	-	-	-	-	-	-	-	(4)
1868042	0	6	findings	NNS	-	-	-	-	-	-	-	-
1868042	0	7	,	,	-	-	-	-	-	-	-	-
1868042	0	8	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	9	propose	VBP	-	-	-	-	-	-	-	-
1868042	0	10	that	IN	-	-	-	-	-	-	-	-
1868042	0	11	α	NN	-	-	-	-	-	-	-	(50
1868042	0	12	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	13	cell	NN	-	-	-	-	-	-	-	-
1868042	0	14	glucagon	NN	-	-	-	-	-	-	-	-
1868042	0	15	secretion	NN	-	-	-	-	-	-	-	50)
1868042	0	16	occurs	VBZ	-	-	-	-	-	-	-	-
1868042	0	17	within	IN	-	-	-	-	-	-	-	-
1868042	0	18	a	DT	-	-	-	-	-	-	-	-
1868042	0	19	narrow	JJ	-	-	-	-	-	-	-	-
1868042	0	20	window	NN	-	-	-	-	-	-	-	-
1868042	0	21	of	IN	-	-	-	-	-	-	-	-
1868042	0	22	intermediate	JJ	-	-	-	-	-	-	-	(107
1868042	0	23	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	24	channel	NN	-	-	-	-	-	-	-	-
1868042	0	25	activity	NN	-	-	-	-	-	-	-	107)
1868042	0	26	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	27	and	CC	-	-	-	-	-	-	-	-
1868042	0	28	thus	RB	-	-	-	-	-	-	-	-
1868042	0	29	membrane	NN	-	-	-	-	-	-	-	(143
1868042	0	30	potential	NN	-	-	-	-	-	-	-	143)
1868042	0	31	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	32	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	33	Figure	NN	-	-	-	-	-	-	-	(196|(81)
1868042	0	34	10	CD	-	-	-	-	-	-	-	196)
1868042	0	35	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	36	.	.	-	-	-	-	-	-	-	-

1868042	0	1	That	RB	-	-	-	-	-	-	-	-
1868042	0	2	is	RB	-	-	-	-	-	-	-	-
1868042	0	3	,	,	-	-	-	-	-	-	-	-
1868042	0	4	if	IN	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	(1
1868042	0	6	α	NN	-	-	-	-	-	-	-	-
1868042	0	7	cell	NN	-	-	-	-	-	-	-	1)
1868042	0	8	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	9	either	DT	-	-	-	-	-	-	-	-
1868042	0	10	too	RB	-	-	-	-	-	-	-	-
1868042	0	11	hyperpolarised	VBN	-	-	-	-	-	-	-	-
1868042	0	12	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	13	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	14	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	15	activity	NN	-	-	-	-	-	-	-	-
1868042	0	16	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	17	or	CC	-	-	-	-	-	-	-	-
1868042	0	18	too	RB	-	-	-	-	-	-	-	-
1868042	0	19	depolarised	VBN	-	-	-	-	-	-	-	-
1868042	0	20	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	21	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	22	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	23	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	24	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	25	,	,	-	-	-	-	-	-	-	-
1868042	0	26	then	RB	-	-	-	-	-	-	-	-
1868042	0	27	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	28	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	29	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	30	suppressed	VBN	-	-	-	-	-	-	-	-
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	supported	VBN	-	-	-	-	-	-	-	-
1868042	0	4	by	IN	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	-
1868042	0	6	biphasic	JJ	-	-	-	-	-	-	-	-
1868042	0	7	effects	NNS	-	-	-	-	-	-	-	-
1868042	0	8	of	IN	-	-	-	-	-	-	-	-
1868042	0	9	both	CC	-	-	-	-	-	-	-	(97
1868042	0	10	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	11	and	CC	-	-	-	-	-	-	-	-
1868042	0	12	tolbutamide	NN	-	-	-	-	-	-	-	(23)|97)
1868042	0	13	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Whereas	IN	-	-	-	-	-	-	-	-
1868042	0	2	the	DT	-	-	-	-	-	-	-	(18
1868042	0	3	former	JJ	-	-	-	-	-	-	-	18)
1868042	0	4	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	5	in	IN	-	-	-	-	-	-	-	-
1868042	0	6	high	JJ	-	-	-	-	-	-	-	(160
1868042	0	7	glucose	NN	-	-	-	-	-	-	-	160)
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	brings	VBZ	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	(1
1868042	0	11	α	NN	-	-	-	-	-	-	-	-
1868042	0	12	cell	NN	-	-	-	-	-	-	-	1)
1868042	0	13	in	IN	-	-	-	-	-	-	-	-
1868042	0	14	a	DT	-	-	-	-	-	-	-	-
1868042	0	15	dose	NN	-	-	-	-	-	-	-	-
1868042	0	16	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	18	manner	NN	-	-	-	-	-	-	-	-
1868042	0	19	through	IN	-	-	-	-	-	-	-	-
1868042	0	20	the	DT	-	-	-	-	-	-	-	(197
1868042	0	21	membrane	NN	-	-	-	-	-	-	-	(143
1868042	0	22	potential	NN	-	-	-	-	-	-	-	143)
1868042	0	23	window	NN	-	-	-	-	-	-	-	197)
1868042	0	24	supporting	VBG	-	-	-	-	-	-	-	-
1868042	0	25	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	26	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	27	in	IN	-	-	-	-	-	-	-	-
1868042	0	28	the	DT	-	-	-	-	-	-	-	-
1868042	0	29	depolarised	VBN	-	-	-	-	-	-	-	-
1868042	0	30	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	31	low	JJ	-	-	-	-	-	-	-	-
1868042	0	32	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	33	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	34	to	IN	-	-	-	-	-	-	-	-
1868042	0	35	hyperpolarised	VBN	-	-	-	-	-	-	-	-
1868042	0	36	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	37	high	JJ	-	-	-	-	-	-	-	-
1868042	0	38	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	39	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	40	direction	NN	-	-	-	-	-	-	-	-
1868042	0	41	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	42	Figure	NN	-	-	-	-	-	-	-	(198|(81)
1868042	0	43	10C	NN	-	-	-	-	-	-	-	198)
1868042	0	44	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	45	,	,	-	-	-	-	-	-	-	-
1868042	0	46	the	DT	-	-	-	-	-	-	-	(23
1868042	0	47	latter	JJ	-	-	-	-	-	-	-	23)
1868042	0	48	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	49	in	IN	-	-	-	-	-	-	-	-
1868042	0	50	zero	CD	-	-	-	-	-	-	-	(199
1868042	0	51	glucose	NN	-	-	-	-	-	-	-	199)
1868042	0	52	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	53	brings	VBZ	-	-	-	-	-	-	-	-
1868042	0	54	the	DT	-	-	-	-	-	-	-	(1
1868042	0	55	α	NN	-	-	-	-	-	-	-	-
1868042	0	56	cell	NN	-	-	-	-	-	-	-	1)
1868042	0	57	through	IN	-	-	-	-	-	-	-	-
1868042	0	58	the	DT	-	-	-	-	-	-	-	(197
1868042	0	59	window	NN	-	-	-	-	-	-	-	197)
1868042	0	60	in	IN	-	-	-	-	-	-	-	-
1868042	0	61	the	DT	-	-	-	-	-	-	-	-
1868042	0	62	opposite	JJ	-	-	-	-	-	-	-	-
1868042	0	63	direction	NN	-	-	-	-	-	-	-	-
1868042	0	64	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	65	from	IN	-	-	-	-	-	-	-	-
1868042	0	66	hyperpolarised	VBN	-	-	-	-	-	-	-	-
1868042	0	67	to	IN	-	-	-	-	-	-	-	-
1868042	0	68	depolarised	VBN	-	-	-	-	-	-	-	-
1868042	0	69	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	70	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	71	Figure	NN	-	-	-	-	-	-	-	(200|(81)
1868042	0	72	10B	NN	-	-	-	-	-	-	-	200)
1868042	0	73	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	74	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Thus	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	4	likely	RB	-	-	-	-	-	-	-	-
1868042	0	5	leads	VBZ	-	-	-	-	-	-	-	-
1868042	0	6	to	IN	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	(141
1868042	0	8	suppression	NN	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	11	secretion	NN	-	-	-	-	-	-	-	25)|141)
1868042	0	12	by	IN	-	-	-	-	-	-	-	-
1868042	0	13	depolarising	VBG	-	-	-	-	-	-	-	-
1868042	0	14	the	DT	-	-	-	-	-	-	-	(201
1868042	0	15	α	NN	-	-	-	-	-	-	-	-
1868042	0	16	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	cell	NN	-	-	-	-	-	-	-	-
1868042	0	18	membrane	NN	-	-	-	-	-	-	-	-
1868042	0	19	potential	NN	-	-	-	-	-	-	-	201)
1868042	0	20	above	IN	-	-	-	-	-	-	-	-
1868042	0	21	the	DT	-	-	-	-	-	-	-	-
1868042	0	22	range	NN	-	-	-	-	-	-	-	-
1868042	0	23	that	WDT	-	-	-	-	-	-	-	-
1868042	0	24	supports	VBZ	-	-	-	-	-	-	-	-
1868042	0	25	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	26	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	27	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	28	Figure	NN	-	-	-	-	-	-	-	(202|(81)
1868042	0	29	10A	NN	-	-	-	-	-	-	-	202)
1868042	0	30	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Indeed	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	in	IN	-	-	-	-	-	-	-	-
1868042	0	4	some	DT	-	-	-	-	-	-	-	-
1868042	0	5	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	6	but	CC	-	-	-	-	-	-	-	-
1868042	0	7	not	RB	-	-	-	-	-	-	-	-
1868042	0	8	all	DT	-	-	-	-	-	-	-	-
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	see	VBP	-	-	-	-	-	-	-	-
1868042	0	11	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	12	55	CD	-	-	-	-	-	-	-	-
1868042	0	13	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	studies	NNS	-	-	-	-	-	-	-	-
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	18	was	VBD	-	-	-	-	-	-	-	-
1868042	0	19	found	VBN	-	-	-	-	-	-	-	-
1868042	0	20	to	TO	-	-	-	-	-	-	-	-
1868042	0	21	depolarize	VB	-	-	-	-	-	-	-	-
1868042	0	22	mouse	NN	-	-	-	-	-	-	-	(145a)
1868042	0	23	and	CC	-	-	-	-	-	-	-	-
1868042	0	24	rat	NN	-	-	-	-	-	-	-	-
1868042	0	25	α	NN	-	-	-	-	-	-	-	(145a
1868042	0	26	cells	NNS	-	-	-	-	-	-	-	145a)
1868042	0	27	and	CC	-	-	-	-	-	-	-	-
1868042	0	28	reduce	VB	-	-	-	-	-	-	-	-
1868042	0	29	action	NN	-	-	-	-	-	-	-	(181|(45
1868042	0	30	potential	JJ	-	-	-	-	-	-	-	45)
1868042	0	31	amplitudes	NNS	-	-	-	-	-	-	-	181)
1868042	0	32	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	33	13	CD	-	-	-	-	-	-	-	-
1868042	0	34	,	,	-	-	-	-	-	-	-	-
1868042	0	35	52	CD	-	-	-	-	-	-	-	-
1868042	0	36	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	37	.	.	-	-	-	-	-	-	-	-

1868042	0	1	It	PRP	-	-	-	-	-	-	-	-
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	interesting	JJ	-	-	-	-	-	-	-	-
1868042	0	4	that	IN	-	-	-	-	-	-	-	-
1868042	0	5	whereas	IN	-	-	-	-	-	-	-	-
1868042	0	6	low	JJ	-	-	-	-	-	-	-	-
1868042	0	7	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	8	of	IN	-	-	-	-	-	-	-	-
1868042	0	9	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	10	were	VBD	-	-	-	-	-	-	-	-
1868042	0	11	without	IN	-	-	-	-	-	-	-	-
1868042	0	12	stimulatory	JJ	-	-	-	-	-	-	-	-
1868042	0	13	effect	NN	-	-	-	-	-	-	-	-
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	tolbutamide	NN	-	-	-	-	-	-	-	(23)
1868042	0	16	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	17	0.1	CD	-	-	-	-	-	-	-	-
1868042	0	18	–	SYM	-	-	-	-	-	-	-	-
1868042	0	19	1	CD	-	-	-	-	-	-	-	-
1868042	0	20	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	21	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	22	stimulated	VBD	-	-	-	-	-	-	-	-
1868042	0	23	glucagon	NN	-	-	-	-	-	-	-	(3
1868042	0	24	release	NN	-	-	-	-	-	-	-	3)
1868042	0	25	beyond	IN	-	-	-	-	-	-	-	-
1868042	0	26	that	DT	-	-	-	-	-	-	-	-
1868042	0	27	observed	VBN	-	-	-	-	-	-	-	-
1868042	0	28	at	IN	-	-	-	-	-	-	-	-
1868042	0	29	zero	CD	-	-	-	-	-	-	-	(199
1868042	0	30	glucose	NN	-	-	-	-	-	-	-	199)
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Thus	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	small	JJ	-	-	-	-	-	-	-	-
1868042	0	4	depolarisations	NNS	-	-	-	-	-	-	-	-
1868042	0	5	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	6	as	IN	-	-	-	-	-	-	-	-
1868042	0	7	previously	RB	-	-	-	-	-	-	-	-
1868042	0	8	documented	VBN	-	-	-	-	-	-	-	-
1868042	0	9	for	IN	-	-	-	-	-	-	-	-
1868042	0	10	arginine	NN	-	-	-	-	-	-	-	-
1868042	0	11	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	12	13	CD	-	-	-	-	-	-	-	-
1868042	0	13	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	exert	VBP	-	-	-	-	-	-	-	-
1868042	0	16	a	DT	-	-	-	-	-	-	-	-
1868042	0	17	positive	JJ	-	-	-	-	-	-	-	-
1868042	0	18	“	``	-	-	-	-	-	-	-	-
1868042	0	19	chronotropic	JJ	-	-	-	-	-	-	-	-
1868042	0	20	”	''	-	-	-	-	-	-	-	-
1868042	0	21	effect	NN	-	-	-	-	-	-	-	-
1868042	0	22	in	IN	-	-	-	-	-	-	-	-
1868042	0	23	α	NN	-	-	-	-	-	-	-	(1
1868042	0	24	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	25	and	CC	-	-	-	-	-	-	-	-
1868042	0	26	thus	RB	-	-	-	-	-	-	-	-
1868042	0	27	stimulate	VBP	-	-	-	-	-	-	-	-
1868042	0	28	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	29	release	NN	-	-	-	-	-	-	-	3)
1868042	0	30	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	fact	NN	-	-	-	-	-	-	-	-
1868042	0	3	that	IN	-	-	-	-	-	-	-	-
1868042	0	4	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	5	did	VBD	-	-	-	-	-	-	-	-
1868042	0	6	not	RB	-	-	-	-	-	-	-	-
1868042	0	7	share	VB	-	-	-	-	-	-	-	-
1868042	0	8	this	DT	-	-	-	-	-	-	-	-
1868042	0	9	ability	NN	-	-	-	-	-	-	-	-
1868042	0	10	indicates	VBZ	-	-	-	-	-	-	-	-
1868042	0	11	that	IN	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	depolarisation	NN	-	-	-	-	-	-	-	-
1868042	0	14	produced	VBN	-	-	-	-	-	-	-	-
1868042	0	15	by	IN	-	-	-	-	-	-	-	-
1868042	0	16	1	CD	-	-	-	-	-	-	-	(101
1868042	0	17	mM	NN	-	-	-	-	-	-	-	-
1868042	0	18	glucose	NN	-	-	-	-	-	-	-	101)
1868042	0	19	results	VBZ	-	-	-	-	-	-	-	-
1868042	0	20	in	IN	-	-	-	-	-	-	-	-
1868042	0	21	sufficient	JJ	-	-	-	-	-	-	-	-
1868042	0	22	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	23	of	IN	-	-	-	-	-	-	-	-
1868042	0	24	the	DT	-	-	-	-	-	-	-	-
1868042	0	25	currents	NNS	-	-	-	-	-	-	-	-
1868042	0	26	to	TO	-	-	-	-	-	-	-	-
1868042	0	27	balance	VB	-	-	-	-	-	-	-	-
1868042	0	28	any	DT	-	-	-	-	-	-	-	-
1868042	0	29	increase	NN	-	-	-	-	-	-	-	-
1868042	0	30	in	IN	-	-	-	-	-	-	-	-
1868042	0	31	action	NN	-	-	-	-	-	-	-	(45
1868042	0	32	potential	NN	-	-	-	-	-	-	-	45)
1868042	0	33	frequency	NN	-	-	-	-	-	-	-	-
1868042	0	34	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Previous	JJ	-	-	-	-	-	-	-	(203
1868042	0	2	human	JJ	-	-	-	-	-	-	-	-
1868042	0	3	studies	NNS	-	-	-	-	-	-	-	203)
1868042	0	4	have	VBP	-	-	-	-	-	-	-	-
1868042	0	5	employed	VBN	-	-	-	-	-	-	-	-
1868042	0	6	pharmacological	JJ	-	-	-	-	-	-	-	-
1868042	0	7	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	8	channel	NN	-	-	-	-	-	-	-	-
1868042	0	9	antagonists	NNS	-	-	-	-	-	-	-	-
1868042	0	10	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	11	23	CD	-	-	-	-	-	-	-	-
1868042	0	12	,	,	-	-	-	-	-	-	-	-
1868042	0	13	24	CD	-	-	-	-	-	-	-	-
1868042	0	14	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	or	CC	-	-	-	-	-	-	-	-
1868042	0	16	agonists	NNS	-	-	-	-	-	-	-	-
1868042	0	17	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	18	25	CD	-	-	-	-	-	-	-	-
1868042	0	19	,	,	-	-	-	-	-	-	-	-
1868042	0	20	26	CD	-	-	-	-	-	-	-	-
1868042	0	21	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	22	to	TO	-	-	-	-	-	-	-	-
1868042	0	23	examine	VB	-	-	-	-	-	-	-	-
1868042	0	24	the	DT	-	-	-	-	-	-	-	-
1868042	0	25	regulation	NN	-	-	-	-	-	-	-	-
1868042	0	26	of	IN	-	-	-	-	-	-	-	-
1868042	0	27	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	28	release	NN	-	-	-	-	-	-	-	-
1868042	0	29	in	FW	-	-	-	-	-	-	-	-
1868042	0	30	vivo	FW	-	-	-	-	-	-	-	-
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	These	DT	-	-	-	-	-	-	-	(203)
1868042	0	2	were	VBD	-	-	-	-	-	-	-	-
1868042	0	3	interpreted	VBN	-	-	-	-	-	-	-	-
1868042	0	4	with	IN	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	-
1868042	0	6	assumption	NN	-	-	-	-	-	-	-	-
1868042	0	7	that	IN	-	-	-	-	-	-	-	-
1868042	0	8	pharmacological	JJ	-	-	-	-	-	-	-	-
1868042	0	9	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	10	modulation	NN	-	-	-	-	-	-	-	-
1868042	0	11	only	RB	-	-	-	-	-	-	-	-
1868042	0	12	affects	VBZ	-	-	-	-	-	-	-	-
1868042	0	13	the	DT	-	-	-	-	-	-	-	(21
1868042	0	14	β	NN	-	-	-	-	-	-	-	-
1868042	0	15	cells	NNS	-	-	-	-	-	-	-	21)
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	and	CC	-	-	-	-	-	-	-	-
1868042	0	18	that	IN	-	-	-	-	-	-	-	-
1868042	0	19	any	DT	-	-	-	-	-	-	-	-
1868042	0	20	change	NN	-	-	-	-	-	-	-	-
1868042	0	21	in	IN	-	-	-	-	-	-	-	-
1868042	0	22	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	23	release	NN	-	-	-	-	-	-	-	3)
1868042	0	24	was	VBD	-	-	-	-	-	-	-	-
1868042	0	25	therefore	RB	-	-	-	-	-	-	-	-
1868042	0	26	secondary	JJ	-	-	-	-	-	-	-	-
1868042	0	27	to	IN	-	-	-	-	-	-	-	-
1868042	0	28	altered	JJ	-	-	-	-	-	-	-	-
1868042	0	29	β	NN	-	-	-	-	-	-	-	-
1868042	0	30	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	31	cell	NN	-	-	-	-	-	-	-	-
1868042	0	32	function	NN	-	-	-	-	-	-	-	-
1868042	0	33	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Our	PRP$	-	-	-	-	-	-	-	(194|(4)
1868042	0	2	data	NNS	-	-	-	-	-	-	-	194)
1868042	0	3	establish	VBP	-	-	-	-	-	-	-	-
1868042	0	4	that	IN	-	-	-	-	-	-	-	-
1868042	0	5	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	6	channel	NN	-	-	-	-	-	-	-	32)
1868042	0	7	modulation	NN	-	-	-	-	-	-	-	-
1868042	0	8	has	VBZ	-	-	-	-	-	-	-	-
1868042	0	9	dramatic	JJ	-	-	-	-	-	-	-	-
1868042	0	10	and	CC	-	-	-	-	-	-	-	-
1868042	0	11	direct	JJ	-	-	-	-	-	-	-	-
1868042	0	12	effects	NNS	-	-	-	-	-	-	-	-
1868042	0	13	on	IN	-	-	-	-	-	-	-	-
1868042	0	14	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	15	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	16	and	CC	-	-	-	-	-	-	-	-
1868042	0	17	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	18	signalling	NN	-	-	-	-	-	-	-	-
1868042	0	19	in	IN	-	-	-	-	-	-	-	-
1868042	0	20	human	JJ	-	-	-	-	-	-	-	(10
1868042	0	21	α	NN	-	-	-	-	-	-	-	-
1868042	0	22	cells	NNS	-	-	-	-	-	-	-	10)
1868042	0	23	under	IN	-	-	-	-	-	-	-	-
1868042	0	24	conditions	NNS	-	-	-	-	-	-	-	-
1868042	0	25	in	IN	-	-	-	-	-	-	-	-
1868042	0	26	which	WDT	-	-	-	-	-	-	-	-
1868042	0	27	insulin	NN	-	-	-	-	-	-	-	(27|(19)
1868042	0	28	secretion	NN	-	-	-	-	-	-	-	27)
1868042	0	29	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	30	unaffected	JJ	-	-	-	-	-	-	-	-
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Thus	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	-
1868042	0	4	in	FW	-	-	-	-	-	-	-	-
1868042	0	5	vivo	FW	-	-	-	-	-	-	-	-
1868042	0	6	manipulation	NN	-	-	-	-	-	-	-	-
1868042	0	7	of	IN	-	-	-	-	-	-	-	-
1868042	0	8	α	NN	-	-	-	-	-	-	-	(63|(95
1868042	0	9	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	cell	NN	-	-	-	-	-	-	-	-
1868042	0	11	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	12	channel	NN	-	-	-	-	-	-	-	63)
1868042	0	13	activity	NN	-	-	-	-	-	-	-	95)
1868042	0	14	in	IN	-	-	-	-	-	-	-	-
1868042	0	15	the	DT	-	-	-	-	-	-	-	(203
1868042	0	16	above	JJ	-	-	-	-	-	-	-	-
1868042	0	17	studies	NNS	-	-	-	-	-	-	-	203)
1868042	0	18	may	MD	-	-	-	-	-	-	-	-
1868042	0	19	well	RB	-	-	-	-	-	-	-	-
1868042	0	20	have	VB	-	-	-	-	-	-	-	-
1868042	0	21	involved	VBN	-	-	-	-	-	-	-	-
1868042	0	22	direct	JJ	-	-	-	-	-	-	-	-
1868042	0	23	effects	NNS	-	-	-	-	-	-	-	-
1868042	0	24	on	IN	-	-	-	-	-	-	-	-
1868042	0	25	α	NN	-	-	-	-	-	-	-	(68
1868042	0	26	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	27	cell	NN	-	-	-	-	-	-	-	-
1868042	0	28	function	NN	-	-	-	-	-	-	-	68)
1868042	0	29	that	WDT	-	-	-	-	-	-	-	-
1868042	0	30	contributed	VBD	-	-	-	-	-	-	-	-
1868042	0	31	to	IN	-	-	-	-	-	-	-	-
1868042	0	32	the	DT	-	-	-	-	-	-	-	-
1868042	0	33	observed	VBN	-	-	-	-	-	-	-	-
1868042	0	34	changes	NNS	-	-	-	-	-	-	-	-
1868042	0	35	in	IN	-	-	-	-	-	-	-	-
1868042	0	36	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	37	release	NN	-	-	-	-	-	-	-	3)
1868042	0	38	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	importance	NN	-	-	-	-	-	-	-	-
1868042	0	3	of	IN	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	human	JJ	-	-	-	-	-	-	-	-
1868042	0	6	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	7	channel	NN	-	-	-	-	-	-	-	-
1868042	0	8	pathway	NN	-	-	-	-	-	-	-	-
1868042	0	9	for	IN	-	-	-	-	-	-	-	-
1868042	0	10	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	11	release	NN	-	-	-	-	-	-	-	3)
1868042	0	12	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	13	nicely	RB	-	-	-	-	-	-	-	-
1868042	0	14	highlighted	VBN	-	-	-	-	-	-	-	-
1868042	0	15	by	IN	-	-	-	-	-	-	-	-
1868042	0	16	a	DT	-	-	-	-	-	-	-	-
1868042	0	17	study	NN	-	-	-	-	-	-	-	-
1868042	0	18	investigating	VBG	-	-	-	-	-	-	-	-
1868042	0	19	the	DT	-	-	-	-	-	-	-	-
1868042	0	20	effects	NNS	-	-	-	-	-	-	-	-
1868042	0	21	of	IN	-	-	-	-	-	-	-	-
1868042	0	22	the	DT	-	-	-	-	-	-	-	(204
1868042	0	23	common	JJ	-	-	-	-	-	-	-	-
1868042	0	24	Glu23Lys	NN	-	-	-	-	-	-	-	-
1868042	0	25	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	26	E23K	NN	-	-	-	-	-	-	-	-
1868042	0	27	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	28	polymorphism	NN	-	-	-	-	-	-	-	-
1868042	0	29	of	IN	-	-	-	-	-	-	-	-
1868042	0	30	the	DT	-	-	-	-	-	-	-	-
1868042	0	31	Kir6.2	NN	-	-	-	-	-	-	-	-
1868042	0	32	subunit	NN	-	-	-	-	-	-	-	-
1868042	0	33	of	IN	-	-	-	-	-	-	-	-
1868042	0	34	the	DT	-	-	-	-	-	-	-	(32
1868042	0	35	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	36	channel	NN	-	-	-	-	-	-	-	32)|204)
1868042	0	37	on	IN	-	-	-	-	-	-	-	-
1868042	0	38	insulin	NN	-	-	-	-	-	-	-	(24|(19)
1868042	0	39	and	CC	-	-	-	-	-	-	-	-
1868042	0	40	glucagon	NN	-	-	-	-	-	-	-	(2)|24)
1868042	0	41	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	42	in	IN	-	-	-	-	-	-	-	-
1868042	0	43	non-diabetic	JJ	-	-	-	-	-	-	-	-
1868042	0	44	human	JJ	-	-	-	-	-	-	-	-
1868042	0	45	patients	NNS	-	-	-	-	-	-	-	-
1868042	0	46	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	47	29	CD	-	-	-	-	-	-	-	-
1868042	0	48	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	49	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	(204
1868042	0	2	variant	NN	-	-	-	-	-	-	-	-
1868042	0	3	of	IN	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	(32
1868042	0	5	channel	NN	-	-	-	-	-	-	-	32)|204)
1868042	0	6	leads	VBZ	-	-	-	-	-	-	-	-
1868042	0	7	to	IN	-	-	-	-	-	-	-	-
1868042	0	8	a	DT	-	-	-	-	-	-	-	(205
1868042	0	9	slight	JJ	-	-	-	-	-	-	-	-
1868042	0	10	decrease	NN	-	-	-	-	-	-	-	-
1868042	0	11	in	IN	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	ATP	NN	-	-	-	-	-	-	-	-
1868042	0	14	sensitivity	NN	-	-	-	-	-	-	-	-
1868042	0	15	of	IN	-	-	-	-	-	-	-	-
1868042	0	16	the	DT	-	-	-	-	-	-	-	(32
1868042	0	17	channel	NN	-	-	-	-	-	-	-	32)|205)
1868042	0	18	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	functional	JJ	-	-	-	-	-	-	-	-
1868042	0	3	significance	NN	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	this	DT	-	-	-	-	-	-	-	(205)
1868042	0	6	was	VBD	-	-	-	-	-	-	-	-
1868042	0	7	examined	VBN	-	-	-	-	-	-	-	-
1868042	0	8	by	IN	-	-	-	-	-	-	-	-
1868042	0	9	comparing	VBG	-	-	-	-	-	-	-	-
1868042	0	10	hormone	NN	-	-	-	-	-	-	-	-
1868042	0	11	release	NN	-	-	-	-	-	-	-	-
1868042	0	12	during	IN	-	-	-	-	-	-	-	-
1868042	0	13	hyperglycaemic	JJ	-	-	-	-	-	-	-	-
1868042	0	14	clamps	NNS	-	-	-	-	-	-	-	-
1868042	0	15	in	IN	-	-	-	-	-	-	-	-
1868042	0	16	individuals	NNS	-	-	-	-	-	-	-	-
1868042	0	17	carrying	VBG	-	-	-	-	-	-	-	-
1868042	0	18	the	DT	-	-	-	-	-	-	-	(204
1868042	0	19	polymorphism	NN	-	-	-	-	-	-	-	204)
1868042	0	20	or	CC	-	-	-	-	-	-	-	-
1868042	0	21	not	RB	-	-	-	-	-	-	-	-
1868042	0	22	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Although	IN	-	-	-	-	-	-	-	-
1868042	0	2	insulin	NN	-	-	-	-	-	-	-	(19)
1868042	0	3	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	4	in	IN	-	-	-	-	-	-	-	-
1868042	0	5	homozygous	JJ	-	-	-	-	-	-	-	-
1868042	0	6	Glu23Lys	NN	-	-	-	-	-	-	-	-
1868042	0	7	individuals	NNS	-	-	-	-	-	-	-	-
1868042	0	8	was	VBD	-	-	-	-	-	-	-	-
1868042	0	9	not	RB	-	-	-	-	-	-	-	-
1868042	0	10	different	JJ	-	-	-	-	-	-	-	-
1868042	0	11	from	IN	-	-	-	-	-	-	-	-
1868042	0	12	controls	NNS	-	-	-	-	-	-	-	(206)
1868042	0	13	,	,	-	-	-	-	-	-	-	-
1868042	0	14	glucose	NN	-	-	-	-	-	-	-	(130
1868042	0	15	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	induced	VBN	-	-	-	-	-	-	-	-
1868042	0	17	suppression	NN	-	-	-	-	-	-	-	-
1868042	0	18	of	IN	-	-	-	-	-	-	-	-
1868042	0	19	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	20	release	NN	-	-	-	-	-	-	-	3)|130)
1868042	0	21	was	VBD	-	-	-	-	-	-	-	-
1868042	0	22	blunted	VBN	-	-	-	-	-	-	-	-
1868042	0	23	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	24	29	CD	-	-	-	-	-	-	-	-
1868042	0	25	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	26	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	becomes	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	understandable	JJ	-	-	-	-	-	-	-	-
1868042	0	4	in	IN	-	-	-	-	-	-	-	-
1868042	0	5	light	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	-
1868042	0	8	effect	NN	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	11	on	IN	-	-	-	-	-	-	-	-
1868042	0	12	isolated	VBN	-	-	-	-	-	-	-	(62
1868042	0	13	human	JJ	-	-	-	-	-	-	-	-
1868042	0	14	islets	NNS	-	-	-	-	-	-	-	62)
1868042	0	15	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	16	Figures	NNS	-	-	-	-	-	-	-	(207|(208a)|(81)
1868042	0	17	4	CD	-	-	-	-	-	-	-	207)
1868042	0	18	and	CC	-	-	-	-	-	-	-	-
1868042	0	19	5	CD	-	-	-	-	-	-	-	(208a)
1868042	0	20	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	21	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Half	RB	-	-	-	-	-	-	-	-
1868042	0	2	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	3	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	4	activation	NN	-	-	-	-	-	-	-	-
1868042	0	5	of	IN	-	-	-	-	-	-	-	-
1868042	0	6	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	7	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	8	occurs	VBZ	-	-	-	-	-	-	-	-
1868042	0	9	at	IN	-	-	-	-	-	-	-	-
1868042	0	10	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	11	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	12	of	IN	-	-	-	-	-	-	-	-
1868042	0	13	20	CD	-	-	-	-	-	-	-	-
1868042	0	14	–	SYM	-	-	-	-	-	-	-	-
1868042	0	15	100	CD	-	-	-	-	-	-	-	-
1868042	0	16	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	17	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	18	depending	IN	-	-	-	-	-	-	-	-
1868042	0	19	on	IN	-	-	-	-	-	-	-	-
1868042	0	20	the	DT	-	-	-	-	-	-	-	-
1868042	0	21	intracellular	JJ	-	-	-	-	-	-	-	-
1868042	0	22	ATP	NN	-	-	-	-	-	-	-	-
1868042	0	23	level	NN	-	-	-	-	-	-	-	-
1868042	0	24	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	25	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	26	56	CD	-	-	-	-	-	-	-	-
1868042	0	27	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	28	.	.	-	-	-	-	-	-	-	-

1868042	0	1	If	IN	-	-	-	-	-	-	-	-
1868042	0	2	the	DT	-	-	-	-	-	-	-	(204
1868042	0	3	Glu23Lys	NN	-	-	-	-	-	-	-	-
1868042	0	4	polymorphism	NN	-	-	-	-	-	-	-	204)
1868042	0	5	increases	VBZ	-	-	-	-	-	-	-	-
1868042	0	6	KATP	NN	-	-	-	-	-	-	-	(92
1868042	0	7	channel	NN	-	-	-	-	-	-	-	-
1868042	0	8	activity	NN	-	-	-	-	-	-	-	92)
1868042	0	9	to	IN	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	-
1868042	0	11	same	JJ	-	-	-	-	-	-	-	-
1868042	0	12	extent	NN	-	-	-	-	-	-	-	-
1868042	0	13	as	IN	-	-	-	-	-	-	-	-
1868042	0	14	0.3	CD	-	-	-	-	-	-	-	-
1868042	0	15	–	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	1.5	CD	-	-	-	-	-	-	-	-
1868042	0	17	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	18	diazoxide	NN	-	-	-	-	-	-	-	-
1868042	0	19	,	,	-	-	-	-	-	-	-	-
1868042	0	20	the	DT	-	-	-	-	-	-	-	-
1868042	0	21	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	22	at	IN	-	-	-	-	-	-	-	-
1868042	0	23	which	WDT	-	-	-	-	-	-	-	-
1868042	0	24	an	DT	-	-	-	-	-	-	-	-
1868042	0	25	effect	NN	-	-	-	-	-	-	-	-
1868042	0	26	on	IN	-	-	-	-	-	-	-	-
1868042	0	27	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	28	release	NN	-	-	-	-	-	-	-	3)
1868042	0	29	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	30	first	RB	-	-	-	-	-	-	-	-
1868042	0	31	seen	VBN	-	-	-	-	-	-	-	-
1868042	0	32	,	,	-	-	-	-	-	-	-	-
1868042	0	33	then	RB	-	-	-	-	-	-	-	-
1868042	0	34	the	DT	-	-	-	-	-	-	-	-
1868042	0	35	effect	NN	-	-	-	-	-	-	-	-
1868042	0	36	will	MD	-	-	-	-	-	-	-	-
1868042	0	37	be	VB	-	-	-	-	-	-	-	-
1868042	0	38	very	RB	-	-	-	-	-	-	-	-
1868042	0	39	difficult	JJ	-	-	-	-	-	-	-	-
1868042	0	40	to	TO	-	-	-	-	-	-	-	-
1868042	0	41	detect	VB	-	-	-	-	-	-	-	-
1868042	0	42	with	IN	-	-	-	-	-	-	-	-
1868042	0	43	electrophysiology	NN	-	-	-	-	-	-	-	-
1868042	0	44	,	,	-	-	-	-	-	-	-	-
1868042	0	45	perhaps	RB	-	-	-	-	-	-	-	-
1868042	0	46	explaining	VBG	-	-	-	-	-	-	-	-
1868042	0	47	why	WRB	-	-	-	-	-	-	-	-
1868042	0	48	some	DT	-	-	-	-	-	-	-	-
1868042	0	49	studies	NNS	-	-	-	-	-	-	-	-
1868042	0	50	have	VBP	-	-	-	-	-	-	-	-
1868042	0	51	failed	VBN	-	-	-	-	-	-	-	-
1868042	0	52	to	TO	-	-	-	-	-	-	-	-
1868042	0	53	detect	VB	-	-	-	-	-	-	-	-
1868042	0	54	a	DT	-	-	-	-	-	-	-	-
1868042	0	55	functional	JJ	-	-	-	-	-	-	-	-
1868042	0	56	effect	NN	-	-	-	-	-	-	-	-
1868042	0	57	of	IN	-	-	-	-	-	-	-	-
1868042	0	58	the	DT	-	-	-	-	-	-	-	(204
1868042	0	59	polymorphism	NN	-	-	-	-	-	-	-	204)
1868042	0	60	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	61	reviewed	VBN	-	-	-	-	-	-	-	-
1868042	0	62	in	IN	-	-	-	-	-	-	-	-
1868042	0	63	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	64	57	CD	-	-	-	-	-	-	-	-
1868042	0	65	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	66	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	67	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Nevertheless	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	such	JJ	-	-	-	-	-	-	-	-
1868042	0	4	small	JJ	-	-	-	-	-	-	-	-
1868042	0	5	changes	NNS	-	-	-	-	-	-	-	-
1868042	0	6	can	MD	-	-	-	-	-	-	-	-
1868042	0	7	have	VB	-	-	-	-	-	-	-	-
1868042	0	8	significant	JJ	-	-	-	-	-	-	-	-
1868042	0	9	biological	JJ	-	-	-	-	-	-	-	-
1868042	0	10	effects	NNS	-	-	-	-	-	-	-	-
1868042	0	11	,	,	-	-	-	-	-	-	-	-
1868042	0	12	as	IN	-	-	-	-	-	-	-	-
1868042	0	13	illustrated	VBN	-	-	-	-	-	-	-	-
1868042	0	14	by	IN	-	-	-	-	-	-	-	-
1868042	0	15	the	DT	-	-	-	-	-	-	-	-
1868042	0	16	glucagon	NN	-	-	-	-	-	-	-	-
1868042	0	17	release	NN	-	-	-	-	-	-	-	-
1868042	0	18	data	NNS	-	-	-	-	-	-	-	-
1868042	0	19	,	,	-	-	-	-	-	-	-	-
1868042	0	20	and	CC	-	-	-	-	-	-	-	-
1868042	0	21	may	MD	-	-	-	-	-	-	-	-
1868042	0	22	contribute	VB	-	-	-	-	-	-	-	-
1868042	0	23	to	IN	-	-	-	-	-	-	-	-
1868042	0	24	pathological	JJ	-	-	-	-	-	-	-	-
1868042	0	25	states	NNS	-	-	-	-	-	-	-	-
1868042	0	26	such	JJ	-	-	-	-	-	-	-	-
1868042	0	27	as	IN	-	-	-	-	-	-	-	-
1868042	0	28	impaired	VBN	-	-	-	-	-	-	-	-
1868042	0	29	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	30	tolerance	NN	-	-	-	-	-	-	-	-
1868042	0	31	and	CC	-	-	-	-	-	-	-	-
1868042	0	32	diabetes	NN	-	-	-	-	-	-	-	(52)
1868042	0	33	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Thus	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	-
1868042	0	4	reduced	VBN	-	-	-	-	-	-	-	-
1868042	0	5	ability	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	8	to	TO	-	-	-	-	-	-	-	-
1868042	0	9	inhibit	VB	-	-	-	-	-	-	-	-
1868042	0	10	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	11	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	12	in	IN	-	-	-	-	-	-	-	-
1868042	0	13	individuals	NNS	-	-	-	-	-	-	-	-
1868042	0	14	carrying	VBG	-	-	-	-	-	-	-	-
1868042	0	15	the	DT	-	-	-	-	-	-	-	(204
1868042	0	16	Glu23Lys	NN	-	-	-	-	-	-	-	-
1868042	0	17	variant	NN	-	-	-	-	-	-	-	-
1868042	0	18	of	IN	-	-	-	-	-	-	-	-
1868042	0	19	the	DT	-	-	-	-	-	-	-	(32
1868042	0	20	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	21	channel	NN	-	-	-	-	-	-	-	32)|204)
1868042	0	22	likely	RB	-	-	-	-	-	-	-	-
1868042	0	23	results	VBZ	-	-	-	-	-	-	-	-
1868042	0	24	from	IN	-	-	-	-	-	-	-	-
1868042	0	25	the	DT	-	-	-	-	-	-	-	-
1868042	0	26	failure	NN	-	-	-	-	-	-	-	-
1868042	0	27	of	IN	-	-	-	-	-	-	-	-
1868042	0	28	these	DT	-	-	-	-	-	-	-	(32
1868042	0	29	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	30	to	TO	-	-	-	-	-	-	-	-
1868042	0	31	undergo	VB	-	-	-	-	-	-	-	-
1868042	0	32	complete	JJ	-	-	-	-	-	-	-	-
1868042	0	33	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	34	in	IN	-	-	-	-	-	-	-	-
1868042	0	35	response	NN	-	-	-	-	-	-	-	-
1868042	0	36	to	IN	-	-	-	-	-	-	-	-
1868042	0	37	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	38	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	have	VBP	-	-	-	-	-	-	-	-
1868042	0	3	proposed	VBN	-	-	-	-	-	-	-	-
1868042	0	4	that	IN	-	-	-	-	-	-	-	-
1868042	0	5	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	6	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	7	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	8	stimulated	VBN	-	-	-	-	-	-	-	-
1868042	0	9	within	IN	-	-	-	-	-	-	-	-
1868042	0	10	a	DT	-	-	-	-	-	-	-	(209
1868042	0	11	window	NN	-	-	-	-	-	-	-	-
1868042	0	12	of	IN	-	-	-	-	-	-	-	-
1868042	0	13	intermediate	JJ	-	-	-	-	-	-	-	-
1868042	0	14	α	NN	-	-	-	-	-	-	-	-
1868042	0	15	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	cell	NN	-	-	-	-	-	-	-	-
1868042	0	17	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	18	channel	NN	-	-	-	-	-	-	-	-
1868042	0	19	activity	NN	-	-	-	-	-	-	-	209)
1868042	0	20	,	,	-	-	-	-	-	-	-	-
1868042	0	21	and	CC	-	-	-	-	-	-	-	-
1868042	0	22	that	IN	-	-	-	-	-	-	-	-
1868042	0	23	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	24	release	NN	-	-	-	-	-	-	-	-
1868042	0	25	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	26	suppressed	VBN	-	-	-	-	-	-	-	-
1868042	0	27	by	IN	-	-	-	-	-	-	-	-
1868042	0	28	either	CC	-	-	-	-	-	-	-	-
1868042	0	29	increases	NNS	-	-	-	-	-	-	-	-
1868042	0	30	or	CC	-	-	-	-	-	-	-	-
1868042	0	31	decreases	NNS	-	-	-	-	-	-	-	-
1868042	0	32	in	IN	-	-	-	-	-	-	-	-
1868042	0	33	KATP	NN	-	-	-	-	-	-	-	(32|(92
1868042	0	34	channel	NN	-	-	-	-	-	-	-	32)
1868042	0	35	activity	NN	-	-	-	-	-	-	-	92)
1868042	0	36	.	.	-	-	-	-	-	-	-	-

1868042	0	1	How	WRB	-	-	-	-	-	-	-	-
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	this	DT	-	-	-	-	-	-	-	-
1868042	0	4	accomplished	VBN	-	-	-	-	-	-	-	-
1868042	0	5	?	.	-	-	-	-	-	-	-	-

1868042	0	1	Briefly	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	4	suggest	VBP	-	-	-	-	-	-	-	-
1868042	0	5	that	IN	-	-	-	-	-	-	-	-
1868042	0	6	this	DT	-	-	-	-	-	-	-	(209
1868042	0	7	window	NN	-	-	-	-	-	-	-	209)
1868042	0	8	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	9	the	DT	-	-	-	-	-	-	-	-
1868042	0	10	result	NN	-	-	-	-	-	-	-	-
1868042	0	11	of	IN	-	-	-	-	-	-	-	-
1868042	0	12	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	13	1	LS	-	-	-	-	-	-	-	-
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	the	DT	-	-	-	-	-	-	-	-
1868042	0	16	ability	NN	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	intermediate	JJ	-	-	-	-	-	-	-	(107
1868042	0	19	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	20	channel	NN	-	-	-	-	-	-	-	-
1868042	0	21	activity	NN	-	-	-	-	-	-	-	107)
1868042	0	22	to	TO	-	-	-	-	-	-	-	-
1868042	0	23	support	VB	-	-	-	-	-	-	-	-
1868042	0	24	regenerative	JJ	-	-	-	-	-	-	-	-
1868042	0	25	electrical	JJ	-	-	-	-	-	-	-	-
1868042	0	26	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	27	through	IN	-	-	-	-	-	-	-	-
1868042	0	28	the	DT	-	-	-	-	-	-	-	-
1868042	0	29	activation	NN	-	-	-	-	-	-	-	-
1868042	0	30	of	IN	-	-	-	-	-	-	-	-
1868042	0	31	voltage	NN	-	-	-	-	-	-	-	(210a
1868042	0	32	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	33	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	34	Na+	NN	-	-	-	-	-	-	-	210a)
1868042	0	35	and	CC	-	-	-	-	-	-	-	-
1868042	0	36	N	NN	-	-	-	-	-	-	-	(35
1868042	0	37	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	38	type	NN	-	-	-	-	-	-	-	-
1868042	0	39	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	40	channels	NNS	-	-	-	-	-	-	-	(210a)|35)
1868042	0	41	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	42	grey	JJ	-	-	-	-	-	-	-	-
1868042	0	43	in	IN	-	-	-	-	-	-	-	-
1868042	0	44	Figure	NN	-	-	-	-	-	-	-	(196|(81)
1868042	0	45	10	CD	-	-	-	-	-	-	-	196)
1868042	0	46	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	47	;	:	-	-	-	-	-	-	-	-
1868042	0	48	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	49	2	LS	-	-	-	-	-	-	-	-
1868042	0	50	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	51	the	DT	-	-	-	-	-	-	-	-
1868042	0	52	failure	NN	-	-	-	-	-	-	-	-
1868042	0	53	of	IN	-	-	-	-	-	-	-	-
1868042	0	54	the	DT	-	-	-	-	-	-	-	(54a|(55a)
1868042	0	55	Na+	NN	-	-	-	-	-	-	-	54a)
1868042	0	56	and	CC	-	-	-	-	-	-	-	-
1868042	0	57	Ca2+	NN	-	-	-	-	-	-	-	(55a|(5)
1868042	0	58	channels	NNS	-	-	-	-	-	-	-	(54a)|55a)
1868042	0	59	to	TO	-	-	-	-	-	-	-	-
1868042	0	60	activate	VB	-	-	-	-	-	-	-	-
1868042	0	61	when	WRB	-	-	-	-	-	-	-	-
1868042	0	62	α	NN	-	-	-	-	-	-	-	(1
1868042	0	63	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	64	are	VBP	-	-	-	-	-	-	-	-
1868042	0	65	hyperpolarised	VBN	-	-	-	-	-	-	-	-
1868042	0	66	by	IN	-	-	-	-	-	-	-	-
1868042	0	67	the	DT	-	-	-	-	-	-	-	-
1868042	0	68	opening	NN	-	-	-	-	-	-	-	-
1868042	0	69	of	IN	-	-	-	-	-	-	-	-
1868042	0	70	a	DT	-	-	-	-	-	-	-	-
1868042	0	71	major	JJ	-	-	-	-	-	-	-	-
1868042	0	72	fraction	NN	-	-	-	-	-	-	-	-
1868042	0	73	of	IN	-	-	-	-	-	-	-	-
1868042	0	74	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	75	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	76	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	77	above	IN	-	-	-	-	-	-	-	-
1868042	0	78	the	DT	-	-	-	-	-	-	-	-
1868042	0	79	grey	NN	-	-	-	-	-	-	-	-
1868042	0	80	in	IN	-	-	-	-	-	-	-	-
1868042	0	81	Figure	NN	-	-	-	-	-	-	-	(196|(81)
1868042	0	82	10	CD	-	-	-	-	-	-	-	196)
1868042	0	83	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	84	;	:	-	-	-	-	-	-	-	-
1868042	0	85	and	CC	-	-	-	-	-	-	-	-
1868042	0	86	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	87	3	LS	-	-	-	-	-	-	-	-
1868042	0	88	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	89	the	DT	-	-	-	-	-	-	-	(187a
1868042	0	90	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	91	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	92	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	93	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	94	of	IN	-	-	-	-	-	-	-	-
1868042	0	95	the	DT	-	-	-	-	-	-	-	(54b|187a)
1868042	0	96	Na+	NN	-	-	-	-	-	-	-	54b)
1868042	0	97	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	98	14	CD	-	-	-	-	-	-	-	-
1868042	0	99	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	100	and	CC	-	-	-	-	-	-	-	-
1868042	0	101	N	NN	-	-	-	-	-	-	-	(187a|(35
1868042	0	102	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	103	type	NN	-	-	-	-	-	-	-	-
1868042	0	104	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	105	channels	NNS	-	-	-	-	-	-	-	(54b)|35)|187a)
1868042	0	106	when	WRB	-	-	-	-	-	-	-	-
1868042	0	107	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	108	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	109	are	VBP	-	-	-	-	-	-	-	-
1868042	0	110	closed	VBN	-	-	-	-	-	-	-	-
1868042	0	111	and	CC	-	-	-	-	-	-	-	-
1868042	0	112	the	DT	-	-	-	-	-	-	-	(201
1868042	0	113	α	NN	-	-	-	-	-	-	-	-
1868042	0	114	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	115	cell	NN	-	-	-	-	-	-	-	-
1868042	0	116	membrane	NN	-	-	-	-	-	-	-	-
1868042	0	117	potential	NN	-	-	-	-	-	-	-	201)
1868042	0	118	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	119	depolarised	VBN	-	-	-	-	-	-	-	-
1868042	0	120	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	121	below	IN	-	-	-	-	-	-	-	-
1868042	0	122	the	DT	-	-	-	-	-	-	-	-
1868042	0	123	grey	NN	-	-	-	-	-	-	-	-
1868042	0	124	in	IN	-	-	-	-	-	-	-	-
1868042	0	125	Figure	NN	-	-	-	-	-	-	-	(196|(81)
1868042	0	126	10	CD	-	-	-	-	-	-	-	196)
1868042	0	127	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	128	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Thus	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	-
1868042	0	4	differential	JJ	-	-	-	-	-	-	-	-
1868042	0	5	responsiveness	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	α	NN	-	-	-	-	-	-	-	(66|(1a)
1868042	0	8	and	CC	-	-	-	-	-	-	-	-
1868042	0	9	β	NN	-	-	-	-	-	-	-	(21
1868042	0	10	cells	NNS	-	-	-	-	-	-	-	(1a)|66)|21)
1868042	0	11	to	IN	-	-	-	-	-	-	-	-
1868042	0	12	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	13	does	VBZ	-	-	-	-	-	-	-	-
1868042	0	14	not	RB	-	-	-	-	-	-	-	-
1868042	0	15	result	VB	-	-	-	-	-	-	-	-
1868042	0	16	from	IN	-	-	-	-	-	-	-	-
1868042	0	17	differential	JJ	-	-	-	-	-	-	-	-
1868042	0	18	sensitivities	NNS	-	-	-	-	-	-	-	-
1868042	0	19	of	IN	-	-	-	-	-	-	-	-
1868042	0	20	the	DT	-	-	-	-	-	-	-	(32
1868042	0	21	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	22	channels	NNS	-	-	-	-	-	-	-	32)
1868042	0	23	in	IN	-	-	-	-	-	-	-	-
1868042	0	24	these	DT	-	-	-	-	-	-	-	(66
1868042	0	25	cells	NNS	-	-	-	-	-	-	-	66)
1868042	0	26	,	,	-	-	-	-	-	-	-	-
1868042	0	27	but	CC	-	-	-	-	-	-	-	-
1868042	0	28	to	IN	-	-	-	-	-	-	-	-
1868042	0	29	the	DT	-	-	-	-	-	-	-	-
1868042	0	30	downstream	JJ	-	-	-	-	-	-	-	-
1868042	0	31	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	32	to	IN	-	-	-	-	-	-	-	-
1868042	0	33	titrated	VBN	-	-	-	-	-	-	-	-
1868042	0	34	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	35	channel	NN	-	-	-	-	-	-	-	-
1868042	0	36	activity	NN	-	-	-	-	-	-	-	-
1868042	0	37	.	.	-	-	-	-	-	-	-	-

1868042	0	1	One	CD	-	-	-	-	-	-	-	-
1868042	0	2	important	JJ	-	-	-	-	-	-	-	-
1868042	0	3	difference	NN	-	-	-	-	-	-	-	-
1868042	0	4	between	IN	-	-	-	-	-	-	-	-
1868042	0	5	mouse	NN	-	-	-	-	-	-	-	(145c|(211a)
1868042	0	6	α	NN	-	-	-	-	-	-	-	145c)
1868042	0	7	and	CC	-	-	-	-	-	-	-	-
1868042	0	8	β	NN	-	-	-	-	-	-	-	(211a
1868042	0	9	cells	NNS	-	-	-	-	-	-	-	(145c)|211a)
1868042	0	10	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	11	that	IN	-	-	-	-	-	-	-	-
1868042	0	12	whereas	IN	-	-	-	-	-	-	-	-
1868042	0	13	the	DT	-	-	-	-	-	-	-	(211
1868042	0	14	latter	JJ	-	-	-	-	-	-	-	211)
1868042	0	15	rely	VBP	-	-	-	-	-	-	-	-
1868042	0	16	exclusively	RB	-	-	-	-	-	-	-	-
1868042	0	17	on	IN	-	-	-	-	-	-	-	-
1868042	0	18	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	19	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	20	gated	VBN	-	-	-	-	-	-	-	-
1868042	0	21	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	22	channels	NNS	-	-	-	-	-	-	-	-
1868042	0	23	for	IN	-	-	-	-	-	-	-	-
1868042	0	24	the	DT	-	-	-	-	-	-	-	-
1868042	0	25	upstroke	NN	-	-	-	-	-	-	-	-
1868042	0	26	of	IN	-	-	-	-	-	-	-	-
1868042	0	27	the	DT	-	-	-	-	-	-	-	(45
1868042	0	28	action	NN	-	-	-	-	-	-	-	-
1868042	0	29	potentials	NNS	-	-	-	-	-	-	-	45)
1868042	0	30	,	,	-	-	-	-	-	-	-	-
1868042	0	31	glucagon	NN	-	-	-	-	-	-	-	(195
1868042	0	32	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	33	producing	VBG	-	-	-	-	-	-	-	-
1868042	0	34	α	NN	-	-	-	-	-	-	-	-
1868042	0	35	cells	NNS	-	-	-	-	-	-	-	195)
1868042	0	36	are	VBP	-	-	-	-	-	-	-	-
1868042	0	37	equipped	VBN	-	-	-	-	-	-	-	-
1868042	0	38	with	IN	-	-	-	-	-	-	-	-
1868042	0	39	voltage	NN	-	-	-	-	-	-	-	(33
1868042	0	40	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	41	gated	VBN	-	-	-	-	-	-	-	-
1868042	0	42	Na+	NN	-	-	-	-	-	-	-	-
1868042	0	43	channels	NNS	-	-	-	-	-	-	-	33)
1868042	0	44	.	.	-	-	-	-	-	-	-	-

1868042	0	1	These	DT	-	-	-	-	-	-	-	(33
1868042	0	2	channels	NNS	-	-	-	-	-	-	-	33)
1868042	0	3	undergo	VBP	-	-	-	-	-	-	-	-
1868042	0	4	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	5	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	6	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	7	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	8	at	IN	-	-	-	-	-	-	-	-
1868042	0	9	voltages	NNS	-	-	-	-	-	-	-	(212
1868042	0	10	more	RBR	-	-	-	-	-	-	-	-
1868042	0	11	positive	JJ	-	-	-	-	-	-	-	-
1868042	0	12	than	IN	-	-	-	-	-	-	-	-
1868042	0	13	−	SYM	-	-	-	-	-	-	-	(175
1868042	0	14	50	CD	-	-	-	-	-	-	-	-
1868042	0	15	mV	NNS	-	-	-	-	-	-	-	212)|175)
1868042	0	16	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	17	14	CD	-	-	-	-	-	-	-	-
1868042	0	18	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	19	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	will	MD	-	-	-	-	-	-	-	-
1868042	0	3	reduce	VB	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	(181
1868042	0	5	action	NN	-	-	-	-	-	-	-	(45
1868042	0	6	potential	NN	-	-	-	-	-	-	-	45)
1868042	0	7	amplitude	NN	-	-	-	-	-	-	-	181)
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	indeed	RB	-	-	-	-	-	-	-	-
1868042	0	11	it	PRP	-	-	-	-	-	-	-	-
1868042	0	12	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	13	reported	VBN	-	-	-	-	-	-	-	-
1868042	0	14	that	IN	-	-	-	-	-	-	-	-
1868042	0	15	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	16	reduces	VBZ	-	-	-	-	-	-	-	-
1868042	0	17	the	DT	-	-	-	-	-	-	-	-
1868042	0	18	peak	JJ	-	-	-	-	-	-	-	-
1868042	0	19	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	20	in	IN	-	-	-	-	-	-	-	-
1868042	0	21	α	NN	-	-	-	-	-	-	-	(1
1868042	0	22	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	23	from	IN	-	-	-	-	-	-	-	-
1868042	0	24	+	SYM	-	-	-	-	-	-	-	-
1868042	0	25	11	CD	-	-	-	-	-	-	-	-
1868042	0	26	mV	NNS	-	-	-	-	-	-	-	-
1868042	0	27	to	IN	-	-	-	-	-	-	-	-
1868042	0	28	−	SYM	-	-	-	-	-	-	-	-
1868042	0	29	1	CD	-	-	-	-	-	-	-	-
1868042	0	30	mV	NNS	-	-	-	-	-	-	-	-
1868042	0	31	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	32	13	CD	-	-	-	-	-	-	-	-
1868042	0	33	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	34	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	will	MD	-	-	-	-	-	-	-	-
1868042	0	3	in	IN	-	-	-	-	-	-	-	-
1868042	0	4	itself	PRP	-	-	-	-	-	-	-	-
1868042	0	5	result	VB	-	-	-	-	-	-	-	-
1868042	0	6	in	IN	-	-	-	-	-	-	-	-
1868042	0	7	an	DT	-	-	-	-	-	-	-	-
1868042	0	8	approximately	RB	-	-	-	-	-	-	-	-
1868042	0	9	35	CD	-	-	-	-	-	-	-	-
1868042	0	10	%	NN	-	-	-	-	-	-	-	-
1868042	0	11	reduction	NN	-	-	-	-	-	-	-	-
1868042	0	12	of	IN	-	-	-	-	-	-	-	-
1868042	0	13	exocytosis	NN	-	-	-	-	-	-	-	(43)
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	which	WDT	-	-	-	-	-	-	-	-
1868042	0	16	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	17	steeply	RB	-	-	-	-	-	-	-	-
1868042	0	18	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	19	on	IN	-	-	-	-	-	-	-	-
1868042	0	20	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	21	between	IN	-	-	-	-	-	-	-	-
1868042	0	22	−	SYM	-	-	-	-	-	-	-	(179a|(180
1868042	0	23	10	CD	-	-	-	-	-	-	-	179a)
1868042	0	24	and	CC	-	-	-	-	-	-	-	-
1868042	0	25	+	SYM	-	-	-	-	-	-	-	(169
1868042	0	26	10	CD	-	-	-	-	-	-	-	-
1868042	0	27	mV	NNS	-	-	-	-	-	-	-	(179a)|180)|169)
1868042	0	28	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	29	Figure	NN	-	-	-	-	-	-	-	(178|(81)
1868042	0	30	9E	NN	-	-	-	-	-	-	-	178)
1868042	0	31	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	32	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	functional	JJ	-	-	-	-	-	-	-	-
1868042	0	3	significance	NN	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	this	DT	-	-	-	-	-	-	-	-
1868042	0	6	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	7	illustrated	VBN	-	-	-	-	-	-	-	-
1868042	0	8	by	IN	-	-	-	-	-	-	-	-
1868042	0	9	the	DT	-	-	-	-	-	-	-	-
1868042	0	10	observations	NNS	-	-	-	-	-	-	-	-
1868042	0	11	that	IN	-	-	-	-	-	-	-	-
1868042	0	12	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	13	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	14	and	CC	-	-	-	-	-	-	-	-
1868042	0	15	α	NN	-	-	-	-	-	-	-	-
1868042	0	16	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	cell	NN	-	-	-	-	-	-	-	-
1868042	0	18	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	19	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	20	at	IN	-	-	-	-	-	-	-	-
1868042	0	21	low	JJ	-	-	-	-	-	-	-	(111
1868042	0	22	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	23	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	24	concentrations	NNS	-	-	-	-	-	-	-	111)
1868042	0	25	are	VBP	-	-	-	-	-	-	-	-
1868042	0	26	suppressed	VBN	-	-	-	-	-	-	-	-
1868042	0	27	by	IN	-	-	-	-	-	-	-	-
1868042	0	28	the	DT	-	-	-	-	-	-	-	(34
1868042	0	29	Na+	NN	-	-	-	-	-	-	-	-
1868042	0	30	channel	NN	-	-	-	-	-	-	-	-
1868042	0	31	blocker	NN	-	-	-	-	-	-	-	-
1868042	0	32	TTX	NN	-	-	-	-	-	-	-	34)
1868042	0	33	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	exact	JJ	-	-	-	-	-	-	-	-
1868042	0	3	ion	NN	-	-	-	-	-	-	-	-
1868042	0	4	channel	NN	-	-	-	-	-	-	-	-
1868042	0	5	complement	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	human	JJ	-	-	-	-	-	-	-	(10
1868042	0	8	α	NN	-	-	-	-	-	-	-	-
1868042	0	9	cells	NNS	-	-	-	-	-	-	-	10)
1868042	0	10	remains	VBZ	-	-	-	-	-	-	-	-
1868042	0	11	to	TO	-	-	-	-	-	-	-	-
1868042	0	12	be	VB	-	-	-	-	-	-	-	-
1868042	0	13	established	VBN	-	-	-	-	-	-	-	-
1868042	0	14	.	.	-	-	-	-	-	-	-	-

1868042	0	1	However	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	-
1868042	0	4	fact	NN	-	-	-	-	-	-	-	-
1868042	0	5	that	IN	-	-	-	-	-	-	-	-
1868042	0	6	glucagon	NN	-	-	-	-	-	-	-	(40|(2)
1868042	0	7	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	8	from	IN	-	-	-	-	-	-	-	-
1868042	0	9	human	JJ	-	-	-	-	-	-	-	-
1868042	0	10	islets	NNS	-	-	-	-	-	-	-	40)
1868042	0	11	shows	VBZ	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	same	JJ	-	-	-	-	-	-	-	-
1868042	0	14	bell	NN	-	-	-	-	-	-	-	-
1868042	0	15	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	shaped	VBN	-	-	-	-	-	-	-	-
1868042	0	17	diazoxide	NN	-	-	-	-	-	-	-	-
1868042	0	18	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	19	dependence	NN	-	-	-	-	-	-	-	-
1868042	0	20	as	IN	-	-	-	-	-	-	-	-
1868042	0	21	in	IN	-	-	-	-	-	-	-	-
1868042	0	22	mouse	NN	-	-	-	-	-	-	-	(71
1868042	0	23	islets	NNS	-	-	-	-	-	-	-	71)
1868042	0	24	suggests	VBZ	-	-	-	-	-	-	-	-
1868042	0	25	that	IN	-	-	-	-	-	-	-	-
1868042	0	26	the	DT	-	-	-	-	-	-	-	-
1868042	0	27	depolarization	NN	-	-	-	-	-	-	-	-
1868042	0	28	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	29	induced	VBN	-	-	-	-	-	-	-	-
1868042	0	30	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	31	of	IN	-	-	-	-	-	-	-	-
1868042	0	32	ion	NN	-	-	-	-	-	-	-	-
1868042	0	33	channels	NNS	-	-	-	-	-	-	-	-
1868042	0	34	involved	VBN	-	-	-	-	-	-	-	-
1868042	0	35	in	IN	-	-	-	-	-	-	-	-
1868042	0	36	α	NN	-	-	-	-	-	-	-	-
1868042	0	37	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	38	cell	NN	-	-	-	-	-	-	-	-
1868042	0	39	regenerative	JJ	-	-	-	-	-	-	-	-
1868042	0	40	electrical	JJ	-	-	-	-	-	-	-	-
1868042	0	41	activity	NN	-	-	-	-	-	-	-	-
1868042	0	42	underlies	VBZ	-	-	-	-	-	-	-	-
1868042	0	43	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	44	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	45	induced	VBN	-	-	-	-	-	-	-	-
1868042	0	46	suppression	NN	-	-	-	-	-	-	-	-
1868042	0	47	of	IN	-	-	-	-	-	-	-	-
1868042	0	48	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	49	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	50	in	IN	-	-	-	-	-	-	-	-
1868042	0	51	man	NN	-	-	-	-	-	-	-	-
1868042	0	52	as	RB	-	-	-	-	-	-	-	-
1868042	0	53	well	RB	-	-	-	-	-	-	-	-
1868042	0	54	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Although	IN	-	-	-	-	-	-	-	-
1868042	0	2	L	NN	-	-	-	-	-	-	-	(37
1868042	0	3	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	4	type	NN	-	-	-	-	-	-	-	-
1868042	0	5	VDCCs	NNS	-	-	-	-	-	-	-	37)
1868042	0	6	mediate	VBP	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	-
1868042	0	8	majority	NN	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	11	current	NN	-	-	-	-	-	-	-	-
1868042	0	12	in	IN	-	-	-	-	-	-	-	-
1868042	0	13	α	NN	-	-	-	-	-	-	-	(1
1868042	0	14	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	15	,	,	-	-	-	-	-	-	-	-
1868042	0	16	this	DT	-	-	-	-	-	-	-	-
1868042	0	17	work	NN	-	-	-	-	-	-	-	-
1868042	0	18	and	CC	-	-	-	-	-	-	-	-
1868042	0	19	previous	JJ	-	-	-	-	-	-	-	-
1868042	0	20	studies	NNS	-	-	-	-	-	-	-	-
1868042	0	21	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	22	33	CD	-	-	-	-	-	-	-	-
1868042	0	23	,	,	-	-	-	-	-	-	-	-
1868042	0	24	44	CD	-	-	-	-	-	-	-	-
1868042	0	25	,	,	-	-	-	-	-	-	-	-
1868042	0	26	45	CD	-	-	-	-	-	-	-	-
1868042	0	27	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	28	demonstrate	VBP	-	-	-	-	-	-	-	-
1868042	0	29	that	IN	-	-	-	-	-	-	-	-
1868042	0	30	it	PRP	-	-	-	-	-	-	-	-
1868042	0	31	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	32	the	DT	-	-	-	-	-	-	-	(213
1868042	0	33	N	NN	-	-	-	-	-	-	-	-
1868042	0	34	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	35	type	NN	-	-	-	-	-	-	-	-
1868042	0	36	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	37	ω	NN	-	-	-	-	-	-	-	-
1868042	0	38	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	39	conotoxin	NN	-	-	-	-	-	-	-	-
1868042	0	40	–	HYPH	-	-	-	-	-	-	-	-
1868042	0	41	sensitive	JJ	-	-	-	-	-	-	-	-
1868042	0	42	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	43	VDCCs	NNS	-	-	-	-	-	-	-	213)
1868042	0	44	that	WDT	-	-	-	-	-	-	-	-
1868042	0	45	mediate	VBP	-	-	-	-	-	-	-	-
1868042	0	46	the	DT	-	-	-	-	-	-	-	-
1868042	0	47	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	48	influx	NN	-	-	-	-	-	-	-	-
1868042	0	49	necessary	JJ	-	-	-	-	-	-	-	-
1868042	0	50	for	IN	-	-	-	-	-	-	-	-
1868042	0	51	α	NN	-	-	-	-	-	-	-	(39
1868042	0	52	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	53	cell	NN	-	-	-	-	-	-	-	-
1868042	0	54	exocytosis	NN	-	-	-	-	-	-	-	39)
1868042	0	55	and	CC	-	-	-	-	-	-	-	-
1868042	0	56	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	57	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	58	under	IN	-	-	-	-	-	-	-	-
1868042	0	59	hypoglycaemic	JJ	-	-	-	-	-	-	-	-
1868042	0	60	conditions	NNS	-	-	-	-	-	-	-	-
1868042	0	61	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	now	RB	-	-	-	-	-	-	-	-
1868042	0	3	show	VBP	-	-	-	-	-	-	-	-
1868042	0	4	that	IN	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	-
1868042	0	6	α	NN	-	-	-	-	-	-	-	-
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	cell	NN	-	-	-	-	-	-	-	-
1868042	0	9	N	NN	-	-	-	-	-	-	-	-
1868042	0	10	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	11	type	NN	-	-	-	-	-	-	-	-
1868042	0	12	VDCCs	NNS	-	-	-	-	-	-	-	-
1868042	0	13	are	VBP	-	-	-	-	-	-	-	-
1868042	0	14	also	RB	-	-	-	-	-	-	-	-
1868042	0	15	subject	JJ	-	-	-	-	-	-	-	-
1868042	0	16	to	IN	-	-	-	-	-	-	-	-
1868042	0	17	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	18	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	19	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	20	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	21	at	IN	-	-	-	-	-	-	-	-
1868042	0	22	voltages	NNS	-	-	-	-	-	-	-	(212
1868042	0	23	more	RBR	-	-	-	-	-	-	-	-
1868042	0	24	positive	JJ	-	-	-	-	-	-	-	-
1868042	0	25	than	IN	-	-	-	-	-	-	-	-
1868042	0	26	−	SYM	-	-	-	-	-	-	-	(175
1868042	0	27	50	CD	-	-	-	-	-	-	-	-
1868042	0	28	mV	NNS	-	-	-	-	-	-	-	212)|175)
1868042	0	29	and	CC	-	-	-	-	-	-	-	-
1868042	0	30	furthermore	RB	-	-	-	-	-	-	-	-
1868042	0	31	that	IN	-	-	-	-	-	-	-	-
1868042	0	32	this	DT	-	-	-	-	-	-	-	-
1868042	0	33	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	34	associated	VBN	-	-	-	-	-	-	-	-
1868042	0	35	with	IN	-	-	-	-	-	-	-	-
1868042	0	36	reduced	VBN	-	-	-	-	-	-	-	-
1868042	0	37	exocytotic	JJ	-	-	-	-	-	-	-	-
1868042	0	38	capacity	NN	-	-	-	-	-	-	-	-
1868042	0	39	.	.	-	-	-	-	-	-	-	-

1868042	0	1	It	PRP	-	-	-	-	-	-	-	-
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	pertinent	JJ	-	-	-	-	-	-	-	-
1868042	0	4	that	IN	-	-	-	-	-	-	-	-
1868042	0	5	N	NN	-	-	-	-	-	-	-	-
1868042	0	6	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	type	NN	-	-	-	-	-	-	-	-
1868042	0	8	VDCC	NN	-	-	-	-	-	-	-	-
1868042	0	9	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	deficient	JJ	-	-	-	-	-	-	-	-
1868042	0	11	mice	NNS	-	-	-	-	-	-	-	-
1868042	0	12	exhibit	VBP	-	-	-	-	-	-	-	-
1868042	0	13	reduced	VBN	-	-	-	-	-	-	-	-
1868042	0	14	serum	NN	-	-	-	-	-	-	-	-
1868042	0	15	glucagon	NN	-	-	-	-	-	-	-	-
1868042	0	16	levels	NNS	-	-	-	-	-	-	-	-
1868042	0	17	and	CC	-	-	-	-	-	-	-	-
1868042	0	18	improved	VBN	-	-	-	-	-	-	-	-
1868042	0	19	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	20	tolerance	NN	-	-	-	-	-	-	-	-
1868042	0	21	despite	IN	-	-	-	-	-	-	-	-
1868042	0	22	a	DT	-	-	-	-	-	-	-	-
1868042	0	23	parallel	JJ	-	-	-	-	-	-	-	-
1868042	0	24	reduction	NN	-	-	-	-	-	-	-	-
1868042	0	25	in	IN	-	-	-	-	-	-	-	-
1868042	0	26	plasma	NN	-	-	-	-	-	-	-	-
1868042	0	27	insulin	NN	-	-	-	-	-	-	-	-
1868042	0	28	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	29	44	CD	-	-	-	-	-	-	-	-
1868042	0	30	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Although	IN	-	-	-	-	-	-	-	-
1868042	0	2	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	3	influx	NN	-	-	-	-	-	-	-	-
1868042	0	4	through	IN	-	-	-	-	-	-	-	-
1868042	0	5	L	NN	-	-	-	-	-	-	-	(37
1868042	0	6	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	type	NN	-	-	-	-	-	-	-	-
1868042	0	8	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	9	channels	NNS	-	-	-	-	-	-	-	37)
1868042	0	10	does	VBZ	-	-	-	-	-	-	-	-
1868042	0	11	not	RB	-	-	-	-	-	-	-	-
1868042	0	12	appear	VB	-	-	-	-	-	-	-	-
1868042	0	13	to	TO	-	-	-	-	-	-	-	-
1868042	0	14	contribute	VB	-	-	-	-	-	-	-	-
1868042	0	15	much	RB	-	-	-	-	-	-	-	-
1868042	0	16	to	IN	-	-	-	-	-	-	-	-
1868042	0	17	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	18	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	19	under	IN	-	-	-	-	-	-	-	-
1868042	0	20	the	DT	-	-	-	-	-	-	-	-
1868042	0	21	experimental	JJ	-	-	-	-	-	-	-	-
1868042	0	22	conditions	NNS	-	-	-	-	-	-	-	-
1868042	0	23	used	VBN	-	-	-	-	-	-	-	-
1868042	0	24	in	IN	-	-	-	-	-	-	-	-
1868042	0	25	this	DT	-	-	-	-	-	-	-	(189
1868042	0	26	study	NN	-	-	-	-	-	-	-	189)
1868042	0	27	,	,	-	-	-	-	-	-	-	-
1868042	0	28	these	DT	-	-	-	-	-	-	-	(37
1868042	0	29	channels	NNS	-	-	-	-	-	-	-	37)
1868042	0	30	become	VBP	-	-	-	-	-	-	-	-
1868042	0	31	the	DT	-	-	-	-	-	-	-	-
1868042	0	32	predominant	JJ	-	-	-	-	-	-	-	-
1868042	0	33	conduit	NN	-	-	-	-	-	-	-	-
1868042	0	34	of	IN	-	-	-	-	-	-	-	-
1868042	0	35	Ca2+	NN	-	-	-	-	-	-	-	(58|(5)
1868042	0	36	entry	NN	-	-	-	-	-	-	-	58)
1868042	0	37	in	IN	-	-	-	-	-	-	-	-
1868042	0	38	the	DT	-	-	-	-	-	-	-	-
1868042	0	39	presence	NN	-	-	-	-	-	-	-	-
1868042	0	40	of	IN	-	-	-	-	-	-	-	-
1868042	0	41	agents	NNS	-	-	-	-	-	-	-	-
1868042	0	42	increasing	VBG	-	-	-	-	-	-	-	-
1868042	0	43	cAMP	NN	-	-	-	-	-	-	-	-
1868042	0	44	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	45	41	CD	-	-	-	-	-	-	-	-
1868042	0	46	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	47	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	48	unpublished	JJ	-	-	-	-	-	-	-	(133
1868042	0	49	data	NNS	-	-	-	-	-	-	-	133)
1868042	0	50	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	51	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	mechanism	NN	-	-	-	-	-	-	-	-
1868042	0	3	underlying	VBG	-	-	-	-	-	-	-	-
1868042	0	4	this	DT	-	-	-	-	-	-	-	-
1868042	0	5	switch	NN	-	-	-	-	-	-	-	-
1868042	0	6	in	IN	-	-	-	-	-	-	-	-
1868042	0	7	Ca2+	NN	-	-	-	-	-	-	-	(55
1868042	0	8	channel	NN	-	-	-	-	-	-	-	55)
1868042	0	9	dependence	NN	-	-	-	-	-	-	-	-
1868042	0	10	remains	VBZ	-	-	-	-	-	-	-	-
1868042	0	11	obscure	JJ	-	-	-	-	-	-	-	-
1868042	0	12	,	,	-	-	-	-	-	-	-	-
1868042	0	13	but	CC	-	-	-	-	-	-	-	-
1868042	0	14	may	MD	-	-	-	-	-	-	-	-
1868042	0	15	depend	VB	-	-	-	-	-	-	-	-
1868042	0	16	on	IN	-	-	-	-	-	-	-	-
1868042	0	17	the	DT	-	-	-	-	-	-	-	-
1868042	0	18	strength	NN	-	-	-	-	-	-	-	-
1868042	0	19	of	IN	-	-	-	-	-	-	-	-
1868042	0	20	depolarisation	NN	-	-	-	-	-	-	-	-
1868042	0	21	because	IN	-	-	-	-	-	-	-	-
1868042	0	22	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	23	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	24	stimulated	VBN	-	-	-	-	-	-	-	-
1868042	0	25	by	IN	-	-	-	-	-	-	-	-
1868042	0	26	strong	JJ	-	-	-	-	-	-	-	-
1868042	0	27	depolarisation	NN	-	-	-	-	-	-	-	-
1868042	0	28	with	IN	-	-	-	-	-	-	-	-
1868042	0	29	increased	VBN	-	-	-	-	-	-	-	-
1868042	0	30	K+	NN	-	-	-	-	-	-	-	-
1868042	0	31	in	IN	-	-	-	-	-	-	-	-
1868042	0	32	combination	NN	-	-	-	-	-	-	-	-
1868042	0	33	with	IN	-	-	-	-	-	-	-	-
1868042	0	34	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	35	channel	NN	-	-	-	-	-	-	-	32)
1868042	0	36	block	NN	-	-	-	-	-	-	-	-
1868042	0	37	can	MD	-	-	-	-	-	-	-	-
1868042	0	38	be	VB	-	-	-	-	-	-	-	-
1868042	0	39	prevented	VBN	-	-	-	-	-	-	-	-
1868042	0	40	by	IN	-	-	-	-	-	-	-	-
1868042	0	41	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	42	of	IN	-	-	-	-	-	-	-	-
1868042	0	43	L	NN	-	-	-	-	-	-	-	(37
1868042	0	44	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	45	type	NN	-	-	-	-	-	-	-	-
1868042	0	46	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	47	channels	NNS	-	-	-	-	-	-	-	37)
1868042	0	48	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	49	47	CD	-	-	-	-	-	-	-	-
1868042	0	50	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	51	.	.	-	-	-	-	-	-	-	-

1868042	0	1	We	PRP	-	-	-	-	-	-	-	(4)
1868042	0	2	finally	RB	-	-	-	-	-	-	-	-
1868042	0	3	point	VBP	-	-	-	-	-	-	-	-
1868042	0	4	out	RP	-	-	-	-	-	-	-	-
1868042	0	5	that	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	model	NN	-	-	-	-	-	-	-	-
1868042	0	8	we	PRP	-	-	-	-	-	-	-	(4)
1868042	0	9	propose	VBP	-	-	-	-	-	-	-	-
1868042	0	10	here	RB	-	-	-	-	-	-	-	-
1868042	0	11	for	IN	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	control	NN	-	-	-	-	-	-	-	-
1868042	0	14	of	IN	-	-	-	-	-	-	-	-
1868042	0	15	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	16	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	17	shares	VBZ	-	-	-	-	-	-	-	-
1868042	0	18	many	JJ	-	-	-	-	-	-	-	-
1868042	0	19	features	NNS	-	-	-	-	-	-	-	-
1868042	0	20	with	IN	-	-	-	-	-	-	-	-
1868042	0	21	what	WP	-	-	-	-	-	-	-	-
1868042	0	22	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	23	known	VBN	-	-	-	-	-	-	-	-
1868042	0	24	about	IN	-	-	-	-	-	-	-	-
1868042	0	25	the	DT	-	-	-	-	-	-	-	-
1868042	0	26	metabolic	JJ	-	-	-	-	-	-	-	-
1868042	0	27	control	NN	-	-	-	-	-	-	-	-
1868042	0	28	of	IN	-	-	-	-	-	-	-	-
1868042	0	29	insulin	NN	-	-	-	-	-	-	-	(27|(19)
1868042	0	30	secretion	NN	-	-	-	-	-	-	-	27)
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	in	IN	-	-	-	-	-	-	-	-
1868042	0	3	turn	NN	-	-	-	-	-	-	-	-
1868042	0	4	means	VBZ	-	-	-	-	-	-	-	-
1868042	0	5	that	IN	-	-	-	-	-	-	-	-
1868042	0	6	processes	NNS	-	-	-	-	-	-	-	-
1868042	0	7	that	WDT	-	-	-	-	-	-	-	-
1868042	0	8	interfere	VBP	-	-	-	-	-	-	-	-
1868042	0	9	with	IN	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	-
1868042	0	11	ability	NN	-	-	-	-	-	-	-	-
1868042	0	12	of	IN	-	-	-	-	-	-	-	-
1868042	0	13	,	,	-	-	-	-	-	-	-	-
1868042	0	14	for	IN	-	-	-	-	-	-	-	-
1868042	0	15	example	NN	-	-	-	-	-	-	-	-
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	18	to	TO	-	-	-	-	-	-	-	-
1868042	0	19	stimulate	VB	-	-	-	-	-	-	-	-
1868042	0	20	insulin	NN	-	-	-	-	-	-	-	(27|(19)
1868042	0	21	secretion	NN	-	-	-	-	-	-	-	27)
1868042	0	22	will	MD	-	-	-	-	-	-	-	-
1868042	0	23	have	VB	-	-	-	-	-	-	-	-
1868042	0	24	the	DT	-	-	-	-	-	-	-	-
1868042	0	25	opposite	JJ	-	-	-	-	-	-	-	-
1868042	0	26	effect	NN	-	-	-	-	-	-	-	-
1868042	0	27	on	IN	-	-	-	-	-	-	-	-
1868042	0	28	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	29	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	30	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	would	MD	-	-	-	-	-	-	-	-
1868042	0	3	provide	VB	-	-	-	-	-	-	-	-
1868042	0	4	a	DT	-	-	-	-	-	-	-	-
1868042	0	5	simple	JJ	-	-	-	-	-	-	-	-
1868042	0	6	explanation	NN	-	-	-	-	-	-	-	-
1868042	0	7	for	IN	-	-	-	-	-	-	-	-
1868042	0	8	the	DT	-	-	-	-	-	-	-	-
1868042	0	9	fact	NN	-	-	-	-	-	-	-	-
1868042	0	10	that	IN	-	-	-	-	-	-	-	-
1868042	0	11	both	CC	-	-	-	-	-	-	-	(24|(26
1868042	0	12	insulin	NN	-	-	-	-	-	-	-	(19)
1868042	0	13	and	CC	-	-	-	-	-	-	-	-
1868042	0	14	glucagon	NN	-	-	-	-	-	-	-	(25|(2)|24)
1868042	0	15	secretion	NN	-	-	-	-	-	-	-	26)|25)
1868042	0	16	become	VBD	-	-	-	-	-	-	-	-
1868042	0	17	perturbed	VBN	-	-	-	-	-	-	-	-
1868042	0	18	in	IN	-	-	-	-	-	-	-	-
1868042	0	19	diabetes	NN	-	-	-	-	-	-	-	(52)
1868042	0	20	and	CC	-	-	-	-	-	-	-	-
1868042	0	21	why	WRB	-	-	-	-	-	-	-	-
1868042	0	22	oversecretion	NN	-	-	-	-	-	-	-	-
1868042	0	23	of	IN	-	-	-	-	-	-	-	-
1868042	0	24	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	25	exacerbates	VBZ	-	-	-	-	-	-	-	-
1868042	0	26	the	DT	-	-	-	-	-	-	-	-
1868042	0	27	hyperglycaemic	JJ	-	-	-	-	-	-	-	-
1868042	0	28	effects	NNS	-	-	-	-	-	-	-	-
1868042	0	29	of	IN	-	-	-	-	-	-	-	-
1868042	0	30	insufficient	JJ	-	-	-	-	-	-	-	-
1868042	0	31	insulin	NN	-	-	-	-	-	-	-	-
1868042	0	32	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	33	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Materials	NNS	-	-	-	-	-	-	-	-
1868042	0	2	and	CC	-	-	-	-	-	-	-	-
1868042	0	3	Methods	NNS	-	-	-	-	-	-	-	-

1868042	0	1	Islet	NN	-	-	-	-	-	-	-	(215|(214)
1868042	0	2	isolation	NN	-	-	-	-	-	-	-	215)
1868042	0	3	and	CC	-	-	-	-	-	-	-	-
1868042	0	4	culture	NN	-	-	-	-	-	-	-	-
1868042	0	5	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Islets	NNS	-	-	-	-	-	-	-	(216
1868042	0	2	from	IN	-	-	-	-	-	-	-	-
1868042	0	3	female	JJ	-	-	-	-	-	-	-	-
1868042	0	4	NMRI	NN	-	-	-	-	-	-	-	-
1868042	0	5	mice	NNS	-	-	-	-	-	-	-	216)
1868042	0	6	were	VBD	-	-	-	-	-	-	-	-
1868042	0	7	isolated	VBN	-	-	-	-	-	-	-	-
1868042	0	8	by	IN	-	-	-	-	-	-	-	-
1868042	0	9	collagenase	NN	-	-	-	-	-	-	-	-
1868042	0	10	digestion	NN	-	-	-	-	-	-	-	-
1868042	0	11	and	CC	-	-	-	-	-	-	-	-
1868042	0	12	cultured	VBN	-	-	-	-	-	-	-	-
1868042	0	13	in	IN	-	-	-	-	-	-	-	-
1868042	0	14	RPMI	NN	-	-	-	-	-	-	-	(217
1868042	0	15	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	1640	CD	-	-	-	-	-	-	-	-
1868042	0	17	media	NNS	-	-	-	-	-	-	-	217)
1868042	0	18	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	19	5	CD	-	-	-	-	-	-	-	(115
1868042	0	20	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	21	glucose	NN	-	-	-	-	-	-	-	115)
1868042	0	22	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	at	IN	-	-	-	-	-	-	-	-
1868042	0	24	37	CD	-	-	-	-	-	-	-	(218
1868042	0	25	°	SYM	-	-	-	-	-	-	-	-
1868042	0	26	C	NNP	-	-	-	-	-	-	-	218)
1868042	0	27	and	CC	-	-	-	-	-	-	-	-
1868042	0	28	5	CD	-	-	-	-	-	-	-	(219
1868042	0	29	%	NN	-	-	-	-	-	-	-	-
1868042	0	30	CO2	NN	-	-	-	-	-	-	-	219)
1868042	0	31	for	IN	-	-	-	-	-	-	-	-
1868042	0	32	2	CD	-	-	-	-	-	-	-	-
1868042	0	33	−	SYM	-	-	-	-	-	-	-	-
1868042	0	34	24	CD	-	-	-	-	-	-	-	-
1868042	0	35	h	NNS	-	-	-	-	-	-	-	-
1868042	0	36	prior	IN	-	-	-	-	-	-	-	-
1868042	0	37	to	IN	-	-	-	-	-	-	-	-
1868042	0	38	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	39	or	CC	-	-	-	-	-	-	-	-
1868042	0	40	intracellular	JJ	-	-	-	-	-	-	-	-
1868042	0	41	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	42	assays	NNS	-	-	-	-	-	-	-	-
1868042	0	43	.	.	-	-	-	-	-	-	-	-

1868042	0	1	For	IN	-	-	-	-	-	-	-	-
1868042	0	2	single	JJ	-	-	-	-	-	-	-	-
1868042	0	3	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	4	cell	NN	-	-	-	-	-	-	-	-
1868042	0	5	studies	NNS	-	-	-	-	-	-	-	-
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	islets	NNS	-	-	-	-	-	-	-	(216)
1868042	0	8	were	VBD	-	-	-	-	-	-	-	-
1868042	0	9	dispersed	VBN	-	-	-	-	-	-	-	-
1868042	0	10	in	IN	-	-	-	-	-	-	-	-
1868042	0	11	a	DT	-	-	-	-	-	-	-	-
1868042	0	12	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	13	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	14	free	JJ	-	-	-	-	-	-	-	-
1868042	0	15	buffer	NN	-	-	-	-	-	-	-	-
1868042	0	16	and	CC	-	-	-	-	-	-	-	-
1868042	0	17	plated	VBN	-	-	-	-	-	-	-	-
1868042	0	18	in	IN	-	-	-	-	-	-	-	-
1868042	0	19	35	CD	-	-	-	-	-	-	-	-
1868042	0	20	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	21	mm	NN	-	-	-	-	-	-	-	-
1868042	0	22	plastic	NN	-	-	-	-	-	-	-	-
1868042	0	23	dishes	NNS	-	-	-	-	-	-	-	-
1868042	0	24	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Generation	NN	-	-	-	-	-	-	-	-
1868042	0	2	of	IN	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	(109
1868042	0	4	Kir6.2Y12X	NN	-	-	-	-	-	-	-	-
1868042	0	5	mice	NNS	-	-	-	-	-	-	-	-
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	which	WDT	-	-	-	-	-	-	-	-
1868042	0	8	possess	VBP	-	-	-	-	-	-	-	-
1868042	0	9	a	DT	-	-	-	-	-	-	-	-
1868042	0	10	Tyr12STOP	NN	-	-	-	-	-	-	-	-
1868042	0	11	mutation	NN	-	-	-	-	-	-	-	-
1868042	0	12	in	IN	-	-	-	-	-	-	-	-
1868042	0	13	the	DT	-	-	-	-	-	-	-	(110
1868042	0	14	Kcnj11	NN	-	-	-	-	-	-	-	-
1868042	0	15	gene	NN	-	-	-	-	-	-	-	110)
1868042	0	16	on	IN	-	-	-	-	-	-	-	-
1868042	0	17	a	DT	-	-	-	-	-	-	-	-
1868042	0	18	BALB	NN	-	-	-	-	-	-	-	-
1868042	0	19	/	HYPH	-	-	-	-	-	-	-	-
1868042	0	20	c	NN	-	-	-	-	-	-	-	-
1868042	0	21	background	NN	-	-	-	-	-	-	-	109)
1868042	0	22	,	,	-	-	-	-	-	-	-	-
1868042	0	23	has	VBZ	-	-	-	-	-	-	-	-
1868042	0	24	been	VBN	-	-	-	-	-	-	-	-
1868042	0	25	described	VBN	-	-	-	-	-	-	-	-
1868042	0	26	previously	RB	-	-	-	-	-	-	-	-
1868042	0	27	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	28	48	CD	-	-	-	-	-	-	-	-
1868042	0	29	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	30	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	results	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	in	IN	-	-	-	-	-	-	-	-
1868042	0	4	nonfunctional	JJ	-	-	-	-	-	-	-	-
1868042	0	5	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	6	channels	NNS	-	-	-	-	-	-	-	-
1868042	0	7	in	IN	-	-	-	-	-	-	-	-
1868042	0	8	both	CC	-	-	-	-	-	-	-	(66
1868042	0	9	α	NN	-	-	-	-	-	-	-	(1c)
1868042	0	10	and	CC	-	-	-	-	-	-	-	-
1868042	0	11	β	NN	-	-	-	-	-	-	-	(21
1868042	0	12	cells	NNS	-	-	-	-	-	-	-	(1c)|66)|21)
1868042	0	13	.	.	-	-	-	-	-	-	-	-

1868042	0	1	These	DT	-	-	-	-	-	-	-	(109
1868042	0	2	animals	NNS	-	-	-	-	-	-	-	109)
1868042	0	3	are	VBP	-	-	-	-	-	-	-	-
1868042	0	4	not	RB	-	-	-	-	-	-	-	-
1868042	0	5	overtly	RB	-	-	-	-	-	-	-	-
1868042	0	6	diabetic	JJ	-	-	-	-	-	-	-	-
1868042	0	7	,	,	-	-	-	-	-	-	-	-
1868042	0	8	exhibiting	VBG	-	-	-	-	-	-	-	-
1868042	0	9	normal	JJ	-	-	-	-	-	-	-	-
1868042	0	10	fasting	NN	-	-	-	-	-	-	-	-
1868042	0	11	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	12	,	,	-	-	-	-	-	-	-	-
1868042	0	13	but	CC	-	-	-	-	-	-	-	-
1868042	0	14	are	VBP	-	-	-	-	-	-	-	-
1868042	0	15	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	16	intolerant	JJ	-	-	-	-	-	-	-	-
1868042	0	17	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	18	R.	NNP	-	-	-	-	-	-	-	-
1868042	0	19	Cox	NNP	-	-	-	-	-	-	-	-
1868042	0	20	,	,	-	-	-	-	-	-	-	-
1868042	0	21	unpublished	JJ	-	-	-	-	-	-	-	(133
1868042	0	22	data	NNS	-	-	-	-	-	-	-	133)
1868042	0	23	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	24	.	.	-	-	-	-	-	-	-	-

1868042	0	1	For	IN	-	-	-	-	-	-	-	-
1868042	0	2	these	DT	-	-	-	-	-	-	-	-
1868042	0	3	experiments	NNS	-	-	-	-	-	-	-	-
1868042	0	4	,	,	-	-	-	-	-	-	-	-
1868042	0	5	age	NN	-	-	-	-	-	-	-	-
1868042	0	6	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	and	CC	-	-	-	-	-	-	-	-
1868042	0	8	weight	NN	-	-	-	-	-	-	-	-
1868042	0	9	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	matched	VBN	-	-	-	-	-	-	-	-
1868042	0	11	wild	JJ	-	-	-	-	-	-	-	-
1868042	0	12	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	13	type	NN	-	-	-	-	-	-	-	-
1868042	0	14	C3HB	NN	-	-	-	-	-	-	-	-
1868042	0	15	mice	NNS	-	-	-	-	-	-	-	-
1868042	0	16	were	VBD	-	-	-	-	-	-	-	-
1868042	0	17	used	VBN	-	-	-	-	-	-	-	-
1868042	0	18	as	IN	-	-	-	-	-	-	-	-
1868042	0	19	controls	NNS	-	-	-	-	-	-	-	(206)
1868042	0	20	because	IN	-	-	-	-	-	-	-	-
1868042	0	21	the	DT	-	-	-	-	-	-	-	(109
1868042	0	22	Kir6.2Y12X	NN	-	-	-	-	-	-	-	-
1868042	0	23	mice	NNS	-	-	-	-	-	-	-	109)
1868042	0	24	were	VBD	-	-	-	-	-	-	-	-
1868042	0	25	back	RB	-	-	-	-	-	-	-	-
1868042	0	26	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	27	crossed	VBN	-	-	-	-	-	-	-	-
1868042	0	28	into	IN	-	-	-	-	-	-	-	-
1868042	0	29	this	DT	-	-	-	-	-	-	-	-
1868042	0	30	background	NN	-	-	-	-	-	-	-	-
1868042	0	31	over	IN	-	-	-	-	-	-	-	-
1868042	0	32	several	JJ	-	-	-	-	-	-	-	-
1868042	0	33	generations	NNS	-	-	-	-	-	-	-	-
1868042	0	34	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Human	JJ	-	-	-	-	-	-	-	(128
1868042	0	2	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	3	from	IN	-	-	-	-	-	-	-	-
1868042	0	4	four	CD	-	-	-	-	-	-	-	-
1868042	0	5	healthy	JJ	-	-	-	-	-	-	-	-
1868042	0	6	donors	NNS	-	-	-	-	-	-	-	128)
1868042	0	7	were	VBD	-	-	-	-	-	-	-	-
1868042	0	8	obtained	VBN	-	-	-	-	-	-	-	-
1868042	0	9	from	IN	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	-
1868042	0	11	Oxford	NNP	-	-	-	-	-	-	-	-
1868042	0	12	DRWF	NNP	-	-	-	-	-	-	-	-
1868042	0	13	Human	NNP	-	-	-	-	-	-	-	-
1868042	0	14	Islet	NNP	-	-	-	-	-	-	-	-
1868042	0	15	Isolation	NNP	-	-	-	-	-	-	-	-
1868042	0	16	Facility	NNP	-	-	-	-	-	-	-	-
1868042	0	17	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Experiments	NNS	-	-	-	-	-	-	-	-
1868042	0	2	were	VBD	-	-	-	-	-	-	-	-
1868042	0	3	performed	VBN	-	-	-	-	-	-	-	-
1868042	0	4	in	IN	-	-	-	-	-	-	-	-
1868042	0	5	duplicate	NN	-	-	-	-	-	-	-	-
1868042	0	6	or	CC	-	-	-	-	-	-	-	-
1868042	0	7	triplicate	NN	-	-	-	-	-	-	-	-
1868042	0	8	using	VBG	-	-	-	-	-	-	-	-
1868042	0	9	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	10	from	IN	-	-	-	-	-	-	-	-
1868042	0	11	each	DT	-	-	-	-	-	-	-	-
1868042	0	12	donor	NN	-	-	-	-	-	-	-	-
1868042	0	13	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Human	JJ	-	-	-	-	-	-	-	-
1868042	0	2	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	3	were	VBD	-	-	-	-	-	-	-	-
1868042	0	4	cultured	VBN	-	-	-	-	-	-	-	-
1868042	0	5	in	IN	-	-	-	-	-	-	-	-
1868042	0	6	RPMI	NN	-	-	-	-	-	-	-	(217
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	1640	CD	-	-	-	-	-	-	-	217)
1868042	0	9	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	10	10	CD	-	-	-	-	-	-	-	(220
1868042	0	11	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	12	glucose	NN	-	-	-	-	-	-	-	220)
1868042	0	13	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	14	at	IN	-	-	-	-	-	-	-	-
1868042	0	15	37	CD	-	-	-	-	-	-	-	(218
1868042	0	16	°	SYM	-	-	-	-	-	-	-	-
1868042	0	17	C	NNP	-	-	-	-	-	-	-	218)
1868042	0	18	and	CC	-	-	-	-	-	-	-	-
1868042	0	19	5	CD	-	-	-	-	-	-	-	(219
1868042	0	20	%	NN	-	-	-	-	-	-	-	-
1868042	0	21	CO2	NN	-	-	-	-	-	-	-	219)
1868042	0	22	,	,	-	-	-	-	-	-	-	-
1868042	0	23	and	CC	-	-	-	-	-	-	-	-
1868042	0	24	experiments	NNS	-	-	-	-	-	-	-	-
1868042	0	25	were	VBD	-	-	-	-	-	-	-	-
1868042	0	26	performed	VBN	-	-	-	-	-	-	-	-
1868042	0	27	within	IN	-	-	-	-	-	-	-	-
1868042	0	28	48	CD	-	-	-	-	-	-	-	-
1868042	0	29	h	NNS	-	-	-	-	-	-	-	-
1868042	0	30	of	IN	-	-	-	-	-	-	-	-
1868042	0	31	isolation	NN	-	-	-	-	-	-	-	(215)
1868042	0	32	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Intracellular	JJ	-	-	-	-	-	-	-	(122
1868042	0	2	Ca2+	NN	-	-	-	-	-	-	-	122)
1868042	0	3	measurements	NNS	-	-	-	-	-	-	-	-
1868042	0	4	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Intact	JJ	-	-	-	-	-	-	-	(93
1868042	0	2	islets	NNS	-	-	-	-	-	-	-	93)
1868042	0	3	were	VBD	-	-	-	-	-	-	-	-
1868042	0	4	loaded	VBN	-	-	-	-	-	-	-	-
1868042	0	5	with	IN	-	-	-	-	-	-	-	-
1868042	0	6	fluo	NN	-	-	-	-	-	-	-	-
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	4	CD	-	-	-	-	-	-	-	-
1868042	0	9	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	AM	NN	-	-	-	-	-	-	-	-
1868042	0	11	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	12	1	CD	-	-	-	-	-	-	-	-
1868042	0	13	μM	NN	-	-	-	-	-	-	-	-
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	and	CC	-	-	-	-	-	-	-	-
1868042	0	16	fura	NN	-	-	-	-	-	-	-	-
1868042	0	17	red	NN	-	-	-	-	-	-	-	-
1868042	0	18	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	19	5	CD	-	-	-	-	-	-	-	-
1868042	0	20	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	21	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	22	in	IN	-	-	-	-	-	-	-	-
1868042	0	23	0.5	CD	-	-	-	-	-	-	-	(221
1868042	0	24	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	25	glucose	NN	-	-	-	-	-	-	-	221)
1868042	0	26	buffer	NN	-	-	-	-	-	-	-	-
1868042	0	27	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	28	see	VB	-	-	-	-	-	-	-	-
1868042	0	29	below	RB	-	-	-	-	-	-	-	-
1868042	0	30	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	31	with	IN	-	-	-	-	-	-	-	-
1868042	0	32	0.01	CD	-	-	-	-	-	-	-	-
1868042	0	33	%	NN	-	-	-	-	-	-	-	-
1868042	0	34	pluronic	JJ	-	-	-	-	-	-	-	-
1868042	0	35	acid	NN	-	-	-	-	-	-	-	-
1868042	0	36	for	IN	-	-	-	-	-	-	-	-
1868042	0	37	30	CD	-	-	-	-	-	-	-	(222
1868042	0	38	min	NNS	-	-	-	-	-	-	-	222)
1868042	0	39	at	IN	-	-	-	-	-	-	-	-
1868042	0	40	37	CD	-	-	-	-	-	-	-	(218
1868042	0	41	°C	NN	-	-	-	-	-	-	-	218)
1868042	0	42	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Islets	NNS	-	-	-	-	-	-	-	(214)
1868042	0	2	were	VBD	-	-	-	-	-	-	-	-
1868042	0	3	fixed	VBN	-	-	-	-	-	-	-	-
1868042	0	4	with	IN	-	-	-	-	-	-	-	-
1868042	0	5	a	DT	-	-	-	-	-	-	-	-
1868042	0	6	wide	JJ	-	-	-	-	-	-	-	-
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	bore	NN	-	-	-	-	-	-	-	-
1868042	0	9	holding	NN	-	-	-	-	-	-	-	-
1868042	0	10	pipette	NN	-	-	-	-	-	-	-	-
1868042	0	11	within	IN	-	-	-	-	-	-	-	-
1868042	0	12	a	DT	-	-	-	-	-	-	-	-
1868042	0	13	continuously	RB	-	-	-	-	-	-	-	-
1868042	0	14	superfused	VBN	-	-	-	-	-	-	-	-
1868042	0	15	and	CC	-	-	-	-	-	-	-	-
1868042	0	16	temperature	NN	-	-	-	-	-	-	-	-
1868042	0	17	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	18	controlled	VBN	-	-	-	-	-	-	-	-
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	37	CD	-	-	-	-	-	-	-	(218
1868042	0	21	°C	NN	-	-	-	-	-	-	-	218)
1868042	0	22	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	bath	NN	-	-	-	-	-	-	-	-
1868042	0	24	on	IN	-	-	-	-	-	-	-	-
1868042	0	25	an	DT	-	-	-	-	-	-	-	-
1868042	0	26	Axioskop	NN	-	-	-	-	-	-	-	-
1868042	0	27	2	CD	-	-	-	-	-	-	-	-
1868042	0	28	FS	NN	-	-	-	-	-	-	-	-
1868042	0	29	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	30	mot	NN	-	-	-	-	-	-	-	-
1868042	0	31	microscope	NN	-	-	-	-	-	-	-	-
1868042	0	32	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	33	Carl	NNP	-	-	-	-	-	-	-	(223
1868042	0	34	Zeiss	NNP	-	-	-	-	-	-	-	223)
1868042	0	35	,	,	-	-	-	-	-	-	-	-
1868042	0	36	http://www.zeiss.com	NN	-	-	-	-	-	-	-	-
1868042	0	37	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	38	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	(224
1868042	0	2	perfusion	NN	-	-	-	-	-	-	-	-
1868042	0	3	buffer	NN	-	-	-	-	-	-	-	224)
1868042	0	4	contained	VBD	-	-	-	-	-	-	-	-
1868042	0	5	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	6	in	IN	-	-	-	-	-	-	-	-
1868042	0	7	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	:	:	-	-	-	-	-	-	-	-
1868042	0	10	140	CD	-	-	-	-	-	-	-	-
1868042	0	11	NaCl	NN	-	-	-	-	-	-	-	-
1868042	0	12	;	:	-	-	-	-	-	-	-	-
1868042	0	13	3.6	CD	-	-	-	-	-	-	-	-
1868042	0	14	KCl	NN	-	-	-	-	-	-	-	-
1868042	0	15	;	:	-	-	-	-	-	-	-	-
1868042	0	16	2	CD	-	-	-	-	-	-	-	-
1868042	0	17	NaHCO3	NN	-	-	-	-	-	-	-	-
1868042	0	18	;	:	-	-	-	-	-	-	-	-
1868042	0	19	0.5	CD	-	-	-	-	-	-	-	-
1868042	0	20	NaH2PO4	NN	-	-	-	-	-	-	-	-
1868042	0	21	;	:	-	-	-	-	-	-	-	-
1868042	0	22	0.5	CD	-	-	-	-	-	-	-	-
1868042	0	23	MgSO4	NN	-	-	-	-	-	-	-	-
1868042	0	24	;	:	-	-	-	-	-	-	-	-
1868042	0	25	5	CD	-	-	-	-	-	-	-	(225
1868042	0	26	HEPES	NNS	-	-	-	-	-	-	-	225)
1868042	0	27	;	:	-	-	-	-	-	-	-	-
1868042	0	28	2.5	CD	-	-	-	-	-	-	-	-
1868042	0	29	CaCl2	NN	-	-	-	-	-	-	-	-
1868042	0	30	;	:	-	-	-	-	-	-	-	-
1868042	0	31	0.5	CD	-	-	-	-	-	-	-	-
1868042	0	32	,	,	-	-	-	-	-	-	-	-
1868042	0	33	3	CD	-	-	-	-	-	-	-	-
1868042	0	34	,	,	-	-	-	-	-	-	-	-
1868042	0	35	or	CC	-	-	-	-	-	-	-	-
1868042	0	36	11	CD	-	-	-	-	-	-	-	-
1868042	0	37	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	38	;	:	-	-	-	-	-	-	-	-
1868042	0	39	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	40	pH	NN	-	-	-	-	-	-	-	(226
1868042	0	41	7.4	CD	-	-	-	-	-	-	-	226)
1868042	0	42	with	IN	-	-	-	-	-	-	-	-
1868042	0	43	NaOH	NN	-	-	-	-	-	-	-	(227)
1868042	0	44	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	45	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Laser	NN	-	-	-	-	-	-	-	-
1868042	0	2	scanning	VBG	-	-	-	-	-	-	-	-
1868042	0	3	confocal	JJ	-	-	-	-	-	-	-	-
1868042	0	4	microscopy	NN	-	-	-	-	-	-	-	-
1868042	0	5	was	VBD	-	-	-	-	-	-	-	-
1868042	0	6	performed	VBN	-	-	-	-	-	-	-	-
1868042	0	7	using	VBG	-	-	-	-	-	-	-	-
1868042	0	8	an	DT	-	-	-	-	-	-	-	-
1868042	0	9	LSM	NN	-	-	-	-	-	-	-	-
1868042	0	10	510meta	NN	-	-	-	-	-	-	-	-
1868042	0	11	system	NN	-	-	-	-	-	-	-	-
1868042	0	12	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	13	Zeiss	NNP	-	-	-	-	-	-	-	(223)
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Excitation	NN	-	-	-	-	-	-	-	-
1868042	0	2	was	VBD	-	-	-	-	-	-	-	-
1868042	0	3	with	IN	-	-	-	-	-	-	-	-
1868042	0	4	a	DT	-	-	-	-	-	-	-	-
1868042	0	5	488	CD	-	-	-	-	-	-	-	-
1868042	0	6	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	nm	NN	-	-	-	-	-	-	-	-
1868042	0	8	argon	NN	-	-	-	-	-	-	-	-
1868042	0	9	laser	NN	-	-	-	-	-	-	-	-
1868042	0	10	,	,	-	-	-	-	-	-	-	-
1868042	0	11	and	CC	-	-	-	-	-	-	-	-
1868042	0	12	emitted	VBN	-	-	-	-	-	-	-	-
1868042	0	13	fluorescence	NN	-	-	-	-	-	-	-	-
1868042	0	14	was	VBD	-	-	-	-	-	-	-	-
1868042	0	15	collected	VBN	-	-	-	-	-	-	-	-
1868042	0	16	through	IN	-	-	-	-	-	-	-	-
1868042	0	17	500	CD	-	-	-	-	-	-	-	-
1868042	0	18	–	SYM	-	-	-	-	-	-	-	-
1868042	0	19	550	CD	-	-	-	-	-	-	-	-
1868042	0	20	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	21	nm	NN	-	-	-	-	-	-	-	-
1868042	0	22	and	CC	-	-	-	-	-	-	-	-
1868042	0	23	650	CD	-	-	-	-	-	-	-	-
1868042	0	24	–	SYM	-	-	-	-	-	-	-	-
1868042	0	25	710	CD	-	-	-	-	-	-	-	-
1868042	0	26	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	27	nm	NN	-	-	-	-	-	-	-	-
1868042	0	28	band	NN	-	-	-	-	-	-	-	-
1868042	0	29	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	30	pass	NN	-	-	-	-	-	-	-	-
1868042	0	31	filters	NNS	-	-	-	-	-	-	-	-
1868042	0	32	for	IN	-	-	-	-	-	-	-	-
1868042	0	33	the	DT	-	-	-	-	-	-	-	-
1868042	0	34	fluo	NN	-	-	-	-	-	-	-	-
1868042	0	35	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	36	4	CD	-	-	-	-	-	-	-	-
1868042	0	37	and	CC	-	-	-	-	-	-	-	-
1868042	0	38	fura	NN	-	-	-	-	-	-	-	(228
1868042	0	39	red	NN	-	-	-	-	-	-	-	228)
1868042	0	40	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	41	FuraR	NN	-	-	-	-	-	-	-	-
1868042	0	42	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	43	signals	NNS	-	-	-	-	-	-	-	-
1868042	0	44	,	,	-	-	-	-	-	-	-	-
1868042	0	45	respectively	RB	-	-	-	-	-	-	-	-
1868042	0	46	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Increases	NNS	-	-	-	-	-	-	-	-
1868042	0	2	in	IN	-	-	-	-	-	-	-	-
1868042	0	3	intracellular	JJ	-	-	-	-	-	-	-	(122
1868042	0	4	Ca2+	NN	-	-	-	-	-	-	-	122)
1868042	0	5	are	VBP	-	-	-	-	-	-	-	-
1868042	0	6	displayed	VBN	-	-	-	-	-	-	-	-
1868042	0	7	as	IN	-	-	-	-	-	-	-	-
1868042	0	8	upward	JJ	-	-	-	-	-	-	-	-
1868042	0	9	deflections	NNS	-	-	-	-	-	-	-	-
1868042	0	10	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Images	NNS	-	-	-	-	-	-	-	-
1868042	0	2	were	VBD	-	-	-	-	-	-	-	-
1868042	0	3	acquired	VBN	-	-	-	-	-	-	-	-
1868042	0	4	at	IN	-	-	-	-	-	-	-	-
1868042	0	5	1.5	CD	-	-	-	-	-	-	-	-
1868042	0	6	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	s	NN	-	-	-	-	-	-	-	-
1868042	0	8	intervals	NNS	-	-	-	-	-	-	-	-
1868042	0	9	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Individual	JJ	-	-	-	-	-	-	-	(229
1868042	0	2	cells	NNS	-	-	-	-	-	-	-	229)
1868042	0	3	were	VBD	-	-	-	-	-	-	-	-
1868042	0	4	selected	VBN	-	-	-	-	-	-	-	-
1868042	0	5	as	IN	-	-	-	-	-	-	-	-
1868042	0	6	regions	NNS	-	-	-	-	-	-	-	-
1868042	0	7	of	IN	-	-	-	-	-	-	-	-
1868042	0	8	interest	NN	-	-	-	-	-	-	-	-
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	and	CC	-	-	-	-	-	-	-	-
1868042	0	11	the	DT	-	-	-	-	-	-	-	-
1868042	0	12	average	JJ	-	-	-	-	-	-	-	-
1868042	0	13	ratio	NN	-	-	-	-	-	-	-	-
1868042	0	14	intensity	NN	-	-	-	-	-	-	-	-
1868042	0	15	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	16	RI	NN	-	-	-	-	-	-	-	-
1868042	0	17	=	SYM	-	-	-	-	-	-	-	-
1868042	0	18	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	19	Fluo	NN	-	-	-	-	-	-	-	-
1868042	0	20	+	SYM	-	-	-	-	-	-	-	-
1868042	0	21	1	CD	-	-	-	-	-	-	-	-
1868042	0	22	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	/	SYM	-	-	-	-	-	-	-	-
1868042	0	24	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	25	FuraR	NN	-	-	-	-	-	-	-	-
1868042	0	26	+	SYM	-	-	-	-	-	-	-	-
1868042	0	27	20	CD	-	-	-	-	-	-	-	-
1868042	0	28	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	29	×	SYM	-	-	-	-	-	-	-	-
1868042	0	30	128	CD	-	-	-	-	-	-	-	-
1868042	0	31	+	SYM	-	-	-	-	-	-	-	-
1868042	0	32	1	CD	-	-	-	-	-	-	-	-
1868042	0	33	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	34	of	IN	-	-	-	-	-	-	-	-
1868042	0	35	these	DT	-	-	-	-	-	-	-	(229)
1868042	0	36	were	VBD	-	-	-	-	-	-	-	-
1868042	0	37	analysed	VBN	-	-	-	-	-	-	-	-
1868042	0	38	over	IN	-	-	-	-	-	-	-	-
1868042	0	39	time	NN	-	-	-	-	-	-	-	-
1868042	0	40	with	IN	-	-	-	-	-	-	-	-
1868042	0	41	Origin	NN	-	-	-	-	-	-	-	-
1868042	0	42	v7.0220	NN	-	-	-	-	-	-	-	-
1868042	0	43	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	44	OriginLab	NNP	-	-	-	-	-	-	-	-
1868042	0	45	Corporation	NNP	-	-	-	-	-	-	-	-
1868042	0	46	,	,	-	-	-	-	-	-	-	-
1868042	0	47	http://www.originlab.com	NN	-	-	-	-	-	-	-	-
1868042	0	48	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	49	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Prior	IN	-	-	-	-	-	-	-	-
1868042	0	2	to	IN	-	-	-	-	-	-	-	-
1868042	0	3	experimental	JJ	-	-	-	-	-	-	-	-
1868042	0	4	recordings	NNS	-	-	-	-	-	-	-	-
1868042	0	5	,	,	-	-	-	-	-	-	-	-
1868042	0	6	islets	NNS	-	-	-	-	-	-	-	(214)
1868042	0	7	were	VBD	-	-	-	-	-	-	-	-
1868042	0	8	perfused	VBN	-	-	-	-	-	-	-	-
1868042	0	9	for	IN	-	-	-	-	-	-	-	-
1868042	0	10	10	CD	-	-	-	-	-	-	-	(230
1868042	0	11	min	NNS	-	-	-	-	-	-	-	230)
1868042	0	12	with	IN	-	-	-	-	-	-	-	-
1868042	0	13	the	DT	-	-	-	-	-	-	-	-
1868042	0	14	appropriate	JJ	-	-	-	-	-	-	-	-
1868042	0	15	control	NN	-	-	-	-	-	-	-	-
1868042	0	16	solution	NN	-	-	-	-	-	-	-	-
1868042	0	17	,	,	-	-	-	-	-	-	-	-
1868042	0	18	and	CC	-	-	-	-	-	-	-	-
1868042	0	19	Ca2+	NN	-	-	-	-	-	-	-	(231|(5)
1868042	0	20	responses	NNS	-	-	-	-	-	-	-	231)
1868042	0	21	were	VBD	-	-	-	-	-	-	-	-
1868042	0	22	monitored	VBN	-	-	-	-	-	-	-	-
1868042	0	23	periodically	RB	-	-	-	-	-	-	-	-
1868042	0	24	during	IN	-	-	-	-	-	-	-	-
1868042	0	25	this	DT	-	-	-	-	-	-	-	(230
1868042	0	26	time	NN	-	-	-	-	-	-	-	230)
1868042	0	27	to	TO	-	-	-	-	-	-	-	-
1868042	0	28	ensure	VB	-	-	-	-	-	-	-	-
1868042	0	29	that	IN	-	-	-	-	-	-	-	-
1868042	0	30	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	31	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	32	or	CC	-	-	-	-	-	-	-	-
1868042	0	33	lack	NN	-	-	-	-	-	-	-	-
1868042	0	34	thereof	RB	-	-	-	-	-	-	-	-
1868042	0	35	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	36	were	VBD	-	-	-	-	-	-	-	-
1868042	0	37	stable	JJ	-	-	-	-	-	-	-	-
1868042	0	38	prior	IN	-	-	-	-	-	-	-	-
1868042	0	39	to	IN	-	-	-	-	-	-	-	-
1868042	0	40	beginning	VBG	-	-	-	-	-	-	-	-
1868042	0	41	the	DT	-	-	-	-	-	-	-	-
1868042	0	42	experimental	JJ	-	-	-	-	-	-	-	-
1868042	0	43	recording	NN	-	-	-	-	-	-	-	-
1868042	0	44	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Ca2+	NN	-	-	-	-	-	-	-	(231|(5)
1868042	0	2	responses	NNS	-	-	-	-	-	-	-	231)
1868042	0	3	were	VBD	-	-	-	-	-	-	-	-
1868042	0	4	determined	VBN	-	-	-	-	-	-	-	-
1868042	0	5	by	IN	-	-	-	-	-	-	-	-
1868042	0	6	baseline	NN	-	-	-	-	-	-	-	-
1868042	0	7	subtraction	NN	-	-	-	-	-	-	-	-
1868042	0	8	and	CC	-	-	-	-	-	-	-	-
1868042	0	9	calculation	NN	-	-	-	-	-	-	-	-
1868042	0	10	of	IN	-	-	-	-	-	-	-	-
1868042	0	11	the	DT	-	-	-	-	-	-	-	(232
1868042	0	12	integrated	VBN	-	-	-	-	-	-	-	-
1868042	0	13	response	NN	-	-	-	-	-	-	-	232)
1868042	0	14	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	15	i.e.	FW	-	-	-	-	-	-	-	-
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	the	DT	-	-	-	-	-	-	-	-
1868042	0	18	area	NN	-	-	-	-	-	-	-	-
1868042	0	19	under	IN	-	-	-	-	-	-	-	-
1868042	0	20	the	DT	-	-	-	-	-	-	-	-
1868042	0	21	curve	NN	-	-	-	-	-	-	-	-
1868042	0	22	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	slope	NN	-	-	-	-	-	-	-	-
1868042	0	3	of	IN	-	-	-	-	-	-	-	-
1868042	0	4	this	DT	-	-	-	-	-	-	-	(232
1868042	0	5	response	NN	-	-	-	-	-	-	-	232)
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	reported	VBN	-	-	-	-	-	-	-	-
1868042	0	8	here	RB	-	-	-	-	-	-	-	-
1868042	0	9	as	IN	-	-	-	-	-	-	-	-
1868042	0	10	arbitrary	JJ	-	-	-	-	-	-	-	-
1868042	0	11	units	NNS	-	-	-	-	-	-	-	-
1868042	0	12	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	13	AU	NN	-	-	-	-	-	-	-	-
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	,	,	-	-	-	-	-	-	-	-
1868042	0	16	was	VBD	-	-	-	-	-	-	-	-
1868042	0	17	calculated	VBN	-	-	-	-	-	-	-	-
1868042	0	18	for	IN	-	-	-	-	-	-	-	-
1868042	0	19	the	DT	-	-	-	-	-	-	-	-
1868042	0	20	final	JJ	-	-	-	-	-	-	-	-
1868042	0	21	60	CD	-	-	-	-	-	-	-	-
1868042	0	22	%	NN	-	-	-	-	-	-	-	-
1868042	0	23	–	SYM	-	-	-	-	-	-	-	-
1868042	0	24	90	CD	-	-	-	-	-	-	-	-
1868042	0	25	%	NN	-	-	-	-	-	-	-	-
1868042	0	26	of	IN	-	-	-	-	-	-	-	-
1868042	0	27	a	DT	-	-	-	-	-	-	-	-
1868042	0	28	given	VBN	-	-	-	-	-	-	-	-
1868042	0	29	treatment	NN	-	-	-	-	-	-	-	-
1868042	0	30	period	NN	-	-	-	-	-	-	-	-
1868042	0	31	to	TO	-	-	-	-	-	-	-	-
1868042	0	32	allow	VB	-	-	-	-	-	-	-	-
1868042	0	33	for	IN	-	-	-	-	-	-	-	-
1868042	0	34	equilibration	NN	-	-	-	-	-	-	-	-
1868042	0	35	of	IN	-	-	-	-	-	-	-	-
1868042	0	36	the	DT	-	-	-	-	-	-	-	(232
1868042	0	37	responses	NNS	-	-	-	-	-	-	-	232)
1868042	0	38	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Hormone	NN	-	-	-	-	-	-	-	-
1868042	0	2	release	NN	-	-	-	-	-	-	-	-
1868042	0	3	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Insulin	NN	-	-	-	-	-	-	-	(24|(26|(19)
1868042	0	2	and	CC	-	-	-	-	-	-	-	-
1868042	0	3	glucagon	NN	-	-	-	-	-	-	-	(25|(2)|24)
1868042	0	4	secretion	NN	-	-	-	-	-	-	-	26)|25)
1868042	0	5	were	VBD	-	-	-	-	-	-	-	-
1868042	0	6	measured	VBN	-	-	-	-	-	-	-	-
1868042	0	7	as	IN	-	-	-	-	-	-	-	-
1868042	0	8	described	VBN	-	-	-	-	-	-	-	-
1868042	0	9	elsewhere	RB	-	-	-	-	-	-	-	-
1868042	0	10	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	11	45	CD	-	-	-	-	-	-	-	-
1868042	0	12	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	13	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Briefly	RB	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	batches	NNS	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	ten	CD	-	-	-	-	-	-	-	-
1868042	0	6	freshly	RB	-	-	-	-	-	-	-	-
1868042	0	7	isolated	VBN	-	-	-	-	-	-	-	-
1868042	0	8	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	9	were	VBD	-	-	-	-	-	-	-	-
1868042	0	10	pre-incubated	VBN	-	-	-	-	-	-	-	-
1868042	0	11	in	IN	-	-	-	-	-	-	-	-
1868042	0	12	1	CD	-	-	-	-	-	-	-	(233
1868042	0	13	ml	NN	-	-	-	-	-	-	-	-
1868042	0	14	of	IN	-	-	-	-	-	-	-	-
1868042	0	15	Krebs	NNP	-	-	-	-	-	-	-	(234
1868042	0	16	–	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	Ringer	NNP	-	-	-	-	-	-	-	-
1868042	0	18	buffer	NN	-	-	-	-	-	-	-	-
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	KRB	NN	-	-	-	-	-	-	-	-
1868042	0	21	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	22	supplemented	VBN	-	-	-	-	-	-	-	-
1868042	0	23	with	IN	-	-	-	-	-	-	-	-
1868042	0	24	1	CD	-	-	-	-	-	-	-	(101
1868042	0	25	mM	NN	-	-	-	-	-	-	-	-
1868042	0	26	glucose	NN	-	-	-	-	-	-	-	234)|233)|101)
1868042	0	27	for	IN	-	-	-	-	-	-	-	-
1868042	0	28	30	CD	-	-	-	-	-	-	-	(222
1868042	0	29	min	NNS	-	-	-	-	-	-	-	222)
1868042	0	30	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	31	rodent	NN	-	-	-	-	-	-	-	(60)
1868042	0	32	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	33	or	CC	-	-	-	-	-	-	-	-
1868042	0	34	1	CD	-	-	-	-	-	-	-	(235
1868042	0	35	h	NN	-	-	-	-	-	-	-	235)
1868042	0	36	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	37	human	JJ	-	-	-	-	-	-	-	-
1868042	0	38	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	39	followed	VBN	-	-	-	-	-	-	-	-
1868042	0	40	by	IN	-	-	-	-	-	-	-	-
1868042	0	41	1	CD	-	-	-	-	-	-	-	(235
1868042	0	42	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	43	h	NN	-	-	-	-	-	-	-	235)
1868042	0	44	incubation	NN	-	-	-	-	-	-	-	-
1868042	0	45	in	IN	-	-	-	-	-	-	-	-
1868042	0	46	1	CD	-	-	-	-	-	-	-	-
1868042	0	47	ml	NN	-	-	-	-	-	-	-	-
1868042	0	48	of	IN	-	-	-	-	-	-	-	-
1868042	0	49	test	NN	-	-	-	-	-	-	-	(234
1868042	0	50	KRB	NN	-	-	-	-	-	-	-	-
1868042	0	51	medium	NN	-	-	-	-	-	-	-	-
1868042	0	52	supplemented	VBN	-	-	-	-	-	-	-	-
1868042	0	53	as	IN	-	-	-	-	-	-	-	-
1868042	0	54	indicated	VBN	-	-	-	-	-	-	-	234)
1868042	0	55	.	.	-	-	-	-	-	-	-	-

1868042	0	1	For	IN	-	-	-	-	-	-	-	-
1868042	0	2	experiments	NNS	-	-	-	-	-	-	-	-
1868042	0	3	in	IN	-	-	-	-	-	-	-	-
1868042	0	4	which	WDT	-	-	-	-	-	-	-	-
1868042	0	5	Zn2+	NN	-	-	-	-	-	-	-	(16)
1868042	0	6	was	VBD	-	-	-	-	-	-	-	-
1868042	0	7	chelated	VBN	-	-	-	-	-	-	-	-
1868042	0	8	or	CC	-	-	-	-	-	-	-	-
1868042	0	9	GABAA	NN	-	-	-	-	-	-	-	(90
1868042	0	10	receptors	NNS	-	-	-	-	-	-	-	90)
1868042	0	11	were	VBD	-	-	-	-	-	-	-	-
1868042	0	12	antagonised	VBN	-	-	-	-	-	-	-	-
1868042	0	13	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	14	Figure	NN	-	-	-	-	-	-	-	(86|(81)
1868042	0	15	1	CD	-	-	-	-	-	-	-	86)
1868042	0	16	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	17	,	,	-	-	-	-	-	-	-	-
1868042	0	18	the	DT	-	-	-	-	-	-	-	(77
1868042	0	19	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	20	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	21	EDTA	NN	-	-	-	-	-	-	-	77)
1868042	0	22	and	CC	-	-	-	-	-	-	-	-
1868042	0	23	SR	NN	-	-	-	-	-	-	-	(75
1868042	0	24	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	25	95531	CD	-	-	-	-	-	-	-	75)
1868042	0	26	,	,	-	-	-	-	-	-	-	-
1868042	0	27	respectively	RB	-	-	-	-	-	-	-	-
1868042	0	28	,	,	-	-	-	-	-	-	-	-
1868042	0	29	were	VBD	-	-	-	-	-	-	-	-
1868042	0	30	present	JJ	-	-	-	-	-	-	-	-
1868042	0	31	in	IN	-	-	-	-	-	-	-	-
1868042	0	32	both	CC	-	-	-	-	-	-	-	-
1868042	0	33	the	DT	-	-	-	-	-	-	-	(233a
1868042	0	34	pre-incubation	JJ	-	-	-	-	-	-	-	233a)
1868042	0	35	and	CC	-	-	-	-	-	-	-	-
1868042	0	36	test	NN	-	-	-	-	-	-	-	-
1868042	0	37	solutions	NNS	-	-	-	-	-	-	-	(233a)
1868042	0	38	.	.	-	-	-	-	-	-	-	-

1868042	0	1	When	WRB	-	-	-	-	-	-	-	-
1868042	0	2	extracellular	JJ	-	-	-	-	-	-	-	-
1868042	0	3	KCl	NN	-	-	-	-	-	-	-	-
1868042	0	4	was	VBD	-	-	-	-	-	-	-	-
1868042	0	5	increased	VBN	-	-	-	-	-	-	-	-
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	NaCl	NN	-	-	-	-	-	-	-	-
1868042	0	8	was	VBD	-	-	-	-	-	-	-	-
1868042	0	9	correspondingly	RB	-	-	-	-	-	-	-	-
1868042	0	10	reduced	VBN	-	-	-	-	-	-	-	-
1868042	0	11	to	TO	-	-	-	-	-	-	-	-
1868042	0	12	maintain	VB	-	-	-	-	-	-	-	-
1868042	0	13	iso	NN	-	-	-	-	-	-	-	-
1868042	0	14	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	15	osmolarity	NN	-	-	-	-	-	-	-	-
1868042	0	16	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Single	JJ	-	-	-	-	-	-	-	-
1868042	0	2	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	3	cell	NN	-	-	-	-	-	-	-	-
1868042	0	4	capacitance	NN	-	-	-	-	-	-	-	-
1868042	0	5	and	CC	-	-	-	-	-	-	-	-
1868042	0	6	ion	NN	-	-	-	-	-	-	-	-
1868042	0	7	current	NN	-	-	-	-	-	-	-	-
1868042	0	8	measurements	NNS	-	-	-	-	-	-	-	-
1868042	0	9	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Whole	JJ	-	-	-	-	-	-	-	-
1868042	0	2	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	3	cell	NN	-	-	-	-	-	-	-	-
1868042	0	4	currents	NNS	-	-	-	-	-	-	-	-
1868042	0	5	and	CC	-	-	-	-	-	-	-	-
1868042	0	6	exocytosis	NN	-	-	-	-	-	-	-	(43)
1868042	0	7	were	VBD	-	-	-	-	-	-	-	-
1868042	0	8	recorded	VBN	-	-	-	-	-	-	-	-
1868042	0	9	using	VBG	-	-	-	-	-	-	-	-
1868042	0	10	an	DT	-	-	-	-	-	-	-	-
1868042	0	11	EPC	NN	-	-	-	-	-	-	-	-
1868042	0	12	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	13	9	CD	-	-	-	-	-	-	-	-
1868042	0	14	patch	NN	-	-	-	-	-	-	-	-
1868042	0	15	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	clamp	NN	-	-	-	-	-	-	-	-
1868042	0	17	amplifier	NN	-	-	-	-	-	-	-	-
1868042	0	18	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	19	HEKA	NNP	-	-	-	-	-	-	-	-
1868042	0	20	Electronics	NNP	-	-	-	-	-	-	-	-
1868042	0	21	,	,	-	-	-	-	-	-	-	-
1868042	0	22	http://www.heka.com	NN	-	-	-	-	-	-	-	-
1868042	0	23	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	24	and	CC	-	-	-	-	-	-	-	-
1868042	0	25	Pulse	NNP	-	-	-	-	-	-	-	(236
1868042	0	26	software	NN	-	-	-	-	-	-	-	-
1868042	0	27	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	28	version	NN	-	-	-	-	-	-	-	-
1868042	0	29	8.50	CD	-	-	-	-	-	-	-	-
1868042	0	30	)	-RRB-	-	-	-	-	-	-	-	236)
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Single	JJ	-	-	-	-	-	-	-	(237
1868042	0	2	α	NN	-	-	-	-	-	-	-	-
1868042	0	3	cells	NNS	-	-	-	-	-	-	-	237)
1868042	0	4	were	VBD	-	-	-	-	-	-	-	-
1868042	0	5	identified	VBN	-	-	-	-	-	-	-	-
1868042	0	6	by	IN	-	-	-	-	-	-	-	-
1868042	0	7	their	PRP$	-	-	-	-	-	-	-	(237)
1868042	0	8	small	JJ	-	-	-	-	-	-	-	-
1868042	0	9	size	NN	-	-	-	-	-	-	-	-
1868042	0	10	and	CC	-	-	-	-	-	-	-	-
1868042	0	11	Na+	NN	-	-	-	-	-	-	-	-
1868042	0	12	current	JJ	-	-	-	-	-	-	-	-
1868042	0	13	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	14	properties	NNS	-	-	-	-	-	-	-	-
1868042	0	15	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	16	58	CD	-	-	-	-	-	-	-	-
1868042	0	17	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	18	.	.	-	-	-	-	-	-	-	-

1868042	0	1	This	DT	-	-	-	-	-	-	-	-
1868042	0	2	method	NN	-	-	-	-	-	-	-	-
1868042	0	3	was	VBD	-	-	-	-	-	-	-	-
1868042	0	4	validated	VBN	-	-	-	-	-	-	-	-
1868042	0	5	by	IN	-	-	-	-	-	-	-	-
1868042	0	6	combining	VBG	-	-	-	-	-	-	-	-
1868042	0	7	the	DT	-	-	-	-	-	-	-	-
1868042	0	8	electrophysiological	JJ	-	-	-	-	-	-	-	-
1868042	0	9	recordings	NNS	-	-	-	-	-	-	-	-
1868042	0	10	with	IN	-	-	-	-	-	-	-	-
1868042	0	11	subsequent	JJ	-	-	-	-	-	-	-	-
1868042	0	12	immunostaining	NN	-	-	-	-	-	-	-	-
1868042	0	13	for	IN	-	-	-	-	-	-	-	-
1868042	0	14	glucagon	NN	-	-	-	-	-	-	-	(24|(2)
1868042	0	15	and	CC	-	-	-	-	-	-	-	-
1868042	0	16	insulin	NN	-	-	-	-	-	-	-	(19)|24)
1868042	0	17	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	extracellular	JJ	-	-	-	-	-	-	-	-
1868042	0	3	medium	NN	-	-	-	-	-	-	-	-
1868042	0	4	contained	VBN	-	-	-	-	-	-	-	-
1868042	0	5	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	6	in	IN	-	-	-	-	-	-	-	-
1868042	0	7	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	:	:	-	-	-	-	-	-	-	-
1868042	0	10	118	CD	-	-	-	-	-	-	-	-
1868042	0	11	NaCl	NN	-	-	-	-	-	-	-	-
1868042	0	12	;	:	-	-	-	-	-	-	-	-
1868042	0	13	20	CD	-	-	-	-	-	-	-	-
1868042	0	14	TEA	NN	-	-	-	-	-	-	-	-
1868042	0	15	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	Cl	NN	-	-	-	-	-	-	-	-
1868042	0	17	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	18	tetraethylammonium	NN	-	-	-	-	-	-	-	-
1868042	0	19	chloride	NN	-	-	-	-	-	-	-	-
1868042	0	20	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	21	;	:	-	-	-	-	-	-	-	-
1868042	0	22	5.6	CD	-	-	-	-	-	-	-	-
1868042	0	23	KCl	NN	-	-	-	-	-	-	-	-
1868042	0	24	;	:	-	-	-	-	-	-	-	-
1868042	0	25	2.6	CD	-	-	-	-	-	-	-	-
1868042	0	26	CaCl2	NN	-	-	-	-	-	-	-	-
1868042	0	27	;	:	-	-	-	-	-	-	-	-
1868042	0	28	1.2	CD	-	-	-	-	-	-	-	-
1868042	0	29	MgCl2	NN	-	-	-	-	-	-	-	-
1868042	0	30	;	:	-	-	-	-	-	-	-	-
1868042	0	31	5	CD	-	-	-	-	-	-	-	(225
1868042	0	32	HEPES	NN	-	-	-	-	-	-	-	225)
1868042	0	33	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	34	pH	NN	-	-	-	-	-	-	-	(226
1868042	0	35	7.4	CD	-	-	-	-	-	-	-	226)
1868042	0	36	with	IN	-	-	-	-	-	-	-	-
1868042	0	37	NaOH	NN	-	-	-	-	-	-	-	(227)
1868042	0	38	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	39	;	:	-	-	-	-	-	-	-	-
1868042	0	40	and	CC	-	-	-	-	-	-	-	-
1868042	0	41	5	CD	-	-	-	-	-	-	-	-
1868042	0	42	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	43	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Except	IN	-	-	-	-	-	-	-	-
1868042	0	2	for	IN	-	-	-	-	-	-	-	-
1868042	0	3	Figure	NN	-	-	-	-	-	-	-	(164|(238|(165b)|(81)
1868042	0	4	8B	NN	-	-	-	-	-	-	-	164)
1868042	0	5	and	CC	-	-	-	-	-	-	-	-
1868042	0	6	8C	NN	-	-	-	-	-	-	-	(165b)|238)
1868042	0	7	,	,	-	-	-	-	-	-	-	-
1868042	0	8	in	IN	-	-	-	-	-	-	-	-
1868042	0	9	which	WDT	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	-
1868042	0	11	standard	JJ	-	-	-	-	-	-	-	-
1868042	0	12	whole	JJ	-	-	-	-	-	-	-	-
1868042	0	13	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	14	cell	NN	-	-	-	-	-	-	-	-
1868042	0	15	configuration	NN	-	-	-	-	-	-	-	-
1868042	0	16	was	VBD	-	-	-	-	-	-	-	-
1868042	0	17	used	VBN	-	-	-	-	-	-	-	-
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	the	DT	-	-	-	-	-	-	-	-
1868042	0	20	electrophysiological	JJ	-	-	-	-	-	-	-	-
1868042	0	21	measurements	NNS	-	-	-	-	-	-	-	-
1868042	0	22	were	VBD	-	-	-	-	-	-	-	-
1868042	0	23	conducted	VBN	-	-	-	-	-	-	-	-
1868042	0	24	using	VBG	-	-	-	-	-	-	-	-
1868042	0	25	the	DT	-	-	-	-	-	-	-	-
1868042	0	26	perforated	VBN	-	-	-	-	-	-	-	-
1868042	0	27	patch	NN	-	-	-	-	-	-	-	-
1868042	0	28	technique	NN	-	-	-	-	-	-	-	-
1868042	0	29	,	,	-	-	-	-	-	-	-	-
1868042	0	30	and	CC	-	-	-	-	-	-	-	-
1868042	0	31	the	DT	-	-	-	-	-	-	-	-
1868042	0	32	pipette	NN	-	-	-	-	-	-	-	-
1868042	0	33	solution	NN	-	-	-	-	-	-	-	-
1868042	0	34	contained	VBD	-	-	-	-	-	-	-	-
1868042	0	35	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	36	in	IN	-	-	-	-	-	-	-	-
1868042	0	37	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	38	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	39	:	:	-	-	-	-	-	-	-	-
1868042	0	40	76	CD	-	-	-	-	-	-	-	-
1868042	0	41	Cs2SO4	NN	-	-	-	-	-	-	-	-
1868042	0	42	;	:	-	-	-	-	-	-	-	-
1868042	0	43	10	CD	-	-	-	-	-	-	-	(239
1868042	0	44	NaCl	NN	-	-	-	-	-	-	-	239)
1868042	0	45	;	:	-	-	-	-	-	-	-	-
1868042	0	46	10	CD	-	-	-	-	-	-	-	-
1868042	0	47	KCl	NN	-	-	-	-	-	-	-	-
1868042	0	48	;	:	-	-	-	-	-	-	-	-
1868042	0	49	1	CD	-	-	-	-	-	-	-	(240
1868042	0	50	MgCl2	NN	-	-	-	-	-	-	-	240)
1868042	0	51	;	:	-	-	-	-	-	-	-	-
1868042	0	52	and	CC	-	-	-	-	-	-	-	-
1868042	0	53	5	CD	-	-	-	-	-	-	-	(225
1868042	0	54	HEPES	NN	-	-	-	-	-	-	-	225)
1868042	0	55	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	56	pH	NN	-	-	-	-	-	-	-	-
1868042	0	57	7.35	CD	-	-	-	-	-	-	-	-
1868042	0	58	with	IN	-	-	-	-	-	-	-	-
1868042	0	59	CsOH	NN	-	-	-	-	-	-	-	-
1868042	0	60	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	61	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Exocytosis	NN	-	-	-	-	-	-	-	(43)
1868042	0	2	was	VBD	-	-	-	-	-	-	-	-
1868042	0	3	monitored	VBN	-	-	-	-	-	-	-	-
1868042	0	4	as	IN	-	-	-	-	-	-	-	-
1868042	0	5	changes	NNS	-	-	-	-	-	-	-	-
1868042	0	6	in	IN	-	-	-	-	-	-	-	-
1868042	0	7	α	NN	-	-	-	-	-	-	-	(1
1868042	0	8	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	cell	NN	-	-	-	-	-	-	-	1)
1868042	0	10	capacitance	NN	-	-	-	-	-	-	-	-
1868042	0	11	using	VBG	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	software	NN	-	-	-	-	-	-	-	-
1868042	0	14	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	15	based	VBN	-	-	-	-	-	-	-	-
1868042	0	16	lock	VB	-	-	-	-	-	-	-	-
1868042	0	17	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	18	in	RP	-	-	-	-	-	-	-	-
1868042	0	19	function	NN	-	-	-	-	-	-	-	-
1868042	0	20	of	IN	-	-	-	-	-	-	-	-
1868042	0	21	the	DT	-	-	-	-	-	-	-	(236
1868042	0	22	Pulse	NN	-	-	-	-	-	-	-	-
1868042	0	23	software	NN	-	-	-	-	-	-	-	236)
1868042	0	24	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	standard	JJ	-	-	-	-	-	-	-	-
1868042	0	3	whole	JJ	-	-	-	-	-	-	-	-
1868042	0	4	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	5	cell	NN	-	-	-	-	-	-	-	-
1868042	0	6	measurements	NNS	-	-	-	-	-	-	-	-
1868042	0	7	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	8	Figure	NN	-	-	-	-	-	-	-	(164|(238|(165a)|(81)
1868042	0	9	8B	NN	-	-	-	-	-	-	-	164)
1868042	0	10	and	CC	-	-	-	-	-	-	-	-
1868042	0	11	8C	NN	-	-	-	-	-	-	-	(165a)|238)
1868042	0	12	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	13	were	VBD	-	-	-	-	-	-	-	-
1868042	0	14	conducted	VBN	-	-	-	-	-	-	-	-
1868042	0	15	using	VBG	-	-	-	-	-	-	-	-
1868042	0	16	a	DT	-	-	-	-	-	-	-	-
1868042	0	17	pipette	NN	-	-	-	-	-	-	-	-
1868042	0	18	solution	NN	-	-	-	-	-	-	-	-
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	dialyzing	VBG	-	-	-	-	-	-	-	-
1868042	0	21	the	DT	-	-	-	-	-	-	-	-
1868042	0	22	cell	NN	-	-	-	-	-	-	-	-
1868042	0	23	interior	NN	-	-	-	-	-	-	-	-
1868042	0	24	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	25	consisted	VBN	-	-	-	-	-	-	-	-
1868042	0	26	of	IN	-	-	-	-	-	-	-	-
1868042	0	27	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	28	in	IN	-	-	-	-	-	-	-	-
1868042	0	29	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	30	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	31	125	CD	-	-	-	-	-	-	-	-
1868042	0	32	CsOH	NN	-	-	-	-	-	-	-	-
1868042	0	33	;	:	-	-	-	-	-	-	-	-
1868042	0	34	125	CD	-	-	-	-	-	-	-	-
1868042	0	35	glutamate	NN	-	-	-	-	-	-	-	-
1868042	0	36	;	:	-	-	-	-	-	-	-	-
1868042	0	37	10	CD	-	-	-	-	-	-	-	-
1868042	0	38	CsCl	NN	-	-	-	-	-	-	-	-
1868042	0	39	;	:	-	-	-	-	-	-	-	-
1868042	0	40	10	CD	-	-	-	-	-	-	-	(239
1868042	0	41	NaCl	NN	-	-	-	-	-	-	-	239)
1868042	0	42	;	:	-	-	-	-	-	-	-	-
1868042	0	43	1	CD	-	-	-	-	-	-	-	(240
1868042	0	44	MgCl2	NN	-	-	-	-	-	-	-	240)
1868042	0	45	;	:	-	-	-	-	-	-	-	-
1868042	0	46	5	CD	-	-	-	-	-	-	-	(225
1868042	0	47	HEPES	NN	-	-	-	-	-	-	-	225)
1868042	0	48	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	49	pH	NN	-	-	-	-	-	-	-	-
1868042	0	50	7.15	CD	-	-	-	-	-	-	-	-
1868042	0	51	with	IN	-	-	-	-	-	-	-	-
1868042	0	52	KOH	NN	-	-	-	-	-	-	-	-
1868042	0	53	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	54	;	:	-	-	-	-	-	-	-	-
1868042	0	55	3	CD	-	-	-	-	-	-	-	-
1868042	0	56	Mg	NNS	-	-	-	-	-	-	-	-
1868042	0	57	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	58	ATP	NN	-	-	-	-	-	-	-	-
1868042	0	59	;	:	-	-	-	-	-	-	-	-
1868042	0	60	and	CC	-	-	-	-	-	-	-	-
1868042	0	61	25	CD	-	-	-	-	-	-	-	-
1868042	0	62	μmol	NNS	-	-	-	-	-	-	-	-
1868042	0	63	/	SYM	-	-	-	-	-	-	-	-
1868042	0	64	l	NN	-	-	-	-	-	-	-	-
1868042	0	65	EGTA	NN	-	-	-	-	-	-	-	-
1868042	0	66	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	67	measured	VBN	-	-	-	-	-	-	-	-
1868042	0	68	resting	VBG	-	-	-	-	-	-	-	-
1868042	0	69	free	JJ	-	-	-	-	-	-	-	-
1868042	0	70	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	71	,	,	-	-	-	-	-	-	-	-
1868042	0	72	∼	SYM	-	-	-	-	-	-	-	-
1868042	0	73	0.2	CD	-	-	-	-	-	-	-	-
1868042	0	74	μmol	NNS	-	-	-	-	-	-	-	-
1868042	0	75	/	SYM	-	-	-	-	-	-	-	-
1868042	0	76	l	NN	-	-	-	-	-	-	-	-
1868042	0	77	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	78	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Pulses	NNS	-	-	-	-	-	-	-	(241)
1868042	0	2	were	VBD	-	-	-	-	-	-	-	-
1868042	0	3	applied	VBN	-	-	-	-	-	-	-	-
1868042	0	4	at	IN	-	-	-	-	-	-	-	-
1868042	0	5	low	JJ	-	-	-	-	-	-	-	-
1868042	0	6	frequency	NN	-	-	-	-	-	-	-	-
1868042	0	7	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	8	<	SYM	-	-	-	-	-	-	-	-
1868042	0	9	0.05	CD	-	-	-	-	-	-	-	-
1868042	0	10	Hz	NN	-	-	-	-	-	-	-	-
1868042	0	11	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	12	to	TO	-	-	-	-	-	-	-	-
1868042	0	13	allow	VB	-	-	-	-	-	-	-	-
1868042	0	14	the	DT	-	-	-	-	-	-	-	-
1868042	0	15	exocytotic	JJ	-	-	-	-	-	-	-	-
1868042	0	16	capacity	NN	-	-	-	-	-	-	-	-
1868042	0	17	to	TO	-	-	-	-	-	-	-	-
1868042	0	18	recover	VB	-	-	-	-	-	-	-	-
1868042	0	19	fully	RB	-	-	-	-	-	-	-	-
1868042	0	20	between	IN	-	-	-	-	-	-	-	-
1868042	0	21	the	DT	-	-	-	-	-	-	-	(241
1868042	0	22	pulses	NNS	-	-	-	-	-	-	-	241)
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Statistical	JJ	-	-	-	-	-	-	-	-
1868042	0	2	analysis	NN	-	-	-	-	-	-	-	-
1868042	0	3	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Data	NNS	-	-	-	-	-	-	-	(242)
1868042	0	2	are	VBP	-	-	-	-	-	-	-	-
1868042	0	3	presented	VBN	-	-	-	-	-	-	-	-
1868042	0	4	as	IN	-	-	-	-	-	-	-	-
1868042	0	5	means	NNS	-	-	-	-	-	-	-	-
1868042	0	6	and	CC	-	-	-	-	-	-	-	-
1868042	0	7	standard	JJ	-	-	-	-	-	-	-	-
1868042	0	8	errors	NNS	-	-	-	-	-	-	-	-
1868042	0	9	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Significance	NN	-	-	-	-	-	-	-	-
1868042	0	2	was	VBD	-	-	-	-	-	-	-	-
1868042	0	3	examined	VBN	-	-	-	-	-	-	-	-
1868042	0	4	by	IN	-	-	-	-	-	-	-	-
1868042	0	5	either	CC	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	unpaired	JJ	-	-	-	-	-	-	-	-
1868042	0	8	t	NN	-	-	-	-	-	-	-	-
1868042	0	9	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	test	NN	-	-	-	-	-	-	-	-
1868042	0	11	or	CC	-	-	-	-	-	-	-	-
1868042	0	12	by	IN	-	-	-	-	-	-	-	-
1868042	0	13	multiple	JJ	-	-	-	-	-	-	-	-
1868042	0	14	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	15	comparisons	NNS	-	-	-	-	-	-	-	-
1868042	0	16	analysis	NN	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	variance	NN	-	-	-	-	-	-	-	-
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	ANOVA	NN	-	-	-	-	-	-	-	-
1868042	0	21	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	22	and	CC	-	-	-	-	-	-	-	-
1868042	0	23	post-test	RB	-	-	-	-	-	-	-	-
1868042	0	24	,	,	-	-	-	-	-	-	-	-
1868042	0	25	as	IN	-	-	-	-	-	-	-	-
1868042	0	26	appropriate	JJ	-	-	-	-	-	-	-	-
1868042	0	27	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Acknowledgements	NNS	-	-	-	-	-	-	-	-

1868042	0	1	PEM	NNP	-	-	-	-	-	-	-	(243)
1868042	0	2	was	VBD	-	-	-	-	-	-	-	-
1868042	0	3	supported	VBN	-	-	-	-	-	-	-	-
1868042	0	4	initially	RB	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	-
1868042	0	6	European	JJ	-	-	-	-	-	-	-	-
1868042	0	7	Foundation	NN	-	-	-	-	-	-	-	-
1868042	0	8	for	IN	-	-	-	-	-	-	-	-
1868042	0	9	the	DT	-	-	-	-	-	-	-	-
1868042	0	10	Study	NN	-	-	-	-	-	-	-	-
1868042	0	11	of	IN	-	-	-	-	-	-	-	-
1868042	0	12	Diabetes	NN	-	-	-	-	-	-	-	-
1868042	0	13	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	14	EFSD	NN	-	-	-	-	-	-	-	-
1868042	0	15	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	16	/	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	AstraZeneca	NNP	-	-	-	-	-	-	-	-
1868042	0	18	Fellowship	NNP	-	-	-	-	-	-	-	-
1868042	0	19	in	IN	-	-	-	-	-	-	-	-
1868042	0	20	Islet	NNP	-	-	-	-	-	-	-	(244
1868042	0	21	Biology	NNP	-	-	-	-	-	-	-	244)
1868042	0	22	and	CC	-	-	-	-	-	-	-	-
1868042	0	23	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	24	currently	RB	-	-	-	-	-	-	-	-
1868042	0	25	an	DT	-	-	-	-	-	-	-	-
1868042	0	26	Alberta	NNP	-	-	-	-	-	-	-	-
1868042	0	27	Heritage	NNP	-	-	-	-	-	-	-	-
1868042	0	28	Foundation	NNP	-	-	-	-	-	-	-	-
1868042	0	29	for	IN	-	-	-	-	-	-	-	-
1868042	0	30	Medical	NNP	-	-	-	-	-	-	-	-
1868042	0	31	Research	NNP	-	-	-	-	-	-	-	-
1868042	0	32	Scholar	NNP	-	-	-	-	-	-	-	-
1868042	0	33	,	,	-	-	-	-	-	-	-	-
1868042	0	34	Canadian	NNP	-	-	-	-	-	-	-	-
1868042	0	35	Diabetes	NNP	-	-	-	-	-	-	-	-
1868042	0	36	Association	NNP	-	-	-	-	-	-	-	-
1868042	0	37	Scholar	NNP	-	-	-	-	-	-	-	-
1868042	0	38	,	,	-	-	-	-	-	-	-	-
1868042	0	39	and	CC	-	-	-	-	-	-	-	-
1868042	0	40	the	DT	-	-	-	-	-	-	-	-
1868042	0	41	Canada	NNP	-	-	-	-	-	-	-	-
1868042	0	42	Research	NNP	-	-	-	-	-	-	-	-
1868042	0	43	Chair	NNP	-	-	-	-	-	-	-	-
1868042	0	44	in	IN	-	-	-	-	-	-	-	-
1868042	0	45	Islet	NNP	-	-	-	-	-	-	-	(244
1868042	0	46	Biology	NNP	-	-	-	-	-	-	-	244)
1868042	0	47	.	.	-	-	-	-	-	-	-	-

1868042	0	1	PR	NNP	-	-	-	-	-	-	-	(245)
1868042	0	2	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	a	DT	-	-	-	-	-	-	-	-
1868042	0	4	Wolfson	NNP	-	-	-	-	-	-	-	-
1868042	0	5	Royal	NNP	-	-	-	-	-	-	-	-
1868042	0	6	Society	NNP	-	-	-	-	-	-	-	-
1868042	0	7	Merit	NNP	-	-	-	-	-	-	-	-
1868042	0	8	Award	NNP	-	-	-	-	-	-	-	-
1868042	0	9	Research	NNP	-	-	-	-	-	-	-	-
1868042	0	10	Fellow	NNP	-	-	-	-	-	-	-	-
1868042	0	11	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Abbreviations	NNS	-	-	-	-	-	-	-	-

1868042	0	1	[	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	3	]	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	i	NN	-	-	-	-	-	-	-	-
1868042	0	5	-	:	-	-	-	-	-	-	-	-
1868042	0	6	intracellular	JJ	-	-	-	-	-	-	-	(122
1868042	0	7	Ca2+	NN	-	-	-	-	-	-	-	122)

1868042	0	1	FuraR	NN	-	-	-	-	-	-	-	-
1868042	0	2	-	:	-	-	-	-	-	-	-	-
1868042	0	3	fura	NN	-	-	-	-	-	-	-	(228
1868042	0	4	red	JJ	-	-	-	-	-	-	-	228)

1868042	0	1	GABA	NN	-	-	-	-	-	-	-	-
1868042	0	2	-	:	-	-	-	-	-	-	-	-
1868042	0	3	γ	NN	-	-	-	-	-	-	-	(15
1868042	0	4	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	5	aminobutyric	JJ	-	-	-	-	-	-	-	-
1868042	0	6	acid	NN	-	-	-	-	-	-	-	15)

1868042	0	1	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	2	-	:	-	-	-	-	-	-	-	-
1868042	0	3	ATP	NN	-	-	-	-	-	-	-	-
1868042	0	4	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	5	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	6	K+	NN	-	-	-	-	-	-	-	-
1868042	0	7	,	,	-	-	-	-	-	-	-	-
1868042	0	8	TTX	NN	-	-	-	-	-	-	-	-
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	tetrodotoxin	NN	-	-	-	-	-	-	-	(34)

1868042	0	1	VDCC	NN	-	-	-	-	-	-	-	-
1868042	0	2	-	:	-	-	-	-	-	-	-	-
1868042	0	3	voltage	NN	-	-	-	-	-	-	-	(67
1868042	0	4	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	5	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	6	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	7	channel	NN	-	-	-	-	-	-	-	67)

1868042	0	1	Figures	NNS	-	-	-	-	-	-	-	(81)
1868042	0	2	and	CC	-	-	-	-	-	-	-	-
1868042	0	3	Tables	NNS	-	-	-	-	-	-	-	-

1868042	0	1	Figure	NN	-	-	-	-	-	-	-	(86|(81)
1868042	0	2	1	CD	-	-	-	-	-	-	-	86)

1868042	0	1	Glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	2	Suppresses	VBZ	-	-	-	-	-	-	-	-
1868042	0	3	Glucagon	NN	-	-	-	-	-	-	-	(3
1868042	0	4	Release	NN	-	-	-	-	-	-	-	3)
1868042	0	5	Independently	RB	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	Paracrine	NN	-	-	-	-	-	-	-	-
1868042	0	8	Signals	NNS	-	-	-	-	-	-	-	-
1868042	0	9	Mediated	VBN	-	-	-	-	-	-	-	-
1868042	0	10	by	IN	-	-	-	-	-	-	-	-
1868042	0	11	Zn2+	NN	-	-	-	-	-	-	-	(16)
1868042	0	12	or	CC	-	-	-	-	-	-	-	-
1868042	0	13	GABA	NN	-	-	-	-	-	-	-	(15)
1868042	0	14	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	A	LS	-	-	-	-	-	-	-	(82)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Glucagon	NN	-	-	-	-	-	-	-	(246|(2)
1868042	0	5	release	NN	-	-	-	-	-	-	-	-
1868042	0	6	from	IN	-	-	-	-	-	-	-	-
1868042	0	7	isolated	VBN	-	-	-	-	-	-	-	(80
1868042	0	8	mouse	NN	-	-	-	-	-	-	-	-
1868042	0	9	islets	NNS	-	-	-	-	-	-	-	80)|246)
1868042	0	10	was	VBD	-	-	-	-	-	-	-	-
1868042	0	11	suppressed	VBN	-	-	-	-	-	-	-	-
1868042	0	12	by	IN	-	-	-	-	-	-	-	-
1868042	0	13	60	CD	-	-	-	-	-	-	-	-
1868042	0	14	%	NN	-	-	-	-	-	-	-	-
1868042	0	15	at	IN	-	-	-	-	-	-	-	-
1868042	0	16	7	CD	-	-	-	-	-	-	-	(78
1868042	0	17	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	18	glucose	NN	-	-	-	-	-	-	-	78)
1868042	0	19	compared	VBN	-	-	-	-	-	-	-	-
1868042	0	20	with	IN	-	-	-	-	-	-	-	-
1868042	0	21	1	CD	-	-	-	-	-	-	-	(101
1868042	0	22	mM	NN	-	-	-	-	-	-	-	101)
1868042	0	23	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	24	filled	VBN	-	-	-	-	-	-	-	(247
1868042	0	25	bars	NNS	-	-	-	-	-	-	-	247)
1868042	0	26	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	27	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	2	retained	VBD	-	-	-	-	-	-	-	-
1868042	0	3	its	PRP$	-	-	-	-	-	-	-	(31)
1868042	0	4	suppressive	JJ	-	-	-	-	-	-	-	-
1868042	0	5	effect	NN	-	-	-	-	-	-	-	-
1868042	0	6	on	IN	-	-	-	-	-	-	-	-
1868042	0	7	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	8	release	NN	-	-	-	-	-	-	-	3)
1868042	0	9	under	IN	-	-	-	-	-	-	-	-
1868042	0	10	conditions	NNS	-	-	-	-	-	-	-	-
1868042	0	11	of	IN	-	-	-	-	-	-	-	-
1868042	0	12	Zn2+	NN	-	-	-	-	-	-	-	(76|(16)
1868042	0	13	chelation	NN	-	-	-	-	-	-	-	76)
1868042	0	14	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	15	Ca2+	NN	-	-	-	-	-	-	-	(77
1868042	0	16	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	EDTA	NN	-	-	-	-	-	-	-	77)
1868042	0	18	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	open	JJ	-	-	-	-	-	-	-	(248
1868042	0	21	bars	NNS	-	-	-	-	-	-	-	248)
1868042	0	22	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	and	CC	-	-	-	-	-	-	-	-
1868042	0	24	antagonism	NN	-	-	-	-	-	-	-	(249
1868042	0	25	of	IN	-	-	-	-	-	-	-	-
1868042	0	26	GABAA	NN	-	-	-	-	-	-	-	(90
1868042	0	27	receptors	NNS	-	-	-	-	-	-	-	90)|249)
1868042	0	28	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	29	SR	NN	-	-	-	-	-	-	-	(75
1868042	0	30	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	31	95531	CD	-	-	-	-	-	-	-	75)
1868042	0	32	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	33	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	34	shaded	VBN	-	-	-	-	-	-	-	-
1868042	0	35	bars	NNS	-	-	-	-	-	-	-	-
1868042	0	36	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	37	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Antagonism	NN	-	-	-	-	-	-	-	(249
1868042	0	2	of	IN	-	-	-	-	-	-	-	-
1868042	0	3	GABAA	NN	-	-	-	-	-	-	-	(90
1868042	0	4	receptors	NNS	-	-	-	-	-	-	-	90)|249)
1868042	0	5	increased	VBD	-	-	-	-	-	-	-	-
1868042	0	6	both	CC	-	-	-	-	-	-	-	-
1868042	0	7	basal	JJ	-	-	-	-	-	-	-	-
1868042	0	8	and	CC	-	-	-	-	-	-	-	-
1868042	0	9	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	10	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	11	suppressed	VBN	-	-	-	-	-	-	-	-
1868042	0	12	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	13	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	suggesting	VBG	-	-	-	-	-	-	-	-
1868042	0	16	a	DT	-	-	-	-	-	-	-	-
1868042	0	17	paracrine	JJ	-	-	-	-	-	-	-	-
1868042	0	18	role	NN	-	-	-	-	-	-	-	-
1868042	0	19	for	IN	-	-	-	-	-	-	-	-
1868042	0	20	GABA	NN	-	-	-	-	-	-	-	(15)
1868042	0	21	independent	JJ	-	-	-	-	-	-	-	-
1868042	0	22	of	IN	-	-	-	-	-	-	-	-
1868042	0	23	the	DT	-	-	-	-	-	-	-	(250
1868042	0	24	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	25	effect	NN	-	-	-	-	-	-	-	250)
1868042	0	26	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	B	LS	-	-	-	-	-	-	-	(83)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	As	IN	-	-	-	-	-	-	-	-
1868042	0	5	in	IN	-	-	-	-	-	-	-	-
1868042	0	6	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	7	A	NN	-	-	-	-	-	-	-	(82)
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	but	CC	-	-	-	-	-	-	-	-
1868042	0	11	using	VBG	-	-	-	-	-	-	-	-
1868042	0	12	rat	NN	-	-	-	-	-	-	-	(85
1868042	0	13	islets	NNS	-	-	-	-	-	-	-	85)
1868042	0	14	.	.	-	-	-	-	-	-	-	-

1868042	0	1	*	SYM	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	p	NN	-	-	-	-	-	-	-	-
1868042	0	4	<	SYM	-	-	-	-	-	-	-	-
1868042	0	5	0.05	CD	-	-	-	-	-	-	-	-
1868042	0	6	;	:	-	-	-	-	-	-	-	-
1868042	0	7	**	SYM	-	-	-	-	-	-	-	-
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	p	NN	-	-	-	-	-	-	-	-
1868042	0	10	<	SYM	-	-	-	-	-	-	-	-
1868042	0	11	0.01	CD	-	-	-	-	-	-	-	-
1868042	0	12	;	:	-	-	-	-	-	-	-	-
1868042	0	13	***	SYM	-	-	-	-	-	-	-	-
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	p	NN	-	-	-	-	-	-	-	-
1868042	0	16	<	SYM	-	-	-	-	-	-	-	-
1868042	0	17	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	compared	VBN	-	-	-	-	-	-	-	-
1868042	0	20	with	IN	-	-	-	-	-	-	-	-
1868042	0	21	1	CD	-	-	-	-	-	-	-	(101
1868042	0	22	mM	NN	-	-	-	-	-	-	-	-
1868042	0	23	glucose	NN	-	-	-	-	-	-	-	101)
1868042	0	24	,	,	-	-	-	-	-	-	-	-
1868042	0	25	or	CC	-	-	-	-	-	-	-	-
1868042	0	26	as	IN	-	-	-	-	-	-	-	-
1868042	0	27	indicated	VBN	-	-	-	-	-	-	-	-
1868042	0	28	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Figure	NN	-	-	-	-	-	-	-	(81)
1868042	0	2	2	CD	-	-	-	-	-	-	-	-

1868042	0	1	Glucagon	NN	-	-	-	-	-	-	-	(246a|(2)
1868042	0	2	Release	NN	-	-	-	-	-	-	-	-
1868042	0	3	from	IN	-	-	-	-	-	-	-	-
1868042	0	4	Isolated	VBN	-	-	-	-	-	-	-	(80b)|246a)
1868042	0	5	and	CC	-	-	-	-	-	-	-	-
1868042	0	6	Intact	JJ	-	-	-	-	-	-	-	(73
1868042	0	7	Mouse	NN	-	-	-	-	-	-	-	(246a|(80b
1868042	0	8	Islets	NNS	-	-	-	-	-	-	-	80b)|73)|246a)
1868042	0	9	Is	VBZ	-	-	-	-	-	-	-	-
1868042	0	10	Regulated	VBN	-	-	-	-	-	-	-	-
1868042	0	11	by	IN	-	-	-	-	-	-	-	-
1868042	0	12	a	DT	-	-	-	-	-	-	-	-
1868042	0	13	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	14	Channel	NN	-	-	-	-	-	-	-	-
1868042	0	15	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	Dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	17	Pathway	NN	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	A	LS	-	-	-	-	-	-	-	(98)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	5	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	6	filled	VBN	-	-	-	-	-	-	-	(251
1868042	0	7	circles	NNS	-	-	-	-	-	-	-	251)
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	insulin	NN	-	-	-	-	-	-	-	(19)
1868042	0	11	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	12	open	JJ	-	-	-	-	-	-	-	(252
1868042	0	13	circles	NNS	-	-	-	-	-	-	-	252)
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	16	measured	VBN	-	-	-	-	-	-	-	-
1868042	0	17	from	IN	-	-	-	-	-	-	-	-
1868042	0	18	mouse	NN	-	-	-	-	-	-	-	(71
1868042	0	19	islets	NNS	-	-	-	-	-	-	-	71)
1868042	0	20	in	IN	-	-	-	-	-	-	-	-
1868042	0	21	the	DT	-	-	-	-	-	-	-	-
1868042	0	22	presence	NN	-	-	-	-	-	-	-	-
1868042	0	23	of	IN	-	-	-	-	-	-	-	-
1868042	0	24	8.3	CD	-	-	-	-	-	-	-	(79
1868042	0	25	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	26	glucose	NN	-	-	-	-	-	-	-	79)
1868042	0	27	at	IN	-	-	-	-	-	-	-	-
1868042	0	28	increasing	VBG	-	-	-	-	-	-	-	(96
1868042	0	29	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	30	of	IN	-	-	-	-	-	-	-	-
1868042	0	31	diazoxide	NN	-	-	-	-	-	-	-	(18)|96)
1868042	0	32	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	B	LS	-	-	-	-	-	-	-	(99)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	As	IN	-	-	-	-	-	-	-	-
1868042	0	5	in	IN	-	-	-	-	-	-	-	-
1868042	0	6	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	7	A	NN	-	-	-	-	-	-	-	(98)
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	but	CC	-	-	-	-	-	-	-	-
1868042	0	11	using	VBG	-	-	-	-	-	-	-	-
1868042	0	12	rat	NN	-	-	-	-	-	-	-	(85
1868042	0	13	islets	NNS	-	-	-	-	-	-	-	85)
1868042	0	14	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	3	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	4	to	IN	-	-	-	-	-	-	-	-
1868042	0	5	1	CD	-	-	-	-	-	-	-	(101
1868042	0	6	mM	NN	-	-	-	-	-	-	-	-
1868042	0	7	glucose	NN	-	-	-	-	-	-	-	101)
1868042	0	8	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	9	filled	VBN	-	-	-	-	-	-	-	(253
1868042	0	10	square	NN	-	-	-	-	-	-	-	253)
1868042	0	11	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	12	and	CC	-	-	-	-	-	-	-	-
1868042	0	13	100	CD	-	-	-	-	-	-	-	(136
1868042	0	14	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	15	tolbutamide	NN	-	-	-	-	-	-	-	136)
1868042	0	16	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	17	filled	VBN	-	-	-	-	-	-	-	-
1868042	0	18	triangle	NN	-	-	-	-	-	-	-	-
1868042	0	19	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	20	are	VBP	-	-	-	-	-	-	-	-
1868042	0	21	indicated	VBN	-	-	-	-	-	-	-	-
1868042	0	22	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	C	LS	-	-	-	-	-	-	-	(102)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	As	IN	-	-	-	-	-	-	-	-
1868042	0	5	in	IN	-	-	-	-	-	-	-	-
1868042	0	6	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	7	A	NN	-	-	-	-	-	-	-	(98)
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	but	CC	-	-	-	-	-	-	-	-
1868042	0	11	in	IN	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	(100
1868042	0	13	presence	NN	-	-	-	-	-	-	-	-
1868042	0	14	of	IN	-	-	-	-	-	-	-	-
1868042	0	15	1	CD	-	-	-	-	-	-	-	(101
1868042	0	16	mM	NN	-	-	-	-	-	-	-	-
1868042	0	17	glucose	NN	-	-	-	-	-	-	-	101)|100)
1868042	0	18	and	CC	-	-	-	-	-	-	-	-
1868042	0	19	only	RB	-	-	-	-	-	-	-	-
1868042	0	20	measuring	VBG	-	-	-	-	-	-	-	-
1868042	0	21	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	22	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	D	LS	-	-	-	-	-	-	-	(103)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	As	IN	-	-	-	-	-	-	-	-
1868042	0	5	in	IN	-	-	-	-	-	-	-	-
1868042	0	6	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	7	A	NN	-	-	-	-	-	-	-	(98)
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	but	CC	-	-	-	-	-	-	-	-
1868042	0	11	examining	VBG	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	effect	NN	-	-	-	-	-	-	-	-
1868042	0	14	of	IN	-	-	-	-	-	-	-	-
1868042	0	15	tolbutamide	NN	-	-	-	-	-	-	-	(23)
1868042	0	16	in	IN	-	-	-	-	-	-	-	-
1868042	0	17	the	DT	-	-	-	-	-	-	-	(30
1868042	0	18	absence	NN	-	-	-	-	-	-	-	-
1868042	0	19	of	IN	-	-	-	-	-	-	-	-
1868042	0	20	glucose	NN	-	-	-	-	-	-	-	(31)|30)
1868042	0	21	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	2	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	3	in	IN	-	-	-	-	-	-	-	-
1868042	0	4	response	NN	-	-	-	-	-	-	-	-
1868042	0	5	to	IN	-	-	-	-	-	-	-	-
1868042	0	6	20	CD	-	-	-	-	-	-	-	(116
1868042	0	7	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	8	glucose	NN	-	-	-	-	-	-	-	116)
1868042	0	9	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	10	indicated	VBN	-	-	-	-	-	-	-	-
1868042	0	11	by	IN	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	(253
1868042	0	13	filled	VBN	-	-	-	-	-	-	-	-
1868042	0	14	square	NN	-	-	-	-	-	-	-	253)
1868042	0	15	.	.	-	-	-	-	-	-	-	-

1868042	0	1	*	SYM	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	p	NN	-	-	-	-	-	-	-	-
1868042	0	4	<	SYM	-	-	-	-	-	-	-	-
1868042	0	5	0.05	CD	-	-	-	-	-	-	-	-
1868042	0	6	;	:	-	-	-	-	-	-	-	-
1868042	0	7	**	SYM	-	-	-	-	-	-	-	-
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	p	NN	-	-	-	-	-	-	-	-
1868042	0	10	<	SYM	-	-	-	-	-	-	-	-
1868042	0	11	0.01	CD	-	-	-	-	-	-	-	-
1868042	0	12	;	:	-	-	-	-	-	-	-	-
1868042	0	13	***	SYM	-	-	-	-	-	-	-	-
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	p	NN	-	-	-	-	-	-	-	-
1868042	0	16	<	SYM	-	-	-	-	-	-	-	-
1868042	0	17	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	compared	VBN	-	-	-	-	-	-	-	-
1868042	0	20	with	IN	-	-	-	-	-	-	-	-
1868042	0	21	zero	CD	-	-	-	-	-	-	-	-
1868042	0	22	diazoxide	NN	-	-	-	-	-	-	-	-
1868042	0	23	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	24	A	NN	-	-	-	-	-	-	-	-
1868042	0	25	–	SYM	-	-	-	-	-	-	-	-
1868042	0	26	C	NN	-	-	-	-	-	-	-	-
1868042	0	27	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	28	or	CC	-	-	-	-	-	-	-	-
1868042	0	29	zero	CD	-	-	-	-	-	-	-	-
1868042	0	30	tolbutamide	NN	-	-	-	-	-	-	-	-
1868042	0	31	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	32	D	NN	-	-	-	-	-	-	-	(103)
1868042	0	33	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	34	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Figure	NN	-	-	-	-	-	-	-	(193|(81)
1868042	0	2	3	CD	-	-	-	-	-	-	-	193)

1868042	0	1	Tolbutamide	NN	-	-	-	-	-	-	-	(23)
1868042	0	2	and	CC	-	-	-	-	-	-	-	-
1868042	0	3	Glucose	NN	-	-	-	-	-	-	-	(250|(31)
1868042	0	4	Effects	NNS	-	-	-	-	-	-	-	250)
1868042	0	5	Are	VBP	-	-	-	-	-	-	-	-
1868042	0	6	Non-Additive	JJ	-	-	-	-	-	-	-	-
1868042	0	7	and	CC	-	-	-	-	-	-	-	-
1868042	0	8	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	9	Response	NN	-	-	-	-	-	-	-	-
1868042	0	10	Is	VBZ	-	-	-	-	-	-	-	-
1868042	0	11	Altered	VBN	-	-	-	-	-	-	-	-
1868042	0	12	in	IN	-	-	-	-	-	-	-	-
1868042	0	13	Kir6.2Y12X	NN	-	-	-	-	-	-	-	-
1868042	0	14	Islets	NNS	-	-	-	-	-	-	-	-
1868042	0	15	That	WDT	-	-	-	-	-	-	-	-
1868042	0	16	Express	VBP	-	-	-	-	-	-	-	-
1868042	0	17	a	DT	-	-	-	-	-	-	-	-
1868042	0	18	Truncated	VBN	-	-	-	-	-	-	-	-
1868042	0	19	Kir6.2	NN	-	-	-	-	-	-	-	-
1868042	0	20	Subunit	NN	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	A	LS	-	-	-	-	-	-	-	(104)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	5	release	NN	-	-	-	-	-	-	-	-
1868042	0	6	from	IN	-	-	-	-	-	-	-	-
1868042	0	7	isolated	VBN	-	-	-	-	-	-	-	(80
1868042	0	8	mouse	NN	-	-	-	-	-	-	-	-
1868042	0	9	islets	NNS	-	-	-	-	-	-	-	80)
1868042	0	10	at	IN	-	-	-	-	-	-	-	-
1868042	0	11	1	CD	-	-	-	-	-	-	-	(101e)|(155a)
1868042	0	12	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	13	open	JJ	-	-	-	-	-	-	-	(248
1868042	0	14	bars	NNS	-	-	-	-	-	-	-	248)
1868042	0	15	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	16	and	CC	-	-	-	-	-	-	-	(155a
1868042	0	17	20	CD	-	-	-	-	-	-	-	(116
1868042	0	18	mM	NNS	-	-	-	-	-	-	-	(101e
1868042	0	19	glucose	NN	-	-	-	-	-	-	-	155a)|116)|101e)
1868042	0	20	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	21	filled	VBN	-	-	-	-	-	-	-	(247
1868042	0	22	bars	NNS	-	-	-	-	-	-	-	247)
1868042	0	23	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	24	under	IN	-	-	-	-	-	-	-	-
1868042	0	25	control	NN	-	-	-	-	-	-	-	(152
1868042	0	26	conditions	NNS	-	-	-	-	-	-	-	152)
1868042	0	27	and	CC	-	-	-	-	-	-	-	-
1868042	0	28	presence	NN	-	-	-	-	-	-	-	-
1868042	0	29	of	IN	-	-	-	-	-	-	-	-
1868042	0	30	0.5	CD	-	-	-	-	-	-	-	-
1868042	0	31	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	32	tolbutamide	NN	-	-	-	-	-	-	-	-
1868042	0	33	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	B	LS	-	-	-	-	-	-	-	(113)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	A	DT	-	-	-	-	-	-	-	-
1868042	0	5	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	6	dose	NN	-	-	-	-	-	-	-	-
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	response	NN	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	glucagon	NN	-	-	-	-	-	-	-	(3|(2)
1868042	0	11	release	NN	-	-	-	-	-	-	-	3)
1868042	0	12	from	IN	-	-	-	-	-	-	-	-
1868042	0	13	control	NN	-	-	-	-	-	-	-	(254
1868042	0	14	C3HB	NN	-	-	-	-	-	-	-	-
1868042	0	15	islets	NNS	-	-	-	-	-	-	-	254)
1868042	0	16	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	17	filled	VBN	-	-	-	-	-	-	-	(251
1868042	0	18	circles	NNS	-	-	-	-	-	-	-	251)
1868042	0	19	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	20	and	CC	-	-	-	-	-	-	-	-
1868042	0	21	Kir6.2Y12X	NN	-	-	-	-	-	-	-	(108
1868042	0	22	islets	NNS	-	-	-	-	-	-	-	108)
1868042	0	23	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	24	open	JJ	-	-	-	-	-	-	-	(252
1868042	0	25	circles	NNS	-	-	-	-	-	-	-	252)
1868042	0	26	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	27	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	C	LS	-	-	-	-	-	-	-	(117)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	As	IN	-	-	-	-	-	-	-	-
1868042	0	5	in	IN	-	-	-	-	-	-	-	-
1868042	0	6	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	7	B	NN	-	-	-	-	-	-	-	(113)
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	but	CC	-	-	-	-	-	-	-	-
1868042	0	11	insulin	NN	-	-	-	-	-	-	-	(19)
1868042	0	12	was	VBD	-	-	-	-	-	-	-	-
1868042	0	13	measured	VBN	-	-	-	-	-	-	-	-
1868042	0	14	.	.	-	-	-	-	-	-	-	-

1868042	0	1	*	SYM	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	p	NN	-	-	-	-	-	-	-	-
1868042	0	4	<	SYM	-	-	-	-	-	-	-	-
1868042	0	5	0.05	CD	-	-	-	-	-	-	-	-
1868042	0	6	;	:	-	-	-	-	-	-	-	-
1868042	0	7	**	SYM	-	-	-	-	-	-	-	-
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	p	NN	-	-	-	-	-	-	-	-
1868042	0	10	<	SYM	-	-	-	-	-	-	-	-
1868042	0	11	0.01	CD	-	-	-	-	-	-	-	-
1868042	0	12	;	:	-	-	-	-	-	-	-	-
1868042	0	13	***	SYM	-	-	-	-	-	-	-	-
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	p	NN	-	-	-	-	-	-	-	-
1868042	0	16	<	SYM	-	-	-	-	-	-	-	-
1868042	0	17	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	compared	VBN	-	-	-	-	-	-	-	-
1868042	0	20	with	IN	-	-	-	-	-	-	-	-
1868042	0	21	control	NN	-	-	-	-	-	-	-	(254)
1868042	0	22	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Figure	NN	-	-	-	-	-	-	-	(207|(81)
1868042	0	2	4	CD	-	-	-	-	-	-	-	207)

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	Intracellular	JJ	-	-	-	-	-	-	-	(122
1868042	0	3	Ca2+	NN	-	-	-	-	-	-	-	122)
1868042	0	4	Response	NN	-	-	-	-	-	-	-	-
1868042	0	5	of	IN	-	-	-	-	-	-	-	-
1868042	0	6	Single	JJ	-	-	-	-	-	-	-	-
1868042	0	7	α	NN	-	-	-	-	-	-	-	-
1868042	0	8	Cells	NNS	-	-	-	-	-	-	-	-
1868042	0	9	within	IN	-	-	-	-	-	-	-	-
1868042	0	10	Intact	JJ	-	-	-	-	-	-	-	(93
1868042	0	11	Islets	NNS	-	-	-	-	-	-	-	93)
1868042	0	12	Can	MD	-	-	-	-	-	-	-	-
1868042	0	13	Be	VB	-	-	-	-	-	-	-	-
1868042	0	14	Re-Activated	VBN	-	-	-	-	-	-	-	-
1868042	0	15	by	IN	-	-	-	-	-	-	-	-
1868042	0	16	Low	JJ	-	-	-	-	-	-	-	(17
1868042	0	17	Concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	18	of	IN	-	-	-	-	-	-	-	-
1868042	0	19	Diazoxide	NN	-	-	-	-	-	-	-	(18)|17)

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	A	LS	-	-	-	-	-	-	-	(124)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Representative	JJ	-	-	-	-	-	-	-	-
1868042	0	5	intracellular	JJ	-	-	-	-	-	-	-	-
1868042	0	6	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	7	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	8	from	IN	-	-	-	-	-	-	-	-
1868042	0	9	α	NN	-	-	-	-	-	-	-	-
1868042	0	10	and	CC	-	-	-	-	-	-	-	-
1868042	0	11	β	NN	-	-	-	-	-	-	-	-
1868042	0	12	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	13	within	IN	-	-	-	-	-	-	-	-
1868042	0	14	an	DT	-	-	-	-	-	-	-	-
1868042	0	15	intact	JJ	-	-	-	-	-	-	-	-
1868042	0	16	mouse	NN	-	-	-	-	-	-	-	-
1868042	0	17	islet	NN	-	-	-	-	-	-	-	-
1868042	0	18	exposed	VBN	-	-	-	-	-	-	-	-
1868042	0	19	to	IN	-	-	-	-	-	-	-	-
1868042	0	20	0.5	CD	-	-	-	-	-	-	-	(221
1868042	0	21	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	22	glucose	NN	-	-	-	-	-	-	-	221)
1868042	0	23	,	,	-	-	-	-	-	-	-	-
1868042	0	24	11	CD	-	-	-	-	-	-	-	(123
1868042	0	25	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	26	glucose	NN	-	-	-	-	-	-	-	123)
1868042	0	27	,	,	-	-	-	-	-	-	-	-
1868042	0	28	and	CC	-	-	-	-	-	-	-	-
1868042	0	29	11	CD	-	-	-	-	-	-	-	-
1868042	0	30	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	31	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	32	plus	CC	-	-	-	-	-	-	-	-
1868042	0	33	2	CD	-	-	-	-	-	-	-	(127
1868042	0	34	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	35	diazoxide	NN	-	-	-	-	-	-	-	127)
1868042	0	36	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	37	diaz	NN	-	-	-	-	-	-	-	-
1868042	0	38	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	39	as	IN	-	-	-	-	-	-	-	-
1868042	0	40	indicated	VBN	-	-	-	-	-	-	-	-
1868042	0	41	above	IN	-	-	-	-	-	-	-	-
1868042	0	42	the	DT	-	-	-	-	-	-	-	-
1868042	0	43	traces	NNS	-	-	-	-	-	-	-	-
1868042	0	44	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	B	LS	-	-	-	-	-	-	-	(126)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	The	DT	-	-	-	-	-	-	-	-
1868042	0	5	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	6	response	NN	-	-	-	-	-	-	-	-
1868042	0	7	of	IN	-	-	-	-	-	-	-	-
1868042	0	8	α	NN	-	-	-	-	-	-	-	(1
1868042	0	9	cells	NNS	-	-	-	-	-	-	-	1)
1868042	0	10	was	VBD	-	-	-	-	-	-	-	-
1868042	0	11	suppressed	VBN	-	-	-	-	-	-	-	-
1868042	0	12	by	IN	-	-	-	-	-	-	-	-
1868042	0	13	11	CD	-	-	-	-	-	-	-	(123
1868042	0	14	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	15	glucose	NN	-	-	-	-	-	-	-	123)
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	and	CC	-	-	-	-	-	-	-	-
1868042	0	18	could	MD	-	-	-	-	-	-	-	-
1868042	0	19	be	VB	-	-	-	-	-	-	-	-
1868042	0	20	reactivated	VBN	-	-	-	-	-	-	-	-
1868042	0	21	with	IN	-	-	-	-	-	-	-	-
1868042	0	22	low	JJ	-	-	-	-	-	-	-	(17
1868042	0	23	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	24	of	IN	-	-	-	-	-	-	-	-
1868042	0	25	the	DT	-	-	-	-	-	-	-	(18
1868042	0	26	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	27	channel	NN	-	-	-	-	-	-	-	-
1868042	0	28	agonist	NN	-	-	-	-	-	-	-	-
1868042	0	29	diazoxide	NN	-	-	-	-	-	-	-	18)|17)
1868042	0	30	.	.	-	-	-	-	-	-	-	-

1868042	0	1	***	SYM	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	p	NN	-	-	-	-	-	-	-	-
1868042	0	4	<	SYM	-	-	-	-	-	-	-	-
1868042	0	5	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	compared	VBN	-	-	-	-	-	-	-	-
1868042	0	8	with	IN	-	-	-	-	-	-	-	-
1868042	0	9	the	DT	-	-	-	-	-	-	-	(59
1868042	0	10	low	JJ	-	-	-	-	-	-	-	-
1868042	0	11	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	13	condition	NN	-	-	-	-	-	-	-	59)
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	or	CC	-	-	-	-	-	-	-	-
1868042	0	16	as	IN	-	-	-	-	-	-	-	-
1868042	0	17	indicated	VBN	-	-	-	-	-	-	-	-
1868042	0	18	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Figure	NN	-	-	-	-	-	-	-	(208|(81)
1868042	0	2	5	CD	-	-	-	-	-	-	-	208)

1868042	0	1	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	2	Release	NN	-	-	-	-	-	-	-	-
1868042	0	3	from	IN	-	-	-	-	-	-	-	-
1868042	0	4	Isolated	VBN	-	-	-	-	-	-	-	(62a)
1868042	0	5	and	CC	-	-	-	-	-	-	-	-
1868042	0	6	Intact	JJ	-	-	-	-	-	-	-	(12
1868042	0	7	Human	JJ	-	-	-	-	-	-	-	(62a
1868042	0	8	Islets	NNS	-	-	-	-	-	-	-	62a)|12)
1868042	0	9	Is	VBZ	-	-	-	-	-	-	-	-
1868042	0	10	Regulated	VBN	-	-	-	-	-	-	-	-
1868042	0	11	by	IN	-	-	-	-	-	-	-	-
1868042	0	12	a	DT	-	-	-	-	-	-	-	-
1868042	0	13	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	14	Channel	NN	-	-	-	-	-	-	-	-
1868042	0	15	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	Dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	17	Pathway	NN	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	A	LS	-	-	-	-	-	-	-	(129)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	5	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	6	open	JJ	-	-	-	-	-	-	-	(248
1868042	0	7	bars	NNS	-	-	-	-	-	-	-	248)
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	insulin	NN	-	-	-	-	-	-	-	(19)
1868042	0	11	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	12	filled	VBN	-	-	-	-	-	-	-	(247
1868042	0	13	bars	NNS	-	-	-	-	-	-	-	247)
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	release	NN	-	-	-	-	-	-	-	-
1868042	0	16	was	VBD	-	-	-	-	-	-	-	-
1868042	0	17	measured	VBN	-	-	-	-	-	-	-	-
1868042	0	18	from	IN	-	-	-	-	-	-	-	-
1868042	0	19	isolated	VBN	-	-	-	-	-	-	-	-
1868042	0	20	human	JJ	-	-	-	-	-	-	-	-
1868042	0	21	islets	NNS	-	-	-	-	-	-	-	-
1868042	0	22	under	IN	-	-	-	-	-	-	-	-
1868042	0	23	control	NN	-	-	-	-	-	-	-	(152
1868042	0	24	conditions	NNS	-	-	-	-	-	-	-	152)
1868042	0	25	and	CC	-	-	-	-	-	-	-	-
1868042	0	26	following	VBG	-	-	-	-	-	-	-	-
1868042	0	27	addition	NN	-	-	-	-	-	-	-	-
1868042	0	28	of	IN	-	-	-	-	-	-	-	-
1868042	0	29	10	CD	-	-	-	-	-	-	-	(220
1868042	0	30	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	31	glucose	NN	-	-	-	-	-	-	-	220)
1868042	0	32	or	CC	-	-	-	-	-	-	-	-
1868042	0	33	200	CD	-	-	-	-	-	-	-	-
1868042	0	34	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	35	tolbutamide	NN	-	-	-	-	-	-	-	-
1868042	0	36	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	B	LS	-	-	-	-	-	-	-	(131)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	5	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	6	open	JJ	-	-	-	-	-	-	-	(248
1868042	0	7	bars	NNS	-	-	-	-	-	-	-	248)
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	insulin	NN	-	-	-	-	-	-	-	(19)
1868042	0	11	secretion	NN	-	-	-	-	-	-	-	-
1868042	0	12	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	13	filled	VBN	-	-	-	-	-	-	-	(247
1868042	0	14	bars	NNS	-	-	-	-	-	-	-	247)
1868042	0	15	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	16	measured	VBN	-	-	-	-	-	-	-	-
1868042	0	17	in	IN	-	-	-	-	-	-	-	-
1868042	0	18	the	DT	-	-	-	-	-	-	-	-
1868042	0	19	presence	NN	-	-	-	-	-	-	-	-
1868042	0	20	of	IN	-	-	-	-	-	-	-	-
1868042	0	21	10	CD	-	-	-	-	-	-	-	(220
1868042	0	22	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	23	glucose	NN	-	-	-	-	-	-	-	220)
1868042	0	24	and	CC	-	-	-	-	-	-	-	-
1868042	0	25	increasing	VBG	-	-	-	-	-	-	-	(96
1868042	0	26	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	27	of	IN	-	-	-	-	-	-	-	-
1868042	0	28	diazoxide	NN	-	-	-	-	-	-	-	(18)|96)
1868042	0	29	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	30	0	CD	-	-	-	-	-	-	-	-
1868042	0	31	–	SYM	-	-	-	-	-	-	-	-
1868042	0	32	200	CD	-	-	-	-	-	-	-	-
1868042	0	33	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	34	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	35	.	.	-	-	-	-	-	-	-	-

1868042	0	1	*	SYM	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	p	NN	-	-	-	-	-	-	-	-
1868042	0	4	<	SYM	-	-	-	-	-	-	-	-
1868042	0	5	0.05	CD	-	-	-	-	-	-	-	-
1868042	0	6	;	:	-	-	-	-	-	-	-	-
1868042	0	7	**	SYM	-	-	-	-	-	-	-	-
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	p	NN	-	-	-	-	-	-	-	-
1868042	0	10	<	SYM	-	-	-	-	-	-	-	-
1868042	0	11	0.01	CD	-	-	-	-	-	-	-	-
1868042	0	12	;	:	-	-	-	-	-	-	-	-
1868042	0	13	***	SYM	-	-	-	-	-	-	-	-
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	p	NN	-	-	-	-	-	-	-	-
1868042	0	16	<	SYM	-	-	-	-	-	-	-	-
1868042	0	17	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	compared	VBN	-	-	-	-	-	-	-	-
1868042	0	20	with	IN	-	-	-	-	-	-	-	-
1868042	0	21	controls	NNS	-	-	-	-	-	-	-	(206)
1868042	0	22	,	,	-	-	-	-	-	-	-	-
1868042	0	23	unless	IN	-	-	-	-	-	-	-	-
1868042	0	24	otherwise	RB	-	-	-	-	-	-	-	-
1868042	0	25	indicated	VBN	-	-	-	-	-	-	-	-
1868042	0	26	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Figure	NN	-	-	-	-	-	-	-	(81)
1868042	0	2	6	CD	-	-	-	-	-	-	-	-

1868042	0	1	Intracellular	JJ	-	-	-	-	-	-	-	(122
1868042	0	2	Ca2+	NN	-	-	-	-	-	-	-	122)
1868042	0	3	Responses	NNS	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	α	NN	-	-	-	-	-	-	-	(10
1868042	0	6	Cells	NNS	-	-	-	-	-	-	-	-
1868042	0	7	within	IN	-	-	-	-	-	-	-	-
1868042	0	8	Intact	JJ	-	-	-	-	-	-	-	(12
1868042	0	9	Human	JJ	-	-	-	-	-	-	-	-
1868042	0	10	Islets	NNS	-	-	-	-	-	-	-	12)|10)
1868042	0	11	Are	VBP	-	-	-	-	-	-	-	-
1868042	0	12	Regulated	VBN	-	-	-	-	-	-	-	-
1868042	0	13	by	IN	-	-	-	-	-	-	-	-
1868042	0	14	a	DT	-	-	-	-	-	-	-	-
1868042	0	15	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	16	Channel	NN	-	-	-	-	-	-	-	-
1868042	0	17	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	18	Dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	19	Mechanism	NN	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	A	LS	-	-	-	-	-	-	-	(134)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	5	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	6	measured	VBN	-	-	-	-	-	-	-	-
1868042	0	7	in	IN	-	-	-	-	-	-	-	-
1868042	0	8	two	CD	-	-	-	-	-	-	-	-
1868042	0	9	human	JJ	-	-	-	-	-	-	-	-
1868042	0	10	α	NN	-	-	-	-	-	-	-	-
1868042	0	11	cells	NNS	-	-	-	-	-	-	-	-
1868042	0	12	within	IN	-	-	-	-	-	-	-	-
1868042	0	13	the	DT	-	-	-	-	-	-	-	(255
1868042	0	14	same	JJ	-	-	-	-	-	-	-	-
1868042	0	15	islet	NN	-	-	-	-	-	-	-	255)
1868042	0	16	at	IN	-	-	-	-	-	-	-	-
1868042	0	17	0.5	CD	-	-	-	-	-	-	-	(221a
1868042	0	18	mM	NNS	-	-	-	-	-	-	-	221a)
1868042	0	19	and	CC	-	-	-	-	-	-	-	-
1868042	0	20	11	CD	-	-	-	-	-	-	-	(123
1868042	0	21	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	22	glucose	NN	-	-	-	-	-	-	-	(221a)|123)
1868042	0	23	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	24	glu	NN	-	-	-	-	-	-	-	-
1868042	0	25	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	26	,	,	-	-	-	-	-	-	-	-
1868042	0	27	in	IN	-	-	-	-	-	-	-	-
1868042	0	28	the	DT	-	-	-	-	-	-	-	-
1868042	0	29	presence	NN	-	-	-	-	-	-	-	-
1868042	0	30	of	IN	-	-	-	-	-	-	-	-
1868042	0	31	2	CD	-	-	-	-	-	-	-	(127
1868042	0	32	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	33	diazoxide	NN	-	-	-	-	-	-	-	127)
1868042	0	34	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	35	diaz	NN	-	-	-	-	-	-	-	-
1868042	0	36	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	37	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	B	LS	-	-	-	-	-	-	-	(135)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Summary	NN	-	-	-	-	-	-	-	-
1868042	0	5	of	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	8	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	9	at	IN	-	-	-	-	-	-	-	-
1868042	0	10	0.5	CD	-	-	-	-	-	-	-	(221
1868042	0	11	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	12	glucose	NN	-	-	-	-	-	-	-	221)
1868042	0	13	,	,	-	-	-	-	-	-	-	-
1868042	0	14	at	IN	-	-	-	-	-	-	-	-
1868042	0	15	11	CD	-	-	-	-	-	-	-	(123
1868042	0	16	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	17	glucose	NN	-	-	-	-	-	-	-	123)
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	in	IN	-	-	-	-	-	-	-	-
1868042	0	20	the	DT	-	-	-	-	-	-	-	-
1868042	0	21	presence	NN	-	-	-	-	-	-	-	-
1868042	0	22	of	IN	-	-	-	-	-	-	-	-
1868042	0	23	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	24	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	25	11	CD	-	-	-	-	-	-	-	-
1868042	0	26	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	27	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	28	and	CC	-	-	-	-	-	-	-	-
1868042	0	29	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	30	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	31	2	CD	-	-	-	-	-	-	-	-
1868042	0	32	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	33	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	34	,	,	-	-	-	-	-	-	-	-
1868042	0	35	and	CC	-	-	-	-	-	-	-	-
1868042	0	36	following	IN	-	-	-	-	-	-	-	-
1868042	0	37	the	DT	-	-	-	-	-	-	-	-
1868042	0	38	removal	NN	-	-	-	-	-	-	-	-
1868042	0	39	of	IN	-	-	-	-	-	-	-	-
1868042	0	40	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	41	,	,	-	-	-	-	-	-	-	-
1868042	0	42	but	CC	-	-	-	-	-	-	-	-
1868042	0	43	in	IN	-	-	-	-	-	-	-	-
1868042	0	44	the	DT	-	-	-	-	-	-	-	-
1868042	0	45	continued	VBN	-	-	-	-	-	-	-	-
1868042	0	46	presence	NN	-	-	-	-	-	-	-	-
1868042	0	47	of	IN	-	-	-	-	-	-	-	-
1868042	0	48	11	CD	-	-	-	-	-	-	-	(123
1868042	0	49	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	50	glucose	NN	-	-	-	-	-	-	-	123)
1868042	0	51	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	C	LS	-	-	-	-	-	-	-	(137)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	The	DT	-	-	-	-	-	-	-	-
1868042	0	5	re-activation	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	human	JJ	-	-	-	-	-	-	-	-
1868042	0	8	α	NN	-	-	-	-	-	-	-	-
1868042	0	9	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	cell	NN	-	-	-	-	-	-	-	-
1868042	0	11	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	12	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	13	by	IN	-	-	-	-	-	-	-	-
1868042	0	14	2	CD	-	-	-	-	-	-	-	(127
1868042	0	15	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	16	diazoxide	NN	-	-	-	-	-	-	-	127)
1868042	0	17	was	VBD	-	-	-	-	-	-	-	-
1868042	0	18	reversed	VBN	-	-	-	-	-	-	-	-
1868042	0	19	upon	IN	-	-	-	-	-	-	-	-
1868042	0	20	application	NN	-	-	-	-	-	-	-	-
1868042	0	21	of	IN	-	-	-	-	-	-	-	-
1868042	0	22	the	DT	-	-	-	-	-	-	-	(23
1868042	0	23	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	24	channel	NN	-	-	-	-	-	-	-	-
1868042	0	25	antagonist	NN	-	-	-	-	-	-	-	-
1868042	0	26	tolbutamide	NN	-	-	-	-	-	-	-	23)
1868042	0	27	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	28	100	CD	-	-	-	-	-	-	-	-
1868042	0	29	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	30	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	D	LS	-	-	-	-	-	-	-	(138)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	The	DT	-	-	-	-	-	-	-	-
1868042	0	5	effects	NNS	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	increasing	VBG	-	-	-	-	-	-	-	(96
1868042	0	8	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	diazoxide	NN	-	-	-	-	-	-	-	(18)|96)
1868042	0	11	on	IN	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	14	response	NN	-	-	-	-	-	-	-	-
1868042	0	15	of	IN	-	-	-	-	-	-	-	-
1868042	0	16	a	DT	-	-	-	-	-	-	-	-
1868042	0	17	human	JJ	-	-	-	-	-	-	-	-
1868042	0	18	α	NN	-	-	-	-	-	-	-	-
1868042	0	19	cell	NN	-	-	-	-	-	-	-	-
1868042	0	20	and	CC	-	-	-	-	-	-	-	-
1868042	0	21	β	NN	-	-	-	-	-	-	-	-
1868042	0	22	cell	NN	-	-	-	-	-	-	-	-
1868042	0	23	within	IN	-	-	-	-	-	-	-	-
1868042	0	24	the	DT	-	-	-	-	-	-	-	(255
1868042	0	25	same	JJ	-	-	-	-	-	-	-	-
1868042	0	26	islet	NN	-	-	-	-	-	-	-	255)
1868042	0	27	exposed	VBN	-	-	-	-	-	-	-	-
1868042	0	28	to	IN	-	-	-	-	-	-	-	-
1868042	0	29	11	CD	-	-	-	-	-	-	-	(123
1868042	0	30	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	31	glucose	NN	-	-	-	-	-	-	-	123)
1868042	0	32	.	.	-	-	-	-	-	-	-	-

1868042	0	1	At	IN	-	-	-	-	-	-	-	-
1868042	0	2	the	DT	-	-	-	-	-	-	-	-
1868042	0	3	end	NN	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	-
1868042	0	6	experiment	NN	-	-	-	-	-	-	-	-
1868042	0	7	,	,	-	-	-	-	-	-	-	-
1868042	0	8	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	9	was	VBD	-	-	-	-	-	-	-	-
1868042	0	10	withdrawn	VBN	-	-	-	-	-	-	-	-
1868042	0	11	and	CC	-	-	-	-	-	-	-	-
1868042	0	12	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	13	lowered	VBN	-	-	-	-	-	-	-	-
1868042	0	14	to	IN	-	-	-	-	-	-	-	-
1868042	0	15	0.5	CD	-	-	-	-	-	-	-	-
1868042	0	16	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	17	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	E	LS	-	-	-	-	-	-	-	-
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Dose	NN	-	-	-	-	-	-	-	-
1868042	0	5	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	6	response	JJ	-	-	-	-	-	-	-	-
1868042	0	7	curve	NN	-	-	-	-	-	-	-	-
1868042	0	8	for	IN	-	-	-	-	-	-	-	-
1868042	0	9	the	DT	-	-	-	-	-	-	-	-
1868042	0	10	effect	NN	-	-	-	-	-	-	-	-
1868042	0	11	of	IN	-	-	-	-	-	-	-	-
1868042	0	12	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	13	on	IN	-	-	-	-	-	-	-	-
1868042	0	14	α	NN	-	-	-	-	-	-	-	(28
1868042	0	15	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	cell	NN	-	-	-	-	-	-	-	-
1868042	0	17	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	18	responses	NNS	-	-	-	-	-	-	-	28)
1868042	0	19	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	grey	JJ	-	-	-	-	-	-	-	-
1868042	0	3	horizontal	JJ	-	-	-	-	-	-	-	-
1868042	0	4	line	NN	-	-	-	-	-	-	-	-
1868042	0	5	indicates	VBZ	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	response	NN	-	-	-	-	-	-	-	-
1868042	0	8	with	IN	-	-	-	-	-	-	-	-
1868042	0	9	11	CD	-	-	-	-	-	-	-	(123
1868042	0	10	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	11	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	12	alone	RB	-	-	-	-	-	-	-	123)
1868042	0	13	.	.	-	-	-	-	-	-	-	-

1868042	0	1	*	SYM	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	p	NN	-	-	-	-	-	-	-	-
1868042	0	4	<	SYM	-	-	-	-	-	-	-	-
1868042	0	5	0.05	CD	-	-	-	-	-	-	-	-
1868042	0	6	;	:	-	-	-	-	-	-	-	-
1868042	0	7	**	SYM	-	-	-	-	-	-	-	-
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	p	NN	-	-	-	-	-	-	-	-
1868042	0	10	<	SYM	-	-	-	-	-	-	-	-
1868042	0	11	0.01	CD	-	-	-	-	-	-	-	-
1868042	0	12	;	:	-	-	-	-	-	-	-	-
1868042	0	13	***	SYM	-	-	-	-	-	-	-	-
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	p	NN	-	-	-	-	-	-	-	-
1868042	0	16	<	SYM	-	-	-	-	-	-	-	-
1868042	0	17	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	compared	VBN	-	-	-	-	-	-	-	-
1868042	0	20	with	IN	-	-	-	-	-	-	-	-
1868042	0	21	controls	NNS	-	-	-	-	-	-	-	(206)
1868042	0	22	,	,	-	-	-	-	-	-	-	-
1868042	0	23	unless	IN	-	-	-	-	-	-	-	-
1868042	0	24	otherwise	RB	-	-	-	-	-	-	-	-
1868042	0	25	indicated	VBN	-	-	-	-	-	-	-	-
1868042	0	26	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Figure	NN	-	-	-	-	-	-	-	(81)
1868042	0	2	7	CD	-	-	-	-	-	-	-	-

1868042	0	1	Glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	2	Secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	3	and	CC	-	-	-	-	-	-	-	-
1868042	0	4	α	NN	-	-	-	-	-	-	-	(28
1868042	0	5	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	6	Cell	NN	-	-	-	-	-	-	-	-
1868042	0	7	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	8	Responses	NNS	-	-	-	-	-	-	-	28)
1868042	0	9	Are	VBP	-	-	-	-	-	-	-	-
1868042	0	10	Dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	11	upon	IN	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	Activity	NN	-	-	-	-	-	-	-	-
1868042	0	14	of	IN	-	-	-	-	-	-	-	-
1868042	0	15	Voltage	NN	-	-	-	-	-	-	-	(210
1868042	0	16	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	Dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	18	Na+	NN	-	-	-	-	-	-	-	-
1868042	0	19	Channels	NNS	-	-	-	-	-	-	-	210)

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	A	LS	-	-	-	-	-	-	-	(146)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	5	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	6	open	JJ	-	-	-	-	-	-	-	(248
1868042	0	7	bars	NNS	-	-	-	-	-	-	-	248)
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	insulin	NN	-	-	-	-	-	-	-	(19)
1868042	0	11	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	12	filled	VBN	-	-	-	-	-	-	-	(247
1868042	0	13	bars	NNS	-	-	-	-	-	-	-	247)
1868042	0	14	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	15	release	VBP	-	-	-	-	-	-	-	-
1868042	0	16	from	IN	-	-	-	-	-	-	-	-
1868042	0	17	isolated	VBN	-	-	-	-	-	-	-	(80
1868042	0	18	mouse	NN	-	-	-	-	-	-	-	-
1868042	0	19	islets	NNS	-	-	-	-	-	-	-	80)
1868042	0	20	at	IN	-	-	-	-	-	-	-	-
1868042	0	21	1	CD	-	-	-	-	-	-	-	(101c|(155
1868042	0	22	mM	NN	-	-	-	-	-	-	-	101c)
1868042	0	23	and	CC	-	-	-	-	-	-	-	-
1868042	0	24	20	CD	-	-	-	-	-	-	-	(116
1868042	0	25	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	26	glucose	NN	-	-	-	-	-	-	-	(101c)|155)|116)
1868042	0	27	,	,	-	-	-	-	-	-	-	-
1868042	0	28	under	IN	-	-	-	-	-	-	-	-
1868042	0	29	control	NN	-	-	-	-	-	-	-	(152
1868042	0	30	conditions	NNS	-	-	-	-	-	-	-	152)
1868042	0	31	and	CC	-	-	-	-	-	-	-	-
1868042	0	32	in	IN	-	-	-	-	-	-	-	-
1868042	0	33	the	DT	-	-	-	-	-	-	-	-
1868042	0	34	presence	NN	-	-	-	-	-	-	-	-
1868042	0	35	of	IN	-	-	-	-	-	-	-	-
1868042	0	36	the	DT	-	-	-	-	-	-	-	(34
1868042	0	37	Na+	NN	-	-	-	-	-	-	-	-
1868042	0	38	channel	NN	-	-	-	-	-	-	-	-
1868042	0	39	antagonist	NN	-	-	-	-	-	-	-	-
1868042	0	40	TTX	NN	-	-	-	-	-	-	-	34)
1868042	0	41	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	42	0.1	CD	-	-	-	-	-	-	-	-
1868042	0	43	μg	NNS	-	-	-	-	-	-	-	-
1868042	0	44	/	SYM	-	-	-	-	-	-	-	-
1868042	0	45	ml	NN	-	-	-	-	-	-	-	-
1868042	0	46	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	47	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	B	LS	-	-	-	-	-	-	-	(147)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Intracellular	JJ	-	-	-	-	-	-	-	(122
1868042	0	5	Ca2+	NN	-	-	-	-	-	-	-	122)
1868042	0	6	response	NN	-	-	-	-	-	-	-	-
1868042	0	7	of	IN	-	-	-	-	-	-	-	-
1868042	0	8	single	JJ	-	-	-	-	-	-	-	(237
1868042	0	9	α	NN	-	-	-	-	-	-	-	-
1868042	0	10	cells	NNS	-	-	-	-	-	-	-	237)
1868042	0	11	to	IN	-	-	-	-	-	-	-	-
1868042	0	12	0.5	CD	-	-	-	-	-	-	-	(221
1868042	0	13	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	14	glucose	NN	-	-	-	-	-	-	-	221)
1868042	0	15	.	.	-	-	-	-	-	-	-	-

1868042	0	1	TTX	NN	-	-	-	-	-	-	-	(34)
1868042	0	2	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	3	0.1	CD	-	-	-	-	-	-	-	-
1868042	0	4	μg	NNS	-	-	-	-	-	-	-	-
1868042	0	5	/	SYM	-	-	-	-	-	-	-	-
1868042	0	6	ml	NN	-	-	-	-	-	-	-	-
1868042	0	7	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	8	was	VBD	-	-	-	-	-	-	-	-
1868042	0	9	included	VBN	-	-	-	-	-	-	-	-
1868042	0	10	in	IN	-	-	-	-	-	-	-	-
1868042	0	11	the	DT	-	-	-	-	-	-	-	(224
1868042	0	12	perfusion	NN	-	-	-	-	-	-	-	-
1868042	0	13	medium	NN	-	-	-	-	-	-	-	224)
1868042	0	14	during	IN	-	-	-	-	-	-	-	-
1868042	0	15	the	DT	-	-	-	-	-	-	-	-
1868042	0	16	indicated	VBN	-	-	-	-	-	-	-	-
1868042	0	17	period	NN	-	-	-	-	-	-	-	-
1868042	0	18	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	C	LS	-	-	-	-	-	-	-	(148)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	The	DT	-	-	-	-	-	-	-	-
1868042	0	5	effects	NNS	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	TTX	NN	-	-	-	-	-	-	-	(34)
1868042	0	8	and	CC	-	-	-	-	-	-	-	-
1868042	0	9	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	10	on	IN	-	-	-	-	-	-	-	-
1868042	0	11	α	NN	-	-	-	-	-	-	-	(28
1868042	0	12	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	13	cell	NN	-	-	-	-	-	-	-	-
1868042	0	14	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	15	responses	NNS	-	-	-	-	-	-	-	28)
1868042	0	16	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Note	VB	-	-	-	-	-	-	-	-
1868042	0	2	that	IN	-	-	-	-	-	-	-	-
1868042	0	3	TTX	NN	-	-	-	-	-	-	-	(34)
1868042	0	4	inhibits	VBZ	-	-	-	-	-	-	-	-
1868042	0	5	Ca2+	NN	-	-	-	-	-	-	-	(231|(5)
1868042	0	6	responses	NNS	-	-	-	-	-	-	-	231)
1868042	0	7	as	RB	-	-	-	-	-	-	-	-
1868042	0	8	effectively	RB	-	-	-	-	-	-	-	-
1868042	0	9	as	IN	-	-	-	-	-	-	-	-
1868042	0	10	glucose	NN	-	-	-	-	-	-	-	(31)
1868042	0	11	and	CC	-	-	-	-	-	-	-	-
1868042	0	12	that	IN	-	-	-	-	-	-	-	-
1868042	0	13	the	DT	-	-	-	-	-	-	-	-
1868042	0	14	action	NN	-	-	-	-	-	-	-	-
1868042	0	15	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	16	at	RB	-	-	-	-	-	-	-	-
1868042	0	17	least	RB	-	-	-	-	-	-	-	-
1868042	0	18	partially	RB	-	-	-	-	-	-	-	-
1868042	0	19	reversible	JJ	-	-	-	-	-	-	-	-
1868042	0	20	.	.	-	-	-	-	-	-	-	-

1868042	0	1	*	SYM	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	p	NN	-	-	-	-	-	-	-	-
1868042	0	4	<	SYM	-	-	-	-	-	-	-	-
1868042	0	5	0.05	CD	-	-	-	-	-	-	-	-
1868042	0	6	;	:	-	-	-	-	-	-	-	-
1868042	0	7	**	SYM	-	-	-	-	-	-	-	-
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	p	NN	-	-	-	-	-	-	-	-
1868042	0	10	<	SYM	-	-	-	-	-	-	-	-
1868042	0	11	0.01	CD	-	-	-	-	-	-	-	-
1868042	0	12	;	:	-	-	-	-	-	-	-	-
1868042	0	13	***	SYM	-	-	-	-	-	-	-	-
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	p	NN	-	-	-	-	-	-	-	-
1868042	0	16	<	SYM	-	-	-	-	-	-	-	-
1868042	0	17	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	compared	VBN	-	-	-	-	-	-	-	-
1868042	0	20	with	IN	-	-	-	-	-	-	-	-
1868042	0	21	controls	NNS	-	-	-	-	-	-	-	(206)
1868042	0	22	,	,	-	-	-	-	-	-	-	-
1868042	0	23	unless	IN	-	-	-	-	-	-	-	-
1868042	0	24	otherwise	RB	-	-	-	-	-	-	-	-
1868042	0	25	indicated	VBN	-	-	-	-	-	-	-	-
1868042	0	26	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Figure	NN	-	-	-	-	-	-	-	(81)
1868042	0	2	8	CD	-	-	-	-	-	-	-	-

1868042	0	1	Glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	2	Secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	3	Is	VBZ	-	-	-	-	-	-	-	-
1868042	0	4	Regulated	VBN	-	-	-	-	-	-	-	-
1868042	0	5	by	IN	-	-	-	-	-	-	-	-
1868042	0	6	N	NN	-	-	-	-	-	-	-	(35
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	Type	NN	-	-	-	-	-	-	-	-
1868042	0	9	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	10	Channels	NNS	-	-	-	-	-	-	-	35)

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	A	LS	-	-	-	-	-	-	-	(154)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	5	release	NN	-	-	-	-	-	-	-	-
1868042	0	6	measured	VBN	-	-	-	-	-	-	-	-
1868042	0	7	at	IN	-	-	-	-	-	-	-	-
1868042	0	8	1	CD	-	-	-	-	-	-	-	(101a)|(155b)
1868042	0	9	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	10	open	JJ	-	-	-	-	-	-	-	(248
1868042	0	11	bars	NNS	-	-	-	-	-	-	-	248)
1868042	0	12	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	13	and	CC	-	-	-	-	-	-	-	(155b
1868042	0	14	20	CD	-	-	-	-	-	-	-	(116
1868042	0	15	mM	NNS	-	-	-	-	-	-	-	(101a
1868042	0	16	glucose	NN	-	-	-	-	-	-	-	155b)|116)|101a)
1868042	0	17	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	18	filled	VBN	-	-	-	-	-	-	-	(247
1868042	0	19	bars	NNS	-	-	-	-	-	-	-	247)
1868042	0	20	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	21	under	IN	-	-	-	-	-	-	-	-
1868042	0	22	control	NN	-	-	-	-	-	-	-	(152
1868042	0	23	conditions	NNS	-	-	-	-	-	-	-	152)
1868042	0	24	and	CC	-	-	-	-	-	-	-	-
1868042	0	25	in	IN	-	-	-	-	-	-	-	-
1868042	0	26	the	DT	-	-	-	-	-	-	-	(156|(157a
1868042	0	27	presence	NN	-	-	-	-	-	-	-	-
1868042	0	28	of	IN	-	-	-	-	-	-	-	157a)
1868042	0	29	100	CD	-	-	-	-	-	-	-	(158
1868042	0	30	nM	NNS	-	-	-	-	-	-	-	-
1868042	0	31	ω	NN	-	-	-	-	-	-	-	-
1868042	0	32	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	33	conotoxin	NN	-	-	-	-	-	-	-	158)|156)
1868042	0	34	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	35	middle	JJ	-	-	-	-	-	-	-	-
1868042	0	36	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	37	or	CC	-	-	-	-	-	-	-	-
1868042	0	38	20	CD	-	-	-	-	-	-	-	(157a|(159
1868042	0	39	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	40	nifedipine	NN	-	-	-	-	-	-	-	159)|157a)
1868042	0	41	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	42	right	JJ	-	-	-	-	-	-	-	-
1868042	0	43	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	44	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	B	LS	-	-	-	-	-	-	-	(164)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Exocytosis	NN	-	-	-	-	-	-	-	(43)
1868042	0	5	was	VBD	-	-	-	-	-	-	-	-
1868042	0	6	elicited	VBN	-	-	-	-	-	-	-	-
1868042	0	7	by	IN	-	-	-	-	-	-	-	-
1868042	0	8	500	CD	-	-	-	-	-	-	-	-
1868042	0	9	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	ms	NNS	-	-	-	-	-	-	-	-
1868042	0	11	depolarisations	NNS	-	-	-	-	-	-	-	-
1868042	0	12	from	IN	-	-	-	-	-	-	-	-
1868042	0	13	−	SYM	-	-	-	-	-	-	-	(150d
1868042	0	14	70	CD	-	-	-	-	-	-	-	150d)
1868042	0	15	to	IN	-	-	-	-	-	-	-	-
1868042	0	16	0	CD	-	-	-	-	-	-	-	(151
1868042	0	17	mV	NN	-	-	-	-	-	-	-	(150d)|151)
1868042	0	18	under	IN	-	-	-	-	-	-	-	-
1868042	0	19	control	NN	-	-	-	-	-	-	-	(152
1868042	0	20	conditions	NNS	-	-	-	-	-	-	-	152)
1868042	0	21	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	22	Ctrl	NN	-	-	-	-	-	-	-	-
1868042	0	23	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	24	and	CC	-	-	-	-	-	-	-	-
1868042	0	25	in	IN	-	-	-	-	-	-	-	-
1868042	0	26	the	DT	-	-	-	-	-	-	-	(161a|(256a
1868042	0	27	presence	NN	-	-	-	-	-	-	-	-
1868042	0	28	of	IN	-	-	-	-	-	-	-	256a)|161a)
1868042	0	29	either	CC	-	-	-	-	-	-	-	-
1868042	0	30	nifedipine	NN	-	-	-	-	-	-	-	(256a)|(38)
1868042	0	31	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	32	50	CD	-	-	-	-	-	-	-	-
1868042	0	33	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	34	;	:	-	-	-	-	-	-	-	-
1868042	0	35	nif	NN	-	-	-	-	-	-	-	(38)
1868042	0	36	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	37	or	CC	-	-	-	-	-	-	-	-
1868042	0	38	ω	NN	-	-	-	-	-	-	-	(161a|(36
1868042	0	39	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	40	conotoxin	NN	-	-	-	-	-	-	-	36)|161a)
1868042	0	41	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	42	1	CD	-	-	-	-	-	-	-	-
1868042	0	43	μM	NN	-	-	-	-	-	-	-	-
1868042	0	44	;	:	-	-	-	-	-	-	-	-
1868042	0	45	ω	SYM	-	-	-	-	-	-	-	(36
1868042	0	46	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	47	con	NN	-	-	-	-	-	-	-	36)
1868042	0	48	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	49	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	C	LS	-	-	-	-	-	-	-	(165)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Summary	NN	-	-	-	-	-	-	-	-
1868042	0	5	of	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	exocytotic	JJ	-	-	-	-	-	-	-	-
1868042	0	8	response	NN	-	-	-	-	-	-	-	-
1868042	0	9	under	IN	-	-	-	-	-	-	-	-
1868042	0	10	control	NN	-	-	-	-	-	-	-	(152
1868042	0	11	conditions	NNS	-	-	-	-	-	-	-	152)
1868042	0	12	and	CC	-	-	-	-	-	-	-	-
1868042	0	13	in	IN	-	-	-	-	-	-	-	-
1868042	0	14	the	DT	-	-	-	-	-	-	-	(161b|(256
1868042	0	15	presence	NN	-	-	-	-	-	-	-	-
1868042	0	16	of	IN	-	-	-	-	-	-	-	161b)
1868042	0	17	nifedipine	NN	-	-	-	-	-	-	-	(38)|256)
1868042	0	18	and	CC	-	-	-	-	-	-	-	-
1868042	0	19	ω	NN	-	-	-	-	-	-	-	(161b|(36
1868042	0	20	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	21	conotoxin	NN	-	-	-	-	-	-	-	36)|161b)
1868042	0	22	.	.	-	-	-	-	-	-	-	-

1868042	0	1	*	SYM	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	p	NN	-	-	-	-	-	-	-	-
1868042	0	4	<	SYM	-	-	-	-	-	-	-	-
1868042	0	5	0.05	CD	-	-	-	-	-	-	-	-
1868042	0	6	;	:	-	-	-	-	-	-	-	-
1868042	0	7	**	SYM	-	-	-	-	-	-	-	-
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	p	NN	-	-	-	-	-	-	-	-
1868042	0	10	<	SYM	-	-	-	-	-	-	-	-
1868042	0	11	0.01	CD	-	-	-	-	-	-	-	-
1868042	0	12	,	,	-	-	-	-	-	-	-	-
1868042	0	13	compared	VBN	-	-	-	-	-	-	-	-
1868042	0	14	with	IN	-	-	-	-	-	-	-	-
1868042	0	15	1	CD	-	-	-	-	-	-	-	(101
1868042	0	16	mM	NN	-	-	-	-	-	-	-	-
1868042	0	17	glucose	NN	-	-	-	-	-	-	-	101)
1868042	0	18	and	CC	-	-	-	-	-	-	-	-
1868042	0	19	the	DT	-	-	-	-	-	-	-	-
1868042	0	20	control	NN	-	-	-	-	-	-	-	-
1868042	0	21	capacitance	NN	-	-	-	-	-	-	-	-
1868042	0	22	response	NN	-	-	-	-	-	-	-	-
1868042	0	23	,	,	-	-	-	-	-	-	-	-
1868042	0	24	unless	IN	-	-	-	-	-	-	-	-
1868042	0	25	indicated	VBN	-	-	-	-	-	-	-	-
1868042	0	26	otherwise	RB	-	-	-	-	-	-	-	-
1868042	0	27	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Figure	NN	-	-	-	-	-	-	-	(81)
1868042	0	2	9	CD	-	-	-	-	-	-	-	-

1868042	0	1	Voltage	NN	-	-	-	-	-	-	-	(182a
1868042	0	2	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	3	Dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	4	Inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	5	of	IN	-	-	-	-	-	-	-	-
1868042	0	6	α	NN	-	-	-	-	-	-	-	-
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	Cell	NN	-	-	-	-	-	-	-	182a)
1868042	0	9	N	NN	-	-	-	-	-	-	-	-
1868042	0	10	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	11	Type	NN	-	-	-	-	-	-	-	-
1868042	0	12	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	13	Currents	NNS	-	-	-	-	-	-	-	-
1868042	0	14	and	CC	-	-	-	-	-	-	-	-
1868042	0	15	Exocytosis	NN	-	-	-	-	-	-	-	(182a)

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	A	LS	-	-	-	-	-	-	-	(168)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	N	NN	-	-	-	-	-	-	-	-
1868042	0	5	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	6	type	NN	-	-	-	-	-	-	-	-
1868042	0	7	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	8	currents	NNS	-	-	-	-	-	-	-	-
1868042	0	9	were	VBD	-	-	-	-	-	-	-	-
1868042	0	10	evaluated	VBN	-	-	-	-	-	-	-	-
1868042	0	11	during	IN	-	-	-	-	-	-	-	-
1868042	0	12	blockade	NN	-	-	-	-	-	-	-	-
1868042	0	13	of	IN	-	-	-	-	-	-	-	-
1868042	0	14	the	DT	-	-	-	-	-	-	-	(37
1868042	0	15	L	NN	-	-	-	-	-	-	-	-
1868042	0	16	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	type	NN	-	-	-	-	-	-	-	-
1868042	0	18	channels	NNS	-	-	-	-	-	-	-	37)
1868042	0	19	with	IN	-	-	-	-	-	-	-	-
1868042	0	20	isradipine	NN	-	-	-	-	-	-	-	-
1868042	0	21	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	22	2	CD	-	-	-	-	-	-	-	-
1868042	0	23	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	24	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	25	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	(36
1868042	0	2	N	NN	-	-	-	-	-	-	-	-
1868042	0	3	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	4	type	NN	-	-	-	-	-	-	-	-
1868042	0	5	channel	NN	-	-	-	-	-	-	-	-
1868042	0	6	antagonist	NN	-	-	-	-	-	-	-	-
1868042	0	7	ω	NN	-	-	-	-	-	-	-	-
1868042	0	8	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	conotoxin	NN	-	-	-	-	-	-	-	36)
1868042	0	10	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	11	1	CD	-	-	-	-	-	-	-	-
1868042	0	12	μM	NN	-	-	-	-	-	-	-	-
1868042	0	13	;	:	-	-	-	-	-	-	-	-
1868042	0	14	red	JJ	-	-	-	-	-	-	-	-
1868042	0	15	traces	NNS	-	-	-	-	-	-	-	-
1868042	0	16	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	17	reduced	VBD	-	-	-	-	-	-	-	-
1868042	0	18	the	DT	-	-	-	-	-	-	-	-
1868042	0	19	Ca2+	NN	-	-	-	-	-	-	-	(5)
1868042	0	20	current	NN	-	-	-	-	-	-	-	-
1868042	0	21	elicited	VBN	-	-	-	-	-	-	-	-
1868042	0	22	by	IN	-	-	-	-	-	-	-	-
1868042	0	23	a	DT	-	-	-	-	-	-	-	-
1868042	0	24	step	NN	-	-	-	-	-	-	-	-
1868042	0	25	depolarisation	NN	-	-	-	-	-	-	-	-
1868042	0	26	from	IN	-	-	-	-	-	-	-	-
1868042	0	27	−	SYM	-	-	-	-	-	-	-	(150f
1868042	0	28	70	CD	-	-	-	-	-	-	-	150f)
1868042	0	29	to	IN	-	-	-	-	-	-	-	-
1868042	0	30	0	CD	-	-	-	-	-	-	-	(151
1868042	0	31	mV	NNS	-	-	-	-	-	-	-	(150f)|151)
1868042	0	32	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	33	right	JJ	-	-	-	-	-	-	-	-
1868042	0	34	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	35	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	B	LS	-	-	-	-	-	-	-	(170)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	As	IN	-	-	-	-	-	-	-	-
1868042	0	5	in	IN	-	-	-	-	-	-	-	-
1868042	0	6	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	7	A	NN	-	-	-	-	-	-	-	(168)
1868042	0	8	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	9	,	,	-	-	-	-	-	-	-	-
1868042	0	10	but	CC	-	-	-	-	-	-	-	-
1868042	0	11	the	DT	-	-	-	-	-	-	-	-
1868042	0	12	pulse	NN	-	-	-	-	-	-	-	-
1868042	0	13	to	IN	-	-	-	-	-	-	-	-
1868042	0	14	0	CD	-	-	-	-	-	-	-	(151
1868042	0	15	mV	NNS	-	-	-	-	-	-	-	151)
1868042	0	16	was	VBD	-	-	-	-	-	-	-	-
1868042	0	17	preceded	VBN	-	-	-	-	-	-	-	-
1868042	0	18	by	IN	-	-	-	-	-	-	-	-
1868042	0	19	a	DT	-	-	-	-	-	-	-	-
1868042	0	20	200	CD	-	-	-	-	-	-	-	-
1868042	0	21	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	22	ms	NNS	-	-	-	-	-	-	-	-
1868042	0	23	conditioning	NN	-	-	-	-	-	-	-	-
1868042	0	24	depolarization	NN	-	-	-	-	-	-	-	-
1868042	0	25	to	IN	-	-	-	-	-	-	-	-
1868042	0	26	+	SYM	-	-	-	-	-	-	-	(169
1868042	0	27	10	CD	-	-	-	-	-	-	-	-
1868042	0	28	mV	NNS	-	-	-	-	-	-	-	169)
1868042	0	29	.	.	-	-	-	-	-	-	-	-

1868042	0	1	ω	NN	-	-	-	-	-	-	-	(36
1868042	0	2	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	3	Conotoxin	NN	-	-	-	-	-	-	-	36)
1868042	0	4	was	VBD	-	-	-	-	-	-	-	-
1868042	0	5	without	IN	-	-	-	-	-	-	-	-
1868042	0	6	effect	NN	-	-	-	-	-	-	-	-
1868042	0	7	on	IN	-	-	-	-	-	-	-	-
1868042	0	8	the	DT	-	-	-	-	-	-	-	-
1868042	0	9	current	JJ	-	-	-	-	-	-	-	-
1868042	0	10	measured	VBN	-	-	-	-	-	-	-	-
1868042	0	11	during	IN	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	depolarization	NN	-	-	-	-	-	-	-	-
1868042	0	14	to	IN	-	-	-	-	-	-	-	-
1868042	0	15	0	CD	-	-	-	-	-	-	-	(151
1868042	0	16	mV	NNS	-	-	-	-	-	-	-	151)
1868042	0	17	under	IN	-	-	-	-	-	-	-	-
1868042	0	18	these	DT	-	-	-	-	-	-	-	-
1868042	0	19	conditions	NNS	-	-	-	-	-	-	-	-
1868042	0	20	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	21	right	JJ	-	-	-	-	-	-	-	-
1868042	0	22	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	C	LS	-	-	-	-	-	-	-	(172)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Top	JJ	-	-	-	-	-	-	-	-
1868042	0	5	:	:	-	-	-	-	-	-	-	-
1868042	0	6	peak	JJ	-	-	-	-	-	-	-	-
1868042	0	7	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	8	currents	NNS	-	-	-	-	-	-	-	-
1868042	0	9	measured	VBN	-	-	-	-	-	-	-	-
1868042	0	10	in	IN	-	-	-	-	-	-	-	-
1868042	0	11	the	DT	-	-	-	-	-	-	-	-
1868042	0	12	presence	NN	-	-	-	-	-	-	-	-
1868042	0	13	of	IN	-	-	-	-	-	-	-	-
1868042	0	14	2	CD	-	-	-	-	-	-	-	-
1868042	0	15	μM	NNS	-	-	-	-	-	-	-	-
1868042	0	16	isradipine	NN	-	-	-	-	-	-	-	-
1868042	0	17	alone	RB	-	-	-	-	-	-	-	-
1868042	0	18	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	19	open	JJ	-	-	-	-	-	-	-	(173
1868042	0	20	squares	NNS	-	-	-	-	-	-	-	173)
1868042	0	21	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	22	or	CC	-	-	-	-	-	-	-	-
1868042	0	23	together	RB	-	-	-	-	-	-	-	-
1868042	0	24	with	IN	-	-	-	-	-	-	-	-
1868042	0	25	1	CD	-	-	-	-	-	-	-	-
1868042	0	26	μM	NN	-	-	-	-	-	-	-	-
1868042	0	27	ω	NN	-	-	-	-	-	-	-	-
1868042	0	28	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	29	conotoxin	NN	-	-	-	-	-	-	-	-
1868042	0	30	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	31	red	JJ	-	-	-	-	-	-	-	-
1868042	0	32	circles	NNS	-	-	-	-	-	-	-	-
1868042	0	33	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	34	during	IN	-	-	-	-	-	-	-	-
1868042	0	35	a	DT	-	-	-	-	-	-	-	-
1868042	0	36	depolarization	NN	-	-	-	-	-	-	-	-
1868042	0	37	to	IN	-	-	-	-	-	-	-	-
1868042	0	38	0	CD	-	-	-	-	-	-	-	(151
1868042	0	39	mV	NNS	-	-	-	-	-	-	-	151)
1868042	0	40	following	IN	-	-	-	-	-	-	-	-
1868042	0	41	200	CD	-	-	-	-	-	-	-	-
1868042	0	42	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	43	ms	NNS	-	-	-	-	-	-	-	-
1868042	0	44	conditioning	NN	-	-	-	-	-	-	-	-
1868042	0	45	pulses	NNS	-	-	-	-	-	-	-	-
1868042	0	46	to	IN	-	-	-	-	-	-	-	-
1868042	0	47	between	IN	-	-	-	-	-	-	-	-
1868042	0	48	−	SYM	-	-	-	-	-	-	-	(150a
1868042	0	49	70	CD	-	-	-	-	-	-	-	150a)
1868042	0	50	and	CC	-	-	-	-	-	-	-	-
1868042	0	51	+	SYM	-	-	-	-	-	-	-	-
1868042	0	52	70	CD	-	-	-	-	-	-	-	-
1868042	0	53	mV	NNS	-	-	-	-	-	-	-	(150a)
1868042	0	54	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Lower	JJR	-	-	-	-	-	-	-	-
1868042	0	2	:	:	-	-	-	-	-	-	-	-
1868042	0	3	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	4	of	IN	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	-
1868042	0	6	ω	NN	-	-	-	-	-	-	-	-
1868042	0	7	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	8	conotoxin	NN	-	-	-	-	-	-	-	-
1868042	0	9	–	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	sensitive	JJ	-	-	-	-	-	-	-	-
1868042	0	11	component	NN	-	-	-	-	-	-	-	-
1868042	0	12	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Half	RB	-	-	-	-	-	-	-	-
1868042	0	2	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	3	maximal	JJ	-	-	-	-	-	-	-	-
1868042	0	4	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	5	of	IN	-	-	-	-	-	-	-	-
1868042	0	6	the	DT	-	-	-	-	-	-	-	-
1868042	0	7	N	NN	-	-	-	-	-	-	-	-
1868042	0	8	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	type	NN	-	-	-	-	-	-	-	-
1868042	0	10	current	NN	-	-	-	-	-	-	-	-
1868042	0	11	was	VBD	-	-	-	-	-	-	-	-
1868042	0	12	at	IN	-	-	-	-	-	-	-	-
1868042	0	13	−	SYM	-	-	-	-	-	-	-	-
1868042	0	14	31	CD	-	-	-	-	-	-	-	-
1868042	0	15	±	SYM	-	-	-	-	-	-	-	-
1868042	0	16	6	CD	-	-	-	-	-	-	-	-
1868042	0	17	mV	NNS	-	-	-	-	-	-	-	-
1868042	0	18	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	19	n	NN	-	-	-	-	-	-	-	-
1868042	0	20	=	SYM	-	-	-	-	-	-	-	-
1868042	0	21	5	CD	-	-	-	-	-	-	-	-
1868042	0	22	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	D	LS	-	-	-	-	-	-	-	(174)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Exocytosis	NN	-	-	-	-	-	-	-	(43)
1868042	0	5	was	VBD	-	-	-	-	-	-	-	-
1868042	0	6	elicited	VBN	-	-	-	-	-	-	-	-
1868042	0	7	with	IN	-	-	-	-	-	-	-	-
1868042	0	8	500	CD	-	-	-	-	-	-	-	-
1868042	0	9	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	10	ms	NNS	-	-	-	-	-	-	-	-
1868042	0	11	depolarisations	NNS	-	-	-	-	-	-	-	-
1868042	0	12	from	IN	-	-	-	-	-	-	-	-
1868042	0	13	−	SYM	-	-	-	-	-	-	-	(150
1868042	0	14	70	CD	-	-	-	-	-	-	-	-
1868042	0	15	mV	NNS	-	-	-	-	-	-	-	150)
1868042	0	16	to	IN	-	-	-	-	-	-	-	-
1868042	0	17	between	IN	-	-	-	-	-	-	-	-
1868042	0	18	−	SYM	-	-	-	-	-	-	-	(175b
1868042	0	19	50	CD	-	-	-	-	-	-	-	175b)
1868042	0	20	and	CC	-	-	-	-	-	-	-	-
1868042	0	21	20	CD	-	-	-	-	-	-	-	(176
1868042	0	22	mV	NNS	-	-	-	-	-	-	-	(175b)|176)
1868042	0	23	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	E	LS	-	-	-	-	-	-	-	(178)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	The	DT	-	-	-	-	-	-	-	-
1868042	0	5	voltage	NN	-	-	-	-	-	-	-	-
1868042	0	6	dependence	NN	-	-	-	-	-	-	-	-
1868042	0	7	of	IN	-	-	-	-	-	-	-	-
1868042	0	8	the	DT	-	-	-	-	-	-	-	-
1868042	0	9	exocytotic	JJ	-	-	-	-	-	-	-	-
1868042	0	10	response	NN	-	-	-	-	-	-	-	-
1868042	0	11	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	F	LS	-	-	-	-	-	-	-	(183)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Exocytosis	NN	-	-	-	-	-	-	-	(43)
1868042	0	5	elicited	VBN	-	-	-	-	-	-	-	-
1868042	0	6	by	IN	-	-	-	-	-	-	-	-
1868042	0	7	500	CD	-	-	-	-	-	-	-	-
1868042	0	8	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	ms	NNS	-	-	-	-	-	-	-	-
1868042	0	10	depolarisations	NNS	-	-	-	-	-	-	-	-
1868042	0	11	to	IN	-	-	-	-	-	-	-	-
1868042	0	12	0	CD	-	-	-	-	-	-	-	(151
1868042	0	13	mV	NNS	-	-	-	-	-	-	-	151)
1868042	0	14	from	IN	-	-	-	-	-	-	-	-
1868042	0	15	holding	VBG	-	-	-	-	-	-	-	-
1868042	0	16	potentials	NNS	-	-	-	-	-	-	-	-
1868042	0	17	of	IN	-	-	-	-	-	-	-	-
1868042	0	18	between	IN	-	-	-	-	-	-	-	-
1868042	0	19	−	SYM	-	-	-	-	-	-	-	(150c
1868042	0	20	70	CD	-	-	-	-	-	-	-	150c)
1868042	0	21	and	CC	-	-	-	-	-	-	-	-
1868042	0	22	−	SYM	-	-	-	-	-	-	-	(184
1868042	0	23	30	CD	-	-	-	-	-	-	-	-
1868042	0	24	mV	NNS	-	-	-	-	-	-	-	(150c)|184)
1868042	0	25	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	G	LS	-	-	-	-	-	-	-	(186)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Summary	NN	-	-	-	-	-	-	-	-
1868042	0	5	of	IN	-	-	-	-	-	-	-	-
1868042	0	6	effects	NNS	-	-	-	-	-	-	-	-
1868042	0	7	of	IN	-	-	-	-	-	-	-	-
1868042	0	8	holding	NN	-	-	-	-	-	-	-	(188
1868042	0	9	potential	NN	-	-	-	-	-	-	-	188)
1868042	0	10	on	IN	-	-	-	-	-	-	-	-
1868042	0	11	exocytotic	JJ	-	-	-	-	-	-	-	-
1868042	0	12	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	13	elicited	VBN	-	-	-	-	-	-	-	-
1868042	0	14	by	IN	-	-	-	-	-	-	-	-
1868042	0	15	depolarisations	NNS	-	-	-	-	-	-	-	(185
1868042	0	16	to	IN	-	-	-	-	-	-	-	-
1868042	0	17	0	CD	-	-	-	-	-	-	-	(151
1868042	0	18	mV	NNS	-	-	-	-	-	-	-	185)|151)
1868042	0	19	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Data	NNS	-	-	-	-	-	-	-	(242)
1868042	0	2	have	VBP	-	-	-	-	-	-	-	-
1868042	0	3	been	VBN	-	-	-	-	-	-	-	-
1868042	0	4	normalized	VBN	-	-	-	-	-	-	-	-
1868042	0	5	to	IN	-	-	-	-	-	-	-	-
1868042	0	6	responses	NNS	-	-	-	-	-	-	-	-
1868042	0	7	obtained	VBN	-	-	-	-	-	-	-	-
1868042	0	8	using	VBG	-	-	-	-	-	-	-	-
1868042	0	9	a	DT	-	-	-	-	-	-	-	-
1868042	0	10	holding	NN	-	-	-	-	-	-	-	-
1868042	0	11	potential	NN	-	-	-	-	-	-	-	-
1868042	0	12	of	IN	-	-	-	-	-	-	-	-
1868042	0	13	−	SYM	-	-	-	-	-	-	-	(150
1868042	0	14	70	CD	-	-	-	-	-	-	-	-
1868042	0	15	mV	NNS	-	-	-	-	-	-	-	150)
1868042	0	16	.	.	-	-	-	-	-	-	-	-

1868042	0	1	*	SYM	-	-	-	-	-	-	-	-
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	p	NN	-	-	-	-	-	-	-	-
1868042	0	4	<	SYM	-	-	-	-	-	-	-	-
1868042	0	5	0.05	CD	-	-	-	-	-	-	-	-
1868042	0	6	;	:	-	-	-	-	-	-	-	-
1868042	0	7	**	SYM	-	-	-	-	-	-	-	-
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	p	NN	-	-	-	-	-	-	-	-
1868042	0	10	<	SYM	-	-	-	-	-	-	-	-
1868042	0	11	0.01	CD	-	-	-	-	-	-	-	-
1868042	0	12	;	:	-	-	-	-	-	-	-	-
1868042	0	13	***	SYM	-	-	-	-	-	-	-	-
1868042	0	14	,	,	-	-	-	-	-	-	-	-
1868042	0	15	p	NN	-	-	-	-	-	-	-	-
1868042	0	16	<	SYM	-	-	-	-	-	-	-	-
1868042	0	17	0.001	CD	-	-	-	-	-	-	-	-
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	compared	VBN	-	-	-	-	-	-	-	-
1868042	0	20	with	IN	-	-	-	-	-	-	-	-
1868042	0	21	ω	NN	-	-	-	-	-	-	-	(36
1868042	0	22	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	23	conotoxin	NN	-	-	-	-	-	-	-	36)
1868042	0	24	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	25	C	NN	-	-	-	-	-	-	-	(172)
1868042	0	26	,	,	-	-	-	-	-	-	-	-
1868042	0	27	top	JJ	-	-	-	-	-	-	-	-
1868042	0	28	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	29	or	CC	-	-	-	-	-	-	-	-
1868042	0	30	with	IN	-	-	-	-	-	-	-	-
1868042	0	31	the	DT	-	-	-	-	-	-	-	-
1868042	0	32	initial	JJ	-	-	-	-	-	-	-	-
1868042	0	33	response	NN	-	-	-	-	-	-	-	-
1868042	0	34	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Figure	NN	-	-	-	-	-	-	-	(196|(81)
1868042	0	2	10	CD	-	-	-	-	-	-	-	196)

1868042	0	1	A	DT	-	-	-	-	-	-	-	-
1868042	0	2	Model	NN	-	-	-	-	-	-	-	-
1868042	0	3	for	IN	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	-
1868042	0	5	Suppression	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	Glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	8	Secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	9	by	IN	-	-	-	-	-	-	-	-
1868042	0	10	an	DT	-	-	-	-	-	-	-	-
1868042	0	11	Intrinsic	JJ	-	-	-	-	-	-	-	-
1868042	0	12	α	NN	-	-	-	-	-	-	-	-
1868042	0	13	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	14	Cell	NN	-	-	-	-	-	-	-	-
1868042	0	15	Pathway	NN	-	-	-	-	-	-	-	-

1868042	0	1	Schematic	JJ	-	-	-	-	-	-	-	-
1868042	0	2	representation	NN	-	-	-	-	-	-	-	-
1868042	0	3	of	IN	-	-	-	-	-	-	-	-
1868042	0	4	the	DT	-	-	-	-	-	-	-	(94a
1868042	0	5	effects	NNS	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	glucose	NN	-	-	-	-	-	-	-	(31)|94a)
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	tolbutamide	NN	-	-	-	-	-	-	-	(23)
1868042	0	10	,	,	-	-	-	-	-	-	-	-
1868042	0	11	and	CC	-	-	-	-	-	-	-	-
1868042	0	12	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	13	on	IN	-	-	-	-	-	-	-	(94a
1868042	0	14	α	NN	-	-	-	-	-	-	-	(63b
1868042	0	15	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	16	cell	NN	-	-	-	-	-	-	-	-
1868042	0	17	KATP	NN	-	-	-	-	-	-	-	94a)|63b)
1868042	0	18	,	,	-	-	-	-	-	-	-	-
1868042	0	19	Na+	NN	-	-	-	-	-	-	-	-
1868042	0	20	,	,	-	-	-	-	-	-	-	-
1868042	0	21	and	CC	-	-	-	-	-	-	-	-
1868042	0	22	N	NN	-	-	-	-	-	-	-	(213
1868042	0	23	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	24	type	NN	-	-	-	-	-	-	-	-
1868042	0	25	Ca2+	NN	-	-	-	-	-	-	-	-
1868042	0	26	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	27	VDCC	NN	-	-	-	-	-	-	-	(67)
1868042	0	28	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	29	channel	NN	-	-	-	-	-	-	-	(94a|(63b)|213)
1868042	0	30	activities	NNS	-	-	-	-	-	-	-	94a)
1868042	0	31	and	CC	-	-	-	-	-	-	-	-
1868042	0	32	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	33	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	34	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	35	shown	VBN	-	-	-	-	-	-	-	-
1868042	0	36	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	insulin	NN	-	-	-	-	-	-	-	(19)
1868042	0	3	response	NN	-	-	-	-	-	-	-	-
1868042	0	4	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	5	also	RB	-	-	-	-	-	-	-	-
1868042	0	6	shown	VBN	-	-	-	-	-	-	-	-
1868042	0	7	for	IN	-	-	-	-	-	-	-	-
1868042	0	8	comparison	NN	-	-	-	-	-	-	-	-
1868042	0	9	with	IN	-	-	-	-	-	-	-	-
1868042	0	10	our	PRP$	-	-	-	-	-	-	-	(4)
1868042	0	11	experimental	JJ	-	-	-	-	-	-	-	-
1868042	0	12	results	NNS	-	-	-	-	-	-	-	-
1868042	0	13	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	14	dashed	JJ	-	-	-	-	-	-	-	-
1868042	0	15	lines	NNS	-	-	-	-	-	-	-	-
1868042	0	16	,	,	-	-	-	-	-	-	-	-
1868042	0	17	lower	JJR	-	-	-	-	-	-	-	-
1868042	0	18	panels	NNS	-	-	-	-	-	-	-	-
1868042	0	19	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	20	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	grey	JJ	-	-	-	-	-	-	-	-
1868042	0	3	gradient	NN	-	-	-	-	-	-	-	-
1868042	0	4	represents	VBZ	-	-	-	-	-	-	-	-
1868042	0	5	a	DT	-	-	-	-	-	-	-	(257
1868042	0	6	“	``	-	-	-	-	-	-	-	-
1868042	0	7	window	NN	-	-	-	-	-	-	-	-
1868042	0	8	”	''	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	α	NN	-	-	-	-	-	-	-	(63|(95
1868042	0	11	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	cell	NN	-	-	-	-	-	-	-	-
1868042	0	13	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	14	channel	NN	-	-	-	-	-	-	-	63)
1868042	0	15	activity	NN	-	-	-	-	-	-	-	95)
1868042	0	16	that	WDT	-	-	-	-	-	-	-	-
1868042	0	17	supports	VBZ	-	-	-	-	-	-	-	-
1868042	0	18	the	DT	-	-	-	-	-	-	-	(149a|(258|(259b
1868042	0	19	activation	NN	-	-	-	-	-	-	-	-
1868042	0	20	of	IN	-	-	-	-	-	-	-	149a)
1868042	0	21	Ca2+	NN	-	-	-	-	-	-	-	(260|(5)|259b)
1868042	0	22	and	CC	-	-	-	-	-	-	-	-
1868042	0	23	Na+	NN	-	-	-	-	-	-	-	(140|(149a
1868042	0	24	channels	NNS	-	-	-	-	-	-	-	(259b)|260)|258)|257)|149a)|140)
1868042	0	25	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Above	IN	-	-	-	-	-	-	-	-
1868042	0	2	this	DT	-	-	-	-	-	-	-	(257
1868042	0	3	window	NN	-	-	-	-	-	-	-	257)
1868042	0	4	,	,	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	(261
1868042	0	6	cell	NN	-	-	-	-	-	-	-	261)
1868042	0	7	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	8	hyperpolarized	VBN	-	-	-	-	-	-	-	-
1868042	0	9	and	CC	-	-	-	-	-	-	-	-
1868042	0	10	Ca2+	NN	-	-	-	-	-	-	-	(258|(259a)
1868042	0	11	and	CC	-	-	-	-	-	-	-	-
1868042	0	12	Na+	NN	-	-	-	-	-	-	-	(140|(149
1868042	0	13	channel	NN	-	-	-	-	-	-	-	(259a|140)
1868042	0	14	activation	NN	-	-	-	-	-	-	-	259a)|258)|149)
1868042	0	15	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	16	prevented	VBN	-	-	-	-	-	-	-	-
1868042	0	17	,	,	-	-	-	-	-	-	-	-
1868042	0	18	whereas	IN	-	-	-	-	-	-	-	-
1868042	0	19	KATP	NN	-	-	-	-	-	-	-	(32
1868042	0	20	channel	NN	-	-	-	-	-	-	-	32)
1868042	0	21	activity	NN	-	-	-	-	-	-	-	-
1868042	0	22	below	IN	-	-	-	-	-	-	-	-
1868042	0	23	this	DT	-	-	-	-	-	-	-	(257
1868042	0	24	window	NN	-	-	-	-	-	-	-	257)
1868042	0	25	depolarizes	VBZ	-	-	-	-	-	-	-	-
1868042	0	26	the	DT	-	-	-	-	-	-	-	(261
1868042	0	27	cell	NN	-	-	-	-	-	-	-	261)
1868042	0	28	and	CC	-	-	-	-	-	-	-	-
1868042	0	29	causes	VBZ	-	-	-	-	-	-	-	-
1868042	0	30	voltage	NN	-	-	-	-	-	-	-	(144a
1868042	0	31	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	32	dependent	JJ	-	-	-	-	-	-	-	-
1868042	0	33	inactivation	NN	-	-	-	-	-	-	-	-
1868042	0	34	of	IN	-	-	-	-	-	-	-	144a)
1868042	0	35	Ca2+	NN	-	-	-	-	-	-	-	(260|(5)
1868042	0	36	and	CC	-	-	-	-	-	-	-	-
1868042	0	37	Na+	NN	-	-	-	-	-	-	-	(140|(144a
1868042	0	38	channels	NNS	-	-	-	-	-	-	-	260)|144a)|140)
1868042	0	39	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	A	LS	-	-	-	-	-	-	-	(202)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	High	JJ	-	-	-	-	-	-	-	-
1868042	0	5	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	6	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	7	concentration	NN	-	-	-	-	-	-	-	-
1868042	0	8	reduces	VBZ	-	-	-	-	-	-	-	-
1868042	0	9	α	NN	-	-	-	-	-	-	-	(63|(95
1868042	0	10	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	11	cell	NN	-	-	-	-	-	-	-	-
1868042	0	12	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	13	channel	NN	-	-	-	-	-	-	-	63)
1868042	0	14	activity	NN	-	-	-	-	-	-	-	95)
1868042	0	15	,	,	-	-	-	-	-	-	-	-
1868042	0	16	reducing	VBG	-	-	-	-	-	-	-	-
1868042	0	17	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	18	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	19	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	B	LS	-	-	-	-	-	-	-	(200)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	Graded	VBN	-	-	-	-	-	-	-	-
1868042	0	5	application	NN	-	-	-	-	-	-	-	-
1868042	0	6	of	IN	-	-	-	-	-	-	-	-
1868042	0	7	tolbutamide	NN	-	-	-	-	-	-	-	(23)
1868042	0	8	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	9	in	IN	-	-	-	-	-	-	-	-
1868042	0	10	zero	CD	-	-	-	-	-	-	-	(199
1868042	0	11	glucose	NN	-	-	-	-	-	-	-	199)
1868042	0	12	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	13	transiently	RB	-	-	-	-	-	-	-	-
1868042	0	14	increases	VBZ	-	-	-	-	-	-	-	-
1868042	0	15	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	16	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	17	as	IN	-	-	-	-	-	-	-	-
1868042	0	18	KATP	NN	-	-	-	-	-	-	-	(32|(92
1868042	0	19	channel	NN	-	-	-	-	-	-	-	32)
1868042	0	20	activity	NN	-	-	-	-	-	-	-	92)
1868042	0	21	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	22	reduced	VBN	-	-	-	-	-	-	-	-
1868042	0	23	through	IN	-	-	-	-	-	-	-	-
1868042	0	24	,	,	-	-	-	-	-	-	-	-
1868042	0	25	and	CC	-	-	-	-	-	-	-	-
1868042	0	26	eventually	RB	-	-	-	-	-	-	-	-
1868042	0	27	below	IN	-	-	-	-	-	-	-	-
1868042	0	28	,	,	-	-	-	-	-	-	-	-
1868042	0	29	the	DT	-	-	-	-	-	-	-	(257
1868042	0	30	window	NN	-	-	-	-	-	-	-	-
1868042	0	31	supporting	VBG	-	-	-	-	-	-	-	-
1868042	0	32	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	33	release	NN	-	-	-	-	-	-	-	257)
1868042	0	34	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	C	LS	-	-	-	-	-	-	-	(198)
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	The	DT	-	-	-	-	-	-	-	-
1868042	0	5	graded	VBN	-	-	-	-	-	-	-	-
1868042	0	6	application	NN	-	-	-	-	-	-	-	-
1868042	0	7	of	IN	-	-	-	-	-	-	-	-
1868042	0	8	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	9	in	IN	-	-	-	-	-	-	-	-
1868042	0	10	high	JJ	-	-	-	-	-	-	-	(87
1868042	0	11	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	12	glucose	NN	-	-	-	-	-	-	-	-
1868042	0	13	conditions	NNS	-	-	-	-	-	-	-	87)
1868042	0	14	increases	VBZ	-	-	-	-	-	-	-	-
1868042	0	15	α	NN	-	-	-	-	-	-	-	(63|(95
1868042	0	16	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	17	cell	NN	-	-	-	-	-	-	-	-
1868042	0	18	KATP	NN	-	-	-	-	-	-	-	-
1868042	0	19	channel	NN	-	-	-	-	-	-	-	63)
1868042	0	20	activity	NN	-	-	-	-	-	-	-	95)
1868042	0	21	into	IN	-	-	-	-	-	-	-	-
1868042	0	22	,	,	-	-	-	-	-	-	-	-
1868042	0	23	and	CC	-	-	-	-	-	-	-	-
1868042	0	24	then	RB	-	-	-	-	-	-	-	-
1868042	0	25	above	IN	-	-	-	-	-	-	-	-
1868042	0	26	the	DT	-	-	-	-	-	-	-	(257
1868042	0	27	window	NN	-	-	-	-	-	-	-	-
1868042	0	28	supporting	VBG	-	-	-	-	-	-	-	-
1868042	0	29	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	30	secretion	NN	-	-	-	-	-	-	-	257)|25)
1868042	0	31	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	-
1868042	0	2	result	NN	-	-	-	-	-	-	-	-
1868042	0	3	is	VBZ	-	-	-	-	-	-	-	-
1868042	0	4	a	DT	-	-	-	-	-	-	-	-
1868042	0	5	transient	JJ	-	-	-	-	-	-	-	-
1868042	0	6	“	``	-	-	-	-	-	-	-	-
1868042	0	7	re-activation	NN	-	-	-	-	-	-	-	-
1868042	0	8	”	''	-	-	-	-	-	-	-	-
1868042	0	9	of	IN	-	-	-	-	-	-	-	-
1868042	0	10	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	11	secretion	NN	-	-	-	-	-	-	-	25)
1868042	0	12	at	IN	-	-	-	-	-	-	-	-
1868042	0	13	low	JJ	-	-	-	-	-	-	-	-
1868042	0	14	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	15	diazoxide	NN	-	-	-	-	-	-	-	-
1868042	0	16	concentrations	NNS	-	-	-	-	-	-	-	-
1868042	0	17	.	.	-	-	-	-	-	-	-	-

1868042	0	1	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	2	D	LS	-	-	-	-	-	-	-	-
1868042	0	3	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	4	In	IN	-	-	-	-	-	-	-	-
1868042	0	5	low	JJ	-	-	-	-	-	-	-	(59a
1868042	0	6	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	glucose	NN	-	-	-	-	-	-	-	59a)
1868042	0	8	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	9	1	CD	-	-	-	-	-	-	-	-
1868042	0	10	–	SYM	-	-	-	-	-	-	-	-
1868042	0	11	2	CD	-	-	-	-	-	-	-	-
1868042	0	12	mM	NNS	-	-	-	-	-	-	-	-
1868042	0	13	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	14	conditions	NNS	-	-	-	-	-	-	-	(59a)
1868042	0	15	,	,	-	-	-	-	-	-	-	-
1868042	0	16	graded	VBN	-	-	-	-	-	-	-	-
1868042	0	17	application	NN	-	-	-	-	-	-	-	-
1868042	0	18	of	IN	-	-	-	-	-	-	-	-
1868042	0	19	diazoxide	NN	-	-	-	-	-	-	-	(18)
1868042	0	20	increases	VBZ	-	-	-	-	-	-	-	-
1868042	0	21	KATP	NN	-	-	-	-	-	-	-	(32|(92
1868042	0	22	channel	NN	-	-	-	-	-	-	-	32)
1868042	0	23	activity	NN	-	-	-	-	-	-	-	92)
1868042	0	24	above	IN	-	-	-	-	-	-	-	-
1868042	0	25	the	DT	-	-	-	-	-	-	-	(257
1868042	0	26	window	NN	-	-	-	-	-	-	-	-
1868042	0	27	supporting	VBG	-	-	-	-	-	-	-	-
1868042	0	28	glucagon	NN	-	-	-	-	-	-	-	(25|(2)
1868042	0	29	secretion	NN	-	-	-	-	-	-	-	257)|25)
1868042	0	30	,	,	-	-	-	-	-	-	-	-
1868042	0	31	causing	VBG	-	-	-	-	-	-	-	-
1868042	0	32	a	DT	-	-	-	-	-	-	-	-
1868042	0	33	monotonic	JJ	-	-	-	-	-	-	-	-
1868042	0	34	inhibition	NN	-	-	-	-	-	-	-	-
1868042	0	35	of	IN	-	-	-	-	-	-	-	-
1868042	0	36	glucagon	NN	-	-	-	-	-	-	-	(2)
1868042	0	37	release	NN	-	-	-	-	-	-	-	-
1868042	0	38	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Footnotes	NNS	-	-	-	-	-	-	-	-

1868042	0	1	Competing	JJ	-	-	-	-	-	-	-	-
1868042	0	2	interests	NNS	-	-	-	-	-	-	-	-
1868042	0	3	.	.	-	-	-	-	-	-	-	-

1868042	0	1	The	DT	-	-	-	-	-	-	-	(48
1868042	0	2	authors	NNS	-	-	-	-	-	-	-	48)
1868042	0	3	have	VBP	-	-	-	-	-	-	-	-
1868042	0	4	declared	VBN	-	-	-	-	-	-	-	-
1868042	0	5	that	IN	-	-	-	-	-	-	-	-
1868042	0	6	no	DT	-	-	-	-	-	-	-	-
1868042	0	7	competing	VBG	-	-	-	-	-	-	-	-
1868042	0	8	interests	NNS	-	-	-	-	-	-	-	-
1868042	0	9	exist	VBP	-	-	-	-	-	-	-	-
1868042	0	10	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Author	NN	-	-	-	-	-	-	-	(48)
1868042	0	2	contributions	NNS	-	-	-	-	-	-	-	-
1868042	0	3	.	.	-	-	-	-	-	-	-	-

1868042	0	1	PEM	NNP	-	-	-	-	-	-	-	(243)
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	LE	NNP	-	-	-	-	-	-	-	(262)
1868042	0	4	,	,	-	-	-	-	-	-	-	-
1868042	0	5	and	CC	-	-	-	-	-	-	-	-
1868042	0	6	PR	NNP	-	-	-	-	-	-	-	(245)
1868042	0	7	conceived	VBD	-	-	-	-	-	-	-	-
1868042	0	8	and	CC	-	-	-	-	-	-	-	-
1868042	0	9	designed	VBD	-	-	-	-	-	-	-	-
1868042	0	10	the	DT	-	-	-	-	-	-	-	(263
1868042	0	11	experiments	NNS	-	-	-	-	-	-	-	263)
1868042	0	12	.	.	-	-	-	-	-	-	-	-

1868042	0	1	PEM	NNP	-	-	-	-	-	-	-	(243)
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	YZDM	NNP	-	-	-	-	-	-	-	(264)
1868042	0	4	,	,	-	-	-	-	-	-	-	-
1868042	0	5	RR	NNP	-	-	-	-	-	-	-	(265)
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	AS	NNP	-	-	-	-	-	-	-	(266)
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	XM	NNP	-	-	-	-	-	-	-	-
1868042	0	10	,	,	-	-	-	-	-	-	-	-
1868042	0	11	and	CC	-	-	-	-	-	-	-	-
1868042	0	12	LE	NNP	-	-	-	-	-	-	-	(262)
1868042	0	13	performed	VBD	-	-	-	-	-	-	-	-
1868042	0	14	the	DT	-	-	-	-	-	-	-	(263
1868042	0	15	experiments	NNS	-	-	-	-	-	-	-	263)
1868042	0	16	.	.	-	-	-	-	-	-	-	-

1868042	0	1	PEM	NNP	-	-	-	-	-	-	-	(243)
1868042	0	2	,	,	-	-	-	-	-	-	-	-
1868042	0	3	YZDM	NNP	-	-	-	-	-	-	-	(264)
1868042	0	4	,	,	-	-	-	-	-	-	-	-
1868042	0	5	RR	NNP	-	-	-	-	-	-	-	(265)
1868042	0	6	,	,	-	-	-	-	-	-	-	-
1868042	0	7	AS	NNP	-	-	-	-	-	-	-	(266)
1868042	0	8	,	,	-	-	-	-	-	-	-	-
1868042	0	9	LE	NNP	-	-	-	-	-	-	-	(262)
1868042	0	10	,	,	-	-	-	-	-	-	-	-
1868042	0	11	and	CC	-	-	-	-	-	-	-	-
1868042	0	12	PR	NNP	-	-	-	-	-	-	-	(245)
1868042	0	13	analyzed	VBD	-	-	-	-	-	-	-	-
1868042	0	14	the	DT	-	-	-	-	-	-	-	(242
1868042	0	15	data	NNS	-	-	-	-	-	-	-	242)
1868042	0	16	.	.	-	-	-	-	-	-	-	-

1868042	0	1	PRVJ	NNP	-	-	-	-	-	-	-	-
1868042	0	2	and	CC	-	-	-	-	-	-	-	-
1868042	0	3	RC	NNP	-	-	-	-	-	-	-	-
1868042	0	4	contributed	VBD	-	-	-	-	-	-	-	-
1868042	0	5	reagents	NNS	-	-	-	-	-	-	-	-
1868042	0	6	/	HYPH	-	-	-	-	-	-	-	-
1868042	0	7	materials	NNS	-	-	-	-	-	-	-	-
1868042	0	8	/	HYPH	-	-	-	-	-	-	-	-
1868042	0	9	analysis	NN	-	-	-	-	-	-	-	-
1868042	0	10	tools	NNS	-	-	-	-	-	-	-	-
1868042	0	11	.	.	-	-	-	-	-	-	-	-

1868042	0	1	PEM	NNP	-	-	-	-	-	-	-	(243)
1868042	0	2	and	CC	-	-	-	-	-	-	-	-
1868042	0	3	PR	NNP	-	-	-	-	-	-	-	(245)
1868042	0	4	wrote	VBD	-	-	-	-	-	-	-	-
1868042	0	5	the	DT	-	-	-	-	-	-	-	-
1868042	0	6	paper	NN	-	-	-	-	-	-	-	-
1868042	0	7	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Funding	NN	-	-	-	-	-	-	-	-
1868042	0	2	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Work	NN	-	-	-	-	-	-	-	-
1868042	0	2	in	IN	-	-	-	-	-	-	-	-
1868042	0	3	the	DT	-	-	-	-	-	-	-	-
1868042	0	4	UK	NNP	-	-	-	-	-	-	-	-
1868042	0	5	was	VBD	-	-	-	-	-	-	-	-
1868042	0	6	supported	VBN	-	-	-	-	-	-	-	-
1868042	0	7	by	IN	-	-	-	-	-	-	-	-
1868042	0	8	grants	NNS	-	-	-	-	-	-	-	-
1868042	0	9	to	IN	-	-	-	-	-	-	-	-
1868042	0	10	PR	NN	-	-	-	-	-	-	-	(245)
1868042	0	11	from	IN	-	-	-	-	-	-	-	-
1868042	0	12	the	DT	-	-	-	-	-	-	-	-
1868042	0	13	Wellcome	NNP	-	-	-	-	-	-	-	-
1868042	0	14	Trust	NNP	-	-	-	-	-	-	-	-
1868042	0	15	and	CC	-	-	-	-	-	-	-	-
1868042	0	16	the	DT	-	-	-	-	-	-	-	-
1868042	0	17	European	NNP	-	-	-	-	-	-	-	-
1868042	0	18	Union	NNP	-	-	-	-	-	-	-	-
1868042	0	19	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	20	Eurodia	NNP	-	-	-	-	-	-	-	-
1868042	0	21	LSHM	NN	-	-	-	-	-	-	-	-
1868042	0	22	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	23	CT	NN	-	-	-	-	-	-	-	-
1868042	0	24	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	25	2006	CD	-	-	-	-	-	-	-	-
1868042	0	26	–	HYPH	-	-	-	-	-	-	-	-
1868042	0	27	518153	CD	-	-	-	-	-	-	-	-
1868042	0	28	and	CC	-	-	-	-	-	-	-	-
1868042	0	29	BioSim	NNP	-	-	-	-	-	-	-	-
1868042	0	30	LSHB	NN	-	-	-	-	-	-	-	-
1868042	0	31	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	32	CT	NN	-	-	-	-	-	-	-	-
1868042	0	33	-	HYPH	-	-	-	-	-	-	-	-
1868042	0	34	2004	CD	-	-	-	-	-	-	-	-
1868042	0	35	–	HYPH	-	-	-	-	-	-	-	-
1868042	0	36	005137	CD	-	-	-	-	-	-	-	-
1868042	0	37	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	38	.	.	-	-	-	-	-	-	-	-

1868042	0	1	Work	NN	-	-	-	-	-	-	-	-
1868042	0	2	conducted	VBN	-	-	-	-	-	-	-	-
1868042	0	3	in	IN	-	-	-	-	-	-	-	-
1868042	0	4	Sweden	NNP	-	-	-	-	-	-	-	-
1868042	0	5	was	VBD	-	-	-	-	-	-	-	-
1868042	0	6	supported	VBN	-	-	-	-	-	-	-	-
1868042	0	7	by	IN	-	-	-	-	-	-	-	-
1868042	0	8	the	DT	-	-	-	-	-	-	-	-
1868042	0	9	Swedish	NNP	-	-	-	-	-	-	-	-
1868042	0	10	Strategic	NNP	-	-	-	-	-	-	-	-
1868042	0	11	Foundation	NNP	-	-	-	-	-	-	-	-
1868042	0	12	,	,	-	-	-	-	-	-	-	-
1868042	0	13	the	DT	-	-	-	-	-	-	-	-
1868042	0	14	Göran	NNP	-	-	-	-	-	-	-	-
1868042	0	15	Gustafsson	NNP	-	-	-	-	-	-	-	-
1868042	0	16	Stiftelse	NNP	-	-	-	-	-	-	-	-
1868042	0	17	,	,	-	-	-	-	-	-	-	-
1868042	0	18	the	DT	-	-	-	-	-	-	-	-
1868042	0	19	Swedish	NNP	-	-	-	-	-	-	-	-
1868042	0	20	Research	NNP	-	-	-	-	-	-	-	-
1868042	0	21	Council	NNP	-	-	-	-	-	-	-	-
1868042	0	22	,	,	-	-	-	-	-	-	-	-
1868042	0	23	the	DT	-	-	-	-	-	-	-	-
1868042	0	24	Swedish	NNP	-	-	-	-	-	-	-	-
1868042	0	25	Diabetes	NNP	-	-	-	-	-	-	-	-
1868042	0	26	Association	NNP	-	-	-	-	-	-	-	-
1868042	0	27	,	,	-	-	-	-	-	-	-	-
1868042	0	28	and	CC	-	-	-	-	-	-	-	-
1868042	0	29	the	DT	-	-	-	-	-	-	-	-
1868042	0	30	Novo	NNP	-	-	-	-	-	-	-	-
1868042	0	31	Nordisk	NNP	-	-	-	-	-	-	-	-
1868042	0	32	Foundation	NNP	-	-	-	-	-	-	-	-
1868042	0	33	(	-LRB-	-	-	-	-	-	-	-	-
1868042	0	34	LE	NNP	-	-	-	-	-	-	-	(262)
1868042	0	35	)	-RRB-	-	-	-	-	-	-	-	-
1868042	0	36	.	.	-	-	-	-	-	-	-	-

